
<html lang="en"     class="pb-page"  data-request-id="78695095-0eeb-4827-a1c3-713aace415d4"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2017.60.issue-12;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;article:article:10.1021/acs.jmedchem.7b00449;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure" /></meta><meta name="dc.Creator" content="Markus  Follmann" /></meta><meta name="dc.Creator" content="Jens  Ackerstaff" /></meta><meta name="dc.Creator" content="Gorden  Redlich" /></meta><meta name="dc.Creator" content="Frank  Wunder" /></meta><meta name="dc.Creator" content="Dieter  Lang" /></meta><meta name="dc.Creator" content="Armin  Kern" /></meta><meta name="dc.Creator" content="Peter  Fey" /></meta><meta name="dc.Creator" content="Nils  Griebenow" /></meta><meta name="dc.Creator" content="Walter  Kroh" /></meta><meta name="dc.Creator" content="Eva-Maria  Becker-Pelster" /></meta><meta name="dc.Creator" content="Axel  Kretschmer" /></meta><meta name="dc.Creator" content="Volker  Geiss" /></meta><meta name="dc.Creator" content="Volkhart  Li" /></meta><meta name="dc.Creator" content="Alexander  Straub" /></meta><meta name="dc.Creator" content="Joachim  Mittendorf" /></meta><meta name="dc.Creator" content="Rolf  Jautelat" /></meta><meta name="dc.Creator" content="Hartmut  Schirok" /></meta><meta name="dc.Creator" content="Karl-Heinz  Schlemmer" /></meta><meta name="dc.Creator" content="Klemens  Lustig" /></meta><meta name="dc.Creator" content="Michael  Gerisch" /></meta><meta name="dc.Creator" content="Andreas  Knorr" /></meta><meta name="dc.Creator" content="Hanna  Tinel" /></meta><meta name="dc.Creator" content="Thomas  Mondritzki" /></meta><meta name="dc.Creator" content="Hubert  Trübel" /></meta><meta name="dc.Creator" content="Peter  Sandner" /></meta><meta name="dc.Creator" content="Johannes-Peter  Stasch" /></meta><meta name="dc.Description" content="The first-in-class soluble guanylate cyclase (sGC) stimulator riociguat was recently introduced as a novel treatment option for pulmonary hypertension. Despite its outstanding pharmacological profi..." /></meta><meta name="Description" content="The first-in-class soluble guanylate cyclase (sGC) stimulator riociguat was recently introduced as a novel treatment option for pulmonary hypertension. Despite its outstanding pharmacological profi..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 12, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00449" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00449" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00449" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00449" /></link>
        
    
    

<title>Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00449" /></meta><meta property="og:title" content="Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0022.jpeg" /></meta><meta property="og:description" content="The first-in-class soluble guanylate cyclase (sGC) stimulator riociguat was recently introduced as a novel treatment option for pulmonary hypertension. Despite its outstanding pharmacological profile, application of riociguat in other cardiovascular indications is limited by its short half-life, necessitating a three times daily dosing regimen. In our efforts to further optimize the compound class, we have uncovered interesting structure–activity relationships and were able to decrease oxidative metabolism significantly. These studies resulting in the discovery of once daily sGC stimulator vericiguat (compound 24, BAY 1021189), currently in phase 3 trials for chronic heart failure, are now reported." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="The first-in-class soluble guanylate cyclase (sGC) stimulator riociguat was recently introduced as a novel treatment option for pulmonary hypertension. Despite its outstanding pharmacological profile, application of riociguat in other cardiovascular indications is limited by its short half-life, necessitating a three times daily dosing regimen. In our efforts to further optimize the compound class, we have uncovered interesting structure–activity relationships and were able to decrease oxidative metabolism significantly. These studies resulting in the discovery of once daily sGC stimulator vericiguat (compound 24, BAY 1021189), currently in phase 3 trials for chronic heart failure, are now reported." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0022.jpeg" /></meta><meta name="twitter:title" content="Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00449"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00449">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00449&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00449&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00449&amp;href=/doi/10.1021/acs.jmedchem.7b00449" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 12</span><span class="cit-fg-pageRange">, 5146-5161</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/12" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00475" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b00608" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Markus++Follmann">Markus Follmann</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0003-1246-3603" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jens++Ackerstaff">Jens Ackerstaff</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gorden++Redlich">Gorden Redlich</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Frank++Wunder">Frank Wunder</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dieter++Lang">Dieter Lang</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Armin++Kern">Armin Kern</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Peter++Fey">Peter Fey</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nils++Griebenow">Nils Griebenow</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Walter++Kroh">Walter Kroh</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Eva-Maria++Becker-Pelster">Eva-Maria Becker-Pelster</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Axel++Kretschmer">Axel Kretschmer</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Volker++Geiss">Volker Geiss</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Volkhart++Li">Volkhart Li</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alexander++Straub">Alexander Straub</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joachim++Mittendorf">Joachim Mittendorf</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rolf++Jautelat">Rolf Jautelat</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hartmut++Schirok">Hartmut Schirok</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Karl-Heinz++Schlemmer">Karl-Heinz Schlemmer</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Klemens++Lustig">Klemens Lustig</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Gerisch">Michael Gerisch</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andreas++Knorr">Andreas Knorr</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hanna++Tinel">Hanna Tinel</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Thomas++Mondritzki">Thomas Mondritzki</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hubert++Tr%C3%BCbel">Hubert Trübel</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Peter++Sandner">Peter Sandner</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Johannes-Peter++Stasch">Johannes-Peter Stasch</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Drug Discovery, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany</span></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#3a575b48514f49145c555656575b54547a585b435f4814595557"><span class="__cf_email__" data-cfemail="97faf6e5fce2e4b9f1f8fbfbfaf6f9f9d7f5f6eef2e5b9f4f8fa">[email protected]</span></a>. Phone: +49202365272.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00449&amp;href=/doi/10.1021%2Facs.jmedchem.7b00449" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 12</span><span class="cit-pageRange">, 5146–5161</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 30, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>30 March 2017</li><li><span class="item_label"><b>Published</b> online</span>12 June 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 June 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00449" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00449</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice_termsofuse.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00449"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">10146</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">48</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00449" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Markus&quot;,&quot;last_name&quot;:&quot;Follmann&quot;},{&quot;first_name&quot;:&quot;Jens&quot;,&quot;last_name&quot;:&quot;Ackerstaff&quot;},{&quot;first_name&quot;:&quot;Gorden&quot;,&quot;last_name&quot;:&quot;Redlich&quot;},{&quot;first_name&quot;:&quot;Frank&quot;,&quot;last_name&quot;:&quot;Wunder&quot;},{&quot;first_name&quot;:&quot;Dieter&quot;,&quot;last_name&quot;:&quot;Lang&quot;},{&quot;first_name&quot;:&quot;Armin&quot;,&quot;last_name&quot;:&quot;Kern&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;Fey&quot;},{&quot;first_name&quot;:&quot;Nils&quot;,&quot;last_name&quot;:&quot;Griebenow&quot;},{&quot;first_name&quot;:&quot;Walter&quot;,&quot;last_name&quot;:&quot;Kroh&quot;},{&quot;first_name&quot;:&quot;Eva-Maria&quot;,&quot;last_name&quot;:&quot;Becker-Pelster&quot;},{&quot;first_name&quot;:&quot;Axel&quot;,&quot;last_name&quot;:&quot;Kretschmer&quot;},{&quot;first_name&quot;:&quot;Volker&quot;,&quot;last_name&quot;:&quot;Geiss&quot;},{&quot;first_name&quot;:&quot;Volkhart&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Alexander&quot;,&quot;last_name&quot;:&quot;Straub&quot;},{&quot;first_name&quot;:&quot;Joachim&quot;,&quot;last_name&quot;:&quot;Mittendorf&quot;},{&quot;first_name&quot;:&quot;Rolf&quot;,&quot;last_name&quot;:&quot;Jautelat&quot;},{&quot;first_name&quot;:&quot;Hartmut&quot;,&quot;last_name&quot;:&quot;Schirok&quot;},{&quot;first_name&quot;:&quot;Karl-Heinz&quot;,&quot;last_name&quot;:&quot;Schlemmer&quot;},{&quot;first_name&quot;:&quot;Klemens&quot;,&quot;last_name&quot;:&quot;Lustig&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Gerisch&quot;},{&quot;first_name&quot;:&quot;Andreas&quot;,&quot;last_name&quot;:&quot;Knorr&quot;},{&quot;first_name&quot;:&quot;Hanna&quot;,&quot;last_name&quot;:&quot;Tinel&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;Mondritzki&quot;},{&quot;first_name&quot;:&quot;Hubert&quot;,&quot;last_name&quot;:&quot;Trübel&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;Sandner&quot;},{&quot;first_name&quot;:&quot;Johannes-Peter&quot;,&quot;last_name&quot;:&quot;Stasch&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;12&quot;,&quot;issue&quot;:&quot;12&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;5146-5161&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00449&quot;},&quot;abstract&quot;:&quot;The first-in-class soluble guanylate cyclase (sGC) stimulator riociguat was recently introduced as a novel treatment option for pulmonary hypertension. Despite its outstanding pharmacological profile, application of riociguat in other cardiovascular indications is limited by its short half-life, necessitating a three times daily dosing regimen. In our efforts to further optimize the compound class, we have uncovered interesting structure–activity relationships and were able to decrease oxidative metabolism significantly. These studies resulting in the discovery of once daily sGC stimulator vericiguat (compound 24, BAY 1021189), currently in phase 3 trials for chronic heart failure, are now reported.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00449&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00449" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00449&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00449" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00449&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00449" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00449&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00449&amp;href=/doi/10.1021/acs.jmedchem.7b00449" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00449" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00449" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00449%26sid%3Dliteratum%253Aachs%26pmid%3D28557445%26genre%3Darticle%26aulast%3DFollmann%26date%3D2017%26atitle%3DDiscovery%2Bof%2Bthe%2BSoluble%2BGuanylate%2BCyclase%2BStimulator%2BVericiguat%2B%2528BAY%2B1021189%2529%2Bfor%2Bthe%2BTreatment%2Bof%2BChronic%2BHeart%2BFailure%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D12%26spage%3D5146%26epage%3D5161%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292178" title="Organic compounds">Organic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292349" title="Alkyls">Alkyls</a>,</li><li><a href="/action/doSearch?ConceptID=291675" title="Stability">Stability</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/12" title="Go to Volume 60, Issue 12"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/jmcmar.2017.60.issue-12/20170622/jmcmar.2017.60.issue-12.largecover.jpg" alt="Go to Volume 60, Issue 12"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0022.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00449&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The first-in-class soluble guanylate cyclase (sGC) stimulator riociguat was recently introduced as a novel treatment option for pulmonary hypertension. Despite its outstanding pharmacological profile, application of riociguat in other cardiovascular indications is limited by its short half-life, necessitating a three times daily dosing regimen. In our efforts to further optimize the compound class, we have uncovered interesting structure–activity relationships and were able to decrease oxidative metabolism significantly. These studies resulting in the discovery of once daily sGC stimulator vericiguat (compound <b>24</b>, BAY 1021189), currently in phase 3 trials for chronic heart failure, are now reported.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57638" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57638" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The NO–sGC–cGMP axis belongs to the key signal transduction pathways involved in regulating the cardiovascular system.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> Central to this pathway is soluble guanylate cyclase (sGC), an intracellular enzyme present in the smooth muscle cells of blood vessels and in platelets but also in various other cell types like cardiomyocytes. sGC displays a high affinity for, and is activated by, the first messenger signaling molecule nitric oxide (NO). Biosynthesis of NO is mediated by three distinct isoforms of nitric oxide synthases, endothelial nitric oxide synthase (eNOS), neuronal nitric oxide synthase (nNOS), and the inducible isoform of nitric oxide synthase (iNOS), all synthesizing NO from <span class="smallcaps smallerCapital">l</span>-arginine. Within endothelial cells, NO is produced by eNOS and diffuses rapidly to the underlying smooth muscle cells where it binds to its target enzyme sGC. This binding leads to the stimulation of sGC, resulting in increased production of intracellular second messenger cGMP. cGMP interacts with three types of intracellular proteins such as cGMP-dependent protein kinases, cGMP-regulated ion channels, and phosphodiesterases. Further downstream, these transduction cascades mediate various physiological and tissue-protective effects including smooth muscle relaxation and inhibition of smooth muscle proliferation, leukocyte recruitment, and platelet function. The pathogenesis of various diseases, especially those of the cardiovascular system, has been related to insufficient bioavailability of NO and thus impaired stimulation of sGC and therefore decreased cGMP production.<a onclick="showRef(event, 'ref3 ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6 ref7">(3-7)</a></div><div class="NLM_p">sGC itself is a cytosolic, heterodimeric protein composed of an α- and a β-subunit with a prosthetic heme group located in the β-subunit (heme-binding domain).<a onclick="showRef(event, 'ref8 ref9 ref10 ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10 ref11 ref12 ref13">(8-13)</a> Mechanistically, NO stimulates sGC by binding to the Fe<sup>2+</sup> of the heme group, which induces cleavage of an Fe<sup>2+</sup>–histidine (His<sup>105</sup>) bond, likely resulting in conformational reorganizations which propagate into the catalytic subunit, increasing cGMP production. cGMP interacts with three types of intracellular proteins, namely cGMP-dependent protein kinases, cGMP-regulated ion channels, and phosphodiesterases. Further downstream, these transduction cascades mediate various physiological and tissue-protective effects, including smooth muscle relaxation and inhibition of smooth muscle proliferation, leukocyte recruitment, and platelet function.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div><div class="NLM_p">sGC can exist in two different states, a native heme-containing or reduced form of sGC, which is the endogenous receptor for NO, and a heme-free form of sGC.<a onclick="showRef(event, 'ref1 ref14'); return false;" href="javascript:void(0);" class="ref ref1 ref14">(1, 14)</a> Under conditions of oxidative stress, which is thought to be causal in the pathogenesis of many cardiovascular diseases, reactive oxygen species (ROS) are produced. ROS are capable of oxidizing the heme iron of sGC (Fe<sup>2+</sup> → Fe<sup>3+</sup>), resulting ultimately in heme loss from oxidized sGC. As a consequence, the heme-free form of sGC is no longer binding NO, is not responsive to NO, and thus termed dysfunctional. During the last 20 years, two distinct compound classes have been discovered at Bayer that are capable of activating sGC in a NO-independent manner, the heme-dependent sGC stimulators and the heme-independent sGC activators. sGC stimulators display a dual mode of action: they synergize with endogenous NO and, on top of this, are also able to directly stimulate the native form of the enzyme independently of NO, resulting in increased cGMP production.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> In contrast, sGC activators are capable of activating the dysfunctional heme-free sGC, resulting in increased cGMP production even under conditions of reduced NO bioavailability.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><div class="NLM_p">The discovery of the sGC stimulators at Bayer, along with the efforts of several other pharmaceutical companies to identify sGC stimulators and activators, has recently been reviewed.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Riociguat (<b>1</b>) is the first sGC stimulator to have made a successful transition from animal experiments to controlled clinical studies in patients.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> In 2013, <b>1</b> gained market approval for two life-threatening diseases: pulmonary arterial hypertension (PAH)<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and chronic thromboembolic pulmonary hypertension (CTEPH).<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19, 20)</a> However, application of <b>1</b> in other cardiovascular indications, such as heart failure, is limited by its short half-life.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><div class="NLM_p last">Herein, we report our recent efforts in optimizing the pharmacokinetic profile of sGC stimulators, culminating in the discovery of vericiguat (compound <b>24</b>, BAY 1021189), which has been evaluated in phase 2 studies (SOCRATES trials) in heart failure patients with reduced (HFrEF) and preserved (HFpEF) ejection fraction.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a> Currently, <b>24</b> is being investigated in a phase 3 outcome study (VICTORIA trial) in heart failure patients with HFrEF in codevelopment with MSD (vericiguat code name: MK-1242).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> That study is aimed at assessing whether <b>24</b>, on top of standard of care, is able to decrease mortality and morbidity in such HFrEF patients.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00558" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00558" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Optimization Strategy</h3><div class="NLM_p last">Our goal was to identify orally bioavailable sGC stimulators with a longer duration of action than <b>1</b> in order to support a profile allowing for a once daily oral dosing and less oxidative metabolism in order to lower interaction potentials. <b>1</b> is a very potent sGC stimulator in vitro and in vivo; however, it has a moderate half-life in different animal species<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> and this pharmacokinetic profile translated into a three times daily dosing regimen in patients. <i>N</i>-Demethylation to compound <b>9</b>, as described by Gnoth et al.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> in 2015, is the major biotransformation of <b>1</b> and is mainly catalyzed by CYP1A1 and also by CYP3A4, CYP3A5, and CYP2J2.<a onclick="showRef(event, 'ref21 ref26 ref27 ref28 ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref21 ref26 ref27 ref28 ref29 ref30 ref31">(21, 26-31)</a> Our strategy was to further optimize the metabolic stability of <b>1</b> and hence reduce blood clearance to achieve a longer half-life. We began by optimizing the substituents on the 5-carbamoyl residue on the pyrimidine ring, aiming to achieve metabolically more stable derivatives while maintaining good potency. Later, in a second optimization step, we focused on variations of the central pyrazolopyridine scaffold.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p"><a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> outlines the strategy for the synthesis of the 5-carbamoyl variations. Starting from triamine <b>1c</b>, which is available in two steps from amidine <b>1a</b> and phenyldiazenyl-substituted malonodinitrile <b>1b</b>, selective carbamate formation at the 5-amino group was achieved either by treatment with the corresponding chloroformate or by addition of the respective alcohol preactivated with triphosgene to yield compounds <b>9</b>–<b>14</b>.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Deprotonation of the carbamate NH group and subsequent treatment with the corresponding halide or trichloromethanesulfonate electrophile allowed further derivatization to the corresponding <i>N</i>-alkylated carbamates (<b>1</b>, <b>2</b>, <b>4</b>–<b>8</b>). Alternatively, the alkyl side chain on the 5-amino group could first be introduced via reductive amination and the product <b>1d</b> subsequently treated with methyl chloroformate, giving access to the hydroxyethyl derivative <b>3</b>. For the cyclic 5-(2-oxo-1,3-oxazolidin-3-yl) analogues <b>15</b>–<b>18</b>, the previously employed conditions for the selective formation of carbamates provided <b>1e</b>–<b>g</b> bearing a chloro- or bromo-substituted alkyl chain, allowing for a base-induced intramolecular cyclization (NaHMDS).</div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0008.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>1</b>–<b>18</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00449&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaOMe, DMF, 110 °C; (b) H<sub>2</sub> (65 bar), Raney nickel, DMF; (c) R<sup>2</sup>OCOCl, pyridine, or (i) triphosgene, pyridine, (ii) R<sup>2</sup>OH, pyridine; (d) R<sup>1</sup>X (X = halide or trichloromethanesulfonate), LiHMDS; (e) glycolaldehyde, NaBH<sub>3</sub>CN, AcOH, MeOH, 0 °C to rt; (f) methyl chloroformate, pyridine, rt; (g) NaHMDS, THF, 0 °C to rt.</p></p></figure><div class="NLM_p">The synthesis of the compounds with a core variation is outlined in <a class="ref internalNav" href="#sch2" aria-label="Schemes 2">Schemes 2</a>–<a class="ref internalNav" href="#sch5" aria-label="5">5</a>. For the 1<i>H</i>-pyrazolo[4,3-<i>b</i>]pyridine derivative <b>19</b>, the synthesis started from 3,5-dichloropyridine-2-carbonyl chloride (<b>2a</b>), which was converted into 3-(2-fluorobenzyl)-1<i>H</i>-pyrazolo[4,3-<i>b</i>]pyridine (<b>2b</b>) in four steps. The fluoro derivative <b>2d</b> was synthesized in a similar manner from the corresponding difluoropyridine analogue <b>2c</b>. Both key intermediates <b>2b</b> and <b>2d</b> were then reacted with 2-chloro-5-nitropyrimidine-4,6-diamine,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> followed by reduction of the pyrimidine 5-nitro group and methyl carbamate formation, to give the 1<i>H</i>-pyrazolo[4,3-<i>b</i>]pyridine core analogues <b>19</b> and <b>20</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).</div><figure id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0009.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>19</b> and <b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00449&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) methyl 2-(2-fluorophenyl)acetate, LiHMDS; (b) aq NaCl solution, DMSO, microwave, 150 °C; (c) hydrazine hydrate, pyridine, reflux; (d) H<sub>2</sub>, 10% Pd/C, Et<sub>3</sub>N, EtOH, THF; (e) NaH, DMF, 80 °C; (f) H<sub>2</sub>, 10% Pd/C, pyridine; (g) methyl chloroformate, pyridine.</p></p></figure><div class="NLM_p">A different route was used for the preparation of 1<i>H</i>-pyrazolo[3,4-<i>c</i>]pyridazine <b>21</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>), which began with the cyclization of methyl 2-aminothiophene-3-carboxylate (<b>3a</b>) with hydrazine hydrate to give 1<i>H</i>-pyrazolo[3,4-<i>c</i>]pyridazin-3-ol (<b>3b</b>).<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Subsequent bromination afforded intermediate <b>3c</b>, which was alkylated with 2-fluorobenzyl bromide to yield <b>3d</b>. Then, conversion of the bromide into the cyanide <b>3e</b> and Pinner-type reaction of the cyano group with sodium methoxide and ammonium chloride afforded key intermediate <b>3f</b>. Further modifications, analogous to the formation of carbamate <b>9</b> from <b>1a</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>), yielded the methyl carbamate derivative <b>21</b>.</div><figure id="sch3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0010.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compound <b>21</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00449&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) hydrazine hydrate; (b) POBr<sub>3</sub>, sulfolane, 150 °C; (c) 2-fluorobenzyl bromide, Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt; (d) CuCN, DMSO, 150 °C; (e) NaOMe, NH<sub>4</sub>Cl, AcOH, MeOH; (f) <b>1b</b>, DMF, Et<sub>3</sub>N, 100 °C; (g) H<sub>2</sub> (1 bar), 10% Pd/C, DMF; (h) methyl chloroformate, pyridine, DCM.</p></p></figure><div class="NLM_p">The preparation of imidazo[1,5-<i>a</i>]pyrimidine <b>22</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>) started with condensation of the readily available thioimide <b>4a</b> and amine <b>4b</b> to access aminoimidazole <b>4c</b>. Further orthoester condensation then gave the bicyclic imidazopyrimidine derivative <b>4d</b> bearing an ethyl ester functionality. Subsequent saponification, amidation, and dehydration yielded nitrile <b>4g</b> as a key intermediate. Pinner-type reaction with sodium methoxide and ammonium chloride delivered the corresponding amidine <b>4h</b>, which could be converted into the final compound <b>22</b> in analogy to the previous examples.</div><figure id="sch4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0011.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compound <b>22</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00449&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) MeI, K<sub>2</sub>CO<sub>3</sub>, acetone; (b) TBAI, KO<i>t</i>-Bu, DCM, then aq HCl, Et<sub>2</sub>O; (c) dioxane, 60 °C; (d) 1,1,3,3-tetramethoxypropane, aq HCl, MeOH, EtOH, reflux; (e) NaOH; (f) HATU, NH<sub>4</sub>Cl, Hünig’s base, DMF; (g) POCl<sub>3</sub>, 120 °C; (h) NaOMe, NH<sub>4</sub>Cl, MeOH; (i) <b>1b</b>, DMF, Et<sub>3</sub>N, 100 °C; (j) H<sub>2</sub> (1 bar), 10% Pd/C, DMF, 0 °C; (k) methyl chloroformate, pyridine.</p></p></figure><div class="NLM_p">The synthesis of the related imidazo[1,5-<i>b</i>]pyridazine derivative <b>23</b> (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>) started from methyl 5-aminolevulinate hydrochloride (<b>5a</b>). Addition of hydrazine hydrate yielded the dihydropyridazinone <b>5b</b>, which was reacted with the readily available acid chloride <b>5c</b> under basic conditions. The resulting amide was oxidized with bromine to provide the corresponding pyridazinone <b>5d</b>, which underwent an intramolecular condensation in the presence of phosphoryl chloride to give the bicyclic intermediate <b>5e</b>. Dechlorination of the pyridazine core catalyzed by palladium on charcoal and subsequent bromination of the imidazo core with <i>N</i>-bromosuccinimide gave access to <b>5f</b>. Further modifications, as outlined previously, then yielded amidine <b>5g</b> as a key intermediate which was converted into the final target compound <b>23</b>.</div><figure id="sch5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0012.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compound <b>23</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00449&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) hydrazine hydrate, Et<sub>3</sub>N, reflux; (b) Et<sub>3</sub>N, MeCN; (c) Br<sub>2</sub>, AcOH, 50 °C; (d) POCl<sub>3</sub>, DCE, reflux; (e) H<sub>2</sub>, 5% Pd/C, Et<sub>3</sub>N, EtOAc; (f) NBS, DCM; (g) CuCN; (h) NaOMe, NH<sub>4</sub>Cl, AcOH; (i) <b>1b</b>, DMF, Et<sub>3</sub>N, 100 °C; (j) H<sub>2</sub> (1 bar), 10% Pd/C, DMF, MeOH; (k) methyl chloroformate, pyridine.</p></p></figure><div class="NLM_p">The synthesis of the 1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine derivative (<b>24</b>) (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>), involved initial activation of 2,2,3,3-tetrafluoro-1-propanol (<b>6a</b>) with trifluoromethanesulfonic anhydride and treatment with morpholine to yield <b>6b</b> after aqueous workup and distillation. At 135 °C, <b>6b</b> was alkylated with methylmethanesulfonate, leading to quaternized derivative <b>6c</b> which was converted into <b>6d</b> using sodium hydroxide. Further reaction with morpholine and triethylamine yielded <b>6e</b> after crystallization from toluene. Acrylaldehyde derivative <b>6e</b> was reacted with ethyl 5-amino-1-(2-fluorobenzyl)-1<i>H</i>-pyrazole-3-carboxylate<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> in ethanol, yielding ethyl ester intermediate <b>6f</b>. Ester <b>6f</b> was then converted in three steps into the corresponding amidine <b>6i</b> via amide <b>6g</b> and nitrile <b>6h</b> in analogy to the chemistry outlined in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. The synthesis of <b>24</b> was completed as described for compound <b>9</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) via the diazenyl derivative <b>6j</b> and triamine <b>6k</b>.</div><figure id="sch6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0013.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of <b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00449&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Tf<sub>2</sub>O, 70 °C, then morpholine, 5 °C, then 40 °C; (b) MeSO<sub>3</sub>Me, 135 °C, then 100 °C; (c) 45% aq NaOH, 50 °C; (d) morpholine, Et<sub>3</sub>N, reflux; (e) MsOH, LiCl, EtOH, reflux; (f) formamide, NaOMe, MeOH, EtOH, 95–125 °C; (g) POCl<sub>3</sub>, sulfolane, 107 °C; (h) NaOMe, NH<sub>4</sub>Cl, MeOH, EtOH, 65 °C; (i) <b>1b</b>, DMF, Et<sub>3</sub>N, 100 °C; (j) H<sub>2</sub> (60 bar), 5% Pd/C, DMF, 60 °C; (k) methyl chloroformate, <i>i</i>-PrOH, MeOH, then Et<sub>3</sub>N, 50 °C.</p></p></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> SAR and DMPK Optimization</h3><div class="NLM_p">The SAR of the series of novel N-substituted methyl carbamates <b>1</b>–<b>8</b> was explored using a cGMP formation assay with sGC-overexpressing Chinese hamster ovary (CHO) cells.<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34, 35)</a> In addition, the metabolic stability of the compounds was assessed in vitro by incubation with rat hepatocytes. Initially, different carbamate N-substituents were tested with the aim of achieving higher metabolic stability than <b>1</b> while maintaining high potency (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Increasing steric bulk as in the ethyl derivative <b>2</b> had no beneficial effect on either potency or metabolic stability. The introduction of polarity (e.g., a hydroxyethyl functionality, as in <b>3</b>) led to a significant loss of potency relative to <b>1</b>, along with decreased metabolic stability. The next strategy, the introduction of fluorine atoms at the terminal position of the N-substituent, was designed to block metabolism. Interestingly, both the 2,2-difluoroethyl and 2,2,2-trifluoroethyl derivatives, <b>4</b> and <b>5</b>, exhibited high potency in the cGMP assay but had a 2–4.5-fold higher clearance in rat hepatocytes. <i>N</i>-Fluorobenzyl substitution revealed that the <i>ortho</i>-fluoro derivative <b>6</b> is significantly more potent (MEC = 0.1 μM) than the meta and para isomers, <b>7</b> and <b>8</b> (MEC = 0.2 and 0.7 μM, respectively). Nevertheless, all the benzylic derivatives had a high clearance in rat hepatocytes. These results and the testing of many further derivatives (data not shown) suggested that improving the metabolic stability by altering the N-substitution might be very difficult to achieve. Hence, optimization efforts were focused on the main metabolite of <b>1</b>, the <i>N</i>-desmethyl derivative <b>9</b>. This compound is less potent than <b>1</b> but displayed a somewhat higher metabolic stability in the rat hepatocyte assay, with a clearance of 0.1 L/h/kg. When tested in vivo in rats (iv dosing), compound <b>9</b> had a moderate clearance of 1.2 L/h/kg and a short half-life of only 1.2 h.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Properties of the N-Substituted Methyl Carbamates <b>1</b>–<b>8</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0014.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0015.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">MEC: Minimal effective concentration to achieve stimulation of cGMP formation (≥3-fold increase in basal luminescence) in a recombinant sGC-overexpressing cell line.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></p></div></div><div></div></div><div class="NLM_p">Therefore, variations in the carbamate alkoxy group while leaving the N-position unsubstituted were examined next, with the goal of improving the half-life and other properties relative to compound <b>9</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Properties of the N–H Alkyl Carbamates <b>9</b>–<b>14</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0016.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0017.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">MEC: Minimal effective concentration to achieve stimulation of cGMP formation (≥3-fold increase in basal luminescence) in a recombinant sGC-overexpressing cell line.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">n.d.: not determined.</p></div></div><div></div></div><div class="NLM_p">The introduction of steric bulk in the form of an isopropyl residue (compound <b>10</b>) led to a strong decrease in potency relative to <b>9</b> as well as decreased metabolic stability. Interestingly, there was increased potency with cyclobutyl derivative <b>11</b>; however, <b>11</b> was also unfavorable with respect to rat hepatocyte clearance. The oxetanyl group is well-known in medicinal chemistry for improving metabolic stability<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36, 37)</a> over related alkyl derivatives. Remarkably, the exchange of cyclobutyl for oxetanyl (compound <b>12</b>) led to a 14-fold higher stability in rat hepatocytes, but sGC stimulation was weaker than with derivative <b>9</b> or <b>11</b>. Because the permeability across Caco-2 cell monolayers was also very low (<i>P</i><sub>app</sub> A–B = 2 nm/s), combined with a high efflux ratio of 74, compound <b>12</b> was not pursued further. Additional efforts to improve the overall profile by the introduction of fluorine or steric bulk (compounds <b>13</b> and <b>14</b>) led to a slight increase in potency (MEC = 0.2 vs 0.3 μM for <b>9</b>); however, metabolic stability was dramatically reduced.</div><div class="NLM_p">The oxazolidinone derivatives <b>15</b>–<b>18</b>, as conformationally fixed versions of the foregoing carbamates, were also studied to assess the influence of the constrained nature on sGC stimulation (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). The parent oxazolidinone <b>15</b> was as equipotent as carbamate <b>9</b> and exhibited slightly decreased stability in rat hepatocytes. Intravenous dosing of compound <b>15</b> to rats resulted in a moderate clearance of 1.9 L/h/kg and a short half-life of about 1.0 h, and thus <b>15</b> was not profiled further. Other attempts to increase metabolic stability by the introduction of steric bulk were unsuccessful, probably due to the more lipophilic<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> character of the resulting compounds <b>16</b>–<b>18</b>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Properties of the Oxazolidinones <b>15</b>–<b>18</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0018.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0019.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">MEC: Minimal effective concentration to achieve stimulation of cGMP formation (≥3-fold increase in basal luminescence) in a recombinant sGC-overexpressing cell line.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">n.d.: not determined.</p></div></div><div></div></div><div class="NLM_p">In summary, although further optimization of the carbamate motif of <b>1</b> could not be achieved, a number of interesting and novel SAR observations were made, with the N-unsubstituted carbamate <b>9</b> being identified as the most promising path forward. Thus, the focus of the optimization strategy was shifted away from the carbamate moiety and our efforts were directed to the central scaffold and the identification of alternative cores that could lead to superior overall pharmacokinetic profiles of the corresponding compounds.</div><div class="NLM_p">Our studies with respect to central scaffold modifications are summarized in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>. Efforts were concentrated on novel core systems which had not been tested before in combination with 4,6-diaminopyrimidin-5-ylcarbamates.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Properties of the Core Variation Compounds <b>19</b>–<b>24</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0020.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0021.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">MEC: Minimal effective concentration to achieve stimulation of cGMP formation (≥3-fold increase in basal luminescence) in a recombinant sGC-overexpressing cell line.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></p></div><div class="footnote" id="t4fn2"><sup>Table b</sup><p class="last">n.d.: not determined.</p></div></div><div></div></div><div class="NLM_p">First, changes were made to the pyrazolo portion of the molecule, leading to the 1<i>H</i>-pyrazolo[4,3-<i>b</i>]pyridine derivative <b>19</b>. In addition to the benefit of a shorter synthetic route than that for compound <b>9</b>, <b>19</b> proved to be a moderately potent sGC stimulator with an MEC of 1.2 μM and had high metabolic stability when tested in rat hepatocytes. The introduction of substituents at the 6-position of the 1<i>H</i>-pyrazolo[4,3-<i>b</i>]pyridine core was, in general, not well tolerated, leading to a dramatic loss of potency, with the exception of the 6-fluoro derivative <b>20</b>, which exhibited an MEC of 0.5 μM and good metabolic stability. To our surprise, compounds <b>19</b> and <b>20</b> had very different in vivo clearances when compared in a rat pharmacokinetic experiment (iv dosing): fluoro derivative <b>20</b> had a low clearance of 0.3 vs 1.0 L/h/kg for compound <b>19</b>. As metabolite identification did not point to metabolism occurring at the pyridine core, the rationale for this 3-fold reduction in blood clearance remains unclear.</div><div class="NLM_p">Novel 1<i>H</i>-pyrazolo[3,4-<i>c</i>]pyridazine <b>21</b> proved to be a reasonably potent sGC stimulator but exhibited a high clearance of 3.8 L/h/kg when tested in vivo in rats and thus was not further profiled, along with imidazo[1,5-<i>a</i>]pyrimidine <b>22</b> for similar reasons. In contrast, imidazo[1,5-<i>b</i>]pyridazine <b>23</b> exhibited potent sGC stimulator properties (MEC = 0.7 μM), good metabolic stability in rat hepatocytes, and a low to moderate clearance of 0.9 L/h/kg after intravenous dosing to rats. Finally, revisiting 1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine <b>9</b> with an additional fluorine at the 5-position resulted in the potent sGC stimulator <b>24</b> (MEC = 0.3 μM) with good metabolic stability in rat hepatocytes and a surprisingly low clearance of 0.3 L/h/kg after intravenous dosing to rats (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Thus, the blood clearance of derivative <b>9</b> in rats (1.2 L/h/kg) was reduced 4-fold by fluorination at position 5.</div><div class="NLM_p">Finally, compounds <b>20</b>, <b>23</b>, and <b>24</b> were selected for further pharmacokinetic profiling across species (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). Fluoropyrazolo[3,4-<i>b</i>]pyridine derivative <b>24</b> exhibited the best overall pharmacokinetic profile by far, with a low clearance and long half-life in rats and dogs after intravenous dosing, as well as high oral bioavailability. In addition, <b>24</b> had no inhibitory effects on major CYP isoforms (1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4), as indicated by IC<sub>50</sub> values of >50 μM. Metabolite profiling in human hepatocytes was characterized by a low turnover, with glucuronide <b>25</b> (major) and debenzylated compound <b>26</b> (minor) being the only metabolites identified (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). Thus, the main biotransformation pathway shifted from predominantly phase I oxidative CYP-mediated metabolism (<b>1</b>) to primarily phase II UGT-mediated conjugation with glucuronic acid.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. In Vivo Pharmacokinetic Properties of <b>20</b>, <b>23</b>, and <b>24</b> in Comparison with <b>1</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="center" /></col><col align="char" char="." /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>ss</sub> [L/kg]</th><th class="colsep0 rowsep0" align="center">CL<sub>b</sub> [L/h/kg]</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> [h]</th><th class="colsep0 rowsep0" align="center">bioavailability [%]</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="center">0.3</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="center">26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="center">0.2</td><td class="colsep0 rowsep0" align="char" char=".">4.1</td><td class="colsep0 rowsep0" align="center">56</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">0.3</td><td class="colsep0 rowsep0" align="center">0.9</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="center">37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="center">0.9 (Cl<sub>p</sub>)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">1.8</td><td class="colsep0 rowsep0" align="center">n.d.<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="center">0.3</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="center">65</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="center">0.2</td><td class="colsep0 rowsep0" align="char" char=".">6.2</td><td class="colsep0 rowsep0" align="center">75</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="center">1.3</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="center">46</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="char" char=".">0.7</td><td class="colsep0 rowsep0" align="center">0.3 (Cl<sub>p</sub>)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">2.4</td><td class="colsep0 rowsep0" align="center">79</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Cl<sub>p</sub>: plasma clearance.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">n.d.: not determined.</p></div></div></div><figure id="fig1" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0001.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Biotransformation products of <b>24</b> in human hepatocytes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00449&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Pharmacology</h3><div class="NLM_p last"><b>24</b> was extensively profiled preclinically in vitro, on the isolated sGC enzyme and on isolated vessels, ex vivo in isolated hearts, and in vivo in a rat model of cardiovascular disease associated with cardiorenal syndrome.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Highly Purified Recombinant sGC</h3><div class="NLM_p">Studies on the in vitro effects of <b>24</b> on highly purified sGC revealed that <b>24</b> (0.01 μM to 100 μM) stimulates recombinant sGC concentration dependently, by 1.7-fold to 57.6-fold (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). When combined with the NO donor diethylamine/nitric oxide complex (DEA/NO), <b>24</b> and DEA/NO had a synergistic effect on the enzyme activity over a wide range of concentrations. At highest concentrations of <b>24</b> (100 μM) and DEA/NO (100 nM), the specific activity of sGC was 341.6-fold above baseline (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). Moreover, the effects of <b>24</b> in the presence of the sGC inhibitor 1<i>H</i>-[1,2,4]oxadiazolo[4,3-<i>a</i>]quinoxalin-1-one (ODQ) were evaluated. The sGC stimulation induced by <b>24</b> was nearly completely blocked by ODQ and reduced to 18-fold (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). Thus, <b>24</b> exhibits all the characteristics of a potent and selective sGC stimulator, stimulating sGC NO-independently and in synergy with NO. In addition, <b>24</b> predominantly acts on the heme-containing nonoxidized form of sGC.</div><figure id="fig2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0002.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Effects of <b>24</b> and NO on the stimulation of highly purified sGC and blocking effects of the sGC inhibitor ODQ.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00449&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> sGC-Overexpressing Cells</h3><div class="NLM_p last">The stimulation of sGC by <b>24</b> was examined with a recombinant CHO cell line overexpressing rat sGC. <b>24</b> stimulated the sGC reporter cell line concentration dependently, with an EC<sub>50</sub> of 1005 ± 145 nM. In the presence of the NO donor <i>S</i>-nitroso-<i>N</i>-acetyl-<span class="smallcaps smallerCapital">d</span>,<span class="smallcaps smallerCapital">l</span>-penicillamine (SNAP) (30 and 100 nM), the EC<sub>50</sub> value shifted to 39.0 ± 5.1 and 10.6 ± 1.7 nM, respectively. In the presence of ODQ, pretreatment of the sGC reporter cell line with 10 μM ODQ for 3 h resulted in a significantly reduced efficacy of <b>24</b>, with an EC<sub>50</sub> of 256 ± 40 nM being observed.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Isolated Vessels and Tolerance</h3><div class="NLM_p"><b>24</b> inhibited phenylephrine-induced contractions of rabbit saphenous artery rings, rabbit aortic rings, and canine femoral vein rings concentration dependently, with IC<sub>50</sub> values of 798, 692, and 3072 nM, respectively. In addition, <b>24</b> inhibited the U46619-induced contractions of porcine coronary artery rings concentration dependently, with an IC<sub>50</sub> of 956 nM.</div><div class="NLM_p last">Chronic administration of organic nitrates leads to the rapid development of nitrate tolerance. Thus, the vasorelaxant effect of <b>24</b> on isolated saphenous artery rings taken from normal and nitrate-tolerant rabbits was examined. Treatment with isosorbide dinitrate for 3–4 days resulted in a marked inhibition of glycerol trinitrate (GTN) mediated vasodilation. GTN inhibited phenylephrine-induced contractions with an IC<sub>50</sub> of 1.9 nM in control vessels and an IC<sub>50</sub> of 9.6 nM in tolerant vessels, confirming the presence of nitrate tolerance. In contrast to GTN, <b>24</b> is a potent inhibitor of phenylephrine-induced contractions both in normal and nitrate-tolerant saphenous artery rings, with IC<sub>50</sub> values of 5.6 and 5.8 nM, respectively.</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Langendorff-Perfused Hearts</h3><div class="NLM_p">In rat heart Langendorff preparations, ex vivo, <b>24</b> reduced the coronary perfusion pressure in a concentration-dependent manner (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). Up to the highest concentration tested, <b>24</b> had no effect on heart rate, left ventricular diastolic pressure, and contractility.</div><figure id="fig3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0003.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effects of <b>24</b> on rat heart Langendorff preparations.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00449&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Long-Term Study with L-NAME-Treated Renin Transgenic Rats</h3><div class="NLM_p last">The potential impact on cardiovascular health of the stimulation of sGC was evaluated by determining the long-term effects of <b>24</b> on hemodynamic and hormonal parameters in renin transgenic rats (RenTG) carrying the additional mouse renin gene (mRenR2)27. These RenTG(mRenR2)27 rats were additionally treated with the NO synthase inhibitor <i>N</i><sub>ω</sub>-nitro-<span class="smallcaps smallerCapital">l</span>-arginine methyl ester (L-NAME) in the drinking water. This well-established rodent disease model is characterized by hypertension, heart and kidney failure, and increased mortality.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The RenTG(mRenR2)27/L-NAME-supplemented rats were chronically treated with either placebo (2 mL/kg qd), which served as the control group, or <b>24</b> (3 or 10 mg/kg qd).</div></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Effects on Blood Pressure and on the Heart</h3><div class="NLM_p">Chronic oral treatment with 3 or 10 mg/kg <b>24</b> qd resulted in a significant attenuation of blood pressure increase during the course of the study. However, the overall rise of blood pressure increase was not halted in the 3 and 10 mg/kg treatment groups (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>).</div><figure id="fig4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0004.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Increase in systolic blood pressure in mmHg during the course of the study with L-NAME-treated renin transgenic rats.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00449&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition, a significant and dose-dependent reduction of heart hypertrophy, in both the right and left ventricle, was found in the 3 and 10 mg/kg treatment groups compared to the placebo group (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). Furthermore, plasma ANP levels decreased significantly in both treatment groups, also suggesting a functional improvement of the heart.</div><figure id="fig5" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0005.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Right and left ventricle weight normalized on body weight (left/middle) and plasma atrial natriuretic peptide levels [in pg/mL] at the study end, after 3 weeks of treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00449&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Effects on the Kidneys</h3><div class="NLM_p">With respect to kidney damage, <b>24</b> treatment at 3 or 10 mg/kg led to a significant reduction in kidney injury molecule Kim-1 and osteopontin expression which are used as biomarkers for renal injury and dysfunction (data not shown). In addition, proteinuria was significantly and dose dependently decreased in the treatment groups, also suggesting a functional improvement of the kidneys (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>).</div><figure id="fig6" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0006.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effects on proteinuria at the study end after 3 weeks of treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00449&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Effects on Mortality</h3><div class="NLM_p">Treatment with <b>24</b> resulted in a significant and dose-dependent increase in survival rates. In the 3 and 10 mg/kg qd treatment groups, the rat survival rate was 70% and 90%, respectively, at the study end. In contrast, the survival rate in the placebo group was only 25% after 21 days (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>).</div><figure id="fig7" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0007.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Kaplan–Meier survival curves.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00449&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">These in vivo data strongly suggest that the sGC stimulator <b>24</b> can maintain heart and kidney function in a model of hypertension-induced end-organ damage, with substantially reduced overall mortality, strongly suggesting a beneficial role of <b>24</b> for the treatment of cardiovascular diseases associated with cardiorenal syndrome.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42253" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42253" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we have identified <b>24</b> as a potent, orally available stimulator of sGC. Our optimization work starting from <b>1</b> led to the identification of compounds with superior in vitro and in vivo pharmacokinetic and metabolic profiles. <b>24</b>, the compound with the best overall profile from these preclinical studies, was selected as clinical candidate and proved to have a pharmacokinetic profile in humans suitable for once daily dosing. Additional in vivo studies in animal models of hypertension, heart failure, and kidney disease have revealed dose-dependent antifibrotic and organ-protective properties in line with the sGC stimulator mode of action. <b>24</b> is currently being investigated in a phase 3 clinical trial in HFrEF patients.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71321" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71321" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Chemistry</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> General Procedures</h4><div class="NLM_p">Unless otherwise noted, all nonaqueous reactions were carried out under an argon atmosphere with commercial-grade reagents and solvents. All final products were at least 95% pure, as determined by analytical HPLC.</div><div class="NLM_p last"><sup>1</sup>H NMR spectra were recorded on Bruker Avance spectrometers operating at 400 or 500 MHz. Chemical shifts (δ) are reported in ppm relative to TMS as an internal standard, and coupling constants (<i>J</i>) are given in hertz (Hz). Spin multiplicities are reported as s = singlet, br s = broad singlet, d = doublet, dd = doublet of doublets, t = triplet, q = quartet, m = multiplet. LC-MS analysis was performed using the respective method a–d, as noted. Method a: instrument, Micromass TOF-MUX interface 4× parallel injection with Waters 600 HPLC; column, Phenomenex Synergi 2 μm Hydro-RP Mercury 20 mm × 4 mm; mobile phase A, H<sub>2</sub>O (1 L) + 50% formic acid (0.5 mL); mobile phase B, MeCN (1 L) + 50% formic acid (0.5 mL); gradient, 0.0 min 90% A → 2.5 min 30% A → 3.0 min 5%A → 4.5 min 5% A; oven, 20 °C; flow, 1 mL/min; UV detection, 210 nm. Method b: instrument, Micromass Quattro Premier with Waters Acquity UPLC; column, Thermo Hypersil GOLD 1.9 μm, 50 mm × 1 mm; mobile phase A, H<sub>2</sub>O (1 L) + 50% formic acid (0.5 mL); mobile phase B, MeCN (1 L) + 50% formic acid (0.5 mL); gradient, 0.0 min 90% A → 0.1 min 90% A → 1.5 min 10% A → 2.2 min 10% A; oven, 50 °C; flow, 0.33 mL/min; UV detection, 210 nm. Method c: instrument, Waters Micromass Quattro Micro with Agilent 1100 series HPLC; column, Thermo Hypersil GOLD 3 μm, 20 mm × 4 mm; mobile phase A, H<sub>2</sub>O (1 L) + 50% formic acid (0.5 mL); mobile phase B, MeCN (1 L) + 50% formic acid (0.5 mL); gradient, 0.0 min 100% A → 3.0 min 10% A → 4.0 min 10% A; ove,: 50 °C; flow, 2 mL/min; UV detection, 210 nm. Method d: instrument, Waters Acquity SQD UPLC system; column, Waters Acquity UPLC HSS T3 1.8 μm, 50 mm × 1 mm; mobile phase A, H<sub>2</sub>O (1 L) + 99% formic acid (0.25 mL); mobile phase B, MeCN (1 L) + 99% formic acid (0.25 mL); gradient, 0.0 min 90% A → 1.2 min 5% A → 2.0 min 5% A; oven, 50 °C; flow, 0.4 mL/min; UV detection, 208–400 nm.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> Materials</h4><div class="NLM_p last">Intermediates <b>1a</b>–<b>c</b>,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a><b>3b</b>,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a><b>4h</b>,<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> and compounds <b>1</b>,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a><b>2</b>,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a><b>4</b>–<b>8</b>,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a><b>9</b>,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a><b>10</b>,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a><b>11</b>–<b>14</b>,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a><b>15</b>–<b>18</b>,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a><b>19</b>,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a><b>20</b>,<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> and <b>23</b><a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> were synthesized according to the methods described previously.</div></div><div id="sec4_1_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Methyl {4,6-Diamino-2-[1-(2-fluorobenzyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-3-yl]pyrimidin-5-yl}(2-hydroxyethyl)carbamate (<b>3</b>)</h4><div class="NLM_p"><b>1c</b> (200 mg, 0.57 mmol) and AcOH (33 μL, 0.57 mmol) were dissolved in MeOH (20 mL), and the mixture was cooled to 0 °C. Then a solution of glycolaldehyde (34 mg, 0.57 mmol) in MeOH (20 mL) was added dropwise. After complete addition, the mixture was stirred for a further 15 min at 0 °C. Then NaBH<sub>3</sub>CN (50 mg, 0.80 mmol) was added portionwise. The mixture was stirred at rt for 20 h and then concentrated under reduced pressure. The residue was diluted with EtOAc and washed with concd aq NH<sub>4</sub>Cl solution. The organic layer was concentrated under reduced pressure, and the residue was purified by HPLC (MeCN/H<sub>2</sub>O gradient) to give 2-({4,6-diamino-2-[1-(2-fluorobenzyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-3-yl]pyrimidin-5-yl}amino)ethanol (<b>1d</b>) as a yellow solid. Yield 165 mg (73%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ = 9.04 (dd, <i>J</i> = 8.1, 1.7 Hz, 1H), 8.58 (dd, <i>J</i> = 4.7, 1.7 Hz, 1H), 7.27–7.39 (m, 2H), 7.22 (dd, <i>J</i> = 10.0, 8.8 Hz, 1H), 7.08–7.16 (m, 2H), 6.09 (br s, 4H), 5.77 (s, 2H), 4.77 (t, <i>J</i> = 5.1 Hz, 1H), 3.47 (td, <i>J</i> = 5.6, 5.1 Hz, 2H), 3.27 (t, <i>J</i> = 6.4 Hz, 1H), 2.83 (dt, <i>J</i> = 6.4, 5.6 Hz, 2H). LC-MS (method a): <i>t</i><sub>R</sub> (min) = 1.27. MS (EI+): <i>m</i>/<i>z</i> = 395 [M + H]<sup>+</sup>.</div><div class="NLM_p last"><b>1d</b> (265 mg, 0.67 mmol) was dissolved in pyridine (5.0 mL), and the solution was cooled to 0 °C. Methyl chloroformate (83 mg, 0.87 mmol) was added, and the mixture was stirred at rt overnight. Then, the mixture was concentrated under reduced pressure, and the residue was purified by preparative HPLC (H<sub>2</sub>O/MeCN/1% TFA 56:30:14) to give <b>3</b> as a white solid. Yield 37 mg (12%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ = 9.04 (dd, <i>J</i> = 8.0, 1.5 Hz, 1H), 8.59 (dd, <i>J</i> = 4.5, 1.5 Hz, 1H), 7.34–7.38 (m, 1H), 7.32 (dd, <i>J</i> = 8.0, 4.5 Hz, 1H), 7.22 (dd, <i>J</i> = 10.0, 8.8 Hz, 1H), 7.09–7.15 (m, 2H), 6.07 (br s, 4H), 5.78 (s, 2H), 4.14 (t, <i>J</i> = 5.7 Hz, 2H), 3.70 (s, 3H), 3.54 (t, <i>J</i> = 7.0 Hz, 1H), 3.00 (dt, <i>J</i> = 7.0, 5.7 Hz, 2H). LC-MS (method a): <i>t</i><sub>R</sub> (min) = 1.49. MS (EI+): <i>m</i>/<i>z</i> = 453 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 3-Bromo-1<i>H</i>-pyrazolo[3,4-<i>c</i>]pyridazine (<b>3c</b>)</h4><div class="NLM_p last">1<i>H</i>-Pyrazolo[3,4-<i>c</i>]pyridazin-3-ol<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> (<b>3b</b>; 18.00 g, 132.24 mmol) was dissolved in sulfolane (176 mL), and POBr<sub>3</sub> (39.81 g, 138.85 mmol) was then added to the solution. The mixture was stirred at 150 °C for 3 h. After being cooled to rt, the mixture was poured onto ice–water and extracted with EtOAc (3×). The combined organic extracts were washed with H<sub>2</sub>O and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated until a precipitate formed. The solids were collected by filtration and dried under reduced pressure. Yield 16.27 g (62%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ = 14.90 (br s, 1H), 9.23 (d, <i>J</i> = 5.6 Hz, 1H), 8.10 (d, <i>J</i> = 5.6 Hz, 1H). LC-MS (method b): <i>t</i><sub>R</sub> (min) = 1.15. MS (ESI+): <i>m</i>/<i>z</i> = 199 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 3-Bromo-1-(2-fluorobenzyl)-1<i>H</i>-pyrazolo[3,4-<i>c</i>]pyridazine (<b>3d</b>)</h4><div class="NLM_p last"><b>3c</b> (16.27 g, 81.75 mmol) and Cs<sub>2</sub>CO<sub>3</sub> (31.97 g, 98.10 mmol) were mixed in DMF (150 mL). A solution of 2-fluorobenzyl bromide (17.00 g, 89.93 mmol) in DMF (50 mL) was then added dropwise, and the mixture was stirred at rt overnight. The mixture was then diluted with EtOAc (500 mL) and washed with H<sub>2</sub>O (3×) and brine (1×). The organic phase was separated, dried over MgSO<sub>4</sub>, filtered, and concentrated. The residue was purified by flash column chromatography on silica gel (DCM/MeOH gradient). The obtained crude product was triturated with MTBE and DCM, collected by filtration, washed with MTBE, and dried under reduced pressure. Yield 11.36 g (45%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ = 9.30 (d, <i>J</i> = 5.6 Hz, 1H), 8.15 (d, <i>J</i> = 5.6 Hz, 1H), 7.35–7.44 (m, 2H), 7.16–7.28 (m, 2H), 5.96 (s, 2H). LC-MS (method c): <i>t</i><sub>R</sub> (min) = 1.11. MS (ESI+): <i>m</i>/<i>z</i> = 307 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 1-(2-Fluorobenzyl)-1<i>H</i>-pyrazolo[3,4-<i>c</i>]pyridazine-3-carbonitrile (<b>3e</b>)</h4><div class="NLM_p last"><b>3d</b> (1.00 g, 3.26 mmol) and CuCN (0.32 g, 3.58 mmol) were treated with anhyd DMSO (10 mL), and the mixture was stirred at 150 °C for 9 h. The mixture was brought to rt, then poured onto ice–water and treated with 25% aq NH<sub>4</sub>OH until all solids were dissolved (blue solution). The mixture was then extracted with EtOAc (3×). The combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by flash column chromatography on silica gel (cyclohexane/EtOAc 4:1) to give the crude product which was used without further purification. Yield 0.57 g (51%, purity 74%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ = 9.45 (d, <i>J</i> = 5.9 Hz, 1H), 8.50 (d, <i>J</i> = 5.9 Hz, 1H), 7.39–7.51 (m, 2H), 7.18–7.30 (m, 2H), 6.11 (s, 2H). LC-MS (method d): <i>t</i><sub>R</sub> (min) = 0.94. MS (ESI+): <i>m</i>/<i>z</i> = 254 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 1-(2-Fluorobenzyl)-1<i>H</i>-pyrazolo[3,4-<i>c</i>]pyridazine-3-carboximidamide (<b>3f</b>)</h4><div class="NLM_p last"><b>3e</b> (1.19 g, 4.70 mmol) and NaOMe (0.96 g, 17.86 mmol) were treated with anhyd MeOH (31 mL), and the mixture was stirred at rt for 2 h. NH<sub>4</sub>Cl (0.30 g, 5.64 mmol) and AcOH (1.05 mL) were then added, and the mixture was stirred under reflux overnight. The mixture was then concentrated, and the residue was taken up in EtOAc and 1 M aq NaOH. The organic phase was separated, washed with 1 M aq NaOH, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The solid residue was triturated with MTBE, collected by filtration, washed with DCM/MeOH (50:1), and dried under reduced pressure. Yellow solid; yield 0.43 g (34%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ = 9.26 (d, <i>J</i> = 5.1 Hz, 1H), 8.48 (d, <i>J</i> = 5.1 Hz, 1H), 7.38 (d, <i>J</i> = 5.9 Hz, 1H), 7.11–7.32 (m, 3H), 6.71 (br s, 2H), 5.99 (s, 2H). LC-MS (method c): <i>t</i><sub>R</sub> (min) = 0.52. MS (ESI+): <i>m</i>/<i>z</i> = 271 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 2-[1-(2-Fluorobenzyl)-1<i>H</i>-pyrazolo[3,4-<i>c</i>]pyridazin-3-yl]-5-[(<i>E</i>)-phenyldiazenyl]pyrimidine-4,6-diamine (<b>3i</b>)</h4><div class="NLM_p last">Aniline (0.202 mL, 2.22 mmol) was dissolved in H<sub>2</sub>O (2.0 mL), and the solution was cooled to 0 °C. Aqueous HCl (37%, 0.38 mL) was then added dropwise, followed by a solution of NaNO<sub>2</sub> (153 mg, 2.22 mmol) in H<sub>2</sub>O (0.5 mL). The mixture was stirred for an additional 15 min, and a solution of NaOAc (231 mg, 2.82 mmol) in H<sub>2</sub>O (0.5 mL) was then added dropwise followed by a solution of malononitrile (147 mg, 2.22 mmol) in EtOH (3.0 mL). The mixture was then stirred for an additional 2 h at 0 °C. The resulting precipitate was collected by filtration, washed with H<sub>2</sub>O (3×), and then dissolved in DMF (5.0 mL). In a separate flask, <b>3f</b> (599 mg, 2.22 mmol) was dissolved in DMF (5.0 mL), then Et<sub>3</sub>N (0.309 mL, 2.22 mmol) was added dropwise. The mixture was warmed to 85 °C, and the aforementioned DMF solution was added. The resulting mixture was stirred at 100 °C overnight then cooled to 0 °C and treated with H<sub>2</sub>O. The formed solids were collected by filtration, washed with H<sub>2</sub>O and MeOH, and dried to give 2-[1-(2-fluorobenzyl)-1<i>H</i>-pyrazolo[3,4-<i>c</i>]pyridazin-3-yl]-5-[(<i>E</i>)-phenyldiazenyl]pyrimidine-4,6-diamine as a yellow solid. Yield 0.68 g (68%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ = 9.35 (d, <i>J</i> = 5.4 Hz, 1H), 9.01 (d, <i>J</i> = 5.6 Hz, 1H), 8.54 (br s, 2H), 7.89–8.07 (m, <i>J</i> = 7.8 Hz, 4H), 7.45–7.54 (m, 2H), 7.31–7.44 (m, 3H), 7.16–7.30 (m, 2H), 6.06 (s, 2H). LC-MS (method d): <i>t</i><sub>R</sub> (min) = 1.08. MS (ESI+): <i>m</i>/<i>z</i> = 441 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 2-[1-(2-Fluorobenzyl)-1<i>H</i>-pyrazolo[3,4-<i>c</i>]pyridazin-3-yl]pyrimidine-4,5,6-triamine (<b>3h</b>)</h4><div class="NLM_p last"><b>3i</b> (300 mg, 0.68 mmol) was suspended in DMF (15 mL) and 10% Pd/C (58 mg) was added. The mixture was stirred in an H<sub>2</sub> atmosphere at ambient pressure overnight. The solids were collected by filtration and washed with MeOH and DCM, and the filtrate was concentrated under reduced pressure. The residue was triturated with DCM, and the solids were collected by filtration and dried under reduced pressure at 50 °C to give 2-[1-(2-fluorobenzyl)-1<i>H</i>-pyrazolo[3,4-<i>c</i>]pyridazin-3-yl]pyrimidine-4,5,6-triamine. The crude product was used without further purification. Yield 198 mg (74%, purity 90%). LC-MS (method d): <i>t</i><sub>R</sub> (min) = 1.08. MS (ESI+): <i>m</i>/<i>z</i> = 352 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 2-[8-(2-Fluorobenzyl)imidazo[1,5-<i>a</i>]pyrimidin-6-yl]-5-[(<i>E</i>)-phenyldiazenyl]pyrimidine-4,6-diamine (<b>4i</b>)</h4><div class="NLM_p last">8-(2-Fluorobenzyl)imidazo[1,5-<i>a</i>]pyrimidine-6-carboximidamide<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> (<b>4h</b>; 70% purity, 1.30 g, 3.40 mmol) was mixed with DMF (24.6 mL) and Et<sub>3</sub>N (0.52 mL, 3.74 mmol). At 85 °C, a solution of [(<i>E</i>)-phenyldiazenyl]malononitrile (<b>1b</b>; 694 mg, 4.08 mmol) in DMF (12.0 mL) was added dropwise and the mixture was stirred for an additional 15 h at 100 °C. The resulting mixture was then poured into H<sub>2</sub>O (300 mL), and the resulting precipitate was collected by filtration, washed with H<sub>2</sub>O, and dried. Then, MeCN (160 mL) was added and the remaining solids were collected by filtration and dried again to give 2-[8-(2-fluorobenzyl)imidazo[1,5-<i>a</i>]pyrimidin-6-yl]-5-[(<i>E</i>)-phenyldiazenyl]pyrimidine-4,6-diamine. Yield 419 mg (28%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ = 10.23–10.31 (m, 1H), 9.42 (br s, 1H), 8.60–8.66 (m, 1H), 8.12 (d, <i>J</i> = 7.6 Hz, 2H), 7.51–7.58 (m, 2H), 7.44–7.50 (m, 1H), 7.23–7.36 (m, 3H), 7.15–7.23 (m, 1H), 7.08–7.15 (m, 1H), 4.44 (s, 2H). LC-MS (method c): <i>t</i><sub>R</sub> (min) = 1.14. MS (ESI+): <i>m</i>/<i>z</i> = 440 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 2-[8-(2-Fluorobenzyl)imidazo[1,5-<i>a</i>]pyrimidin-6-yl]pyrimidine-4,5,6-triamine (<b>4j</b>)</h4><div class="NLM_p last"><b>4i</b> (100 mg, 0.228 mmol) was dissolved in DMF (11.4 mL) and MeOH (2.9 mL). The solution was cooled with ice, and then 10% Pd/C (20 mg) was added. The mixture was stirred at 0 °C under 1 atm of H<sub>2</sub> for 48 h. The resulting mixture was filtered through Celite, and the solids were washed with MeOH. The combined filtrate was concentrated under reduced pressure to give crude 2-[8-(2-fluorobenzyl)imidazo[1,5-<i>a</i>]pyrimidin-6-yl]pyrimidine-4,5,6-triamine, which was purified by preparative reversed-phase HPLC (H<sub>2</sub>O + 0.1% NH<sub>3</sub>/MeCN gradient). Brown solid; yield 36 mg (45%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ = 10.13 (br d, <i>J</i> = 7.4 Hz, 1H), 8.20 (br d, <i>J</i> = 3.9 Hz, 1H), 7.19–7.31 (m, 2H), 7.04–7.17 (m, 2H), 6.81 (dd, <i>J</i> = 3.7, 7.6 Hz, 1H), 5.89 (s, 4H), 4.27 (s, 2H), 4.06 (s, 2H). LC-MS (method d): <i>t</i><sub>R</sub> (min) = 0.74. MS (ESI+): <i>m</i>/<i>z</i> = 351 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 4-(2,2,3,3-Tetrafluoropropyl)morpholine (<b>6b</b>)</h4><div class="NLM_p">Tf<sub>2</sub>O (252.5 g, 0.895 mol) was heated to 40 °C and, at this temperature, 2,2,3,3-tetrafluoro-1-propanol (<b>6a</b>; 130.0 g, 0.984 mol) was metered in while cooling. After the addition was completed, the mixture was heated to 70–75 °C and stirred for 2 h. Then the mixture was cooled to 20 °C, and the reaction solution of 2,2,3,3-tetrafluoropropyl trifluoromethanesulfonate was used without further purification.</div><div class="NLM_p last">Morpholine (158.5 g, 1.82 mol) was cooled to 5 °C. At 5–10 °C, the reaction solution of the triflate (189.5 g, max 0.455 mol) was added dropwise while cooling and then the mixture was stirred at 5–10 °C for 30 min. Then, the mixture was heated to 40 °C and stirred for 1 h. After cooling to 20 °C, H<sub>2</sub>O (160 mL) and toluene (160 mL) were added and the phases were separated. The organic phase was washed with H<sub>2</sub>O (160 mL) and concentrated on a rotary evaporator at 50 °C/50 mbar. The residue (81.0 g) was distilled at 67–68 °C/18 mbar to give <b>6b</b>. Yield 77.0 g (84%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ = 5.83–6.22 (m, 1H), 3.61–3.78 (m, 4H), 2.89 (tt, <i>J</i> = 14.0, 1.7 Hz, 2H), 2.53–2.70 (m, 4H).</div></div><div id="sec4_1_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 4-Methyl-4-(2,2,3,3-tetrafluoropropyl)morpholin-4-ium Methanesulfonate (<b>6c</b>)</h4><div class="NLM_p last">Methylmethanesulfonate (143.7 g, 1.31 mol) was heated to 135 °C and, at this temperature, <b>6b</b> (250.0 g, 1.24 mol) was added dropwise. The mixture was stirred at 100 °C for 22 h, then cooled to 85 °C and <i>i</i>-PrOH (375 mL) was added. After cooling to 0–5 °C, the mixture was stirred for a further 30 min. The product was collected by suction filtration, washed with <i>i</i>-PrOH (3 × 125 mL), and dried at 45 °C under a gentle N<sub>2</sub> stream in a vacuum drying cabinet. Yield 336.8 g (87%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O): δ = 6.13–6.48 (m, 1H), 4.33–4.51 (m, 2H), 4.01–4.24 (m, 4H), 3.68–3.93 (m, 4H), 3.55 (s, 3H), 2.81 (s, 3H).</div></div><div id="sec4_1_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 4-Methyl-4-(2,3,3-trifluoroprop-1-enyl)morpholin-4-ium Methanesulfonate (<b>6d</b>)</h4><div class="NLM_p last">First, 45% aq NaOH (16.9 g, 189.9 mmol) was metered into a solution of <b>6c</b> (53.8 g, 172.7 mol) in H<sub>2</sub>O (40 mL) at 50–55 °C, and the mixture was stirred at 50 °C for 1 h then cooled to 20 °C. Then the precipitated salts were removed by suction filtration and washed with H<sub>2</sub>O (5 mL). The aqueous solution of product <b>6d</b> (102.1 g, max 172.7 mmol) was used in the next stage. For analytical purposes, a sample was concentrated and dried. <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O): δ = 6.74–6.83 (m, 1H), 6.39–6.69 (m, 1H), 4.12–4.20 (m, 2H), 3.97–4.09 (m, 4H), 3.76–3.85 (m, 2H), 3.59 (s, 3H), 2.81 (s, 3H).</div></div><div id="sec4_1_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 2-Fluoro-3-(morpholin-4-yl)acrylaldehyde (<b>6e</b>)</h4><div class="NLM_p last">A mixture of morpholine (30.2 g, 345.3 mmol) and Et<sub>3</sub>N (52.5 g, 518.0 mmol) was heated to 75 °C, and the aqueous solution of <b>6d</b> (max 172.7 mmol) was added dropwise at 75–80 °C. The mixture was stirred under reflux for 2 h, cooled to 23 °C, and washed with DCM (100 mL). The aqueous phase was washed twice with DCM/Et<sub>3</sub>N (100:15, 115 mL), and the combined organic phases were washed with satd aq K<sub>2</sub>CO<sub>3</sub> solution (85 mL) and concentrated under reduced pressure at 45–50 °C. Toluene (120 mL) was added, then toluene (60 mL) was distilled off. The suspension was stirred at rt overnight, and the product was collected by suction filtration and dried at 50 °C under a gentle N<sub>2</sub> stream in a vacuum drying cabinet. Yield 19.2 g (68%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ = 8.59 (d, <i>J</i> = 18.9 Hz, 1H), 6.16 (d, <i>J</i> = 27.1 Hz, 1H), 3.72–3.83 (m, 4H), 3.51–3.60 (m, 4H).</div></div><div id="sec4_1_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Ethyl 5-Fluoro-1-(2-fluorobenzyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine-3-carboxylate (<b>6f</b>)</h4><div class="NLM_p last">Ethyl 5-amino-1-(2-fluorobenzyl)-1<i>H</i>-pyrazole-3-carboxylate<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> (22.3 g, 84.8 mmol) was initially charged into EtOH (59.5 mL), and MsOH (11.0 mL, 169.6 mmol), LiCl (9.0 g, 212.1 mmol), and <b>6e</b> (15.0 g, 84.8 mmol) were added at rt. The mixture was stirred under reflux for 4.5 h. After cooling to rt, the product was collected by suction filtration, washed with EtOH (2 × 4.5 mL), and stirred with H<sub>2</sub>O (325 mL) for 1 h. The solids were collected by suction filtration, washed with H<sub>2</sub>O (2 × 11.5 mL), and dried at 50 °C under a gentle N<sub>2</sub> stream in a vacuum drying cabinet. Yield 21.8 g (81%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ = 8.51 (dd, <i>J</i> = 2.7, 1.7 Hz, 1H), 8.15 (dd, <i>J</i> = 7.7, 2.8 Hz, 1H), 7.19–7.33 (m, 1H), 6.93–7.16 (m, 3H), 5.88 (s, 2H), 4.52 (q, <i>J</i> = 7.2 Hz, 2H), 1.48 (t, <i>J</i> = 7.2 Hz, 3H). MS (ESI+): <i>m</i>/<i>z</i> = 318 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_2_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 5-Fluoro-1-(2-fluorobenzyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine-3-carboxamide (<b>6g</b>)</h4><div class="NLM_p last">EtOH (10 mL), formamide (14.9 mL, 441.2 mmol), and 30% NaOMe in MeOH (3.6 g, 19.8 mmol) were added to <b>6f</b> (7.0 g, 22.1 mmol). The reaction mixture was heated to 95–100 °C, and the volatile solvents were distilled off by a downward distillation within 1 h. The mixture was stirred at 125 °C for 1.5 h, H<sub>2</sub>O (30 mL) was added, and the resulting mixture was cooled to rt and stirred for 1 h. The precipitated solids were collected by suction filtration, washed with H<sub>2</sub>O (3 × 8.5 mL), and dried at 45 °C under a gentle N<sub>2</sub> stream in a vacuum drying cabinet. Yield 6.2 g (97%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ = 8.72 (dd, <i>J</i> = 2.7, 1.7 Hz, 1H), 8.28 (dd, <i>J</i> = 8.3, 2.8 Hz, 1H), 7.87 (br s, 1H), 7.60 (br s, 1H), 7.34–7.40 (m, 1H), 7.12–7.26 (m, 3H), 5.87 (s, 2H). MS (ESI+): <i>m</i>/<i>z</i> = 289 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_2_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 5-Fluoro-1-(2-fluorobenzyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine-3-carbonitrile (<b>6h</b>)</h4><div class="NLM_p last"><b>6g</b> (17.3 g, 60.0 mmol) was heated to 103–107 °C in sulfolane (40.5 mL) and MeCN (5.4 mL). POCl<sub>3</sub> (6.9 g, 45.0 mmol) was slowly added dropwise while stirring, the dropping funnel was rinsed with MeCN (2.8 mL), and then the mixture was stirred at 107 °C for 1.5 h until conversion was complete (HPLC). Then the mixture was cooled to rt and sulfolane/MeCN (5:1, 2.8 mL) and then H<sub>2</sub>O (17.8 mL) were added dropwise. The mixture was stirred for 0.5 h, a solution of aq NH<sub>3</sub> (28%, 9.4 g) in H<sub>2</sub>O (22.7 mL) was added dropwise, and the resulting mixture was stirred for a further 2 h. The precipitated solids were collected by suction filtration, washed with H<sub>2</sub>O (3 × 20.5 mL), and dried at 50 °C under a gentle N<sub>2</sub> stream in a vacuum drying cabinet. Yield 14.7 g (92%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ = 8.87 (dd, <i>J</i> = 2.6, 1.7 Hz, 1H), 8.52 (dd, <i>J</i> = 8.1, 2.6 Hz, 1H), 7.17–7.42 (m, 4H), 5.87 (s, 2H). MS (ESI+): <i>m</i>/<i>z</i> = 271 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_2_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 5-Fluoro-1-(2-fluorobenzyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine-3-carboximidamide Hydrochloride (<b>6i</b>)</h4><div class="NLM_p last"><b>6h</b> (406.0 g, 1.50 mol) was suspended in EtOH (2.08 L). Then, 30% NaOMe in MeOH (54.1 g, 0.30 mol) was added and the mixture was stirred at rt overnight. NH<sub>4</sub>Cl (88.4 g, 1.65 mol) was added, and the mixture was heated to 65 °C and stirred at 65 °C for 3.5 h. The solvents were distilled off, and the residue was stirred with EtOAc (1.60 L) overnight. The precipitated solids were collected by suction filtration, washed with EtOAc (2 × 140 mL), and dried at 50 °C under a gentle N<sub>2</sub> stream in a vacuum drying cabinet. Yield 441.4 g (91%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ = 9.35 (br s, 3H), 8.86 (dd, <i>J</i> = 2.5, 1.5 Hz, 1H), 8.48 (dd, <i>J</i> = 8.8, 2.6 Hz, 1H), 7.36–7.43 (m, 1H), 7.29–7.35 (m, 1H), 7.22–7.28 (m, 1H), 7.15–7.20 (m, 1H), 5.90 (s, 2H). MS (ESI+): <i>m</i>/<i>z</i> = 288 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_2_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 2-[5-Fluoro-1-(2-fluorobenzyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-3-yl]-5-[(<i>E</i>)-phenyldiazenyl]pyrimidine-4,6-diamine (<b>6j</b>)</h4><div class="NLM_p last">Concd HCl (262 g, 2.59 mol) and H<sub>2</sub>O (117.5 mL) were added dropwise at 0–5 °C to H<sub>2</sub>O (1.525 L) and aniline (117.5 g, 1.26 mol). Then, a solution of NaNO<sub>2</sub> (87.1 g, 1.26 mol) in H<sub>2</sub>O (222.5 mL) was added dropwise within 1 h, the dropping funnel was rinsed with H<sub>2</sub>O (60 mL), and the mixture was stirred at 0–5 °C for 15 min. Thereafter, at this temperature, a solution of NaOAc (131.4 g, 1.60 mol) in H<sub>2</sub>O (665 mL) was added dropwise within 45 min, the dropping funnel was rinsed with H<sub>2</sub>O (60 mL), and a solution of malononitrile (83.4 g, 1.26 mol) in EtOH (233 mL) was added dropwise within 1 h. The dropping funnel was rinsed with EtOH (68.5 mL), and the mixture was further stirred at 0–5 °C for 2 h. The yellow solids were collected by suction filtration and washed with H<sub>2</sub>O (3 × 625 mL) and cold toluene (488 mL). The still-moist residue was dissolved in DMF (872 g), which gave a DMF solution of [(<i>E</i>)-phenyldiazenyl]malononitrile (1.117 kg). <b>6i</b> (30.0 g, 92.7 mmol) was suspended in DMF (72 mL). The mixture was heated to 100 °C, and a mixture of Et<sub>3</sub>N (14.2 mL, 101.9 mmol) and the DMF solution of [(<i>E</i>)-phenyldiazenyl]malononitrile (150 g) was added dropwise at this temperature within 30 min. The dropping funnel was rinsed with DMF (30 mL), and the mixture was further stirred at 100 °C for 20 h. Then, it was cooled to 95–90 °C, H<sub>2</sub>O (24 mL) was added dropwise within 10 min, and the resulting mixture was cooled to 0–5 °C within 1.5 h and stirred for 1 h. The solids were collected by suction filtration, washed with H<sub>2</sub>O (60 mL)/DMF (63 mL), twice with H<sub>2</sub>O (50 mL)/MeOH (63 mL), and then with MeOH (63 mL), suction-dried, and then dried at 50 °C under a gentle N<sub>2</sub> stream in a vacuum drying cabinet. Yield 35.5 g (84%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ = 9.03 (dd, <i>J</i> = 8.8, 2.8 Hz, 1H), 8.65–8.77 (m, 1H), 8.50 (br s, 2H), 8.02 (d, <i>J</i> = 7.6 Hz, 2H), 7.86–7.98 (m, 2H), 7.44–7.57 (m, 2H), 7.32–7.44 (m, 2H), 7.11–7.31 (m, 3H), 5.84 (s, 2H). LC-MS (method d): <i>t</i><sub>R</sub> (min) = 1.15. MS (ESI+): <i>m</i>/<i>z</i> = 458 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_2_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 2-[5-Fluoro-1-(2-fluorobenzyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-3-yl]pyrimidine-4,5,6-triamine (<b>6k</b>)</h4><div class="NLM_p last"><b>6j</b> (182.0 g, 0.39 mol) was initially charged into DMF (1.82 L), and then 5% Pd/C (50% water-moist, 4.2 g) was added. Hydrogenation was effected at 60 °C and H<sub>2</sub> pressure of 60 bar while stirring overnight. The mixture was filtered through kieselguhr, and the solids were washed thoroughly with DMF (150 mL) and then with MeOH (150 mL). The filtrate was concentrated at 60–70 °C to a weight of 425 g of distillation residue. The residue was heated to 75–80 °C, MeOH (300 mL) was added dropwise at this temperature, and the mixture was stirred for 15 min. The mixture was cooled to rt within 1 h, then H<sub>2</sub>O (1.29 L) was added dropwise and the mixture was stirred overnight. The solids were collected by suction filtration, washed with H<sub>2</sub>O (2 × 500 mL), suction-dried, and then dried at 50 °C under a gentle N<sub>2</sub> stream in a vacuum drying cabinet. Yield 159.7 g. For analytical purposes, a sample was purified by chromatography on silica gel (DCM/MeOH 9:1). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ = 8.85 (dd, <i>J</i> = 9.0, 2.9 Hz, 1H), 8.62 (dd, <i>J</i> = 2.8, 1.7 Hz, 1H), 7.32–7.39 (m, 1H), 7.10–7.26 (m, 3H), 5.86 (br s, 4H), 5.75 (s, 2H), 4.04 (br s, 2H). MS (ESI+): <i>m</i>/<i>z</i> = 369 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_2_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> Methyl {4,6-Diamino-2-[1-(2-fluorobenzyl)-1<i>H</i>-pyrazolo[3,4-<i>c</i>]pyridazin-3-yl]pyrimidin-5-yl}carbamate Formic Acid Salt (<b>21</b>)</h4><div class="NLM_p last">The crude intermediate (<b>3h</b>: 198 mg, 0.51 mmol) was treated with pyridine (15.0 mL), and the mixture was cooled to 0 °C. Next, a solution of methyl chloroformate (43.6 μL, 0.57 mmol) in DCM (1.0 mL) was slowly added and the mixture was stirred at rt for 3 d. Additional methyl chloroformate (0.1 equiv) in DCM (1.0 mL) was added at 0 °C, and the mixture was stirred for a further 30 min at rt. The reaction mixture was then concentrated, and the residue was treated with MeCN. The resulting suspension was filtered, and the filtrate was concentrated. The residue was purified by preparative reversed-phase HPLC (H<sub>2</sub>O + 0.05% formic acid/MeOH gradient) to give <b>21</b> as a white solid. Yield 72 mg (33%, purity 97%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ = 9.28 (d, <i>J</i> = 5.4 Hz, 1H), 8.88 (d, <i>J</i> = 5.6 Hz, 1H), 8.15 (s, 1H), 7.95–8.06 (m, 1H), 7.34–7.43 (m, 1H), 7.12–7.33 (m, 4H), 6.17–6.32 (m, 4H), 6.01 (s, 2H), 3.62 (s, 3H). LC-MS (method d): <i>t</i><sub>R</sub> (min) = 0.66. MS (ESI+): <i>m</i>/<i>z</i> = 410 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_2_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> Methyl {4,6-Diamino-2-[8-(2-fluorobenzyl)imidazo[1,5-<i>a</i>]pyrimidin-6-yl]pyrimidin-5-yl}carbamate (<b>22</b>)</h4><div class="NLM_p last"><b>4j</b> (45 mg, 0.128 mmol) was dissolved in pyridine (3.46 mL), and the solution was cooled to 0 °C. Then, methyl chloroformate (12.9 μL, 0.167 mmol) was added and the mixture was stirred for an additional 5 min at 0 °C and for 19 h at rt. The resulting mixture was concentrated under reduced pressure to a volume of 1.5 mL, and the residue was purified by preparative reversed-phase HPLC (H<sub>2</sub>O + 0.1% NH<sub>3</sub>/MeCN gradient) to give <b>22</b> as a yellow solid. Yield 24 mg (45%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ = 10.22 (d, <i>J</i> = 7.15 Hz, 1H), 8.28 (d, <i>J</i> = 3.8 Hz, 1H), 7.97 (br s, 0.65 H), 7.67 (br s, 0.35 H), 7.20–7.29 (m, 2H), 7.11–7.18 (m, 1H), 7.05–7.11 (m, 1H), 6.89 (dd, <i>J</i> = 3.7, 7.3 Hz, 1H), 6.24 (br s, 4H), 4.30 (s, 2H), 3.61 (br s, 3H). LC-MS (method d): <i>t</i><sub>R</sub> (min) = 0.73. MS (ESI+): <i>m</i>/<i>z</i> = 409 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_2_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> Methyl {4,6-Diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-3-yl]pyrimidin-5-yl}carbamate (<b>24</b>)</h4><div class="NLM_p last"><b>6k</b> (77% by weight, 4.0 g, 8.36 mmol) in <i>i</i>-PrOH (37.9 mL) was heated to 35 °C, and then methyl chloroformate (0.84 mL, 10.87 mmol) was added dropwise. The mixture was stirred at 35–40 °C for 20 h, heated to 50 °C, and MeOH (9.5 mL) was added. Then, Et<sub>3</sub>N (1.9 mL) was added dropwise within 0.5 h, the dropping funnel was rinsed with MeOH (1.3 mL), and the resulting mixture was stirred at 50 °C for 1 h. Thereafter, the mixture was cooled to rt and stirred at rt for 1 h. The solids were collected by suction filtration, washed with EtOH (3 × 8 mL), suction-dried, and then dried at 50 °C under a gentle N<sub>2</sub> stream in a vacuum drying cabinet. Yield 3.4 g of crude product. The crude product (3.0 g) was stirred in DMSO (8 mL) for 5 min, EtOAc (13.0 mL) and activated carbon (50 mg) were added, and the mixture was heated under reflux (84 °C) for 15 min. The suspension was hot-filtered, and the filter residue was washed with EtOAc (1.9 mL). EtOAc (60 mL) and EtOH (16 mL) were heated to 60 °C, the combined filtrates were added dropwise, and the resulting mixture was stirred at 60 °C for 1.5 h. The suspension was cooled to rt within 25 min, stirred for a further 1.5 h, cooled further to 0–5 °C, and stirred for a further 1 h. The solids were collected by suction filtration, washed with EtOAc (2 × 6.4 mL), suction-dried, and then dried at 50 °C under a gentle N<sub>2</sub> stream in a vacuum drying cabinet to give <b>24</b>. Yield 2.2 g (70%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ = 8.89 (dd, <i>J</i> = 9.0, 2.8 Hz, 1H), 8.66 (m, 1H), 7.99 and 7.67 (2 br s, 1H), 7.32–7.40 (m, 1H), 7.19–7.26 (m, 1H), 7.10–7.19 (m, 2H), 6.22 (br s, 4H), 5.79 (s, 2H), 3.62 (br s, 3H). LC-MS (method d): <i>t</i><sub>R</sub> (min) = 0.79. MS (ESI+): <i>m</i>/<i>z</i> = 427 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> Biology</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> General</h4><div class="NLM_p last">Animal experiments were conducted in accordance with the German animal welfare laws, approved by local authorities, and in accordance with the ethical guidelines of Bayer AG.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> CYP Inhibition Assay</h4><div class="NLM_p last">The inhibitory potency of <b>24</b> was assessed in vitro by means on formation of metabolites from standard probes mediated by CYP isoforms (for details, please refer to the <a href="/doi/suppl/10.1021/acs.jmedchem.7b00449/suppl_file/jm7b00449_si_001.pdf" class="ext-link">Supporting Information</a>) based on assay conditions described.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> To investigate time-dependency, preincubation experiments on CYP3A4 were performed.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a></div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> In Vitro Clearance Determinations with Rat and Human Hepatocytes</h4><div class="NLM_p">Incubations with hepatocytes were performed at 37 °C, pH 7.4, in a total volume of 1.5 mL using a modified Janus robotic system (PerkinElmer). The incubation mixtures contained 1 × 10<sup>6</sup> cells/mL (corrected, according to the viability of the cells, determined via microscopy after staining with trypan blue), 1 μM substrate, and Williams’ medium E (Sigma, product no. W1878). The final MeCN concentration was ≤1%. Aliquots of 125 μL were withdrawn from the incubation mixture after 2, 10, 20, 30, 50, 70, and 90 min and dispensed in a 96-well plate, containing MeCN (250 μL) to stop the reaction. After centrifugation at 1000<i>g</i>, supernatants were analyzed by LC-MS/MS (AB Sciex Triple Quad 5500).</div><div class="NLM_p last">The calculation of in vitro clearance values from half-life data using hepatocytes, reflecting substrate depletion, was performed using the following equations: CL′<sub>intrinsic</sub> [mL/(min·kg)] = (0.693/in vitro <i>t</i><sub>1/2</sub> [min]) (liver weight [g liver/kg body mass]) (cell no. [1.1 × 10<sup>8</sup>]/liver weight [g])/(cell no. [1 × 10<sup>6</sup>]/incubation volume [mL]). The CL<sub>blood</sub> was estimated using the nonrestricted well-stirred model: CL<sub>blood</sub> well-stirred [L/(h·kg)] = (Q<sub>H</sub> [L/(h·kg)]·CL′<sub>intrinsic</sub> [L/(h·kg)])/(Q<sub>H</sub>[L/(h·kg)] + CL′<sub>intrinsic</sub> [L/(h·kg)]). For calculations, the following values were used: human specific liver weight of 21 g/kg body mass, hepatic blood flow of 1.32 L/(h·kg), cell number in the liver was estimated to be 1.1 × 10<sup>8</sup> cells/g liver; rat specific liver weight of 32 g/kg body mass, hepatic blood flow of 4.2 L/(h·kg), cell number in the liver was estimated to be 1.1 × 10<sup>8</sup> cells/g liver.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> Caco-2 Permeability Assay</h4><div class="NLM_p last">The in vitro permeation of test compounds across a Caco-2 cell monolayer, a well-established in vitro system to predict the permeability from the gastrointestinal tract, was tested according to Artursson and Karlsson.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Caco-2 cells (ACC 169, DSMZ, German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany) were seeded on 24-well insert plates and were allowed to grow for 14–16 d. For permeability studies, the test compounds were dissolved in DMSO and diluted to the final test concentration of 2 μM with transport buffer [Hanks’ Buffered Salt Solution, Gibco/Invitrogen, further supplemented with glucose (final concentration 19.9 mM) and HEPES (final concentration 9.8 mM)]. For determination of the apical to basolateral permeability (<i>P</i><sub>app</sub> A–B), the test compound solution was added to the apical side of the cell monolayer and transport buffer to the basolateral side of the monolayer. For determination of the basolateral to apical permeability (<i>P</i><sub>app</sub> B–A), the test compound solution was added to the basolateral side of the cell monolayer and transport buffer to the apical side of the monolayer. Samples were taken from the donor compartment at the beginning of the experiment to confirm mass balance. After an incubation of 2 h at 37 °C, samples were taken from both compartments. Samples were analyzed by LC-MS, and the apparent permeability coefficients were calculated. The efflux ratio was calculated as <i>P</i><sub>app</sub> B–A/<i>P</i><sub>app</sub> A–B. Lucifer yellow permeability was assayed for each cell monolayer to ensure cell monolayer integrity, and the permeability of atenolol (low permeability marker) and sulfasalazine (marker for active excretion) was determined for each batch as a quality control.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> Pharmacokinetic Parameters after Intravenous and Oral Application in Rats and Dogs</h4><div class="NLM_p">For in vivo pharmacokinetic experiments, male Wistar rats and female beagle dogs were used. Intravenous application was carried out with a species-specific plasma/DMSO formulation in rats and with a H<sub>2</sub>O/PEG 400/EtOH formulation in dogs. Oral application in both species was by gavage with a H<sub>2</sub>O/PEG 400/EtOH formulation. For simplification of blood drawing in rats, a silicone catheter was implanted into the right vena jugularis externa. The surgery was performed at least 1 d before substance application under isoflurane anesthesia and additional administration of an analgetic (atropine/rimadyl 3:1, 0.1 mL sc). Blood drawing (usually more than 10 time points) was done in a time window that included at least two time points after 24 h (postsubstance application). Blood was passed into heparinized tubes. Afterward, blood plasma was obtained by centrifugation at 1000<i>g</i>. Where necessary, the plasma was stored at −20 °C until further analysis.</div><div class="NLM_p">An internal standard was added to the sample, calibration, and qualifier solutions. The internal standard could also have been a compound from a different chemical class than the analyte of interest. Afterward, protein precipitation was performed by using an excess of MeCN. A buffer solution was added with a composition based on the mobile phases used in subsequent liquid chromatography. After centrifugation at 1000<i>g</i>, the supernatant was analyzed by LC-MS using different C18 reversed-phase columns and various mobile phase compositions. Quantification of the substance was conducted by using peak height or area calculated from extracted ion chromatograms of specific selected ion-monitoring experiments or high-resolution LC-MS experiments.</div><div class="NLM_p">From the plasma concentration–time course, the pharmacokinetic parameters CL (clearance), <i>t</i><sub>1/2</sub> (terminal half-life), <i>V</i><sub>SS</sub> (volume of distribution at steady state), and <i>F</i> (bioavailability after oral administration) were calculated by using a validated internal pharmacokinetic calculation software.</div><div class="NLM_p last">Because substance quantification was done in plasma, the blood/plasma distribution needed to be analyzed to calculate a blood clearance value. Therefore, a defined amount of the substance was added to blood in heparinized tubes and incubated for 20 min by gently swinging. The plasma was obtained by centrifugation at 1000<i>g</i>. The <i>c</i><sub>blood</sub>/<i>c</i><sub>plasma</sub> value was calculated after measurement of the substance concentration in plasma and blood by using peak height or area calculated from extracted ion chromatograms of specific selected ion-monitoring experiments or high-resolution LC-MS experiments.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> Highly Purified sGC</h4><div class="NLM_p last">Enzyme activity was measured by the formation of [<sup>32</sup>P]-cGMP from α-[<sup>32</sup>P]-GTP, modified according to Hoenicka et al.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> and Schermuly et al.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> The modifications included using GTP, Mn<sup>2+</sup>/Mg<sup>2+</sup>, and cGMP at concentrations of 200 μM, 3 mM, and 1 mM, respectively. Enzyme concentrations were chosen carefully to achieve a substrate turnover of less than 10%, thus avoiding substrate or cofactor depletion. The characterization of the purified enzyme was performed at a protein concentration of 0.2 μg/mL. All measurements were performed in duplicate and were repeated five times. For enzyme characterization, the specific activity of sGC was expressed as <i>x</i>-fold stimulation vs specific basal activity. The highest DMSO concentration in the assay was 1% (v/v) and did not elicit any effect per se on cGMP production.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> Recombinant sGC-Overexpressing Cell Line</h4><div class="NLM_p last">The cellular activity of the test compounds was determined using a recombinant sGC-overexpressing cell line, as previously described.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Briefly, cells were plated in a volume of 25 μL on white 384-well Greiner Bio-One microplates and were cultured for 1 or 2 d in medium. Medium was removed, and cells were loaded for 3 h with calcium-free Tyrode-containing coelenterazine. Serial dilutions of the test compounds in a volume of 10 μL in calcium-free Tyrode were applied to the cells for 6 min. Thereafter, 35 μL of Tyrode-containing calcium (final concentration: 3 mM) was added to the cells and the emitted light was measured for 40 s using a CCD camera in a light-tight box. The minimal effective concentration (MEC) was determined as the concentration where a ≥3-fold increase in the basal luminescence value was observed.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> Isolated Vessels and Tolerance</h4><div class="NLM_p last">The relaxing effects of <b>24</b> on aortas, saphenous arteries, coronary arteries, and veins, as well as the investigation on aortic rings taken from either normal or nitrate-tolerant rabbits, were performed as previously described.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> Rat Heart Langendorff Preparation</h4><div class="NLM_p last">Male Wistar rats (200–250 g) were anesthetized using Narcoren (100 mg/kg ip). The heart was rapidly excised and connected to a Langendorff perfusion system (FMI GmbH, Seeheim-Ober Beerbach, Germany). The heart was perfused at a constant flow rate of 10 mL/min with Krebs–Henseleit buffer solution equilibrated with 95% O<sub>2</sub> and 5% CO<sub>2</sub>. The perfusion solution contained (in mmol/L): NaCl 118, KCl 3, NaHCO<sub>3</sub> 22, KH<sub>2</sub>PO<sub>4</sub> 1.2, MgSO<sub>4</sub> 1.2, CaCl<sub>2</sub> 1.8, glucose 10, and sodium pyruvate 2. A pressure transducer registered the perfusion pressure in the system. The left ventricular pressure was measured using a second pressure transducer connected to a water-filled balloon which was inserted into the left ventricle via the left atrium. The end diastolic pressure was initially set to 8–10 mmHg by adjusting the volume of the balloon. The hearts were spontaneously beating. The signals from the pressure transducer were amplified, registered, and used for the calculation of the heart frequency and + d<i>P</i>/d<i>t</i><sub>max</sub> by a personal computer. <b>24</b> was dissolved in a mixture of 10% DMSO and 90% saline and infused for 20 min with increasing concentration steps into the aortic cannula at a rate of 1% of the total flow rate. All values are presented as relative changes of baseline values before compound application.</div></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> Chronic Treatment Study with L-NAME-Treated Renin Transgenic Rats</h4><div class="NLM_p last">Fifty male renin transgenic rats carrying an additional mouse renin gene [RenTG(mRRen2)27] at the age of 8 weeks were used. L-NAME was chronically administered via the drinking water (50 mg/L) in all study groups. Animals were randomly allocated to three study groups: placebo (control) (<i>n</i> = 20), <b>24</b> low dose, and <b>24</b> high dose (3 and 10 mg/kg per day, respectively, administered po by gavage qd, <i>n</i> = 15 per group). Blood pressure was measured via the tail-cuff method once before the start of the study (day 0) to exclude preexisting differences between the groups and on day 7, 14, and 21. Body weight and survival were assessed on day 1, 8, and 15 and at the study end. At the end of the study (day 22), all animals were anesthetized, blood was collected, and animals were sacrificed; blood was taken in order to assess plasma parameters, and the heart was dissected into the left and right ventricles and was weighed to assess potential heart hypertrophy. Creatinine, urea, and renin activity in plasma were determined after extraction, as previously described.<a onclick="showRef(event, 'ref39 ref56'); return false;" href="javascript:void(0);" class="ref ref39 ref56">(39, 56)</a></div></div><div id="sec4_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> Statistics</h4><div class="NLM_p last">The unpaired <i>t</i> test was used to detect significant differences between the groups of interest. Results (mean ± SEM) were considered significant when the probability error (<i>P</i>) was less than 0.05, 0.01,and 0.001 for *, **, and ***, respectively.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i65"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00449">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56542" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56542" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b00449" class="ext-link">10.1021/acs.jmedchem.7b00449</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline"><sup>1</sup>H NMR spectra of selected compounds <b>3</b>, <b>21</b>, <b>22</b>, and <b>24</b>; CYP-inhibition results of <b>24</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00449/suppl_file/jm7b00449_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00449/suppl_file/jm7b00449_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00449/suppl_file/jm7b00449_si_001.pdf">jm7b00449_si_001.pdf (679.41 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00449/suppl_file/jm7b00449_si_002.csv">jm7b00449_si_002.csv (1.38 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b00449" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32232" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32232" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Markus Follmann</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery, Bayer AG, Aprather Weg
18a, 42113 Wuppertal, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1246-3603" title="Orcid link">http://orcid.org/0000-0003-1246-3603</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1f727e6d746a6c3179707373727e71715f7d7e667a6d317c7072"><span class="__cf_email__" data-cfemail="ee838f9c859b9dc088818282838f8080ae8c8f978b9cc08d8183">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jens Ackerstaff</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery, Bayer AG, Aprather Weg
18a, 42113 Wuppertal, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gorden Redlich</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery, Bayer AG, Aprather Weg
18a, 42113 Wuppertal, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Frank Wunder</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery, Bayer AG, Aprather Weg
18a, 42113 Wuppertal, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dieter Lang</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery, Bayer AG, Aprather Weg
18a, 42113 Wuppertal, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Armin Kern</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery, Bayer AG, Aprather Weg
18a, 42113 Wuppertal, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter Fey</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery, Bayer AG, Aprather Weg
18a, 42113 Wuppertal, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nils Griebenow</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery, Bayer AG, Aprather Weg
18a, 42113 Wuppertal, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Walter Kroh</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery, Bayer AG, Aprather Weg
18a, 42113 Wuppertal, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eva-Maria Becker-Pelster</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery, Bayer AG, Aprather Weg
18a, 42113 Wuppertal, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Axel Kretschmer</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery, Bayer AG, Aprather Weg
18a, 42113 Wuppertal, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Volker Geiss</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery, Bayer AG, Aprather Weg
18a, 42113 Wuppertal, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Volkhart Li</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery, Bayer AG, Aprather Weg
18a, 42113 Wuppertal, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alexander Straub</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery, Bayer AG, Aprather Weg
18a, 42113 Wuppertal, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joachim Mittendorf</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery, Bayer AG, Aprather Weg
18a, 42113 Wuppertal, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rolf Jautelat</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery, Bayer AG, Aprather Weg
18a, 42113 Wuppertal, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hartmut Schirok</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery, Bayer AG, Aprather Weg
18a, 42113 Wuppertal, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karl-Heinz Schlemmer</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery, Bayer AG, Aprather Weg
18a, 42113 Wuppertal, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Klemens Lustig</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery, Bayer AG, Aprather Weg
18a, 42113 Wuppertal, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Gerisch</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery, Bayer AG, Aprather Weg
18a, 42113 Wuppertal, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andreas Knorr</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery, Bayer AG, Aprather Weg
18a, 42113 Wuppertal, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hanna Tinel</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery, Bayer AG, Aprather Weg
18a, 42113 Wuppertal, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas Mondritzki</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery, Bayer AG, Aprather Weg
18a, 42113 Wuppertal, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hubert Trübel</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery, Bayer AG, Aprather Weg
18a, 42113 Wuppertal, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter Sandner</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery, Bayer AG, Aprather Weg
18a, 42113 Wuppertal, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Johannes-Peter Stasch</span> - <span class="hlFld-Affiliation affiliation">Drug Discovery, Bayer AG, Aprather Weg
18a, 42113 Wuppertal, Germany</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare the following competing financial interest(s): All authors are or have been employees of Bayer AG.<br /></br></p></li></ul></div><div class="ack" id="ACK-d133e3693-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i67">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55032" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55032" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Picture used for abstract/Table of Contents graphic taken from “Unseen Extremes: Mapping the World’s Greatest Mountains” by courtesy of Deutsches Zentrum für Luft- und Raumfahrt eV.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i68" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i68"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i69" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i69"> Abbreviations Used</h2><tr><td class="NLM_term">sGC</td><td class="NLM_def"><p class="first last">soluble guanylate cyclase</p></td></tr><tr><td class="NLM_term">cGMP</td><td class="NLM_def"><p class="first last">cyclic guanosine 5′-monophosphate</p></td></tr><tr><td class="NLM_term">HMDS</td><td class="NLM_def"><p class="first last">hexamethyldisilazane</p></td></tr><tr><td class="NLM_term">MEC</td><td class="NLM_def"><p class="first last">minimum effective concentration</p></td></tr><tr><td class="NLM_term">ClogD</td><td class="NLM_def"><p class="first last">calculated logarithm of distribution coefficient</p></td></tr><tr><td class="NLM_term">Cl<sub>b</sub></td><td class="NLM_def"><p class="first last">blood clearance</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i70">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34884" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34884" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 56 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Evgenov, O. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacher, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasko, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, H. H. H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stasch, J.-P.</span><span> </span><span class="NLM_article-title">NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">755</span><span class="NLM_x">–</span> <span class="NLM_lpage">768</span><span class="refDoi"> DOI: 10.1038/nrd2038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1038%2Fnrd2038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=16955067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=755-768&author=O.+V.+Evgenovauthor=P.+Pacherauthor=P.+M.+Schmidtauthor=G.+Haskoauthor=H.+H.+H.+W.+Schmidtauthor=J.-P.+Stasch&title=NO-independent+stimulators+and+activators+of+soluble+guanylate+cyclase%3A+discovery+and+therapeutic+potential&doi=10.1038%2Fnrd2038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential</span></div><div class="casAuthors">Evgenov, Oleg V.; Pacher, Pal; Schmidt, Peter M.; Hasko, Gyoergy; Schmidt, Harald H. H. W.; Stasch, Johannes-Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">755-768</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Sol. guanylate cyclase (sGC) is a key signal-transduction enzyme activated by nitric oxide (NO).  Impaired bioavailability and/or responsiveness to endogenous NO has been implicated in the pathogenesis of cardiovascular and other diseases.  Current therapies that involve the use of org. nitrates and other NO donors have limitations, including non-specific interactions of NO with various biomols., lack of response and the development of tolerance following prolonged administration.  Compds. that activate sGC in an NO-independent manner might therefore provide considerable therapeutic advantages.  Here we review the discovery, biochem., pharmacol. and clin. potential of heme-dependent sGC stimulators (including YC-1, BAY 41-2272, BAY 41-8543, CFM-1571 and A-350619) and heme-independent sGC activators (including BAY 58-2667 and HMR-1766).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoq-7FoAzI40LVg90H21EOLACvtfcHk0lj16uAWlVapaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltrw%253D&md5=6c2a2ad7db529a7fe366bcfa0d61a6af</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrd2038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2038%26sid%3Dliteratum%253Aachs%26aulast%3DEvgenov%26aufirst%3DO.%2BV.%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DSchmidt%26aufirst%3DP.%2BM.%26aulast%3DHasko%26aufirst%3DG.%26aulast%3DSchmidt%26aufirst%3DH.%2BH.%2BH.%2BW.%26aulast%3DStasch%26aufirst%3DJ.-P.%26atitle%3DNO-independent%2520stimulators%2520and%2520activators%2520of%2520soluble%2520guanylate%2520cyclase%253A%2520discovery%2520and%2520therapeutic%2520potential%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D755%26epage%3D768%26doi%3D10.1038%2Fnrd2038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Follmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griebenow, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartung, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mais, F.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mittendorf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schirok, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stasch, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoll, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Straub, A.</span><span> </span><span class="NLM_article-title">The chemistry and biology of soluble guanylate cyclase stimulators and activators</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">9442</span><span class="NLM_x">–</span> <span class="NLM_lpage">9462</span><span class="refDoi"> DOI: 10.1002/anie.201302588</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1002%2Fanie.201302588" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSiu77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=9442-9462&author=M.+Follmannauthor=N.+Griebenowauthor=M.+G.+Hahnauthor=I.+Hartungauthor=F.-J.+Maisauthor=J.+Mittendorfauthor=M.+Schaeferauthor=H.+Schirokauthor=J.-P.+Staschauthor=F.+Stollauthor=A.+Straub&title=The+chemistry+and+biology+of+soluble+guanylate+cyclase+stimulators+and+activators&doi=10.1002%2Fanie.201302588"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The Chemistry and Biology of Soluble Guanylate Cyclase Stimulators and Activators</span></div><div class="casAuthors">Follmann, Markus; Griebenow, Nils; Hahn, Michael G.; Hartung, Ingo; Mais, Franz-Josef; Mittendorf, Joachim; Schaefer, Martina; Schirok, Hartmut; Stasch, Johannes-Peter; Stoll, Friederike; Straub, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">9442-9462</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The vasodilatory properties of nitric oxide (NO) have been utilized in pharmacotherapy for more than 130 years.  Still today, NO-donor drugs are important in the management of cardiovascular diseases.  However, inhaled NO or drugs releasing NO and org. nitrates are assocd. with noteworthy therapeutic shortcomings, including resistance to NO in some disease states, the development of tolerance during long-term treatment, and nonspecific effects, such as post-translational modification of proteins.  The beneficial actions of NO are mediated by stimulation of sol. guanylate cyclase (sGC), a heme-contg. enzyme which produces the intracellular signaling mol. cGMP.  Recently, two classes of compds. have been discovered that amplify the function of sGC in a NO-independent manner, the so-called sGC stimulators and sGC activators.  The most advanced drug, the sGC stimulator riociguat, has successfully undergone Phase III clin. trials for different forms of pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1k3LI-HnJc7Vg90H21EOLACvtfcHk0lj16uAWlVapaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSiu77K&md5=d84536785fcea442b23179a6d7bf7246</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Fanie.201302588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201302588%26sid%3Dliteratum%253Aachs%26aulast%3DFollmann%26aufirst%3DM.%26aulast%3DGriebenow%26aufirst%3DN.%26aulast%3DHahn%26aufirst%3DM.%2BG.%26aulast%3DHartung%26aufirst%3DI.%26aulast%3DMais%26aufirst%3DF.-J.%26aulast%3DMittendorf%26aufirst%3DJ.%26aulast%3DSchaefer%26aufirst%3DM.%26aulast%3DSchirok%26aufirst%3DH.%26aulast%3DStasch%26aufirst%3DJ.-P.%26aulast%3DStoll%26aufirst%3DF.%26aulast%3DStraub%26aufirst%3DA.%26atitle%3DThe%2520chemistry%2520and%2520biology%2520of%2520soluble%2520guanylate%2520cyclase%2520stimulators%2520and%2520activators%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D9442%26epage%3D9462%26doi%3D10.1002%2Fanie.201302588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Cerra, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellegrino, D.</span><span> </span><span class="NLM_article-title">Cardiovascular cGMP-generating systems in physiological and pathological conditions</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">585</span><span class="NLM_x">–</span> <span class="NLM_lpage">599</span><span class="refDoi"> DOI: 10.2174/092986707780059715</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.2174%2F092986707780059715" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=17346149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhs1yhur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=585-599&author=M.+C.+Cerraauthor=D.+Pellegrino&title=Cardiovascular+cGMP-generating+systems+in+physiological+and+pathological+conditions&doi=10.2174%2F092986707780059715"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiovascular cGMP-generating systems in physiological and pathological conditions</span></div><div class="casAuthors">Cerra, M. C.; Pellegrino, D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">585-599</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The intracellular messenger cyclic GMP (cGMP) represents the key signal in several transduction pathways throughout the animal world.  In the heart cGMP signaling contributes to functional interaction of different cell types.  Nitric oxide (NO) and natriuretic peptides (NPs), major autocrine-paracrine cardiovascular regulators, increment intracellular cGMP through guanylate cyclases (GCs).  NO and NPs interact with two GC types: cytosolic (sol.: sGC) and membrane bound [particulate: pGC (NP receptor types A and B)], resp.  Depending on sub-cellular localization and regulation of the enzymes, cGMP produced by either pGC or sGC exerts different complementary effects.  The two pathways are reciprocally regulated.  NPs-depending pGC is modulated by NO-cGMP signaling, and the activity of NO is influenced by cellular concns. of both NO itself and NPs.  This heterologous feedback regulates GCs, linking cardiovascular autocrine-paracrine activities of NPs and NO.  Importance of these cGMP converging routes goes far beyond their role under normal conditions.  They are of relevance esp. in disease states when tissue and circulating levels of NPs, and local NO prodn. are altered.  An example is the endothelial dysfunction assocd. with deficient NO prodn. and uncoupled endothelium-myocardium communications.  In this case, NPs-pGC-cGMP could supplement the reduced activity of NO-scGC-cGMP pathway.  In addn., these systems regulate cell growth and apoptosis, playing a role in myocardial pathol. morpho-functional remodeling.  Here we will review recent concepts on NO/NPs dependent control of heart function in vertebrates, also focusing on cGMP-activated downstream signaling and its role in health and disease conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4IxnrYfpG4LVg90H21EOLACvtfcHk0lj16uAWlVapaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhs1yhur8%253D&md5=e908a3f3ba079740f192df00daf01396</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2174%2F092986707780059715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986707780059715%26sid%3Dliteratum%253Aachs%26aulast%3DCerra%26aufirst%3DM.%2BC.%26aulast%3DPellegrino%26aufirst%3DD.%26atitle%3DCardiovascular%2520cGMP-generating%2520systems%2520in%2520physiological%2520and%2520pathological%2520conditions%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2007%26volume%3D14%26spage%3D585%26epage%3D599%26doi%3D10.2174%2F092986707780059715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Gladwin, M. T.</span><span> </span><span class="NLM_article-title">Deconstructing endothelial dysfunction: soluble guanylyl cyclase oxidation and the NO resistance syndrome</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">2330</span><span class="NLM_x">–</span> <span class="NLM_lpage">2332</span><span class="refDoi"> DOI: 10.1172/JCI29807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1172%2FJCI29807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=16955136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD28Xps1Sgs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2006&pages=2330-2332&author=M.+T.+Gladwin&title=Deconstructing+endothelial+dysfunction%3A+soluble+guanylyl+cyclase+oxidation+and+the+NO+resistance+syndrome&doi=10.1172%2FJCI29807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Deconstructing endothelial dysfunction: soluble guanylyl cyclase oxidation and the NO resistance syndrome</span></div><div class="casAuthors">Gladwin, Mark T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2330-2332</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  In this issue of the JCI, Stasch and colleagues suggest that a novel drug, BAY 58-2667, potently activates a pool of oxidized and heme-free sol. guanylyl cyclase (sGC; see the related article beginning on page 2552).  The increased vasodilatory potency of BAY 58-2667 the authors found in a no. of animal models of endothelial dysfunction and in human blood vessels from patients with diabetes suggests that there exists a subphenotype of endothelial dysfunction characterized by receptor-level NO resistance.  Diseases assocd. with NO resistance would appear to be ideally suited for therapies directed at restoring redox homeostasis, sGC activity, and NO sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopNGJgNefaOLVg90H21EOLACvtfcHk0ljMGbPRimik4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xps1Sgs7Y%253D&md5=9e5f9bf0c5d662275529e43902d83368</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1172%2FJCI29807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI29807%26sid%3Dliteratum%253Aachs%26aulast%3DGladwin%26aufirst%3DM.%2BT.%26atitle%3DDeconstructing%2520endothelial%2520dysfunction%253A%2520soluble%2520guanylyl%2520cyclase%2520oxidation%2520and%2520the%2520NO%2520resistance%2520syndrome%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2006%26volume%3D116%26spage%3D2330%26epage%3D2332%26doi%3D10.1172%2FJCI29807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Hoenicka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, C.</span><span> </span><span class="NLM_article-title">Cardiovascular effects of modulators of soluble guanylyl cyclase activity</span> <span class="citation_source-journal">Cardiovasc. Hematol. Agents Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">287</span><span class="NLM_x">–</span> <span class="NLM_lpage">301</span><span class="refDoi"> DOI: 10.2174/187152508785909555</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.2174%2F187152508785909555" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=18855642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlCntbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=287-301&author=M.+Hoenickaauthor=C.+Schmid&title=Cardiovascular+effects+of+modulators+of+soluble+guanylyl+cyclase+activity&doi=10.2174%2F187152508785909555"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiovascular effects of modulators of soluble guanylyl cyclase activity</span></div><div class="casAuthors">Hoenicka, Markus; Schmid, Christof</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular & Hematological Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">287-301</span>CODEN:
                <span class="NLM_cas:coden">CHAAA5</span>;
        ISSN:<span class="NLM_cas:issn">1871-5257</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Sol. guanylyl cyclase (sGC) is one of the key enzymes of the nitric-oxide (NO)/cyclic 3',5'-guanosine monophosphate (cGMP) pathway.  Located in virtually all mammalian cells, it controls the vessel tone, smooth muscle cell growth, platelet aggregation, and leukocyte adhesion.  In vivo sGC activity is mainly regulated by NO which in turn is released from L-arginine by nitric oxide synthases.  One of the main diseases of the cardiovascular system, endothelial dysfunction, leads to a diminished NO synthesis and thus increases vessel tone as well as the risk of thrombosis.  The predominant therapeutic approach to this condition is a NO replacement therapy, as exemplified by org. nitrates, molsidomin, and other NO releasing substances.  Recent advances in drug discovery provided a variety of other approaches to activate sGC, which may help to circumvent both the tolerance problem and some non-specific actions assocd. with NO donor drugs.  Substances like BAY 41-2272 stimulate sGC in a heme-dependent fashion and synergize with NO, allowing to enhance the effects both of endogenous NO and of exogenous NO donors.  On the other hand, heme-independent activators like BAY 58-2667 allow to activate sGC even if it is rendered unresponsive to NO due to oxidative stress or heme loss.  Furthermore, a few substances have been described as specific inhibitors of sGC that allow to alleviate the effects of excess NO prodn. as seen in shock.  This review discusses the cardiovascular effects of heme-dependent and heme-independent activators as well as of inhibitors of sGC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzFCLOV7NKCbVg90H21EOLACvtfcHk0ljMGbPRimik4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlCntbjF&md5=329ce40010581e109f96a6331b8d754f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.2174%2F187152508785909555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152508785909555%26sid%3Dliteratum%253Aachs%26aulast%3DHoenicka%26aufirst%3DM.%26aulast%3DSchmid%26aufirst%3DC.%26atitle%3DCardiovascular%2520effects%2520of%2520modulators%2520of%2520soluble%2520guanylyl%2520cyclase%2520activity%26jtitle%3DCardiovasc.%2520Hematol.%2520Agents%2520Med.%2520Chem.%26date%3D2008%26volume%3D6%26spage%3D287%26epage%3D301%26doi%3D10.2174%2F187152508785909555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Priviero, F. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, R. C.</span><span> </span><span class="NLM_article-title">Heme-dependent and independent soluble guanylate cyclase activators and vasodilation</span> <span class="citation_source-journal">J. Cardiovasc. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">229</span><span class="NLM_x">–</span> <span class="NLM_lpage">233</span><span class="refDoi"> DOI: 10.1097/FJC.0b013e3181eb4e75</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1097%2FFJC.0b013e3181eb4e75" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=20571429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFKmur%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2010&pages=229-233&author=F.+B.+Privieroauthor=R.+C.+Webb&title=Heme-dependent+and+independent+soluble+guanylate+cyclase+activators+and+vasodilation&doi=10.1097%2FFJC.0b013e3181eb4e75"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Heme-Dependent and Independent Soluble Guanylate Cyclase Activators and Vasodilation</span></div><div class="casAuthors">Priviero, Fernanda B. M.; Webb, R. Clinton</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cardiovascular Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">229-233</span>CODEN:
                <span class="NLM_cas:coden">JCPCDT</span>;
        ISSN:<span class="NLM_cas:issn">0160-2446</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Since the discovery of nitric oxide (NO), which is released from endothelial cells as the main mediator of vasodilation, its target, the sol. guanylyl cyclase (sGC), has become a focus of interest for the treatment of diseases assocd. with endothelial dysfunction.  NO donors were developed to suppress NO deficiency; however, tolerance to org. nitrates was reported.  Non-NO-based drugs targeting sGC were developed to overcome the problem of tolerance.  In this review, we briefly describe the process of sGC activation by its main physiol. activator NO and the advances in the development of drugs capable of activating sGC in a NO-independent manner. sGC stimulators, as some of these drugs are called, require the integrity of the reduced heme moiety of the prosthetic group within the sGC and therefore are called heme-dependent stimulators.  Other drugs are able to activate sGC independent of heme moiety and are hence called heme-independent activators.  Because pathol. conditions modulate sGC and oxidize the heme moiety, the heme-independent sGC activators could potentially become drugs of choice because of their higher affinity to the oxidized enzyme.  However, these drugs are still undergoing clin. trials and are not available for clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO69av00aE9bVg90H21EOLACvtfcHk0ljMGbPRimik4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFKmur%252FF&md5=6a2d08cf3f0894a5584cb988ed6ca344</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1097%2FFJC.0b013e3181eb4e75&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFJC.0b013e3181eb4e75%26sid%3Dliteratum%253Aachs%26aulast%3DPriviero%26aufirst%3DF.%2BB.%26aulast%3DWebb%26aufirst%3DR.%2BC.%26atitle%3DHeme-dependent%2520and%2520independent%2520soluble%2520guanylate%2520cyclase%2520activators%2520and%2520vasodilation%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D2010%26volume%3D56%26spage%3D229%26epage%3D233%26doi%3D10.1097%2FFJC.0b013e3181eb4e75" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Packer, C. S.</span><span> </span><span class="NLM_article-title">Soluble guanylate cyclase (sGC) down-regulation by abnormal extracellular matrix proteins as a novel mechanism in vascular dysfunction: implications in metabolic syndrome</span> <span class="citation_source-journal">Cardiovasc. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">302</span><span class="NLM_x">–</span> <span class="NLM_lpage">303</span><span class="refDoi"> DOI: 10.1016/j.cardiores.2005.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1016%2Fj.cardiores.2005.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=16412404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD28Xls1Wrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2006&pages=302-303&author=C.+S.+Packer&title=Soluble+guanylate+cyclase+%28sGC%29+down-regulation+by+abnormal+extracellular+matrix+proteins+as+a+novel+mechanism+in+vascular+dysfunction%3A+implications+in+metabolic+syndrome&doi=10.1016%2Fj.cardiores.2005.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble guanylate cyclase (sGC) down-regulation by abnormal extracellular matrix proteins as a novel mechanism in vascular dysfunction: Implications in metabolic syndrome</span></div><div class="casAuthors">Packer, C. Subah</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">302-303</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The role of endothelial NO prodn., accumulation of extracellular matrix proteins and altered activity of sol. guanylate cyclase in endothelial dysfunction and metabolic syndrome is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6CXr4qyhAqbVg90H21EOLACvtfcHk0lhUAmRwkt2RQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xls1Wrtg%253D%253D&md5=c08169802b8f12d26d67479e3121a02b</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.cardiores.2005.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cardiores.2005.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DPacker%26aufirst%3DC.%2BS.%26atitle%3DSoluble%2520guanylate%2520cyclase%2520%2528sGC%2529%2520down-regulation%2520by%2520abnormal%2520extracellular%2520matrix%2520proteins%2520as%2520a%2520novel%2520mechanism%2520in%2520vascular%2520dysfunction%253A%2520implications%2520in%2520metabolic%2520syndrome%26jtitle%3DCardiovasc.%2520Res.%26date%3D2006%26volume%3D69%26spage%3D302%26epage%3D303%26doi%3D10.1016%2Fj.cardiores.2005.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Mayer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koesling, D.</span><span> </span><span class="NLM_article-title">cGMP signalling beyond nitric oxide</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">546</span><span class="NLM_x">–</span> <span class="NLM_lpage">548</span><span class="refDoi"> DOI: 10.1016/S0165-6147(00)01889-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1016%2FS0165-6147%2800%2901889-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=11698077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD3MXotFSms7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2001&pages=546-548&author=B.+Mayerauthor=D.+Koesling&title=cGMP+signalling+beyond+nitric+oxide&doi=10.1016%2FS0165-6147%2800%2901889-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">cGMP signalling beyond nitric oxide</span></div><div class="casAuthors">Mayer, Bernd; Koesling, Doris</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">546-548</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Many of the physiol. effects of nitric oxide are mediated by activation of sol. guanylyl cyclase, resulting in cellular cGMP accumulation.  In the 1990s, the benzylindazole deriv. YC-1 was identified as a novel modulator of cGMP signaling that exerted complex actions in a NO-independent manner.  A recent study describes a high-affinity YC-1 analog that decreases blood pressure in hypertensive rats and increases bleeding time, which suggests that this drug might have therapeutic potential as a vasodilator with antiplatelet activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxPGoC44V_-LVg90H21EOLACvtfcHk0lhUAmRwkt2RQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXotFSms7o%253D&md5=1904c0c74e65ba81ab8036825ff63826</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0165-6147%2800%2901889-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0165-6147%252800%252901889-7%26sid%3Dliteratum%253Aachs%26aulast%3DMayer%26aufirst%3DB.%26aulast%3DKoesling%26aufirst%3DD.%26atitle%3DcGMP%2520signalling%2520beyond%2520nitric%2520oxide%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2001%26volume%3D22%26spage%3D546%26epage%3D548%26doi%3D10.1016%2FS0165-6147%2800%2901889-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Nioche, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berka, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vipond, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raman, C. S.</span><span> </span><span class="NLM_article-title">Femtomolar sensitivity of a NO sensor from Clostridium botulinum</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">306</span><span class="NLM_x">, </span> <span class="NLM_fpage">1550</span><span class="NLM_x">–</span> <span class="NLM_lpage">1553</span><span class="refDoi"> DOI: 10.1126/science.1103596</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1126%2Fscience.1103596" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=15472039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVeqtr3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=2004&pages=1550-1553&author=P.+Niocheauthor=V.+Berkaauthor=J.+Vipondauthor=N.+Mintonauthor=A.+L.+Tsaiauthor=C.+S.+Raman&title=Femtomolar+sensitivity+of+a+NO+sensor+from+Clostridium+botulinum&doi=10.1126%2Fscience.1103596"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Femtomolar sensitivity of a NO sensor from Clostridium botulinum</span></div><div class="casAuthors">Nioche, Pierre; Berka, Vladimir; Vipond, Julia; Minton, Nigel; Tsai, Ah-Lim; Raman, C. S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">306</span>
        (<span class="NLM_cas:issue">5701</span>),
    <span class="NLM_cas:pages">1550-1553</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Nitric oxide (NO) is extremely toxic to Clostridium botulinum, but its mol. targets are unknown.  Here, the authors identify a heme protein sensor (SONO) that displays femtomolar affinity for NO.  The crystal structure of the SONO heme domain reveals a previously undescribed fold and a strategically placed tyrosine residue that modulates heme-nitrosyl coordination.  Furthermore, the domain architecture of a SONO ortholog cloned from Chlamydomonas reinhardtii indicates that NO signaling through cGMP arose before the origin of multicellular eukaryotes.  The authors' findings have broad implications for understanding bacterial responses to NO, as well as for the activation of mammalian NO-sensitive guanylyl cyclase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHl3CXdPf1ULVg90H21EOLACvtfcHk0lhUAmRwkt2RQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVeqtr3J&md5=b4832ef9edfbcd375eeff366ec35c6a2</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1126%2Fscience.1103596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1103596%26sid%3Dliteratum%253Aachs%26aulast%3DNioche%26aufirst%3DP.%26aulast%3DBerka%26aufirst%3DV.%26aulast%3DVipond%26aufirst%3DJ.%26aulast%3DMinton%26aufirst%3DN.%26aulast%3DTsai%26aufirst%3DA.%2BL.%26aulast%3DRaman%26aufirst%3DC.%2BS.%26atitle%3DFemtomolar%2520sensitivity%2520of%2520a%2520NO%2520sensor%2520from%2520Clostridium%2520botulinum%26jtitle%3DScience%26date%3D2004%26volume%3D306%26spage%3D1550%26epage%3D1553%26doi%3D10.1126%2Fscience.1103596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karow, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boon, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marletta, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Crystal structure of an oxygen-binding heme domain related to soluble guanylate cyclases</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">12854</span><span class="NLM_x">–</span> <span class="NLM_lpage">12859</span><span class="refDoi"> DOI: 10.1073/pnas.0405188101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1073%2Fpnas.0405188101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=15326296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnslCltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=12854-12859&author=P.+Pellicenaauthor=D.+S.+Karowauthor=E.+M.+Boonauthor=M.+A.+Marlettaauthor=J.+Kuriyan&title=Crystal+structure+of+an+oxygen-binding+heme+domain+related+to+soluble+guanylate+cyclases&doi=10.1073%2Fpnas.0405188101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of an oxygen-binding heme domain related to soluble guanylate cyclases</span></div><div class="casAuthors">Pellicena, Patricia; Karow, David S.; Boon, Elizabeth M.; Marletta, Michael A.; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">12854-12859</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Sol. guanylate cyclases are nitric oxide-responsive signaling proteins in which the nitric oxide sensor is a heme-binding domain of unknown structure that we have termed the heme-NO and oxygen binding (H-NOX) domain.  H-NOX domains are also found in bacteria, either as isolated domains, or are fused through a membrane-spanning region to methyl-accepting chemotaxis proteins.  We have detd. the crystal structure of an oxygen-binding H-NOX domain of one such signaling protein from the obligate anaerobe Thermoanaerobacter tengcongensis at 1.77-Å resoln., revealing a protein fold unrelated to known structures.  Particularly striking is the structure of the protoporphyrin IX group, which is distorted from planarity to an extent not seen before in protein-bound heme groups.  Comparison of the structure of the H-NOX domain in two different crystal forms suggests a mechanism whereby alteration in the degree of distortion of the heme group is coupled to changes on the mol. surface of the H-NOX domain and potentially to changes in intermol. interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZbFyxgC3LDbVg90H21EOLACvtfcHk0lhUAmRwkt2RQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnslCltbc%253D&md5=7b3bc4fa35cf69d5b806377466a826df</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0405188101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0405188101%26sid%3Dliteratum%253Aachs%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DKarow%26aufirst%3DD.%2BS.%26aulast%3DBoon%26aufirst%3DE.%2BM.%26aulast%3DMarletta%26aufirst%3DM.%2BA.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520structure%2520of%2520an%2520oxygen-binding%2520heme%2520domain%2520related%2520to%2520soluble%2520guanylate%2520cyclases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2004%26volume%3D101%26spage%3D12854%26epage%3D12859%26doi%3D10.1073%2Fpnas.0405188101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Wedel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humbert, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harteneck, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foerster, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malkewitz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohme, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koesling, D.</span><span> </span><span class="NLM_article-title">Mutation of His-105 in the β<sub>1</sub> subunit yields a nitric oxide-insensitive form of soluble guanylyl cyclase</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">2592</span><span class="NLM_x">–</span> <span class="NLM_lpage">2596</span><span class="refDoi"> DOI: 10.1073/pnas.91.7.2592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1073%2Fpnas.91.7.2592" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=2592-2596&author=B.+Wedelauthor=P.+Humbertauthor=C.+Harteneckauthor=J.+Foersterauthor=J.+Malkewitzauthor=E.+Bohmeauthor=G.+Schultzauthor=D.+Koesling&title=Mutation+of+His-105+in+the+%CE%B21+subunit+yields+a+nitric+oxide-insensitive+form+of+soluble+guanylyl+cyclase&doi=10.1073%2Fpnas.91.7.2592"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.91.7.2592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.91.7.2592%26sid%3Dliteratum%253Aachs%26aulast%3DWedel%26aufirst%3DB.%26aulast%3DHumbert%26aufirst%3DP.%26aulast%3DHarteneck%26aufirst%3DC.%26aulast%3DFoerster%26aufirst%3DJ.%26aulast%3DMalkewitz%26aufirst%3DJ.%26aulast%3DBohme%26aufirst%3DE.%26aulast%3DSchultz%26aufirst%3DG.%26aulast%3DKoesling%26aufirst%3DD.%26atitle%3DMutation%2520of%2520His-105%2520in%2520the%2520%25CE%25B21%2520subunit%2520yields%2520a%2520nitric%2520oxide-insensitive%2520form%2520of%2520soluble%2520guanylyl%2520cyclase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1994%26volume%3D91%26spage%3D2592%26epage%3D2596%26doi%3D10.1073%2Fpnas.91.7.2592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Zabel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hausler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weeger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, H. H.</span><span> </span><span class="NLM_article-title">Homodimerization of soluble guanylyl cyclase subunits. Dimerization analysis using a glutathione <i>S</i>-transferase affinity tag</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">274</span><span class="NLM_x">, </span> <span class="NLM_fpage">18149</span><span class="NLM_x">–</span> <span class="NLM_lpage">18152</span><span class="refDoi"> DOI: 10.1074/jbc.274.26.18149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1074%2Fjbc.274.26.18149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10373411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADyaK1MXktF2rtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=18149-18152&author=U.+Zabelauthor=C.+Hauslerauthor=M.+Weegerauthor=H.+H.+Schmidt&title=Homodimerization+of+soluble+guanylyl+cyclase+subunits.+Dimerization+analysis+using+a+glutathione+S-transferase+affinity+tag&doi=10.1074%2Fjbc.274.26.18149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Homodimerization of soluble guanylyl cyclase subunits. Dimerization analysis using a glutathione S-transferase affinity tag</span></div><div class="casAuthors">Zabel, Ulrike; Hausler, Christoph; Weeger, Monika; Schmidt, Harald H. H. W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">274</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">18149-18152</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Sol. guanylyl cyclase (sGC) is an α/β-heterodimeric hemoprotein that, upon interaction with the intercellular messenger mol. NO, generates cGMP.  Although the related family of particulate guanylyl cyclases (pGCs) forms active homodimeric complexes, it is not known whether homodimerization of sGC subunits occurs.  We report here the expression in Sf9 cells of glutathione S-transferase-tagged recombinant human sGCα1 and β1 subunits, applying a novel and rapid purifn. method based on GSH-Sepharose affinity chromatog.  Surprisingly, in intact Sf9 cells, both homodimeric GSTα/α and GSTβ/β complexes were formed that were catalytically inactive.  Upon coexpression of the resp. complementary subunits, GSTα/β or GSTβ/α heterodimers were preferentially formed, whereas homodimers were still detectable.  When subunits were mixed after expression, e.g. GSTβ and β or GSTα and β, no dimerization was obsd.  In conclusion, our data suggest the previously unrecognized possibility of a physiol. equil. between homo- and heterodimeric sGC complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1XE1FMz92BrVg90H21EOLACvtfcHk0lhhwmGJR5CJ3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXktF2rtL8%253D&md5=12ec14790843c43f8cf099f61c1af118</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1074%2Fjbc.274.26.18149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.274.26.18149%26sid%3Dliteratum%253Aachs%26aulast%3DZabel%26aufirst%3DU.%26aulast%3DHausler%26aufirst%3DC.%26aulast%3DWeeger%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DH.%2BH.%26atitle%3DHomodimerization%2520of%2520soluble%2520guanylyl%2520cyclase%2520subunits.%2520Dimerization%2520analysis%2520using%2520a%2520glutathione%2520S-transferase%2520affinity%2520tag%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D18149%26epage%3D18152%26doi%3D10.1074%2Fjbc.274.26.18149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Zabel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weeger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, H. H. W.</span><span> </span><span class="NLM_article-title">Human soluble guanylate cyclase: functional expression and revised isoenzyme family</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">335</span><span class="NLM_x">, </span> <span class="NLM_fpage">51</span><span class="NLM_x">–</span> <span class="NLM_lpage">57</span><span class="refDoi"> DOI: 10.1042/bj3350051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1042%2Fbj3350051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=9742212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADyaK1cXms1Ohurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=335&publication_year=1998&pages=51-57&author=U.+Zabelauthor=M.+Weegerauthor=M.+Laauthor=H.+H.+W.+Schmidt&title=Human+soluble+guanylate+cyclase%3A+functional+expression+and+revised+isoenzyme+family&doi=10.1042%2Fbj3350051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Human soluble guanylate cyclase: functional expression and revised isoenzyme family</span></div><div class="casAuthors">Zabel, Ulrike; Weeger, Monika; La, Mylinh; Schmidt, Harald H. H. W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">335</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-57</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Sol. guanylate cyclase (sGC), a heterodimeric (α/β) heme protein that converts GTP to the second messenger cGMP, functions as the receptor for nitric oxide (NO) and nitrovasodilator drugs.  Three distinct cDNA species of each subunit (α1-α3, β1-β3) have been reported from various species.  From human sources, none of these have been expressed as functionally active enzyme.  Here the authors described the expression of human α/β heterodimeric sGC in Sf9 cells yielding active recombinant enzyme that was stimulated by the nitrovasodilator sodium nitroprusside or the NO-independent activator 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole (YC-1).  At the protein level, both α and β subunits were detected in human tissues, suggesting co-expression also in vivo.  Moreover, resequencing of the human cDNA clones [originally termed α3 and β3] revealed several sequencing errors in human α3; correction of these eliminated major regions of divergence from rat and bovine α1.  As human β3 also displays more than 98% similarity to rat and bovine β1 at the amino acid level, α3 and β3 represent the human homologs of rat and bovine α1 and β1, and the isoenzyme family is decreased to two isoforms for each subunit (α1, α2; β1, β2).  Having access to the human key enzyme of NO signaling will now permit the study of novel sGC-modulating compds. with therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVl92c04nUBLVg90H21EOLACvtfcHk0lhhwmGJR5CJ3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXms1Ohurg%253D&md5=0eb51bff28b1e54b4f447d60329d3f27</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1042%2Fbj3350051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj3350051%26sid%3Dliteratum%253Aachs%26aulast%3DZabel%26aufirst%3DU.%26aulast%3DWeeger%26aufirst%3DM.%26aulast%3DLa%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DH.%2BH.%2BW.%26atitle%3DHuman%2520soluble%2520guanylate%2520cyclase%253A%2520functional%2520expression%2520and%2520revised%2520isoenzyme%2520family%26jtitle%3DBiochem.%2520J.%26date%3D1998%26volume%3D335%26spage%3D51%26epage%3D57%26doi%3D10.1042%2Fbj3350051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Murad, F.</span><span> </span><span class="NLM_article-title">Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">355</span><span class="NLM_x">, </span> <span class="NLM_fpage">2003</span><span class="NLM_x">–</span> <span class="NLM_lpage">2011</span><span class="refDoi"> DOI: 10.1056/NEJMsa063904</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1056%2FNEJMsa063904" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=17093251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFymur3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2006&pages=2003-2011&author=F.+Murad&title=Shattuck+Lecture.+Nitric+oxide+and+cyclic+GMP+in+cell+signaling+and+drug+development&doi=10.1056%2FNEJMsa063904"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Nitric oxide and cyclic GMP in cell signaling and drug development</span></div><div class="casAuthors">Murad, Ferid</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2003-2011</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  The topics discussed include: guanylyl cyclase activity; endothelial activity; nitric oxide synthase; activation of sol. guanylyl cyclase; steady-state levels of cGMP; and cGMP signaling in drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohrhWHak3qNrVg90H21EOLACvtfcHk0lhhwmGJR5CJ3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFymur3J&md5=39e95c4acecc494cb06967644671887b</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMsa063904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMsa063904%26sid%3Dliteratum%253Aachs%26aulast%3DMurad%26aufirst%3DF.%26atitle%3DShattuck%2520Lecture.%2520Nitric%2520oxide%2520and%2520cyclic%2520GMP%2520in%2520cell%2520signaling%2520and%2520drug%2520development%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D355%26spage%3D2003%26epage%3D2011%26doi%3D10.1056%2FNEJMsa063904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Stasch, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hobbs, A. J.</span><span> </span><span class="NLM_article-title">NO-independent, haem-dependent soluble guanylate cyclase stimulators</span> <span class="citation_source-journal">Handb. Exp. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">191</span><span class="NLM_x">, </span> <span class="NLM_fpage">277</span><span class="NLM_x">–</span> <span class="NLM_lpage">308</span><span class="refDoi"> DOI: 10.1007/978-3-540-68964-5_13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1007%2F978-3-540-68964-5_13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=19089334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitlaisLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2009&pages=277-308&author=J.+P.+Staschauthor=A.+J.+Hobbs&title=NO-independent%2C+haem-dependent+soluble+guanylate+cyclase+stimulators&doi=10.1007%2F978-3-540-68964-5_13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">NO-independent, haem-dependent soluble guanylate cyclase stimulators</span></div><div class="casAuthors">Stasch, Johannes-Peter; Hobbs, Adrian J.</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of Experimental Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">cGMP: Generators, Effectors and Therapeutic Implications</span>),
    <span class="NLM_cas:pages">277-308</span>CODEN:
                <span class="NLM_cas:coden">HEPHD2</span>;
        ISSN:<span class="NLM_cas:issn">0171-2004</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  The nitric oxide (NO) signalling pathway is altered in cardiovascular diseases, including systemic and pulmonary hypertension, stroke, and atherosclerosis.  The vasodilatory properties of NO have been exploited for over a century in cardiovascular disease, but NO donor drugs and inhaled NO are assocd. with significant shortcomings, including resistance to NO in some disease states, the development of tolerance during long-term treatment, and non-specific effects such as post-translational modification of proteins.  The development of pharmacol. agents capable of directly stimulating the NO receptor, sol. guanylate cyclase (sGC), is therefore highly desirable.  The benzylindazole compd. YC-1 was the first sGC stimulator to be identified; this compd. formed a lead structure for the development of optimized sGC stimulators with improved potency and specificity for sGC, including CFM-1571, BAY 41-2272, BAY 41-8543, and BAY 63-2521.  In contrast to the NO- and haem-independent sGC activators such as BAY 58-2667, these compds. stimulate sGC activity independent of NO and also act in synergy with NO to produce anti-aggregatory, anti-proliferative, and vasodilatory effects.  Recently, aryl-acrylamide compds. were identified independent of YC-1 as sGC stimulators; although structurally dissimilar to YC-1, they have a similar mode of action and promote smooth muscle relaxation.  Pharmacol. stimulators of sGC may be beneficial in the treatment of a range of diseases, including systemic and pulmonary hypertension, heart failure, atherosclerosis, erectile dysfunction, and renal fibrosis.  An sGC stimulator, BAY 63-2521, is currently in clin. development as an oral therapy for patients with pulmonary hypertension.  It has demonstrated efficacy in a proof-of-concept study, reducing pulmonary vascular resistance and increasing cardiac output from baseline.  A full, phase 2 trial of BAY 63-2521 in pulmonary hypertension is underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrxCcRDKhcS7Vg90H21EOLACvtfcHk0lgfKrBG8CEMuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitlaisLY%253D&md5=d417b58908ffa19b40838209ac6b90f0</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2F978-3-540-68964-5_13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-540-68964-5_13%26sid%3Dliteratum%253Aachs%26aulast%3DStasch%26aufirst%3DJ.%2BP.%26aulast%3DHobbs%26aufirst%3DA.%2BJ.%26atitle%3DNO-independent%252C%2520haem-dependent%2520soluble%2520guanylate%2520cyclase%2520stimulators%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2009%26volume%3D191%26spage%3D277%26epage%3D308%26doi%3D10.1007%2F978-3-540-68964-5_13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Schmidt, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stasch, J. P.</span><span> </span><span class="NLM_article-title">NO- and haem-independent soluble guanylate cyclase activators</span> <span class="citation_source-journal">Handb. Exp. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">191</span><span class="NLM_x">, </span> <span class="NLM_fpage">309</span><span class="NLM_x">–</span> <span class="NLM_lpage">339</span><span class="refDoi"> DOI: 10.1007/978-3-540-68964-5_14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1007%2F978-3-540-68964-5_14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=19089335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitlaisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2009&pages=309-339&author=H.+H.+Schmidtauthor=P.+M.+Schmidtauthor=J.+P.+Stasch&title=NO-+and+haem-independent+soluble+guanylate+cyclase+activators&doi=10.1007%2F978-3-540-68964-5_14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">NO- and haem-independent soluble guanylate cyclase activators</span></div><div class="casAuthors">Schmidt, Harald H. H. W.; Schmidt, Peter M.; Stasch, Johannes-Peter</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of Experimental Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">cGMP: Generators, Effectors and Therapeutic Implications</span>),
    <span class="NLM_cas:pages">309-339</span>CODEN:
                <span class="NLM_cas:coden">HEPHD2</span>;
        ISSN:<span class="NLM_cas:issn">0171-2004</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  Oxidative stress, a risk factor for several cardiovascular disorders, interferes with the NO/sGC/cGMP signalling pathway through scavenging of NO and formation of the strong intermediate oxidant, peroxynitrite.  Under these conditions, endothelial and vascular dysfunction develops, culminating in different cardio-renal and pulmonary-vascular diseases.  Substituting NO with org. nitrates that release NO (NO donors) has been an important principle in cardiovascular therapy for more than a century.  However, the development of nitrate tolerance limits their continuous clin. application and, under oxidative stress and increased formation of peroxynitrite foils the desired therapeutic effect.  To overcome these obstacles of nitrate therapy, direct NO- and haem-independent sGC activators have been developed, such as BAY 58-2667 (cinaciguat) and HMR1766 (ataciguat), showing unique biochem. and pharmacol. properties.  Both compds. are capable of selectively activating the oxidized/haem-free enzyme via binding to the enzyme's haem pocket, causing pronounced vasodilatation.  The potential importance of these new drugs resides in the fact that they selectively target a modified state of sGC that is prevalent under disease conditions as shown in several animal models and human disease.  Activators of sGC may be beneficial in the treatment of a range of diseases including systemic and pulmonary hypertension (PH), heart failure, atherosclerosis, peripheral arterial occlusive disease (PAOD), thrombosis and renal fibrosis.  The sGC activator HMR1766 is currently in clin. development as an oral therapy for patients with PAOD.  The sGC activator BAY 58-2667 has demonstrated efficacy in a proof-of-concept study in patients with acute decompensated heart failure (ADHF), reducing pre- and afterload and increasing cardiac output from baseline.  A phase IIb clin. study for the indication of ADHF is currently underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYfXnvGGXe2rVg90H21EOLACvtfcHk0lgfKrBG8CEMuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitlaisb4%253D&md5=a38ffd43e7f3769198b1654c74ffa16c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2F978-3-540-68964-5_14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-540-68964-5_14%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DH.%2BH.%26aulast%3DSchmidt%26aufirst%3DP.%2BM.%26aulast%3DStasch%26aufirst%3DJ.%2BP.%26atitle%3DNO-%2520and%2520haem-independent%2520soluble%2520guanylate%2520cyclase%2520activators%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2009%26volume%3D191%26spage%3D309%26epage%3D339%26doi%3D10.1007%2F978-3-540-68964-5_14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Stasch, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evgenov, O. V.</span><span> </span><span class="NLM_article-title">Soluble guanylate cyclase stimulators in pulmonary hypertension</span> <span class="citation_source-journal">Handb. Exp. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">218</span><span class="NLM_x">, </span> <span class="NLM_fpage">279</span><span class="NLM_x">–</span> <span class="NLM_lpage">313</span><span class="refDoi"> DOI: 10.1007/978-3-662-45805-1_12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1007%2F978-3-662-45805-1_12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=24092345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsVOjtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=218&publication_year=2013&pages=279-313&author=J.-P.+Staschauthor=O.+V.+Evgenov&title=Soluble+guanylate+cyclase+stimulators+in+pulmonary+hypertension&doi=10.1007%2F978-3-662-45805-1_12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble Guanylate Cyclase Stimulators in Pulmonary Hypertension</span></div><div class="casAuthors">Stasch, Johannes-Peter; Evgenov, Oleg V.</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of Experimental Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">218</span>
        (<span class="NLM_cas:issue">Pharmacotherapy of Pulmonary Hypertension</span>),
    <span class="NLM_cas:pages">279-313</span>CODEN:
                <span class="NLM_cas:coden">HEPHD2</span>;
        ISSN:<span class="NLM_cas:issn">0171-2004</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  Sol. guanylate cyclase (sGC) is a key enzyme in the nitric oxide (NO) signalling pathway.  On binding of NO to its prosthetic heme group, sGC catalyzes the synthesis of the second messenger cyclic guanosine monophosphate (cGMP), which promotes vasodilation and inhibits smooth muscle proliferation, leukocyte recruitment, platelet aggregation and vascular remodelling through a no. of downstream mechanisms.  The central role of the NO-sGC-cGMP pathway in regulating pulmonary vascular tone is demonstrated by the dysregulation of NO prodn., sGC activity and cGMP degrdn. in pulmonary hypertension (PH).  The sGC stimulators are novel pharmacol. agents that directly stimulate sGC, both independently of NO and in synergy with NO.  Optimization of the first sGC stimulator, YC-1, led to the development of the more potent and more specific sGC stimulators, BAY 41-2272, BAY 41-8543 and riociguat (BAY 63-2521).  Other sGC stimulators include CFM-1571, BAY 60-4552, vericiguat (BAY 1021189), the acrylamide analog A-350619 and the aminopyrimidine analogs.  BAY 41-2272, BAY 41-8543 and riociguat induced marked dose-dependent redns. in mean pulmonary arterial pressure and vascular resistance with a concomitant increase in cardiac output, and they also reversed vascular remodelling and right heart hypertrophy in several exptl. models of PH.  Riociguat is the first sGC stimulator that has entered clin. development.  Clin. trials have shown that it significantly improves pulmonary vascular haemodynamics and increases exercise ability in patients with pulmonary arterial hypertension (PAH), chronic thromboembolic PH and PH assocd. with interstitial lung disease.  Furthermore, riociguat reduces mean pulmonary arterial pressure in patients with PH assocd. with chronic obstructive pulmonary disease and improves cardiac index and pulmonary vascular resistance in patients with PH assocd. with left ventricular systolic dysfunction.  These promising results suggest that sGC stimulators may constitute a valuable new therapy for PH.  Other trials of riociguat are in progress, including a study of the haemodynamic effects and safety of riociguat in patients with PH assocd. with left ventricular diastolic dysfunction, and long-term extensions of the phase 3 trials investigating the efficacy and safety of riociguat in patients with PAH and chronic thromboembolic PH.  Finally, sGC stimulators may also have potential therapeutic applications in other diseases, including heart failure, lung fibrosis, scleroderma and sickle cell disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt7DHbIDkxIrVg90H21EOLACvtfcHk0lgfKrBG8CEMuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsVOjtb0%253D&md5=e03a5623d72204f41ca7f0324482238b</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2F978-3-662-45805-1_12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-662-45805-1_12%26sid%3Dliteratum%253Aachs%26aulast%3DStasch%26aufirst%3DJ.-P.%26aulast%3DEvgenov%26aufirst%3DO.%2BV.%26atitle%3DSoluble%2520guanylate%2520cyclase%2520stimulators%2520in%2520pulmonary%2520hypertension%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2013%26volume%3D218%26spage%3D279%26epage%3D313%26doi%3D10.1007%2F978-3-662-45805-1_12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Ghofrani, H.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galie, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimminger, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruenig, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humbert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jing, Z.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keogh, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langleben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilama, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritsch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuser, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, L. J.</span><span> </span><span class="NLM_article-title">Riociguat for the treatment of pulmonary arterial hypertension</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">369</span><span class="NLM_x">, </span> <span class="NLM_fpage">330</span><span class="NLM_x">–</span> <span class="NLM_lpage">340</span><span class="refDoi"> DOI: 10.1056/NEJMoa1209655</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1056%2FNEJMoa1209655" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=23883378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2nur7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=330-340&author=H.-A.+Ghofraniauthor=N.+Galieauthor=F.+Grimmingerauthor=E.+Gruenigauthor=M.+Humbertauthor=Z.-C.+Jingauthor=A.+M.+Keoghauthor=D.+Langlebenauthor=M.+O.+Kilamaauthor=A.+Fritschauthor=D.+Neuserauthor=L.+J.+Rubin&title=Riociguat+for+the+treatment+of+pulmonary+arterial+hypertension&doi=10.1056%2FNEJMoa1209655"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Riociguat for the treatment of pulmonary arterial hypertension</span></div><div class="casAuthors">Ghofrani, Hossein-Ardeschir; Galie, Nazzareno; Grimminger, Friedrich; Gruenig, Ekkehard; Humbert, Marc; Jing, Zhi-Cheng; Keogh, Anne M.; Langleben, David; Kilama, Michael Ochan; Fritsch, Arno; Neuser, Dieter; Rubin, Lewis J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">330-340</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Riociguat, a sol. guanylate cyclase stimulator, has been shown in a phase 2 trial to be beneficial in the treatment of pulmonary arterial hypertension.  METHODS: In this phase 3, double-blind study, we randomly assigned 443 patients with symptomatic pulmonary arterial hypertension to receive placebo, riociguat in individually adjusted doses of up to 2.5 mg three times daily (2.5 mg-max. group), or riociguat in individually adjusted doses that were capped at 1.5 mg three times daily (1.5 mg-max. group).  The 1.5 mg-max. group was included for exploratory purposes, and the data from that group were analyzed descriptively.  Patients who were receiving no other treatment for pulmonary arterial hypertension and patients who were receiving endothelin-receptor antagonists or (nonintravenous) prostanoids were eligible.  The primary end point was the change from baseline to the end of week 12 in the distance walked in 6 min.  Secondary end points included the change in pulmonary vascular resistance, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, World Health Organization (WHO) functional class, time to clin. worsening, score on the Borg dyspnea scale, quality-of-life variables, and safety.  RESULTS: By week 12, the 6-min walk distance had increased by a mean of 30 m in the 2.5 mg-max. group and had decreased by a mean of 6 m in the placebo group (least-squares mean difference, 36 m; 95% confidence interval, 20 to 52; P<0.001).  Prespecified subgroup analyses showed that riociguat improved the 6-min walk distance both in patients who were receiving no other treatment for the disease and in those who were receiving endothelin-receptor antagonists or prostanoids.  There were significant improvements in pulmonary vascular resistance (P<0.001), NT-proBNP levels (P<0.001), WHO functional class (P = 0.003), time to clin. worsening (P = 0.005), and Borg dyspnea score (P = 0.002).  The most common serious adverse event in the placebo group and the 2.5 mg-max. group was syncope (4% and 1%, resp.).  CONCLUSIONS: Riociguat significantly improved exercise capacity and secondary efficacy end points in patients with pulmonary arterial hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCUP-sJMAaXrVg90H21EOLACvtfcHk0lgfKrBG8CEMuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2nur7K&md5=dc8f91183c5bfc8c1ec0d0f56b2ac0e2</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1209655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1209655%26sid%3Dliteratum%253Aachs%26aulast%3DGhofrani%26aufirst%3DH.-A.%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DGrimminger%26aufirst%3DF.%26aulast%3DGruenig%26aufirst%3DE.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DJing%26aufirst%3DZ.-C.%26aulast%3DKeogh%26aufirst%3DA.%2BM.%26aulast%3DLangleben%26aufirst%3DD.%26aulast%3DKilama%26aufirst%3DM.%2BO.%26aulast%3DFritsch%26aufirst%3DA.%26aulast%3DNeuser%26aufirst%3DD.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26atitle%3DRiociguat%2520for%2520the%2520treatment%2520of%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D330%26epage%3D340%26doi%3D10.1056%2FNEJMoa1209655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Ghofrani, H.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Armini, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimminger, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeper, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonneau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkins, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritsch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuser, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weimann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span> </span><span class="NLM_article-title">Riociguat for the treatment of chronic thromboembolic pulmonary hypertension</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">369</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">329</span><span class="refDoi"> DOI: 10.1056/NEJMoa1209657</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1056%2FNEJMoa1209657" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=23883377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2nur7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=319-329&author=H.-A.+Ghofraniauthor=A.+M.+D%E2%80%99Arminiauthor=F.+Grimmingerauthor=M.+M.+Hoeperauthor=P.+Jansaauthor=N.+H.+Kimauthor=E.+Mayerauthor=G.+Simonneauauthor=M.+R.+Wilkinsauthor=A.+Fritschauthor=D.+Neuserauthor=G.+Weimannauthor=C.+Wang&title=Riociguat+for+the+treatment+of+chronic+thromboembolic+pulmonary+hypertension&doi=10.1056%2FNEJMoa1209657"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Riociguat for the treatment of chronic thromboembolic pulmonary hypertension</span></div><div class="casAuthors">Ghofrani, Hossein-Ardeschir; D'Armini, Andrea M.; Grimminger, Friedrich; Hoeper, Marius M.; Jansa, Pavel; Kim, Nick H.; Mayer, Eckhard; Simonneau, Gerald; Wilkins, Martin R.; Fritsch, Arno; Neuser, Dieter; Weimann, Gerrit; Wang, Chen</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">319-329</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Riociguat, a member of a new class of compds. (sol. guanylate cyclase stimulators), has been shown in previous clin. studies to be beneficial in the treatment of chronic thromboembolic pulmonary hypertension.  METHODS In this phase 3, multicenter, randomized, double-blind, placebo-controlled study, we randomly assigned 261 patients with inoperable chronic thromboembolic pulmonary hypertension or persistent or recurrent pulmonary hypertension after pulmonary endarterectomy to receive placebo or riociguat.  The primary end point was the change from baseline to the end of week 16 in the distance walked in 6 min.  Secondary end points included changes from baseline in pulmonary vascular resistance, N-terminal pro-brain natriuretic peptide (NT-proBNP) level, World Health Organization (WHO) functional class, time to clin. worsening, Borg dyspnea score, quality-of-life variables, and safety.  RESULTS By week 16, the 6-min walk distance had increased by a mean of 39 m in the riociguat group, as compared with a mean decrease of 6 m in the placebo group (least-squares mean difference, 46 m; 95% confidence interval [CI], 25 to 67; P<0.001).  Pulmonary vascular resistance decreased by 226 dyn·sec·cm-5 in the riociguat group and increased by 23 dyn·sec·cm-5 in the placebo group (least-squares mean difference, -246 dyn·sec·cm-5; 95% CI, -303 to -190; P<0.001).  Riociguat was also assocd. with significant improvements in the NT-proBNP level (P<0.001) and WHO functional class (P = 0.003).  The most common serious adverse events were right ventricular failure (in 3% of patients in each group) and syncope (in 2% of the riociguat group and in 3% of the placebo group).  CONCLUSIONS Riociguat significantly improved exercise capacity and pulmonary vascular resistance in patients with chronic thromboembolic pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2KTSYf5k0YLVg90H21EOLACvtfcHk0lgcadKWrttg4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2nur7J&md5=4b274ffd0efef3d69383bd7d4d1c9275</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1209657&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1209657%26sid%3Dliteratum%253Aachs%26aulast%3DGhofrani%26aufirst%3DH.-A.%26aulast%3DD%25E2%2580%2599Armini%26aufirst%3DA.%2BM.%26aulast%3DGrimminger%26aufirst%3DF.%26aulast%3DHoeper%26aufirst%3DM.%2BM.%26aulast%3DJansa%26aufirst%3DP.%26aulast%3DKim%26aufirst%3DN.%2BH.%26aulast%3DMayer%26aufirst%3DE.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DWilkins%26aufirst%3DM.%2BR.%26aulast%3DFritsch%26aufirst%3DA.%26aulast%3DNeuser%26aufirst%3DD.%26aulast%3DWeimann%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DC.%26atitle%3DRiociguat%2520for%2520the%2520treatment%2520of%2520chronic%2520thromboembolic%2520pulmonary%2520hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D319%26epage%3D329%26doi%3D10.1056%2FNEJMoa1209657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Hambly, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granton, J.</span><span> </span><span class="NLM_article-title">Riociguat for the treatment of pulmonary hypertension</span> <span class="citation_source-journal">Expert Rev. Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">679</span><span class="NLM_x">–</span> <span class="NLM_lpage">695</span><span class="refDoi"> DOI: 10.1586/17476348.2015.1106316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1586%2F17476348.2015.1106316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=26599488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFals73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=679-695&author=N.+Hamblyauthor=J.+Granton&title=Riociguat+for+the+treatment+of+pulmonary+hypertension&doi=10.1586%2F17476348.2015.1106316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Riociguat for the treatment of pulmonary hypertension</span></div><div class="casAuthors">Hambly, Nathan; Granton, John</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Respiratory Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">679-695</span>CODEN:
                <span class="NLM_cas:coden">ERRMBF</span>;
        ISSN:<span class="NLM_cas:issn">1747-6348</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Nitric oxide (NO) is a crit. signaling mol. in the pulmonary vasculature.  NO activates sol. guanylate cyclase (sGC) resulting in the synthesis of cGMP - a key mediator of pulmonary artery vasodilatation that may also inhibit smooth muscle proliferation and platelet aggregation.  Pulmonary hypertension, a serious, progressive and often fatal disease is characterized by NO-sGC-sGMP pathway dysregulation.  Riociguat is a member of a novel therapeutic class known as sol. guanylate stimulators.  Riociguat has a dual mode of action, acting in synergy with endogenous NO and also directly stimulating sGC independently of NO availability.  Phase 3 randomized control trials have demonstrated that riociguat improves clin., physiol. and hemodynamic parameters in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.  In this review we will discuss the pharmacol. properties of riociguat and its appropriate implementation into clin. practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxwFllA7zb87Vg90H21EOLACvtfcHk0lgcadKWrttg4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFals73O&md5=cf270fc6d7dc20a805b0a10919644d14</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1586%2F17476348.2015.1106316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F17476348.2015.1106316%26sid%3Dliteratum%253Aachs%26aulast%3DHambly%26aufirst%3DN.%26aulast%3DGranton%26aufirst%3DJ.%26atitle%3DRiociguat%2520for%2520the%2520treatment%2520of%2520pulmonary%2520hypertension%26jtitle%3DExpert%2520Rev.%2520Respir.%2520Med.%26date%3D2015%26volume%3D9%26spage%3D679%26epage%3D695%26doi%3D10.1586%2F17476348.2015.1106316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Frey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueck, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artmeier-Brandt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weimann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wensing, G.</span><span> </span><span class="NLM_article-title">Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63–2521: an ascending-dose study in healthy male volunteers</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">926</span><span class="NLM_x">–</span> <span class="NLM_lpage">934</span><span class="refDoi"> DOI: 10.1177/0091270008319793</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1177%2F0091270008319793" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=18519919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpslWqur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=926-934&author=R.+Freyauthor=W.+Mueckauthor=S.+Ungerauthor=U.+Artmeier-Brandtauthor=G.+Weimannauthor=G.+Wensing&title=Single-dose+pharmacokinetics%2C+pharmacodynamics%2C+tolerability%2C+and+safety+of+the+soluble+guanylate+cyclase+stimulator+BAY+63%E2%80%932521%3A+an+ascending-dose+study+in+healthy+male+volunteers&doi=10.1177%2F0091270008319793"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers</span></div><div class="casAuthors">Frey, Reiner; Mueck, Wolfgang; Unger, Sigrun; Artmeier-Brandt, Ulrike; Weimann, Gerrit; Wensing, Georg</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">926-934</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The aim of the study was to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of BAY 63-2521, a new drug in development for pulmonary hypertension.  Fifty-eight healthy male volunteers received a single oral dose of BAY 63-2521 (0.25-5 mg) or placebo.  No serious adverse events were reported; there were no life-threatening events.  Heart rate over 1 min, an indicator of the effect of a vasodilating agent on the cardiovascular system in healthy subjects, was increased dose dependently vs. placebo at BAY 63-2521 doses of 1 to 5 mg (P < .01).  Mean arterial and diastolic pressures were decreased vs. placebo at doses of 1 mg (P < .05) and 5 mg (P < .01).  Systolic pressure was not significantly affected.  BAY 63-2521 was readily absorbed and exhibited dose-proportional pharmacokinetics.  The pharmacodynamic and pharmacokinetic properties of BAY 63-2521 suggest that it can offer a unique mode of action in the treatment of pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom6tfQEA1oN7Vg90H21EOLACvtfcHk0lgcadKWrttg4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpslWqur0%253D&md5=770d25ef69e46729dbf3a1bc2080d40f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1177%2F0091270008319793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270008319793%26sid%3Dliteratum%253Aachs%26aulast%3DFrey%26aufirst%3DR.%26aulast%3DMueck%26aufirst%3DW.%26aulast%3DUnger%26aufirst%3DS.%26aulast%3DArtmeier-Brandt%26aufirst%3DU.%26aulast%3DWeimann%26aufirst%3DG.%26aulast%3DWensing%26aufirst%3DG.%26atitle%3DSingle-dose%2520pharmacokinetics%252C%2520pharmacodynamics%252C%2520tolerability%252C%2520and%2520safety%2520of%2520the%2520soluble%2520guanylate%2520cyclase%2520stimulator%2520BAY%252063%25E2%2580%25932521%253A%2520an%2520ascending-dose%2520study%2520in%2520healthy%2520male%2520volunteers%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2008%26volume%3D48%26spage%3D926%26epage%3D934%26doi%3D10.1177%2F0091270008319793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Gheorghiade, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippatos, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maggioni, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ponikowski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraigher-Krainer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samano, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roessig, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pieske, B.</span><span> </span><span class="NLM_article-title">Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial</span> <span class="citation_source-journal">JAMA, J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">314</span><span class="NLM_x">, </span> <span class="NLM_fpage">2251</span><span class="NLM_x">–</span> <span class="NLM_lpage">2262</span><span class="refDoi"> DOI: 10.1001/jama.2015.15734</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1001%2Fjama.2015.15734" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=314&publication_year=2015&pages=2251-2262&author=M.+Gheorghiadeauthor=S.+J.+Greeneauthor=J.+Butlerauthor=G.+Filippatosauthor=C.+S.+Lamauthor=A.+P.+Maggioniauthor=P.+Ponikowskiauthor=S.+J.+Shahauthor=S.+D.+Solomonauthor=E.+Kraigher-Krainerauthor=E.+T.+Samanoauthor=K.+M%C3%BCllerauthor=L.+Roessigauthor=B.+Pieske&title=Effect+of+vericiguat%2C+a+soluble+guanylate+cyclase+stimulator%2C+on+natriuretic+peptide+levels+in+patients+with+worsening+chronic+heart+failure+and+reduced+ejection+fraction%3A+the+SOCRATES-REDUCED+randomized+trial&doi=10.1001%2Fjama.2015.15734"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1001%2Fjama.2015.15734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2015.15734%26sid%3Dliteratum%253Aachs%26aulast%3DGheorghiade%26aufirst%3DM.%26aulast%3DGreene%26aufirst%3DS.%2BJ.%26aulast%3DButler%26aufirst%3DJ.%26aulast%3DFilippatos%26aufirst%3DG.%26aulast%3DLam%26aufirst%3DC.%2BS.%26aulast%3DMaggioni%26aufirst%3DA.%2BP.%26aulast%3DPonikowski%26aufirst%3DP.%26aulast%3DShah%26aufirst%3DS.%2BJ.%26aulast%3DSolomon%26aufirst%3DS.%2BD.%26aulast%3DKraigher-Krainer%26aufirst%3DE.%26aulast%3DSamano%26aufirst%3DE.%2BT.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26aulast%3DRoessig%26aufirst%3DL.%26aulast%3DPieske%26aufirst%3DB.%26atitle%3DEffect%2520of%2520vericiguat%252C%2520a%2520soluble%2520guanylate%2520cyclase%2520stimulator%252C%2520on%2520natriuretic%2520peptide%2520levels%2520in%2520patients%2520with%2520worsening%2520chronic%2520heart%2520failure%2520and%2520reduced%2520ejection%2520fraction%253A%2520the%2520SOCRATES-REDUCED%2520randomized%2520trial%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D2015%26volume%3D314%26spage%3D2251%26epage%3D2262%26doi%3D10.1001%2Fjama.2015.15734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Pieske, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippatos, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maggioni, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ponikowski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraigher-Krainer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samano, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scalise, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roessig, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gheorghiade, M.</span><span> </span><span class="NLM_article-title">Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES)</span> <span class="citation_source-journal">Eur. J. Heart Failure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1026</span><span class="NLM_x">–</span> <span class="NLM_lpage">38</span><span class="refDoi"> DOI: 10.1002/ejhf.135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1002%2Fejhf.135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=25056511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFSqtbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&pages=1026-38&author=B.+Pieskeauthor=J.+Butlerauthor=G.+Filippatosauthor=C.+Lamauthor=A.+P.+Maggioniauthor=P.+Ponikowskiauthor=S.+Shahauthor=S.+Solomonauthor=E.+Kraigher-Krainerauthor=E.+T.+Samanoauthor=A.+V.+Scaliseauthor=K.+Muellerauthor=L.+Roessigauthor=M.+Gheorghiade&title=Rationale+and+design+of+the+SOluble+guanylate+Cyclase+stimulatoR+in+heArT+failurE+Studies+%28SOCRATES%29&doi=10.1002%2Fejhf.135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES)</span></div><div class="casAuthors">Pieske, Burkert; Butler, Javed; Filippatos, Gerasimos; Lam, Carolyn; Maggioni, Aldo Pietro; Ponikowski, Piotr; Shah, Sanjiv; Solomon, Scott; Kraigher-Krainer, Elisabeth; Samano, Eliana Tibana; Scalise, Andrea Viviana; Mueller, Katharina; Roessig, Lothar; Gheorghiade, Mihai; N/A</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Heart Failure</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1026-1038</span>CODEN:
                <span class="NLM_cas:coden">EJHFFS</span>;
        ISSN:<span class="NLM_cas:issn">1388-9842</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Aims : The clin. outcomes for patients with worsening chronic heart failure (WCHF) remain exceedingly poor despite contemporary evidence-based therapies, and effective therapies are urgently needed.  Accumulating evidence supports augmentation of cyclic guanosine monophosphate (cGMP) signalling as a potential therapeutic strategy for HF with reduced or preserved ejection fraction (HFrEF and HFpEF, resp.).  Direct sol. guanylate cyclase (sGC) stimulators target reduced cGMP generation due to insufficient sGC stimulation and represent a promising method for cGMP enhancement.  Methods : The phase II Sol. guanylate Cyclase stimulatoR in heArT failurE Study (SOCRATES) program consists of two randomized, parallel-group, placebo-controlled, double-blind, multicentre studies, SOCRATES-REDUCED (in patients with LVEF <45%) and SOCRATES-PRESERVED (in those with LVEF ≥45%), that will explore the pharmacodynamic effects, safety and tolerability, and pharmacokinetics of four dose regimens of the once-daily oral sGC stimulator vericiguat (BAY 1021189) over 12 wk compared with placebo.  These studies will enrol patients stabilized during hospitalization for HF at the time of discharge or within 4 wk thereafter.  The primary endpoint in SOCRATES-REDUCED is change in NT-proBNP at 12 wk.  The primary endpoints in SOCRATES-PRESERVED are change in NT-proBNP and left atrial vol. at 12 wk.  Perspectives : SOCRATES will be the first program to enrol specifically both inpatients and outpatients with WCHF and patients with reduced or preserved ejection fraction.  Results will inform the benefits of pursuing subsequent event-driven clin. outcome trials with sGC stimulators in this patient population.  Trial registration : NCT01951625 (SOCRATES-REDUCED) and NCT01951638 (SOCRATES-PRESERVED).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHF8JLa8U8grVg90H21EOLACvtfcHk0lguAEGec9ipvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFSqtbfO&md5=cbf713b3a50b74cf4334a54a13240614</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fejhf.135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejhf.135%26sid%3Dliteratum%253Aachs%26aulast%3DPieske%26aufirst%3DB.%26aulast%3DButler%26aufirst%3DJ.%26aulast%3DFilippatos%26aufirst%3DG.%26aulast%3DLam%26aufirst%3DC.%26aulast%3DMaggioni%26aufirst%3DA.%2BP.%26aulast%3DPonikowski%26aufirst%3DP.%26aulast%3DShah%26aufirst%3DS.%26aulast%3DSolomon%26aufirst%3DS.%26aulast%3DKraigher-Krainer%26aufirst%3DE.%26aulast%3DSamano%26aufirst%3DE.%2BT.%26aulast%3DScalise%26aufirst%3DA.%2BV.%26aulast%3DMueller%26aufirst%3DK.%26aulast%3DRoessig%26aufirst%3DL.%26aulast%3DGheorghiade%26aufirst%3DM.%26atitle%3DRationale%2520and%2520design%2520of%2520the%2520SOluble%2520guanylate%2520Cyclase%2520stimulatoR%2520in%2520heArT%2520failurE%2520Studies%2520%2528SOCRATES%2529%26jtitle%3DEur.%2520J.%2520Heart%2520Failure%26date%3D2014%26volume%3D16%26spage%3D1026%26epage%3D38%26doi%3D10.1002%2Fejhf.135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><div class="note"><p class="first last">Clinicaltrials.gov. Identifier: NCT02861534 (accessed August 5, 2016).</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinicaltrials.gov.+Identifier%3A+NCT02861534+%28accessed+August+5%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dgov%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Mittendorf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weigand, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alonso-Alija, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bischoff, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feurer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerisch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kern, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knorr, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muenter, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radtke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schirok, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlemmer, K.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahl, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Straub, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wunder, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stasch, J.-P.</span><span> </span><span class="NLM_article-title">Discovery of riociguat (BAY 63–2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">853</span><span class="NLM_x">–</span> <span class="NLM_lpage">865</span><span class="refDoi"> DOI: 10.1002/cmdc.200900014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1002%2Fcmdc.200900014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=19263460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD1MXls1Kgt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=853-865&author=J.+Mittendorfauthor=S.+Weigandauthor=C.+Alonso-Alijaauthor=E.+Bischoffauthor=A.+Feurerauthor=M.+Gerischauthor=A.+Kernauthor=A.+Knorrauthor=D.+Langauthor=K.+Muenterauthor=M.+Radtkeauthor=H.+Schirokauthor=K.-H.+Schlemmerauthor=E.+Stahlauthor=A.+Straubauthor=F.+Wunderauthor=J.-P.+Stasch&title=Discovery+of+riociguat+%28BAY+63%E2%80%932521%29%3A+a+potent%2C+oral+stimulator+of+soluble+guanylate+cyclase+for+the+treatment+of+pulmonary+hypertension&doi=10.1002%2Fcmdc.200900014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Riociguat (BAY 63-2521): A Potent, Oral Stimulator of Soluble Guanylate Cyclase for the Treatment of Pulmonary Hypertension</span></div><div class="casAuthors">Mittendorf, Joachim; Weigand, Stefan; Alonso-Alija, Cristina; Bischoff, Erwin; Feurer, Achim; Gerisch, Michael; Kern, Armin; Knorr, Andreas; Lang, Dieter; Muenter, Klaus; Radtke, Martin; Schirok, Hartmut; Schlemmer, Karl-Heinz; Stahl, Elke; Straub, Alexander; Wunder, Frank; Stasch, Johannes-Peter</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">853-865</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Direct stimulation of sol. guanylate cyclase (sGC),a key signal-transduction enzyme activated by nitric oxide (NO), represents a promising therapeutic strategy for the treatment of a range of diseases, including the severely disabling pulmonary hypertension (PH).  Impairments of the NO-sGC signaling pathway have been implicated in the pathogenesis of cardiovascular and other diseases.  Optimization of the unfavorable drug metab. and pharmacokinetic (DMPK) profile of previous sGC stimulators provided riociguat I, which is currently being investigated in phase III clin. trials for the oral treatment of PH.  The compd. I exhibited an improved DMPK profile and exerted strong effects on pulmonary hemodynamics and exercise capacity in patients with PH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5xPY0dXoV5rVg90H21EOLACvtfcHk0lj9wLUIN6s6CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXls1Kgt70%253D&md5=c31bd046ee1a1de3014867d10a4e161c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200900014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200900014%26sid%3Dliteratum%253Aachs%26aulast%3DMittendorf%26aufirst%3DJ.%26aulast%3DWeigand%26aufirst%3DS.%26aulast%3DAlonso-Alija%26aufirst%3DC.%26aulast%3DBischoff%26aufirst%3DE.%26aulast%3DFeurer%26aufirst%3DA.%26aulast%3DGerisch%26aufirst%3DM.%26aulast%3DKern%26aufirst%3DA.%26aulast%3DKnorr%26aufirst%3DA.%26aulast%3DLang%26aufirst%3DD.%26aulast%3DMuenter%26aufirst%3DK.%26aulast%3DRadtke%26aufirst%3DM.%26aulast%3DSchirok%26aufirst%3DH.%26aulast%3DSchlemmer%26aufirst%3DK.-H.%26aulast%3DStahl%26aufirst%3DE.%26aulast%3DStraub%26aufirst%3DA.%26aulast%3DWunder%26aufirst%3DF.%26aulast%3DStasch%26aufirst%3DJ.-P.%26atitle%3DDiscovery%2520of%2520riociguat%2520%2528BAY%252063%25E2%2580%25932521%2529%253A%2520a%2520potent%252C%2520oral%2520stimulator%2520of%2520soluble%2520guanylate%2520cyclase%2520for%2520the%2520treatment%2520of%2520pulmonary%2520hypertension%26jtitle%3DChemMedChem%26date%3D2009%26volume%3D4%26spage%3D853%26epage%3D865%26doi%3D10.1002%2Fcmdc.200900014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Gnoth, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopfe, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czembor, W.</span><span> </span><span class="NLM_article-title">Determination of riociguat and its major human metabolite M-1 in human plasma by stable-isotope dilution LCMS/MS</span> <span class="citation_source-journal">Bioanalysis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">193</span><span class="NLM_x">–</span> <span class="NLM_lpage">205</span><span class="refDoi"> DOI: 10.4155/bio.14.257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.4155%2Fbio.14.257" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=193-205&author=M.+J.+Gnothauthor=P.+M.+Hopfeauthor=W.+Czembor&title=Determination+of+riociguat+and+its+major+human+metabolite+M-1+in+human+plasma+by+stable-isotope+dilution+LCMS%2FMS&doi=10.4155%2Fbio.14.257"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.4155%2Fbio.14.257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Fbio.14.257%26sid%3Dliteratum%253Aachs%26aulast%3DGnoth%26aufirst%3DM.%2BJ.%26aulast%3DHopfe%26aufirst%3DP.%2BM.%26aulast%3DCzembor%26aufirst%3DW.%26atitle%3DDetermination%2520of%2520riociguat%2520and%2520its%2520major%2520human%2520metabolite%2520M-1%2520in%2520human%2520plasma%2520by%2520stable-isotope%2520dilution%2520LCMS%252FMS%26jtitle%3DBioanalysis%26date%3D2015%26volume%3D7%26spage%3D193%26epage%3D205%26doi%3D10.4155%2Fbio.14.257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Becker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reber, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weimann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arens, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mück, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dietrich, H.</span><span> </span><span class="NLM_article-title">Pharmacokinetic interaction of riociguat with ketoconazole, clarithromycin, and midazolam</span> <span class="citation_source-journal">Pulm. Circ.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">S49</span><span class="NLM_x">–</span> <span class="NLM_lpage">57</span><span class="refDoi"> DOI: 10.1086/685016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1086%2F685016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=27162627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFSrsLfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=S49-57&author=C.+Beckerauthor=R.+Freyauthor=D.+Thomasauthor=M.+Reberauthor=G.+Weimannauthor=E.+R.+Arensauthor=W.+M%C3%BCckauthor=S.+Ungerauthor=H.+Dietrich&title=Pharmacokinetic+interaction+of+riociguat+with+ketoconazole%2C+clarithromycin%2C+and+midazolam&doi=10.1086%2F685016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic interaction of riociguat with ketoconazole, clarithromycin, and midazolam</span></div><div class="casAuthors">Becker, Corina; Frey, Reiner; Unger, Sigrun; Thomas, Dirk; Reber, Michael; Weimann, Gerrit; Dietrich, Hartmut; Arens, Erich R.; Mueck, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Circulation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">Suppl.1</span>),
    <span class="NLM_cas:pages">S49-S57</span>CODEN:
                <span class="NLM_cas:coden">PCUIAX</span>;
        ISSN:<span class="NLM_cas:issn">2045-8940</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Riociguat is a sol. guanylate cyclase stimulator for the treatment of pulmonary hypertension that is principally metabolized via the cytochrome P 450 (CYP) pathway.  Three studies in healthy males investigated potential pharmacokinetic interactions between riociguat and CYP inhibitors (ketoconazole, clarithromycin, and midazolam).  In two studies, subjects were pretreated with either oncedaily ketoconazole 400 mg or twice-daily clarithromycin 500 mg for 4 days before cotreatment with either riociguat 0.5 mg ± ketoconazole 400 mg or riociguat 1.0 mg ± clarithromycin 500 mg.  In the third study, subjects received riociguat 2.5 mg 3 times daily (tid) for 3 days, followed by cotreatment with riociguat 2.5 mg tid ± midazolam 7.5 mg.  Pharmacokinetic parameters, the effect of smoking on riociguat pharmacokinetics, safety, and tolerability were assessed.  Pre- and cotreatment with ketoconazole and clarithromycin led to increased riociguat exposure.  Pre- and cotreatment with riociguat had no significant effect on midazolam plasma concns.  In all studies, the bioavailability of riociguat was reduced in smokers because its clearance to the metabolite M1 increased.  Riociguat ± ketoconazole, clarithromycin, or midazolam was generally well tolerated.  The most common treatment-emergent adverse events (TEAEs) across all studies were headache and dyspepsia.  One serious TEAE was reported in the midazolam study.  Owing to the potential for hypotension, concomitant use of riociguat with multipathway inhibitors, such as ketoconazole, should be approached with caution.  Coadministration of riociguat with strong CYP3A4 inhibitors, for example, clarithromycin, does not require addnl. dose adjustment.  No significant drugdrug interaction was revealed between riociguat and midazolam.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHFwlD1XDMPrVg90H21EOLACvtfcHk0lj9wLUIN6s6CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFSrsLfL&md5=1f1f0a6e9638cc98bf7e7e9d19eb6cdc</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1086%2F685016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F685016%26sid%3Dliteratum%253Aachs%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DFrey%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DD.%26aulast%3DReber%26aufirst%3DM.%26aulast%3DWeimann%26aufirst%3DG.%26aulast%3DArens%26aufirst%3DE.%2BR.%26aulast%3DM%25C3%25BCck%26aufirst%3DW.%26aulast%3DUnger%26aufirst%3DS.%26aulast%3DDietrich%26aufirst%3DH.%26atitle%3DPharmacokinetic%2520interaction%2520of%2520riociguat%2520with%2520ketoconazole%252C%2520clarithromycin%252C%2520and%2520midazolam%26jtitle%3DPulm.%2520Circ.%26date%3D2016%26volume%3D6%26spage%3DS49%26epage%3D57%26doi%3D10.1086%2F685016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Frey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wensing, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mück, W.</span><span> </span><span class="NLM_article-title">Assessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63–2521)</span> <span class="citation_source-journal">Pulm. Circ.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">S15</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span><span class="refDoi"> DOI: 10.1086/685017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1086%2F685017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=27162624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFSrsb%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=S15-26&author=R.+Freyauthor=C.+Beckerauthor=S.+Ungerauthor=A.+Schmidtauthor=G.+Wensingauthor=W.+M%C3%BCck&title=Assessment+of+the+effects+of+renal+impairment+and+smoking+on+the+pharmacokinetics+of+a+single+oral+dose+of+the+soluble+guanylate+cyclase+stimulator+riociguat+%28BAY+63%E2%80%932521%29&doi=10.1086%2F685017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)</span></div><div class="casAuthors">Frey, Reiner; Becker, Corina; Unger, Sigrun; Schmidt, Anja; Wensing, Georg; Mueck, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Circulation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">Suppl.1</span>),
    <span class="NLM_cas:pages">S15-S26</span>CODEN:
                <span class="NLM_cas:coden">PCUIAX</span>;
        ISSN:<span class="NLM_cas:issn">2045-8940</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Renal impairment is a common comborbidity in patients with pulmonary hypertension.  The breakdown of riociguat, an oral sol. guanylate cyclase stimulator used to treat pulmonary hypertension, may be affected by smoking because polycyclic arom. hydrocarbons in tobacco smoke induce expression of one of the metabolizing enzymes, CYP1A1.  Two nonrandomized, nonblinded studies were therefore performed to investigate the pharmacokinetics and safety of a single oral dose of riociguat 1.0 mg in individuals with mild, moderate, or severe renal impairment compared with age-, wt.-, and sex-matched healthy controls, including either smokers and nonsmokers (study I) or nonsmokers alone (study II).  Pharmacokinetic analyses focused on the integrated per-protocol data set of both studies (N = 63).  In patients with renal impairment, the renal clearance of riociguat was reduced and its terminal half-life prolonged compared with those in healthy controls.  There was a monotonic relationship between creatinine clearance on treatment day and riociguat renal clearance (R2 = 0.62).  However, increased riociguat exposure with decreasing renal function was not strictly proportional.  Riociguat exposure appeared to be greater in nonsmokers than in the combined population of smokers and nonsmokers, irresp. of renal function.  Adverse events were mild to moderate and in line with the mode of action of riociguat.  No serious adverse events occurred.  In conclusion, renal impairment was assocd. with reduced riociguat clearance compared with that in controls; however, riociguat exposure in patients with renal impairment was highly variable, and ranges overlapped with those obsd. in healthy controls.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRNCc4ajIfn7Vg90H21EOLACvtfcHk0lj9wLUIN6s6CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFSrsb%252FP&md5=c6ba0209863fa85dd89bda789526d5cf</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1086%2F685017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F685017%26sid%3Dliteratum%253Aachs%26aulast%3DFrey%26aufirst%3DR.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DUnger%26aufirst%3DS.%26aulast%3DSchmidt%26aufirst%3DA.%26aulast%3DWensing%26aufirst%3DG.%26aulast%3DM%25C3%25BCck%26aufirst%3DW.%26atitle%3DAssessment%2520of%2520the%2520effects%2520of%2520renal%2520impairment%2520and%2520smoking%2520on%2520the%2520pharmacokinetics%2520of%2520a%2520single%2520oral%2520dose%2520of%2520the%2520soluble%2520guanylate%2520cyclase%2520stimulator%2520riociguat%2520%2528BAY%252063%25E2%2580%25932521%2529%26jtitle%3DPulm.%2520Circ.%26date%3D2016%26volume%3D6%26spage%3DS15%26epage%3D26%26doi%3D10.1086%2F685017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Saleh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wensing, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mück, W.</span><span> </span><span class="NLM_article-title">Bioavailability, pharmacokinetics, and safety of riociguat given as an oral suspension or crushed tablet with and without food</span> <span class="citation_source-journal">Pulm. Circ.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">S66</span><span class="NLM_x">–</span> <span class="NLM_lpage">74</span><span class="refDoi"> DOI: 10.1086/685020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1086%2F685020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=27162630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFSrsb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=S66-74&author=S.+Salehauthor=R.+Freyauthor=C.+Beckerauthor=S.+Ungerauthor=G.+Wensingauthor=W.+M%C3%BCck&title=Bioavailability%2C+pharmacokinetics%2C+and+safety+of+riociguat+given+as+an+oral+suspension+or+crushed+tablet+with+and+without+food&doi=10.1086%2F685020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Bioavailability, pharmacokinetics, and safety of riociguat given as an oral suspension or crushed tablet with and without food</span></div><div class="casAuthors">Saleh, Soundos; Frey, Reiner; Becker, Corina; Unger, Sigrun; Wensing, Georg; Mueck, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Circulation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">Suppl.1</span>),
    <span class="NLM_cas:pages">S66-S74</span>CODEN:
                <span class="NLM_cas:coden">PCUIAX</span>;
        ISSN:<span class="NLM_cas:issn">2045-8940</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Riociguat is approved for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.  Some patients have difficulty swallowing tablets; therefore, 2 randomized, nonblinded, crossover studies compared the relative bioavailability of riociguat oral suspensions and immediate-release (IR) tablet and of crushed-tablet prepns. vs. whole IR tablet.  In study 1, 30 healthy subjects received 5 single riociguat doses: 0.3 and 2.4 mg (0.15 mg/mL suspensions), 0.15 mg (0.03 mg/mL), and 1.0 mg (whole IR tablet) under fasted conditions and 2.4 mg (0.15 mg/mL) after a high-fat, high-calorie American-style breakfast.  In study 2, 25 healthy men received 4 single 2.5-mg doses: whole IR tablet and crushed IR tablet suspended in applesauce and water, resp., under fasted conditions, and whole IR tablet after a continental breakfast.  In study 1, dose-normalized pharmacokinetics of riociguat oral suspensions and 1.0-mg whole IR tablet were similar in fasted conditions; 90% confidence intervals for riociguat area under the curve (AUC) to dose and mean max. concn. (Cmax) to dose were within bioequivalence criteria.  After food, dosenormalized AUC and Cmax decreased by 15% and 38%, resp.  In study 2, riociguat exposure was similar for all prepns.; AUC ratios for crushed-IR-tablet prepns. to whole IR tablet were within bioequivalence criteria.  The Cmax increased by 17% for crushed IR tablet in water vs. whole IR tablet.  Food intake decreased Cmax of the whole tablet by 16%, with unaltered AUC vs. fasted conditions.  Riociguat bioavailability was similar between the oral suspensions and the whole IR tablet; exposure was similar between whole IR tablet and crushed-IR-tablet prepns.  Minor food effects were obsd.  Results suggest that riociguat formulations are interchangeable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCzk2V8OkU_7Vg90H21EOLACvtfcHk0ljlTP3Z6lRrnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFSrsb7E&md5=cf030ca125a218be4d27507767c73bf1</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1086%2F685020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F685020%26sid%3Dliteratum%253Aachs%26aulast%3DSaleh%26aufirst%3DS.%26aulast%3DFrey%26aufirst%3DR.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DUnger%26aufirst%3DS.%26aulast%3DWensing%26aufirst%3DG.%26aulast%3DM%25C3%25BCck%26aufirst%3DW.%26atitle%3DBioavailability%252C%2520pharmacokinetics%252C%2520and%2520safety%2520of%2520riociguat%2520given%2520as%2520an%2520oral%2520suspension%2520or%2520crushed%2520tablet%2520with%2520and%2520without%2520food%26jtitle%3DPulm.%2520Circ.%26date%3D2016%26volume%3D6%26spage%3DS66%26epage%3D74%26doi%3D10.1086%2F685020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blode, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshikawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, Y.</span><span> </span><span class="NLM_article-title">Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in healthy young Chinese male non-smokers and smokers: results of a randomized, double-blind, placebo-controlled study</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">615</span><span class="NLM_x">–</span> <span class="NLM_lpage">624</span><span class="refDoi"> DOI: 10.1007/s40262-015-0337-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1007%2Fs40262-015-0337-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=26507720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsleku7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=615-624&author=X.+Zhaoauthor=Z.+Wangauthor=Y.+Wangauthor=H.+Zhangauthor=H.+Blodeauthor=K.+Yoshikawaauthor=C.+Beckerauthor=S.+Ungerauthor=R.+Freyauthor=Y.+Cui&title=Pharmacokinetics+of+the+soluble+guanylate+cyclase+stimulator+riociguat+in+healthy+young+Chinese+male+non-smokers+and+smokers%3A+results+of+a+randomized%2C+double-blind%2C+placebo-controlled+study&doi=10.1007%2Fs40262-015-0337-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat in Healthy Young Chinese Male Non-Smokers and Smokers: Results of a Randomized, Double-Blind, Placebo-Controlled Study</span></div><div class="casAuthors">Zhao, Xia; Wang, Zining; Wang, Yukun; Zhang, Hong; Blode, Hartmut; Yoshikawa, Kenichi; Becker, Corina; Unger, Sigrun; Frey, Reiner; Cui, Yimin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">615-624</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Background and Objectives: The aim of this study was to investigate the pharmacokinetics, safety, and tolerability of riociguat after single and multiple oral doses of 1 or 2 mg three times daily (tid), and to det. the effect of smoking on riociguat pharmacokinetics in Chinese men.  Methods: In a randomized, double-blind, placebo-controlled, single-center study stratified for smokers and non-smokers, healthy Chinese men aged 18-45 years received two riociguat doses: Dose Step 1 (1 mg) then Dose Step 2 (2 mg) conducted after the safety and tolerability at Dose Step 1 was confirmed.  For each step, 12 subjects received riociguat and six received placebo.  A single dose was given on Day 1, followed by a 48-h pharmacokinetic profile.  Multiple-dose treatment tid was then given for 6 days (Days 3-8), with a last single dose on Day 9, followed by a 72-h pharmacokinetic profile.  Primary outcomes were pharmacokinetic parameters for riociguat after single and multiple dosing.  Results: Thirty-six subjects (18 smokers; 18 non-smokers) were randomized and provided valid pharmacokinetic data.  Riociguat and its pharmacol. active metabolite M1 (BAY 60-4552) showed nearly dose-proportional pharmacokinetics.  Accumulation was minimal in smokers and approx. two-fold in non-smokers.  Exposure for riociguat was decreased by ≥60 % in smokers.  No serious or significant adverse events occurred during the study.  Conclusions: Riociguat pharmacokinetics showed dose proportionality in healthy Chinese men, as previously demonstrated in healthy white male individuals.  Exposure to riociguat was substantially decreased in smokers compared with non-smokers.  Riociguat was well tolerated in Chinese men.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8zNDtaEJ7y7Vg90H21EOLACvtfcHk0ljlTP3Z6lRrnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsleku7nI&md5=7883041ec30d2df946fffc9b6166f843</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1007%2Fs40262-015-0337-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-015-0337-4%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DBlode%26aufirst%3DH.%26aulast%3DYoshikawa%26aufirst%3DK.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DUnger%26aufirst%3DS.%26aulast%3DFrey%26aufirst%3DR.%26aulast%3DCui%26aufirst%3DY.%26atitle%3DPharmacokinetics%2520of%2520the%2520soluble%2520guanylate%2520cyclase%2520stimulator%2520riociguat%2520in%2520healthy%2520young%2520Chinese%2520male%2520non-smokers%2520and%2520smokers%253A%2520results%2520of%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520study%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2016%26volume%3D55%26spage%3D615%26epage%3D624%26doi%3D10.1007%2Fs40262-015-0337-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span>Highlights of Prescribing Information: Riociguat (Adempas); <span class="NLM_contrib-group">U.S. Food and Drug Administration</span><span class="NLM_x">: </span><span class="NLM_publisher-loc">Silver Spring, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">; </span><a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204819s002lbl.pdf" class="extLink">http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204819s002lbl.pdf</a> (accessed April 4, 2014).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=U.S.+Food+and+Drug+Administration&title=Highlights+of+Prescribing+Information%3A+Riociguat+%28Adempas%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DHighlights%2520of%2520Prescribing%2520Information%253A%2520Riociguat%2520%2528Adempas%2529%26aulast%3D%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Bitterli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlenmeyer, H.</span><span> </span><span class="NLM_article-title">Some derivatives of triazolopyrimidine</span> <span class="citation_source-journal">Helv. Chim. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1951</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">835</span><span class="NLM_x">–</span> <span class="NLM_lpage">840</span><span class="refDoi"> DOI: 10.1002/hlca.19510340311</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1002%2Fhlca.19510340311" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1951&pages=835-840&author=P.+Bitterliauthor=H.+Erlenmeyer&title=Some+derivatives+of+triazolopyrimidine&doi=10.1002%2Fhlca.19510340311"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fhlca.19510340311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhlca.19510340311%26sid%3Dliteratum%253Aachs%26aulast%3DBitterli%26aufirst%3DP.%26aulast%3DErlenmeyer%26aufirst%3DH.%26atitle%3DSome%2520derivatives%2520of%2520triazolopyrimidine%26jtitle%3DHelv.%2520Chim.%2520Acta%26date%3D1951%26volume%3D34%26spage%3D835%26epage%3D840%26doi%3D10.1002%2Fhlca.19510340311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Reinecke, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodrow, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, E. S.</span><span> </span><span class="NLM_article-title">Pyrazolo[3,4-<i>c</i>]pyridazines from hydrazine and aminothiophenecarboxylates</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1018</span><span class="NLM_x">–</span> <span class="NLM_lpage">1021</span><span class="refDoi"> DOI: 10.1021/jo00029a046</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00029a046" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1992&pages=1018-1021&author=M.+G.+Reineckeauthor=T.+A.+Woodrowauthor=E.+S.+Brown&title=Pyrazolo%5B3%2C4-c%5Dpyridazines+from+hydrazine+and+aminothiophenecarboxylates&doi=10.1021%2Fjo00029a046"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjo00029a046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00029a046%26sid%3Dliteratum%253Aachs%26aulast%3DReinecke%26aufirst%3DM.%2BG.%26aulast%3DWoodrow%26aufirst%3DT.%2BA.%26aulast%3DBrown%26aufirst%3DE.%2BS.%26atitle%3DPyrazolo%255B3%252C4-c%255Dpyridazines%2520from%2520hydrazine%2520and%2520aminothiophenecarboxylates%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1992%26volume%3D57%26spage%3D1018%26epage%3D1021%26doi%3D10.1021%2Fjo00029a046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Wunder, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stasch, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hütter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alonso-Alija, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hüser, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohrmann, E.</span><span> </span><span class="NLM_article-title">A cell-based cGMP assay useful for ultra-high-throughput screening and identification of modulators of the nitric oxide/cGMP pathway</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">339</span><span class="NLM_x">, </span> <span class="NLM_fpage">104</span><span class="NLM_x">–</span> <span class="NLM_lpage">112</span><span class="refDoi"> DOI: 10.1016/j.ab.2004.12.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1016%2Fj.ab.2004.12.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=15766716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD2MXit1eqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=2005&pages=104-112&author=F.+Wunderauthor=J.-P.+Staschauthor=J.+H%C3%BCtterauthor=C.+Alonso-Alijaauthor=J.+H%C3%BCserauthor=E.+Lohrmann&title=A+cell-based+cGMP+assay+useful+for+ultra-high-throughput+screening+and+identification+of+modulators+of+the+nitric+oxide%2FcGMP+pathway&doi=10.1016%2Fj.ab.2004.12.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A cell-based cGMP assay useful for ultra-high-throughput screening and identification of modulators of the nitric oxide/cGMP pathway</span></div><div class="casAuthors">Wunder, Frank; Stasch, Johannes-Peter; Huetter, Joachim; Alonso-Alija, Cristina; Hueser, Joerg; Lohrmann, Emanuel</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">104-112</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">We have established a rapid, homogeneous, cell-based, and highly sensitive assay for guanosine 3'-5'-cyclic monophosphate (cGMP) that is suitable for fully automated ultra-high-throughput screening.  In this assay system, cGMP prodn. is monitored in living cells via Ca2+ influx through the olfactory cyclic nucleotide-gated cation channel CNGA2, acting as the intracellular cGMP sensor.  A stably transfected Chinese hamster ovary (CHO) cell line was generated recombinantly expressing sol. guanylate cyclase, CNGA2, and aequorin as a luminescence indicator for the intracellular calcium concn.  This cell line was used to screen more than 900,000 compds. in an automated ultra-high-throughput screening assay using 1536-well microtiter plates.  In this way, we have been able to identify BAY 58-2667, a member of a new class of amino dicarboxylic acids that directly activate sol. guanylate cyclase.  The assay system allows the real-time cGMP detection within living cells and makes it possible to screen for activators and inhibitors of enzymes involved in the nitric oxide/cGMP pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlaXais-WpGbVg90H21EOLACvtfcHk0lja60QbwZjBdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXit1eqsLs%253D&md5=786bd47ac381d859ce8eee7af9ac498b</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2004.12.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2004.12.025%26sid%3Dliteratum%253Aachs%26aulast%3DWunder%26aufirst%3DF.%26aulast%3DStasch%26aufirst%3DJ.-P.%26aulast%3DH%25C3%25BCtter%26aufirst%3DJ.%26aulast%3DAlonso-Alija%26aufirst%3DC.%26aulast%3DH%25C3%25BCser%26aufirst%3DJ.%26aulast%3DLohrmann%26aufirst%3DE.%26atitle%3DA%2520cell-based%2520cGMP%2520assay%2520useful%2520for%2520ultra-high-throughput%2520screening%2520and%2520identification%2520of%2520modulators%2520of%2520the%2520nitric%2520oxide%252FcGMP%2520pathway%26jtitle%3DAnal.%2520Biochem.%26date%3D2005%26volume%3D339%26spage%3D104%26epage%3D112%26doi%3D10.1016%2Fj.ab.2004.12.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Hillisch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wild, H.</span><span> </span><span class="NLM_article-title">Computational chemistry in the pharmaceutical industry: from childhood to adolescence</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1958</span><span class="NLM_x">–</span> <span class="NLM_lpage">1962</span><span class="refDoi"> DOI: 10.1002/cmdc.201500346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1002%2Fcmdc.201500346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=26358802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVyju73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1958-1962&author=A.+Hillischauthor=N.+Heinrichauthor=H.+Wild&title=Computational+chemistry+in+the+pharmaceutical+industry%3A+from+childhood+to+adolescence&doi=10.1002%2Fcmdc.201500346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Computational Chemistry in the Pharmaceutical Industry: From Childhood to Adolescence</span></div><div class="casAuthors">Hillisch, Alexander; Heinrich, Nikolaus; Wild, Hanno</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1958-1962</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Computational chem. within the pharmaceutical industry has grown into a field that proactively contributes to many aspects of drug design, including target selection and lead identification and optimization.  While methodol. advancements have been key to this development, organizational developments have been crucial to our success as well.  In particular, the interaction between computational and medicinal chem. and the integration of computational chem. into the entire drug discovery process have been invaluable.  Over the past ten years we have shaped and developed a highly efficient computational chem. group for small-mol. drug discovery at Bayer HealthCare that has significantly impacted the clin. development pipeline.  In this article we describe the setup and tasks of the computational group and discuss external collaborations.  We explain what we have found to be the most valuable and productive methods and discuss future directions for computational chem. method development.  We share this information with the hope of igniting interesting discussions around this topic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAFXZ0bBJeBrVg90H21EOLACvtfcHk0lja60QbwZjBdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVyju73L&md5=1d5d7d908463585ac45b048a395b0dac</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500346%26sid%3Dliteratum%253Aachs%26aulast%3DHillisch%26aufirst%3DA.%26aulast%3DHeinrich%26aufirst%3DN.%26aulast%3DWild%26aufirst%3DH.%26atitle%3DComputational%2520chemistry%2520in%2520the%2520pharmaceutical%2520industry%253A%2520from%2520childhood%2520to%2520adolescence%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D1958%26epage%3D1962%26doi%3D10.1002%2Fcmdc.201500346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Burkhard, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wuitschik, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers-Evans, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carreira, E. M.</span><span> </span><span class="NLM_article-title">Oxetanes as versatile elements in drug discovery and synthesis</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">9052</span><span class="NLM_x">–</span> <span class="NLM_lpage">9067</span><span class="refDoi"> DOI: 10.1002/anie.200907155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1002%2Fanie.200907155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVCjsb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=9052-9067&author=J.+A.+Burkhardauthor=G.+Wuitschikauthor=M.+Rogers-Evansauthor=K.+M%C3%BCllerauthor=E.+M.+Carreira&title=Oxetanes+as+versatile+elements+in+drug+discovery+and+synthesis&doi=10.1002%2Fanie.200907155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Oxetanes as Versatile Elements in Drug Discovery and Synthesis</span></div><div class="casAuthors">Burkhard, Johannes A.; Wuitschik, Georg; Rogers-Evans, Mark; Mueller, Klaus; Carreira, Erick M.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">9052-9067</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Sizable resources, both financial and human, are invested each year in the development of new pharmaceutical agents.  However, despite improved techniques, the new compds. often encounter difficulties in satisfying and overcoming the numerous physicochem. and many pharmacol. constraints and hurdles.  Oxetanes have been shown to improve key properties when grafted onto mol. scaffolds.  Of particular interest are oxetanes that are substituted only in the 3-position, since such units remain achiral and their introduction into a mol. scaffold does not create a new stereocenter.  This Minireview gives an overview of the recent advances made in the prepn. and use of 3-substituted oxetanes.  It also includes a discussion of the site-dependent modifications of various physicochem. and biochem. properties that result from the incorporation of the oxetane unit in mol. architectures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrV5kqCeZ5EGbVg90H21EOLACvtfcHk0lja60QbwZjBdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVCjsb7M&md5=52d9b21c280702ff7f95d27d07ea5eed</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Fanie.200907155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200907155%26sid%3Dliteratum%253Aachs%26aulast%3DBurkhard%26aufirst%3DJ.%2BA.%26aulast%3DWuitschik%26aufirst%3DG.%26aulast%3DRogers-Evans%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26aulast%3DCarreira%26aufirst%3DE.%2BM.%26atitle%3DOxetanes%2520as%2520versatile%2520elements%2520in%2520drug%2520discovery%2520and%2520synthesis%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2010%26volume%3D49%26spage%3D9052%26epage%3D9067%26doi%3D10.1002%2Fanie.200907155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Wuitschik, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carreira, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parrilla, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuler, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers-Evans, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, K.</span><span> </span><span class="NLM_article-title">Oxetanes in drug discovery: structural and synthetic insights</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3227</span><span class="NLM_x">–</span> <span class="NLM_lpage">3246</span><span class="refDoi"> DOI: 10.1021/jm9018788</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9018788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFKjt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3227-3246&author=G.+Wuitschikauthor=E.+M.+Carreiraauthor=B.+Wagnerauthor=H.+Fischerauthor=I.+Parrillaauthor=F.+Schulerauthor=M.+Rogers-Evansauthor=K.+M%C3%BCller&title=Oxetanes+in+drug+discovery%3A+structural+and+synthetic+insights&doi=10.1021%2Fjm9018788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Oxetanes in Drug Discovery: Structural and Synthetic Insights</span></div><div class="casAuthors">Wuitschik, Georg; Carreira, Erick M.; Wagner, Bjorn; Fischer, Holger; Parrilla, Isabelle; Schuler, Franz; Rogers-Evans, Mark; Muller, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3227-3246</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The use of oxetanes as replacements for gem-di-Me or carbonyl groups and their effects on the aq. soly., lipophilicity, metabolic stability, and conformation for various compds. are studied; methods for the prepn. of a variety of substituted oxetanes are given.  The magnitude of changes in properties and in metabolic stability with oxetane substitution depends on the structural context; for example, substitution of a gem-di-Me group with an oxetane, aq. soly. may increase by a factor of 4 to more than 4000 while reducing the rate of metabolic degrdn. in most cases.  Incorporation of an oxetane into an aliph. chain increases in some cases the preference for synclinal conformations rather than antiplanar conformations of the chain.  Spirocyclic oxetanes such as an oxazaspiroheptane resemble commonly used fragments in drug discovery, such as morpholines, and in some cases increase aq. soly. more effectively than morpholines.  An improved chemoselective oxidn. of 3-oxetanol to 3-oxetanone is disclosed; olefination of 3-oxetanone by a variety of methods yields alkylideneoxetanes I [R = (EtO)2P(:O), OHC, O2N, EtO2C, NC, PhO2S, MeCO, 1-(4-chlorophenyl)-1-cyclobutanecarbonyl].  I (R = EtO2C, OHC, O2N) undergo addn. reactions with nucleophiles such as amines, carbonyl compds., and arylboronic acids to give oxetanes such as II.  The crystal structures of a variety of oxetanes are detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYbJqJGrlPJrVg90H21EOLACvtfcHk0liK1Uqo08VnRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFKjt7s%253D&md5=e95742d38e933c2fb0d76d638ccc773c</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm9018788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9018788%26sid%3Dliteratum%253Aachs%26aulast%3DWuitschik%26aufirst%3DG.%26aulast%3DCarreira%26aufirst%3DE.%2BM.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DParrilla%26aufirst%3DI.%26aulast%3DSchuler%26aufirst%3DF.%26aulast%3DRogers-Evans%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26atitle%3DOxetanes%2520in%2520drug%2520discovery%253A%2520structural%2520and%2520synthetic%2520insights%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3227%26epage%3D3246%26doi%3D10.1021%2Fjm9018788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. J.</span><span> </span><span class="NLM_article-title">Molecular property design: does everyone get it?</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">722</span><span class="NLM_x">–</span> <span class="NLM_lpage">725</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00157</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00157" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptVGksr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=722-725&author=P.+D.+Leesonauthor=R.+J.+Young&title=Molecular+property+design%3A+does+everyone+get+it%3F&doi=10.1021%2Facsmedchemlett.5b00157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Property Design: Does Everyone Get It?</span></div><div class="casAuthors">Leeson, Paul D.; Young, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">722-725</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The principles of mol. property optimization in drug design have been understood for decades, yet much drug discovery activity today is conducted at the periphery of historical druglike property space.  Lead optimization trajectories aimed at reducing physicochem. risk, assisted by ligand efficiency metrics, could help to reduce clin. attrition rates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_t8gIn79arVg90H21EOLACvtfcHk0liK1Uqo08VnRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptVGksr4%253D&md5=5a807a8d049ce8cf4adc186891a9234d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00157%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26atitle%3DMolecular%2520property%2520design%253A%2520does%2520everyone%2520get%2520it%253F%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D722%26epage%3D725%26doi%3D10.1021%2Facsmedchemlett.5b00157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Sharkovska, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrenz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wellkisch, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geschka, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Relle, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hocher, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stasch, J.-P.</span><span> </span><span class="NLM_article-title">Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models</span> <span class="citation_source-journal">J. Hypertens.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1666</span><span class="NLM_x">–</span> <span class="NLM_lpage">1675</span><span class="refDoi"> DOI: 10.1097/HJH.0b013e32833b558c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1097%2FHJH.0b013e32833b558c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=20613628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptVCnu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=1666-1675&author=Y.+Sharkovskaauthor=P.+Kalkauthor=B.+Lawrenzauthor=M.+Godesauthor=L.+S.+Hoffmannauthor=K.+Wellkischauthor=S.+Geschkaauthor=K.+Relleauthor=B.+Hocherauthor=J.-P.+Stasch&title=Nitric+oxide-independent+stimulation+of+soluble+guanylate+cyclase+reduces+organ+damage+in+experimental+low-renin+and+high-renin+models&doi=10.1097%2FHJH.0b013e32833b558c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models</span></div><div class="casAuthors">Sharkovska, Yuliya; Kalk, Philipp; Lawrenz, Bettina; Godes, Michael; Hoffmann, Linda Sarah; Wellkisch, Kathrin; Geschka, Sandra; Relle, Katharina; Hocher, Berthold; Stasch, Johannes-Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hypertension</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1666-1675</span>CODEN:
                <span class="NLM_cas:coden">JOHYD3</span>;
        ISSN:<span class="NLM_cas:issn">0263-6352</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The nitric oxide-sol. guanylate cyclase (sGC)-cGMP signal transduction pathway is impaired in different cardiovascular diseases, including pulmonary hypertension, heart failure and arterial hypertension.  Riociguat is a novel stimulator of sol. guanylate cyclase (sGC).  However, little is known about the effects of sGC stimulators in exptl. models of hypertension.  We thus investigated the cardio-renal protective effects of riociguat in low-renin and high-renin rat models of hypertension.  The vasorelaxant effect of riociguat was tested in vitro on isolated saphenous artery rings of normal and nitrate tolerant rabbits.  The cardiovascular in-vivo effects of sGC stimulation were evaluated in hypertensive renin-transgenic rats treated with the nitric oxide-synthase inhibitor N-nitro-L-arginine Me ester (L-NAME) (high-renin model) and in rats with 5/6 nephrectomy (low-renin model).  In both animal models, riociguat treatment improved survival and normalized blood pressure.  Moreover, in the L-NAME study part, riociguat reduced cardiac target organ damage as indicated by lower plasma ANP, lower relative left ventricular wt. and lower cardiac interstitial fibrosis, and reduced renal target organ damage as indicated by lower plasma creatinine and urea, less glomerulosclerosis and less renal interstitial fibrosis.  In the 5/6 nephrectomy study part, riociguat reduced cardiac target organ damage as indicated by lower plasma ANP, lower relative left ventricular wt., lower myocyte diam. and lower arterial media/lm ratio, and reduced renal target organ damage as indicated by improved creatinine clearance and less renal interstitial fibrosis.  We demonstrate for the first time that the novel sGC stimulator riociguat shows in 2 independent models of hypertension a potent protection against cardiac and renal target organ damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0juIRGvsi4bVg90H21EOLACvtfcHk0liK1Uqo08VnRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptVCnu7c%253D&md5=ab79d2d2ca05457bc9e23f9cbfca9960</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1097%2FHJH.0b013e32833b558c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FHJH.0b013e32833b558c%26sid%3Dliteratum%253Aachs%26aulast%3DSharkovska%26aufirst%3DY.%26aulast%3DKalk%26aufirst%3DP.%26aulast%3DLawrenz%26aufirst%3DB.%26aulast%3DGodes%26aufirst%3DM.%26aulast%3DHoffmann%26aufirst%3DL.%2BS.%26aulast%3DWellkisch%26aufirst%3DK.%26aulast%3DGeschka%26aufirst%3DS.%26aulast%3DRelle%26aufirst%3DK.%26aulast%3DHocher%26aufirst%3DB.%26aulast%3DStasch%26aufirst%3DJ.-P.%26atitle%3DNitric%2520oxide-independent%2520stimulation%2520of%2520soluble%2520guanylate%2520cyclase%2520reduces%2520organ%2520damage%2520in%2520experimental%2520low-renin%2520and%2520high-renin%2520models%26jtitle%3DJ.%2520Hypertens.%26date%3D2010%26volume%3D28%26spage%3D1666%26epage%3D1675%26doi%3D10.1097%2FHJH.0b013e32833b558c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Dubin, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, S. J.</span><span> </span><span class="NLM_article-title">Soluble guanylate cyclase stimulators: a novel treatment option for heart failure associated with cardiorenal syndromes?</span> <span class="citation_source-journal">Curr. Heart Failure Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">132</span><span class="NLM_x">–</span> <span class="NLM_lpage">139</span><span class="refDoi"> DOI: 10.1007/s11897-016-0290-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1007%2Fs11897-016-0290-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=27118234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC28XntVOgur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=132-139&author=R.+F.+Dubinauthor=S.+J.+Shah&title=Soluble+guanylate+cyclase+stimulators%3A+a+novel+treatment+option+for+heart+failure+associated+with+cardiorenal+syndromes%3F&doi=10.1007%2Fs11897-016-0290-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble Guanylate Cyclase Stimulators: a Novel Treatment Option for Heart Failure Associated with Cardiorenal Syndromes?</span></div><div class="casAuthors">Dubin, Ruth F.; Shah, Sanjiv J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Heart Failure Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">132-139</span>CODEN:
                <span class="NLM_cas:coden">CHFRCF</span>;
        ISSN:<span class="NLM_cas:issn">1546-9549</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Heart failure in the setting of chronic kidney disease (CKD) is an increasingly common scenario and carries a poor prognosis.  Clinicians lack tools for primary or secondary heart failure prevention in patients with cardiorenal syndromes.  In patients without CKD, angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARB) and statins mitigate cardiovascular risk in large part due to salutary effects on the endothelium.  In the setting of CKD, use of these therapies is limited by adverse effects of hyperkalemia in pre-dialysis CKD (ACE-I/ARB), or potential increased risk of stroke in end-stage renal disease (statins).  The sol. guanylate cyclase (sGC) stimulators are a novel class of medications that promote endothelial and myocardial function with no known risk of hyperkalemia or stroke.  In this review, we discuss the evidence emerging from recent clin. trials of sGC stimulators in pulmonary hypertension and heart failure, the diseased pathways involved in cardiorenal syndromes likely to be restored by sGC stimulators, and several strategies for designing future clin. trials of cardiorenal syndromes that might shorten the timeline for discovery and approval of effective cardiovascular therapies in these high-risk patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxrjVgp8bdTbVg90H21EOLACvtfcHk0liprAqpHnABIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntVOgur4%253D&md5=dd2f59e79d0515c7a2064cd41024ce57</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1007%2Fs11897-016-0290-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11897-016-0290-z%26sid%3Dliteratum%253Aachs%26aulast%3DDubin%26aufirst%3DR.%2BF.%26aulast%3DShah%26aufirst%3DS.%2BJ.%26atitle%3DSoluble%2520guanylate%2520cyclase%2520stimulators%253A%2520a%2520novel%2520treatment%2520option%2520for%2520heart%2520failure%2520associated%2520with%2520cardiorenal%2520syndromes%253F%26jtitle%3DCurr.%2520Heart%2520Failure%2520Rep.%26date%3D2016%26volume%3D13%26spage%3D132%26epage%3D139%26doi%3D10.1007%2Fs11897-016-0290-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Follmann, M.; Stasch, J.-P.; Redlich, G.; Griebenow, N.; Lang, D.; Wunder, F.; Huebsch, W.; Lindner, N.; Vakalopoulos, A.; Tersteegen, A.</span><span> </span><span class="NLM_article-title">Preparation of annelated pyrimidine derivatives useful in the treatment and prophylaxis of cardiovascular diseases</span>. WO2013030288,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=M.+Follmann&author=J.-P.+Stasch&author=G.+Redlich&author=N.+Griebenow&author=D.+Lang&author=F.+Wunder&author=W.+Huebsch&author=N.+Lindner&author=A.+Vakalopoulos&author=A.+Tersteegen&title=Preparation+of+annelated+pyrimidine+derivatives+useful+in+the+treatment+and+prophylaxis+of+cardiovascular+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFollmann%26aufirst%3DM.%26atitle%3DPreparation%2520of%2520annelated%2520pyrimidine%2520derivatives%2520useful%2520in%2520the%2520treatment%2520and%2520prophylaxis%2520of%2520cardiovascular%2520diseases%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Follmann, M.; Stasch, J.-P.; Redlich, G.; Ackerstaff, J.; Griebenow, N.; Knorr, A.; Wunder, F.; Li, V. M.-J.; Baerfacker, L.; Weigand, S.</span><span> </span><span class="NLM_article-title">Bicyclic aza-heterocycles as guanylate cyclase inhibitors and their preparation and use in the treatment of cardiovascular diseases</span>. WO 2012028647,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+Follmann&author=J.-P.+Stasch&author=G.+Redlich&author=J.+Ackerstaff&author=N.+Griebenow&author=A.+Knorr&author=F.+Wunder&author=V.+M.-J.+Li&author=L.+Baerfacker&author=S.+Weigand&title=Bicyclic+aza-heterocycles+as+guanylate+cyclase+inhibitors+and+their+preparation+and+use+in+the+treatment+of+cardiovascular+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFollmann%26aufirst%3DM.%26atitle%3DBicyclic%2520aza-heterocycles%2520as%2520guanylate%2520cyclase%2520inhibitors%2520and%2520their%2520preparation%2520and%2520use%2520in%2520the%2520treatment%2520of%2520cardiovascular%2520diseases%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Follmann, M.; Stasch, J.-P.; Redlich, G.; Ackerstaff, J.; Griebenow, N.; Knorr, A.; Wunder, F.; Li, V. M.-J.; Schirok, H.; Jautelat, R.</span><span> </span><span class="NLM_article-title">Substituted methyl pyrimidin-5-yl carbamates as guanylate cyclase inhibitors and their preparation and use in the treatment of cardiovascular diseases</span>. WO 2012010578,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+Follmann&author=J.-P.+Stasch&author=G.+Redlich&author=J.+Ackerstaff&author=N.+Griebenow&author=A.+Knorr&author=F.+Wunder&author=V.+M.-J.+Li&author=H.+Schirok&author=R.+Jautelat&title=Substituted+methyl+pyrimidin-5-yl+carbamates+as+guanylate+cyclase+inhibitors+and+their+preparation+and+use+in+the+treatment+of+cardiovascular+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFollmann%26aufirst%3DM.%26atitle%3DSubstituted%2520methyl%2520pyrimidin-5-yl%2520carbamates%2520as%2520guanylate%2520cyclase%2520inhibitors%2520and%2520their%2520preparation%2520and%2520use%2520in%2520the%2520treatment%2520of%2520cardiovascular%2520diseases%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Alonso-Alija, C.; Bischoff, E.; Muenter, K.; Stasch, J.-P.; Stahl, E.; Weigand, S.; Feurer, A.</span><span> </span><span class="NLM_article-title">Preparation of [(pyrazolopyridinyl)pyrimidinyl]carbamates stimulating soluble guanylate cyclase for treating cardiovascular diseases and/or sexual dysfunction</span>. WO 2003095451,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=C.+Alonso-Alija&author=E.+Bischoff&author=K.+Muenter&author=J.-P.+Stasch&author=E.+Stahl&author=S.+Weigand&author=A.+Feurer&title=Preparation+of+%5B%28pyrazolopyridinyl%29pyrimidinyl%5Dcarbamates+stimulating+soluble+guanylate+cyclase+for+treating+cardiovascular+diseases+and%2For+sexual+dysfunction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlonso-Alija%26aufirst%3DC.%26atitle%3DPreparation%2520of%2520%255B%2528pyrazolopyridinyl%2529pyrimidinyl%255Dcarbamates%2520stimulating%2520soluble%2520guanylate%2520cyclase%2520for%2520treating%2520cardiovascular%2520diseases%2520and%252For%2520sexual%2520dysfunction%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Follmann, M.; Stasch, J.-P.; Redlich, G.; Ackerstaff, J.; Griebenow, N.; Wunder, F.; Li, V. M.-J.; Mittendorf, J.; Jautelat, R.</span><span> </span><span class="NLM_article-title">Carbamate-substituted diaminopyrimidines as guanylate cyclase inhibitors and their preparation and use in the treatment of cardiovascular diseases</span>. WO 2012010576,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+Follmann&author=J.-P.+Stasch&author=G.+Redlich&author=J.+Ackerstaff&author=N.+Griebenow&author=F.+Wunder&author=V.+M.-J.+Li&author=J.+Mittendorf&author=R.+Jautelat&title=Carbamate-substituted+diaminopyrimidines+as+guanylate+cyclase+inhibitors+and+their+preparation+and+use+in+the+treatment+of+cardiovascular+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFollmann%26aufirst%3DM.%26atitle%3DCarbamate-substituted%2520diaminopyrimidines%2520as%2520guanylate%2520cyclase%2520inhibitors%2520and%2520their%2520preparation%2520and%2520use%2520in%2520the%2520treatment%2520of%2520cardiovascular%2520diseases%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Schirok, H.; Mittendorf, J.; Stasch, J.-P.; Wunder, F.; Stoll, F.; Schlemmer, K.-H.</span><span> </span><span class="NLM_article-title">Azabicyclic derivatives as stimulators of guanylate cyclase, their preparation, pharmaceutical compositions, and use for the treatment of cardiovascular disorders</span>. WO 2008031513,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=H.+Schirok&author=J.+Mittendorf&author=J.-P.+Stasch&author=F.+Wunder&author=F.+Stoll&author=K.-H.+Schlemmer&title=Azabicyclic+derivatives+as+stimulators+of+guanylate+cyclase%2C+their+preparation%2C+pharmaceutical+compositions%2C+and+use+for+the+treatment+of+cardiovascular+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSchirok%26aufirst%3DH.%26atitle%3DAzabicyclic%2520derivatives%2520as%2520stimulators%2520of%2520guanylate%2520cyclase%252C%2520their%2520preparation%252C%2520pharmaceutical%2520compositions%252C%2520and%2520use%2520for%2520the%2520treatment%2520of%2520cardiovascular%2520disorders%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Follmann, M.; Stasch, J.-P.; Redlich, G.; Ackerstaff, J.; Griebenow, N.; Knorr, A.; Wunder, F.; Li, V. M.-J.; Mittendorf, J.; Schlemmer, K.-H.; Jautelat, R.</span><span> </span><span class="NLM_article-title">Substituted 6-fluoro-1<i>H</i>-pyrazolo[4,3-<i>b</i>]pyridines as guanylate cyclase inhibitors and their preparation and use in the treatment of cardiovascular diseases</span>. WO 2012059549,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+Follmann&author=J.-P.+Stasch&author=G.+Redlich&author=J.+Ackerstaff&author=N.+Griebenow&author=A.+Knorr&author=F.+Wunder&author=V.+M.-J.+Li&author=J.+Mittendorf&author=K.-H.+Schlemmer&author=R.+Jautelat&title=Substituted+6-fluoro-1H-pyrazolo%5B4%2C3-b%5Dpyridines+as+guanylate+cyclase+inhibitors+and+their+preparation+and+use+in+the+treatment+of+cardiovascular+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFollmann%26aufirst%3DM.%26atitle%3DSubstituted%25206-fluoro-1H-pyrazolo%255B4%252C3-b%255Dpyridines%2520as%2520guanylate%2520cyclase%2520inhibitors%2520and%2520their%2520preparation%2520and%2520use%2520in%2520the%2520treatment%2520of%2520cardiovascular%2520diseases%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Follmann, M.; Stasch, J.-P.; Redlich, G.; Straub, A.; Ackerstaff, J.; Griebenow, N.; Knorr, A.; Wunder, F.; Li, V. M.-J.</span><span> </span><span class="NLM_article-title">Substituted imidazopyridazines as guanylate cyclase inhibitors and their preparation and use in the treatment of cardiovascular diseases</span>. WO 2012152630,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+Follmann&author=J.-P.+Stasch&author=G.+Redlich&author=A.+Straub&author=J.+Ackerstaff&author=N.+Griebenow&author=A.+Knorr&author=F.+Wunder&author=V.+M.-J.+Li&title=Substituted+imidazopyridazines+as+guanylate+cyclase+inhibitors+and+their+preparation+and+use+in+the+treatment+of+cardiovascular+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFollmann%26aufirst%3DM.%26atitle%3DSubstituted%2520imidazopyridazines%2520as%2520guanylate%2520cyclase%2520inhibitors%2520and%2520their%2520preparation%2520and%2520use%2520in%2520the%2520treatment%2520of%2520cardiovascular%2520diseases%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Straub, A.; Feurer, A.; Alonso-Alija, C.; Stasch, J.-P.; Perzborn, E.; Huetter, J.; Dembowsky, K.; Stahl, E.</span><span> </span><span class="NLM_article-title">Substituted pyrazole derivatives condensed with six-membered heterocyclic rings as cardiovascular agents and their preparation</span>. WO 2000006569,<span class="NLM_x"> </span><span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=A.+Straub&author=A.+Feurer&author=C.+Alonso-Alija&author=J.-P.+Stasch&author=E.+Perzborn&author=J.+Huetter&author=K.+Dembowsky&author=E.+Stahl&title=Substituted+pyrazole+derivatives+condensed+with+six-membered+heterocyclic+rings+as+cardiovascular+agents+and+their+preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DStraub%26aufirst%3DA.%26atitle%3DSubstituted%2520pyrazole%2520derivatives%2520condensed%2520with%2520six-membered%2520heterocyclic%2520rings%2520as%2520cardiovascular%2520agents%2520and%2520their%2520preparation%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Walsky, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span> </span><span class="NLM_article-title">Validated assays for human cytochrome P450 activities</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">647</span><span class="NLM_x">–</span> <span class="NLM_lpage">660</span><span class="refDoi"> DOI: 10.1124/dmd.32.6.647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1124%2Fdmd.32.6.647" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=15155557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktlOgt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2004&pages=647-660&author=R.+L.+Walskyauthor=R.+S.+Obach&title=Validated+assays+for+human+cytochrome+P450+activities&doi=10.1124%2Fdmd.32.6.647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Validated assays for human cytochrome P450 activities</span></div><div class="casAuthors">Walsky, Robert L.; Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">647-660</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The measurement of the effect of new chem. entities on human cytochrome P 450 marker activities using in vitro experimentation represents an important exptl. approach in drug development.  In vitro drug interaction data can be used in guiding the design of clin. drug interaction studies, or, when no effect is obsd. in vitro, the data can be used in place of an in vivo study to claim that no interaction will occur in vivo.  To make such a claim, it must be assured that the in vitro expts. are performed with abs. confidence in the methods used and data obtained.  To meet this need, 12 semiautomated assays for human P 450 marker substrate activities have been developed and validated using approaches described in the GLP (good lab. practices) as per the code of U.S. Federal Regulations.  The assays that were validated are: phenacetin O-deethylase (CYP1A2), coumarin 7-hydroxylase (CYP2A6), bupropion hydroxylase (CYP2B6), amodiaquine N-deethylase (CYP2C8), diclofenac 4'-hydroxylase and tolbutamide methylhydroxylase (CYP2C9), (S)-mephenytoin 4'-hydroxylase (CYP2C19), dextromethorphan O-demethylase (CYP2D6), chlorzoxazone 6-hydroxylase (CYP2E1), felodipine dehydrogenase, testosterone 6β-hydroxylase, and midazolam 1'-hydroxylase (CYP3A4 and CYP3A5).  High-pressure liq. chromatog.-tandem mass spectrometry, using stable isotope-labeled internal stds., has been applied as the anal. method.  This anal. approach, through its high sensitivity and selectivity, has permitted the use of very low incubation concns. of microsomal protein (0.01-0.2 mg/mL).  Anal. assay accuracy and precision values were excellent.  Enzyme kinetic and inhibition parameters obtained using these methods demonstrated high precision and were within the range of values previously reported in the scientific literature.  These methods should prove useful in the routine assessments of the potential for new drug candidates to elicit pharmacokinetic drug interactions via inhibition of cytochrome P 450 activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwF04TGeyYbbVg90H21EOLACvtfcHk0lhLWoj7fH-xuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktlOgt74%253D&md5=35532b907c15f1053aa8233dab2ec581</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1124%2Fdmd.32.6.647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.32.6.647%26sid%3Dliteratum%253Aachs%26aulast%3DWalsky%26aufirst%3DR.%2BL.%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DValidated%2520assays%2520for%2520human%2520cytochrome%2520P450%2520activities%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2004%26volume%3D32%26spage%3D647%26epage%3D660%26doi%3D10.1124%2Fdmd.32.6.647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsky, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkatakrishnan, K.</span><span> </span><span class="NLM_article-title">Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">246</span><span class="NLM_x">–</span> <span class="NLM_lpage">255</span><span class="refDoi"> DOI: 10.1124/dmd.106.012633</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1124%2Fdmd.106.012633" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=17093004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVKrs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=246-255&author=R.+S.+Obachauthor=R.+L.+Walskyauthor=K.+Venkatakrishnan&title=Mechanism-based+inactivation+of+human+cytochrome+p450+enzymes+and+the+prediction+of+drug-drug+interactions&doi=10.1124%2Fdmd.106.012633"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions</span></div><div class="casAuthors">Obach, R. Scott; Walsky, Robert L.; Venkatakrishnan, Karthik</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">246-255</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The ability to use vitro inactivation kinetic parameters in scaling to in vivo drug-drug interactions (DDIs) for mechanism-based inactivators of human cytochrome P 450 (P 450) enzymes was examd. using eight human P 450-selective marker activities in pooled human liver microsomes.  These data were combined with other parameters (systemic Cmax, estd. hepatic inlet Cmax, fraction unbound, in vivo P 450 enzyme degrdn. rate consts. estd. from clin. pharmacokinetic data, and fraction of the affected drug cleared by the inhibited enzyme) to predict increases in exposure to drugs, and the predictions were compared with in vivo DDIs gathered from clin. studies reported in the scientific literature.  In general, the use of unbound systemic Cmax as the inactivator concn. in vivo yielded the most accurate predictions of DDI with a mean -fold error of 1.64.  Abbreviated in vitro approaches to identifying mechanism-based inactivators were developed.  Testing potential inactivators at a single concn. (IC25) in a 30-min preincubation with human liver microsomes in the absence and presence of NADPH followed by assessment of P 450 marker activities readily identified those compds. known to be mechanism-based inactivators and represents an approach that can be used with greater throughput.  Measurement of decreases in IC50 occurring with a 30-min preincubation with liver microsomes and NADPH was also useful in identifying mechanism-based inactivators, and the IC50 measured after such a preincubation was highly correlated with the kinact/K1 ratio measured after a full characterization of inactivation.  Overall, these findings support the conclusion that P 450 in vitro inactivation data are valuable in predicting clin. DDIs that can occur via this mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpPRf5ZGrW6LVg90H21EOLACvtfcHk0lhLWoj7fH-xuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVKrs7k%253D&md5=71733cfafba3b2c9cc6b47a46e7b3f40</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1124%2Fdmd.106.012633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.106.012633%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DWalsky%26aufirst%3DR.%2BL.%26aulast%3DVenkatakrishnan%26aufirst%3DK.%26atitle%3DMechanism-based%2520inactivation%2520of%2520human%2520cytochrome%2520p450%2520enzymes%2520and%2520the%2520prediction%2520of%2520drug-drug%2520interactions%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2007%26volume%3D35%26spage%3D246%26epage%3D255%26doi%3D10.1124%2Fdmd.106.012633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Obach, R. S.</span><span> </span><span class="NLM_article-title">Predicting clearance in humans from in vitro data</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">334</span><span class="NLM_x">–</span> <span class="NLM_lpage">339</span><span class="refDoi"> DOI: 10.2174/156802611794480873</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.2174%2F156802611794480873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=21320062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslSntbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=334-339&author=R.+S.+Obach&title=Predicting+clearance+in+humans+from+in+vitro+data&doi=10.2174%2F156802611794480873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting clearance in humans from in vitro data</span></div><div class="casAuthors">Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">334-339</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The use of in vitro metab. in scaling to predict human clearance of new chem. entities has become a commonplace activity in the research and development of new drugs.  The measurement of in vitro lability in human liver microsomes, a rich source of drug metabolizing cytochrome P 450 enzymes, has become a high throughput screen in many research organizations which is a testament to its usefulness in drug design.  In this chapter, the methods used to scale in vitro intrinsic clearance data to predict in vivo clearance are described.  Importantly, the numerous assumptions that are required in order to use in vitro data in this manner are laid out.  These include assumptions regarding the scaling process as well as tech. aspects of the generation of the in vitro data.  Finally, some other drug clearance processes that have been emerging as important are described with regard to ongoing research efforts to develop clearance prediction methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHL7BnSTNtWbVg90H21EOLACvtfcHk0lhLWoj7fH-xuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslSntbk%253D&md5=38df8707bb77fdc8b6bb6ef2144a79da</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.2174%2F156802611794480873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611794480873%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DPredicting%2520clearance%2520in%2520humans%2520from%2520in%2520vitro%2520data%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D334%26epage%3D339%26doi%3D10.2174%2F156802611794480873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Artursson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlsson, J.</span><span> </span><span class="NLM_article-title">Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">175</span><span class="NLM_x">, </span> <span class="NLM_fpage">880</span><span class="NLM_x">–</span> <span class="NLM_lpage">885</span><span class="refDoi"> DOI: 10.1016/0006-291X(91)91647-U</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1016%2F0006-291X%2891%2991647-U" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1673839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADyaK3MXhslOrt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=1991&pages=880-885&author=P.+Arturssonauthor=J.+Karlsson&title=Correlation+between+oral+drug+absorption+in+humans+and+apparent+drug+permeability+coefficients+in+human+intestinal+epithelial+%28Caco-2%29+cells&doi=10.1016%2F0006-291X%2891%2991647-U"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells</span></div><div class="casAuthors">Artursson, P.; Karlsson, J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">880-5</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    </div><div class="casAbstract">Monolayers of a well differentiated human intestinal epithelial cell line, Caco-2, were used as a model to study passive drug absorption across the intestinal epithelium.  Absorption rate consts. (expressed as apparent permeability coeffs.) were detd. for 20 drugs and peptides with different structural properties.  The permeability coeffs. ranged from approx. 5 × 10-8 to 5 × 10-5 cm/s.  A good correlation was obtained between data on oral absorption in humans and the results in the Caco-2 model.  Drugs that are completely absorbed in humans had permeability coeffs. >1 × 10-6 cm/s.  Drugs that are absorbed to >1% but <100% had permeability coeffs. of 0.1-1.0 × 10-6 cm/s while drugs and peptides that are absorbed to <1% had permeability coeffs. of ≤1 × 10-7 cm/s.  The results indicate that Caco-2 monolayers can be used as a model for studies on intestinal drug absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdvsEluSXCILVg90H21EOLACvtfcHk0liD8YQiJOlRaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhslOrt7c%253D&md5=3b1e14cae3beb0345014284e3aa6a7c0</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2F0006-291X%2891%2991647-U&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-291X%252891%252991647-U%26sid%3Dliteratum%253Aachs%26aulast%3DArtursson%26aufirst%3DP.%26aulast%3DKarlsson%26aufirst%3DJ.%26atitle%3DCorrelation%2520between%2520oral%2520drug%2520absorption%2520in%2520humans%2520and%2520apparent%2520drug%2520permeability%2520coefficients%2520in%2520human%2520intestinal%2520epithelial%2520%2528Caco-2%2529%2520cells%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1991%26volume%3D175%26spage%3D880%26epage%3D885%26doi%3D10.1016%2F0006-291X%2891%2991647-U" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Hoenicka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, E.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apeler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirichoke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schröder, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerzer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stasch, J.-P.</span><span> </span><span class="NLM_article-title">Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: stimulation by YC-1, nitric oxide, and carbon monoxide</span> <span class="citation_source-journal">J. Mol. Med. (Heidelberg, Ger.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">14</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span><span class="refDoi"> DOI: 10.1007/s001090050292</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1007%2Fs001090050292" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=9930922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADyaK1MXjtVKrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=1999&pages=14-23&author=M.+Hoenickaauthor=E.-M.+Beckerauthor=H.+Apelerauthor=T.+Sirichokeauthor=H.+Schr%C3%B6derauthor=R.+Gerzerauthor=J.-P.+Stasch&title=Purified+soluble+guanylyl+cyclase+expressed+in+a+baculovirus%2FSf9+system%3A+stimulation+by+YC-1%2C+nitric+oxide%2C+and+carbon+monoxide&doi=10.1007%2Fs001090050292"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: Stimulation by YC-1, nitric oxide, and carbon monoxide</span></div><div class="casAuthors">Hoenicka, Markus; Becker, Eva-Maria; Apeler, Heiner; Sirichoke, Tim; Schroder, Henning; Gerzer, Rupert; Stasch, Johannes-Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Medicine (Berlin)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14-23</span>CODEN:
                <span class="NLM_cas:coden">JMLME8</span>;
        ISSN:<span class="NLM_cas:issn">0946-2716</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">Sol. guanylyl cyclase (sGC) is the main receptor for nitric oxide, a messenger mol. with multiple clin. implications.  Understanding the activation of sGC is an important step for establishing new therapeutic principles.  We have now overexpressed sGC in a baculovirus/Sf9 system optimized for high protein yields to facilitate spectral and kinetic studies of the activation mechanisms of this enzyme.  It was expressed in a batch fermenter using a defined mixt. of viruses encoding the α1 and β1 subunits of the rat lung enzyme.  The expressed enzyme was purified from the cytosolic fraction by anion exchange chromatog., hydroxyapatite chromatog., and size exclusion chromatog.  By use of this new method 2.5 L culture yielded about 1 mg of apparently homogeneous sGC with a content of about one heme per heterodimer without the need of a heme reconstitution step.  The enzyme did not contain stoichiometric amts. of copper.  The basal activities of the purified enzyme were 153 and 1259 nmol min-1 mg-1 in the presence of Mg2+ and Mn2+, resp.  The nitric oxide releasing agent 2-(N,N-diethylamino)-diazenolate-2-oxide (DEA/NO) stimulated the enzyme 160-fold with Mg2+, whereas the NO-independent activator 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole (YC-1) induced an increase in the activity of 101-fold at a concn. of 300 μM.  The combination of DEA/NO (10 μM) and YC-1 (100 μM) elicited a dose-dependent synergistic stimulation with a max. of a 792-fold increase over the basal activity in the presence of Mg2+, resulting in a specific activity of 121 μmol min-1 mg-1.  The synergistic stimulation of DEA/NO and YC-1 was attenuated by the sGC inhibitor 1H-(1,2,4)oxadiazole(4,3-a)quinoxalin-1-one (ODQ) (10 μM) by 94%.  In a different exptl. setup a satd. carbon monoxide soln. in the absence of ambient oxygen or NO stimulated the enzyme 15-fold in the absence and 1260-fold in the presence of YC-1 compared to an argon control.  The heme spectra of the enzyme showed a shift of the Soret peak from 432 to 399 and 424 nm in the presence of DEA/NO or carbon monoxide, resp.  The heme spectra were not affected by YC-1 in the absence or in the presence of DEA/NO or of carbon monoxide, which reflects the fact that YC-1 does not interact directly with the heme group of the enzyme.  In summary, this study shows that our expression/purifn. procedure is suitable for producing large amts. of highly pure sGC which contains one heme per heterodimer without a reconstitution step.  The activator expts. show that in a synergistic stimulation with YC-1 sGC can be activated maximally both by nitric oxide and by carbon monoxide and that YC-1 does not directly act via heme.  The described method should help to facilitate the investigation of the new therapeutic principle of NO-independent guanylyl cyclase activators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0MAMDq3YYc7Vg90H21EOLACvtfcHk0liD8YQiJOlRaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjtVKrsA%253D%253D&md5=0c1873bb3bde09bb9096fef30343da1a</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1007%2Fs001090050292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs001090050292%26sid%3Dliteratum%253Aachs%26aulast%3DHoenicka%26aufirst%3DM.%26aulast%3DBecker%26aufirst%3DE.-M.%26aulast%3DApeler%26aufirst%3DH.%26aulast%3DSirichoke%26aufirst%3DT.%26aulast%3DSchr%25C3%25B6der%26aufirst%3DH.%26aulast%3DGerzer%26aufirst%3DR.%26aulast%3DStasch%26aufirst%3DJ.-P.%26atitle%3DPurified%2520soluble%2520guanylyl%2520cyclase%2520expressed%2520in%2520a%2520baculovirus%252FSf9%2520system%253A%2520stimulation%2520by%2520YC-1%252C%2520nitric%2520oxide%252C%2520and%2520carbon%2520monoxide%26jtitle%3DJ.%2520Mol.%2520Med.%2520%2528Heidelberg%252C%2520Ger.%2529%26date%3D1999%26volume%3D77%26spage%3D14%26epage%3D23%26doi%3D10.1007%2Fs001090050292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Schermuly, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stasch, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pullamsetti, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middendorff, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlüter, K.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dingendorf, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hackemack, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolosionek, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaulen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumitrascu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissmann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mittendorf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klepetko, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeger, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghofrani, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimminger, F.</span><span> </span><span class="NLM_article-title">Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">–</span> <span class="NLM_lpage">891</span><span class="refDoi"> DOI: 10.1183/09031936.00114407</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1183%2F09031936.00114407" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=18550612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1KqsbjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2008&pages=881-891&author=R.+T.+Schermulyauthor=J.-P.+Staschauthor=S.+S.+Pullamsettiauthor=R.+Middendorffauthor=D.+M%C3%BCllerauthor=K.-D.+Schl%C3%BCterauthor=A.+Dingendorfauthor=S.+Hackemackauthor=E.+Kolosionekauthor=C.+Kaulenauthor=R.+Dumitrascuauthor=N.+Weissmannauthor=J.+Mittendorfauthor=W.+Klepetkoauthor=W.+Seegerauthor=H.+A.+Ghofraniauthor=F.+Grimminger&title=Expression+and+function+of+soluble+guanylate+cyclase+in+pulmonary+arterial+hypertension&doi=10.1183%2F09031936.00114407"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension</span></div><div class="casAuthors">Schermuly, R. T.; Stasch, J.-P.; Pullamsetti, S. S.; Middendorff, R.; Mueller, D.; Schlueter, K.-D.; Dingendorf, A.; Hackemack, S.; Kolosionek, E.; Kaulen, C.; Dumitrascu, R.; Weissmann, N.; Mittendorf, J.; Klepetko, W.; Seeger, W.; Ghofrani, H. A.; Grimminger, F.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">881-891</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Alterations of the nitric oxide receptor, sol. guanylate cyclase (sGC) may contribute to the pathophysiol. of pulmonary arterial hypertension (PAH).  In the present study, the expression of sGC in explanted lung tissue of PAH patients was studied and the effects of the sGC stimulator BAY 63-2521 on enzyme activity, and hemodynamics and vascular remodelling were investigated in two independent animal models of PAH.  Strong upregulation of sGC in pulmonary arterial vessels in the idiopathic PAH lungs compared with healthy donor lungs was demonstrated by immunohistochem.  Upregulation of sGC was detected, similarly to humans, in the structurally remodelled smooth muscle layer in chronic hypoxic mouse lungs and lungs from monocrotaline (MCT)-injected rats.  BAY 63-2521 is a novel, orally available compd. that directly stimulates sGC and sensitizes it to its physiol. stimulator, nitric oxide.  Chronic treatment of hypoxic mice and MCT-injected rats, with fully established PAH, with BAY 63-2521 (10 mg·kg-1·day-1) partially reversed the PAH, the right heart hypertrophy and the structural remodelling of the lung vasculature.  Upregulation of sol. guanylate cyclase in pulmonary arterial smooth muscle cells was noted in human idiopathic pulmonary arterial hypertension lungs and lungs from animal models of pulmonary arterial hypertension.  Stimulation of sol. guanylate cyclase reversed right heart hypertrophy and structural lung vascular remodelling.  Sol. guanylate cyclase may thus offer a new target for therapeutic intervention in pulmonary arterial hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1n8mqzLY9hLVg90H21EOLACvtfcHk0liD8YQiJOlRaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1KqsbjM&md5=f45a8e5f806616cd5b20363b6c8dec8a</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1183%2F09031936.00114407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00114407%26sid%3Dliteratum%253Aachs%26aulast%3DSchermuly%26aufirst%3DR.%2BT.%26aulast%3DStasch%26aufirst%3DJ.-P.%26aulast%3DPullamsetti%26aufirst%3DS.%2BS.%26aulast%3DMiddendorff%26aufirst%3DR.%26aulast%3DM%25C3%25BCller%26aufirst%3DD.%26aulast%3DSchl%25C3%25BCter%26aufirst%3DK.-D.%26aulast%3DDingendorf%26aufirst%3DA.%26aulast%3DHackemack%26aufirst%3DS.%26aulast%3DKolosionek%26aufirst%3DE.%26aulast%3DKaulen%26aufirst%3DC.%26aulast%3DDumitrascu%26aufirst%3DR.%26aulast%3DWeissmann%26aufirst%3DN.%26aulast%3DMittendorf%26aufirst%3DJ.%26aulast%3DKlepetko%26aufirst%3DW.%26aulast%3DSeeger%26aufirst%3DW.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DGrimminger%26aufirst%3DF.%26atitle%3DExpression%2520and%2520function%2520of%2520soluble%2520guanylate%2520cyclase%2520in%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2008%26volume%3D32%26spage%3D881%26epage%3D891%26doi%3D10.1183%2F09031936.00114407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Geschka, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kretschmer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharkovska, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evgenov, O. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrenz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hucke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hocher, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stasch, J.-P.</span><span> </span><span class="NLM_article-title">Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">e21853</span><span class="refDoi"> DOI: 10.1371/journal.pone.0021853</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1371%2Fjournal.pone.0021853" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e21853&author=S.+Geschkaauthor=A.+Kretschmerauthor=Y.+Sharkovskaauthor=O.+V.+Evgenovauthor=B.+Lawrenzauthor=A.+Huckeauthor=B.+Hocherauthor=J.-P.+Stasch&title=Soluble+guanylate+cyclase+stimulation+prevents+fibrotic+tissue+remodeling+and+improves+survival+in+salt-sensitive+Dahl+rats&doi=10.1371%2Fjournal.pone.0021853"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0021853&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0021853%26sid%3Dliteratum%253Aachs%26aulast%3DGeschka%26aufirst%3DS.%26aulast%3DKretschmer%26aufirst%3DA.%26aulast%3DSharkovska%26aufirst%3DY.%26aulast%3DEvgenov%26aufirst%3DO.%2BV.%26aulast%3DLawrenz%26aufirst%3DB.%26aulast%3DHucke%26aufirst%3DA.%26aulast%3DHocher%26aufirst%3DB.%26aulast%3DStasch%26aufirst%3DJ.-P.%26atitle%3DSoluble%2520guanylate%2520cyclase%2520stimulation%2520prevents%2520fibrotic%2520tissue%2520remodeling%2520and%2520improves%2520survival%2520in%2520salt-sensitive%2520Dahl%2520rats%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26spage%3De21853%26doi%3D10.1371%2Fjournal.pone.0021853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 48 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Michael G. Hahn, Thomas Lampe, Sherif El Sheikh, Nils Griebenow, Elisabeth Woltering, Karl-Heinz Schlemmer, Lisa Dietz, Michael Gerisch, Frank Wunder, Eva-Maria Becker-Pelster, Thomas Mondritzki, Hanna Tinel, Andreas Knorr, Armin Kern, Dieter Lang, Joerg Hueser, Tibor Schomber, Agnes Benardeau, Frank Eitner, Hubert Truebel, Joachim Mittendorf, Vijay Kumar, Focco van den Akker, Martina Schaefer, Volker Geiss, Peter Sandner, <span class="NLM_string-name hlFld-ContribAuthor">Johannes-Peter Stasch</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (9)
                                     , 5323-5344. <a href="https://doi.org/10.1021/acs.jmedchem.0c02154" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02154</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02154%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bthe%252BSoluble%252BGuanylate%252BCyclase%252BActivator%252BRuncaciguat%252B%252528BAY%252B1101042%252529%26aulast%3DHahn%26aufirst%3DMichael%2BG.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D14122020%26date%3D19042021%26volume%3D64%26issue%3D9%26spage%3D5323%26epage%3D5344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Wei Zheng, Zhen Wang, Xiangrui Jiang, Qingjie Zhao, <span class="NLM_string-name hlFld-ContribAuthor">Jingshan Shen</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (24)
                                     , 15153-15186. <a href="https://doi.org/10.1021/acs.jmedchem.0c01093" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01093</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01093%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeted%252BDrugs%252Bfor%252BTreatment%252Bof%252BPulmonary%252BArterial%252BHypertension%25253A%252BPast%25252C%252BPresent%25252C%252Band%252BFuture%252BPerspectives%26aulast%3DZheng%26aufirst%3DWei%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D26062020%26date%3D14122020%26volume%3D63%26issue%3D24%26spage%3D15153%26epage%3D15186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Vincent Le Fouler, Yu Chen, Vincent Gandon, Vincent Bizet, Christophe Salomé, Thomas Fessard, Fang Liu, K. N. Houk, <span class="NLM_string-name hlFld-ContribAuthor">Nicolas Blanchard</span>. </span><span class="cited-content_cbyCitation_article-title">Activating Pyrimidines by Pre-distortion for the General Synthesis of 7-Aza-indazoles from 2-Hydrazonylpyrimidines via Intramolecular Diels–Alder Reactions. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2019,</strong> <em>141 </em>
                                    (40)
                                     , 15901-15909. <a href="https://doi.org/10.1021/jacs.9b07037" title="DOI URL">https://doi.org/10.1021/jacs.9b07037</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.9b07037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.9b07037%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DActivating%252BPyrimidines%252Bby%252BPre-distortion%252Bfor%252Bthe%252BGeneral%252BSynthesis%252Bof%252B7-Aza-indazoles%252Bfrom%252B2-Hydrazonylpyrimidines%252Bvia%252BIntramolecular%252BDiels%2525E2%252580%252593Alder%252BReactions%26aulast%3DLe%2BFouler%26aufirst%3DVincent%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D03072019%26date%3D09092019%26date%3D02092019%26volume%3D141%26issue%3D40%26spage%3D15901%26epage%3D15909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexey A.  Kruzhilin</span>, <span class="hlFld-ContribAuthor ">Evgeniya A.  Kosheleva</span>, <span class="hlFld-ContribAuthor ">Khidmet S.  Shikhaliev</span>, <span class="hlFld-ContribAuthor ">Gleb L.  Denisov</span>, <span class="hlFld-ContribAuthor ">Dmitriy Yu.  Vandyshev</span>. </span><span class="cited-content_cbyCitation_article-title">Regioselective Synthesis of Imidazo[1,5‐
              b
              ]pyridazines by Cascade Cyclizations of 1,2‐Diamino‐4H‐phenylimidazole with 1,3‐Diketones, Acetoacetic Ester and Their Derivatives. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2021,</strong> <em>6 </em>
                                    (23)
                                     , 5801-5806. <a href="https://doi.org/10.1002/slct.202101372" title="DOI URL">https://doi.org/10.1002/slct.202101372</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.202101372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.202101372%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DRegioselective%252BSynthesis%252Bof%252BImidazo%25255B1%25252C5%2525E2%252580%252590%252Bb%252B%25255Dpyridazines%252Bby%252BCascade%252BCyclizations%252Bof%252B1%25252C2%2525E2%252580%252590Diamino%2525E2%252580%2525904H%2525E2%252580%252590phenylimidazole%252Bwith%252B1%25252C3%2525E2%252580%252590Diketones%25252C%252BAcetoacetic%252BEster%252Band%252BTheir%252BDerivatives%26aulast%3DKruzhilin%26aufirst%3DAlexey%2BA.%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D23%26spage%3D5801%26epage%3D5806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jean-Sébastien  Hulot</span>, <span class="hlFld-ContribAuthor ">Jean-Noël  Trochu</span>, <span class="hlFld-ContribAuthor ">Erwan  Donal</span>, <span class="hlFld-ContribAuthor ">Michel  Galinier</span>, <span class="hlFld-ContribAuthor ">Damien  Logeart</span>, <span class="hlFld-ContribAuthor ">Pascal  De Groote</span>, <span class="hlFld-ContribAuthor ">Yves  Juillière</span>. </span><span class="cited-content_cbyCitation_article-title">Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Pharmacotherapy</span><span> <strong>2021,</strong> <em>773 </em>, 1-9. <a href="https://doi.org/10.1080/14656566.2021.1937121" title="DOI URL">https://doi.org/10.1080/14656566.2021.1937121</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14656566.2021.1937121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14656566.2021.1937121%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Pharmacotherapy%26atitle%3DVericiguat%252Bfor%252Bthe%252Btreatment%252Bof%252Bheart%252Bfailure%25253A%252Bmechanism%252Bof%252Baction%252Band%252Bpharmacological%252Bproperties%252Bcompared%252Bwith%252Bother%252Bemerging%252Btherapeutic%252Boptions%26aulast%3DHulot%26aufirst%3DJean-S%25C3%25A9bastien%26date%3D2021%26date%3D2021%26volume%3D773%26spage%3D1%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hauke  Ruehs</span>, <span class="hlFld-ContribAuthor ">Dagmar  Klein</span>, <span class="hlFld-ContribAuthor ">Matthias  Frei</span>, <span class="hlFld-ContribAuthor ">Joachim  Grevel</span>, <span class="hlFld-ContribAuthor ">Rupert  Austin</span>, <span class="hlFld-ContribAuthor ">Corina  Becker</span>, <span class="hlFld-ContribAuthor ">Lothar  Roessig</span>, <span class="hlFld-ContribAuthor ">Burkert  Pieske</span>, <span class="hlFld-ContribAuthor ">Dirk  Garmann</span>, <span class="hlFld-ContribAuthor ">Michaela  Meyer</span>. </span><span class="cited-content_cbyCitation_article-title">Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. </span><span class="cited-content_cbyCitation_journal-name">Clinical Pharmacokinetics</span><span> <strong>2021,</strong> <em>137 </em><a href="https://doi.org/10.1007/s40262-021-01024-y" title="DOI URL">https://doi.org/10.1007/s40262-021-01024-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40262-021-01024-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40262-021-01024-y%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Pharmacokinetics%26atitle%3DPopulation%252BPharmacokinetics%252Band%252BPharmacodynamics%252Bof%252BVericiguat%252Bin%252BPatients%252Bwith%252BHeart%252BFailure%252Band%252BReduced%252BEjection%252BFraction%26aulast%3DRuehs%26aufirst%3DHauke%26date%3D2021%26date%3D2021%26volume%3D137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Susana S.  Correia</span>, <span class="hlFld-ContribAuthor ">Rajesh R.  Iyengar</span>, <span class="hlFld-ContribAuthor ">Peter  Germano</span>, <span class="hlFld-ContribAuthor ">Kim  Tang</span>, <span class="hlFld-ContribAuthor ">Sylvie G.  Bernier</span>, <span class="hlFld-ContribAuthor ">Chad D.  Schwartzkopf</span>, <span class="hlFld-ContribAuthor ">Jenny  Tobin</span>, <span class="hlFld-ContribAuthor ">Thomas W.-H.  Lee</span>, <span class="hlFld-ContribAuthor ">Guang  Liu</span>, <span class="hlFld-ContribAuthor ">Sarah  Jacobson</span>, <span class="hlFld-ContribAuthor ">Andrew  Carvalho</span>, <span class="hlFld-ContribAuthor ">Glen R.  Rennie</span>, <span class="hlFld-ContribAuthor ">Joon  Jung</span>, <span class="hlFld-ContribAuthor ">Paul A.  Renhowe</span>, <span class="hlFld-ContribAuthor ">Elisabeth  Lonie</span>, <span class="hlFld-ContribAuthor ">Christopher J.  Winrow</span>, <span class="hlFld-ContribAuthor ">John R.  Hadcock</span>, <span class="hlFld-ContribAuthor ">Juli E.  Jones</span>, <span class="hlFld-ContribAuthor ">Mark G.  Currie</span>. </span><span class="cited-content_cbyCitation_article-title">The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 Reveals its Therapeutic Potential in Neurodegenerative Diseases. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2021,</strong> <em>12 </em><a href="https://doi.org/10.3389/fphar.2021.656561" title="DOI URL">https://doi.org/10.3389/fphar.2021.656561</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2021.656561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2021.656561%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DThe%252BCNS-Penetrant%252BSoluble%252BGuanylate%252BCyclase%252BStimulator%252BCY6463%252BReveals%252Bits%252BTherapeutic%252BPotential%252Bin%252BNeurodegenerative%252BDiseases%26aulast%3DCorreia%26aufirst%3DSusana%2BS.%26date%3D2021%26date%3D2021%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amr  Abdin</span>, <span class="hlFld-ContribAuthor ">Johann  Bauersachs</span>, <span class="hlFld-ContribAuthor ">Norbert  Frey</span>, <span class="hlFld-ContribAuthor ">Ingrid  Kindermann</span>, <span class="hlFld-ContribAuthor ">Andreas  Link</span>, <span class="hlFld-ContribAuthor ">Nikolaus  Marx</span>, <span class="hlFld-ContribAuthor ">Mitja  Lainscak</span>, <span class="hlFld-ContribAuthor ">Jonathan  Slawik</span>, <span class="hlFld-ContribAuthor ">Christian  Werner</span>, <span class="hlFld-ContribAuthor ">Jan  Wintrich</span>, <span class="hlFld-ContribAuthor ">Michael  Böhm</span>. </span><span class="cited-content_cbyCitation_article-title">Timely and individualized heart failure management: need for implementation into the new guidelines. </span><span class="cited-content_cbyCitation_journal-name">Clinical Research in Cardiology</span><span> <strong>2021,</strong> <em>393 </em><a href="https://doi.org/10.1007/s00392-021-01867-2" title="DOI URL">https://doi.org/10.1007/s00392-021-01867-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00392-021-01867-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00392-021-01867-2%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Research%2520in%2520Cardiology%26atitle%3DTimely%252Band%252Bindividualized%252Bheart%252Bfailure%252Bmanagement%25253A%252Bneed%252Bfor%252Bimplementation%252Binto%252Bthe%252Bnew%252Bguidelines%26aulast%3DAbdin%26aufirst%3DAmr%26date%3D2021%26date%3D2021%26volume%3D393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bibhuti B.  Das</span>, <span class="hlFld-ContribAuthor ">William B.  Moskowitz</span>, <span class="hlFld-ContribAuthor ">Javed  Butler</span>. </span><span class="cited-content_cbyCitation_article-title">Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials. </span><span class="cited-content_cbyCitation_journal-name">Children</span><span> <strong>2021,</strong> <em>8 </em>
                                    (5)
                                     , 322. <a href="https://doi.org/10.3390/children8050322" title="DOI URL">https://doi.org/10.3390/children8050322</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/children8050322&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fchildren8050322%26sid%3Dliteratum%253Aachs%26jtitle%3DChildren%26atitle%3DCurrent%252Band%252BFuture%252BDrug%252Band%252BDevice%252BTherapies%252Bfor%252BPediatric%252BHeart%252BFailure%252BPatients%25253A%252BPotential%252BLessons%252Bfrom%252BAdult%252BTrials%26aulast%3DDas%26aufirst%3DBibhuti%2BB.%26date%3D2021%26date%3D2021%26volume%3D8%26issue%3D5%26spage%3D322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Valery S.  Tolkunov</span>, <span class="hlFld-ContribAuthor ">Andrew S.  Tolkunov</span>, <span class="hlFld-ContribAuthor ">Olga V.  Smirnova</span>, <span class="hlFld-ContribAuthor ">Sergei V.  Tolkunov</span>. </span><span class="cited-content_cbyCitation_article-title">Convenient synthesis of imidazo[1,5-a]pyrimidine derivatives and their unusual recyclization into 3H-imidazo[4,5-b]pyridine derivatives. </span><span class="cited-content_cbyCitation_journal-name">Chemistry of Heterocyclic Compounds</span><span> <strong>2021,</strong> <em>57 </em>
                                    (5)
                                     , 554-559. <a href="https://doi.org/10.1007/s10593-021-02942-2" title="DOI URL">https://doi.org/10.1007/s10593-021-02942-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10593-021-02942-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10593-021-02942-2%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520of%2520Heterocyclic%2520Compounds%26atitle%3DConvenient%252Bsynthesis%252Bof%252Bimidazo%25255B1%25252C5-a%25255Dpyrimidine%252Bderivatives%252Band%252Btheir%252Bunusual%252Brecyclization%252Binto%252B3H-imidazo%25255B4%25252C5-b%25255Dpyridine%252Bderivatives%26aulast%3DTolkunov%26aufirst%3DValery%2BS.%26date%3D2021%26date%3D2021%26volume%3D57%26issue%3D5%26spage%3D554%26epage%3D559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David  St. Jean</span>, <span class="hlFld-ContribAuthor ">Justin  Malinowski</span>, <span class="hlFld-ContribAuthor ">Antonio  Romero</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances Toward New Small Molecule Therapies for Heart Failure. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-48. <a href="https://doi.org/10.1002/0471266949.bmc262" title="DOI URL">https://doi.org/10.1002/0471266949.bmc262</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc262%26sid%3Dliteratum%253Aachs%26atitle%3DRecent%252BAdvances%252BToward%252BNew%252BSmall%252BMolecule%252BTherapies%252Bfor%252BHeart%252BFailure%26aulast%3DSt.%2BJean%26aufirst%3DDavid%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D48%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Steven G.  Chrysant</span>. </span><span class="cited-content_cbyCitation_article-title">A novel approach for the treatment of hypertension with the soluble guanylate cyclase stimulating drug. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Safety</span><span> <strong>2021,</strong> <em>76 </em>, 1-6. <a href="https://doi.org/10.1080/14740338.2021.1906221" title="DOI URL">https://doi.org/10.1080/14740338.2021.1906221</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14740338.2021.1906221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14740338.2021.1906221%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Safety%26atitle%3DA%252Bnovel%252Bapproach%252Bfor%252Bthe%252Btreatment%252Bof%252Bhypertension%252Bwith%252Bthe%252Bsoluble%252Bguanylate%252Bcyclase%252Bstimulating%252Bdrug%26aulast%3DChrysant%26aufirst%3DSteven%2BG.%26date%3D2021%26date%3D2021%26volume%3D76%26spage%3D1%26epage%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael  Boettcher</span>, <span class="hlFld-ContribAuthor ">Dirk  Thomas</span>, <span class="hlFld-ContribAuthor ">Wolfgang  Mueck</span>, <span class="hlFld-ContribAuthor ">Stephanie  Loewen</span>, <span class="hlFld-ContribAuthor ">Erich  Arens</span>, <span class="hlFld-ContribAuthor ">Kenichi  Yoshikawa</span>, <span class="hlFld-ContribAuthor ">Corina  Becker</span>. </span><span class="cited-content_cbyCitation_article-title">Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Clinical Pharmacology</span><span> <strong>2021,</strong> <em>77 </em>
                                    (4)
                                     , 527-537. <a href="https://doi.org/10.1007/s00228-020-03023-7" title="DOI URL">https://doi.org/10.1007/s00228-020-03023-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00228-020-03023-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00228-020-03023-7%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Clinical%2520Pharmacology%26atitle%3DSafety%25252C%252Bpharmacodynamic%25252C%252Band%252Bpharmacokinetic%252Bcharacterization%252Bof%252Bvericiguat%25253A%252Bresults%252Bfrom%252Bsix%252Bphase%252BI%252Bstudies%252Bin%252Bhealthy%252Bsubjects%26aulast%3DBoettcher%26aufirst%3DMichael%26date%3D2021%26date%3D2020%26volume%3D77%26issue%3D4%26spage%3D527%26epage%3D537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anthony  Markham</span>, <span class="hlFld-ContribAuthor ">Sean  Duggan</span>. </span><span class="cited-content_cbyCitation_article-title">Vericiguat: First Approval. </span><span class="cited-content_cbyCitation_journal-name">Drugs</span><span> <strong>2021,</strong> <em>81 </em>
                                    (6)
                                     , 721-726. <a href="https://doi.org/10.1007/s40265-021-01496-z" title="DOI URL">https://doi.org/10.1007/s40265-021-01496-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40265-021-01496-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40265-021-01496-z%26sid%3Dliteratum%253Aachs%26jtitle%3DDrugs%26atitle%3DVericiguat%25253A%252BFirst%252BApproval%26aulast%3DMarkham%26aufirst%3DAnthony%26date%3D2021%26date%3D2021%26volume%3D81%26issue%3D6%26spage%3D721%26epage%3D726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter  Sandner</span>, <span class="hlFld-ContribAuthor ">Alexandros  Vakalopoulos</span>, <span class="hlFld-ContribAuthor ">Michael G.  Hahn</span>, <span class="hlFld-ContribAuthor ">Johannes-Peter  Stasch</span>, <span class="hlFld-ContribAuthor ">Markus  Follmann</span>. </span><span class="cited-content_cbyCitation_article-title">Soluble guanylate cyclase stimulators and their potential use: a patent review. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2021,</strong> <em>31 </em>
                                    (3)
                                     , 203-222. <a href="https://doi.org/10.1080/13543776.2021.1866538" title="DOI URL">https://doi.org/10.1080/13543776.2021.1866538</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2021.1866538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2021.1866538%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DSoluble%252Bguanylate%252Bcyclase%252Bstimulators%252Band%252Btheir%252Bpotential%252Buse%25253A%252Ba%252Bpatent%252Breview%26aulast%3DSandner%26aufirst%3DPeter%26date%3D2021%26date%3D2021%26volume%3D31%26issue%3D3%26spage%3D203%26epage%3D222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eddie L  Myers</span>. </span><span class="cited-content_cbyCitation_article-title">Bicyclic 5–6 Systems: Other Four Heteroatoms 2:2. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-818655-8.00056-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-818655-8.00056-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-818655-8.00056-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-818655-8.00056-1%26sid%3Dliteratum%253Aachs%26atitle%3DBicyclic%252B5%2525E2%252580%2525936%252BSystems%25253A%252BOther%252BFour%252BHeteroatoms%252B2%25253A2%26aulast%3DMyers%26aufirst%3DEddie%2BL%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2021%26volume%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Linda  Brockunier</span>, <span class="hlFld-ContribAuthor ">John  Stelmach</span>, <span class="hlFld-ContribAuthor ">Jian  Guo</span>, <span class="hlFld-ContribAuthor ">Tracy  Spencer</span>, <span class="hlFld-ContribAuthor ">Keith  Rosauer</span>, <span class="hlFld-ContribAuthor ">Alka  Bansal</span>, <span class="hlFld-ContribAuthor ">Sheng-Jian  Cai</span>, <span class="hlFld-ContribAuthor ">Nancy  Chen</span>, <span class="hlFld-ContribAuthor ">John  Cummings</span>, <span class="hlFld-ContribAuthor ">Li  Huang</span>, <span class="hlFld-ContribAuthor ">Timothy  Johnson</span>, <span class="hlFld-ContribAuthor ">Sonia  Levesque</span>, <span class="hlFld-ContribAuthor ">Lin  Luo</span>, <span class="hlFld-ContribAuthor ">Kevin  Maloney</span>, <span class="hlFld-ContribAuthor ">Joseph  Metzger</span>, <span class="hlFld-ContribAuthor ">Christopher  Mortko</span>, <span class="hlFld-ContribAuthor ">Karen  Ortega</span>, <span class="hlFld-ContribAuthor ">Lee-Yuh  Pai</span>, <span class="hlFld-ContribAuthor ">Antonio  Pereira</span>, <span class="hlFld-ContribAuthor ">Gino  Salituro</span>, <span class="hlFld-ContribAuthor ">Jackie  Shang</span>, <span class="hlFld-ContribAuthor ">Cherrie  Shepherd</span>, <span class="hlFld-ContribAuthor ">Shiyao  Sherrie Xu</span>, <span class="hlFld-ContribAuthor ">Qifeng  Yang</span>, <span class="hlFld-ContribAuthor ">Jisong  Cui</span>, <span class="hlFld-ContribAuthor ">Sophie  Roy</span>, <span class="hlFld-ContribAuthor ">Emma  Parmee</span>, <span class="hlFld-ContribAuthor ">Subharekha  Raghavan</span>. </span><span class="cited-content_cbyCitation_article-title">Soluble guanylate cyclase stimulators for the treatment of hypertension: Discovery of MK-2947. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (21)
                                     , 127574. <a href="https://doi.org/10.1016/j.bmcl.2020.127574" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127574</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127574%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSoluble%252Bguanylate%252Bcyclase%252Bstimulators%252Bfor%252Bthe%252Btreatment%252Bof%252Bhypertension%25253A%252BDiscovery%252Bof%252BMK-2947%26aulast%3DBrockunier%26aufirst%3DLinda%26date%3D2020%26volume%3D30%26issue%3D21%26spage%3D127574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael  Boettcher</span>, <span class="hlFld-ContribAuthor ">Michael  Gerisch</span>, <span class="hlFld-ContribAuthor ">Maximilian  Lobmeyer</span>, <span class="hlFld-ContribAuthor ">Nina  Besche</span>, <span class="hlFld-ContribAuthor ">Dirk  Thomas</span>, <span class="hlFld-ContribAuthor ">Mireille  Gerrits</span>, <span class="hlFld-ContribAuthor ">Julia  Lemmen</span>, <span class="hlFld-ContribAuthor ">Wolfgang  Mueck</span>, <span class="hlFld-ContribAuthor ">Martin  Radtke</span>, <span class="hlFld-ContribAuthor ">Corina  Becker</span>. </span><span class="cited-content_cbyCitation_article-title">Metabolism and Pharmacokinetic Drug–Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. </span><span class="cited-content_cbyCitation_journal-name">Clinical Pharmacokinetics</span><span> <strong>2020,</strong> <em>59 </em>
                                    (11)
                                     , 1407-1418. <a href="https://doi.org/10.1007/s40262-020-00895-x" title="DOI URL">https://doi.org/10.1007/s40262-020-00895-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40262-020-00895-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40262-020-00895-x%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Pharmacokinetics%26atitle%3DMetabolism%252Band%252BPharmacokinetic%252BDrug%2525E2%252580%252593Drug%252BInteraction%252BProfile%252Bof%252BVericiguat%25252C%252BA%252BSoluble%252BGuanylate%252BCyclase%252BStimulator%25253A%252BResults%252BFrom%252BPreclinical%252Band%252BPhase%252BI%252BHealthy%252BVolunteer%252BStudies%26aulast%3DBoettcher%26aufirst%3DMichael%26date%3D2020%26date%3D2020%26volume%3D59%26issue%3D11%26spage%3D1407%26epage%3D1418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Waqas  Ullah</span>, <span class="hlFld-ContribAuthor ">Maryam  Mukhtar</span>, <span class="hlFld-ContribAuthor ">Aws  Al-Mukhtar</span>, <span class="hlFld-ContribAuthor ">Rehan  Saeed</span>, <span class="hlFld-ContribAuthor ">Margot  Boigon</span>, <span class="hlFld-ContribAuthor ">Donald  Haas</span>, <span class="hlFld-ContribAuthor ">Eduardo  Rame</span>. </span><span class="cited-content_cbyCitation_article-title">Safety and efficacy of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis. </span><span class="cited-content_cbyCitation_journal-name">World Journal of Cardiology</span><span> <strong>2020,</strong> <em>12 </em>
                                    (10)
                                     , 501-511. <a href="https://doi.org/10.4330/wjc.v12.i10.501" title="DOI URL">https://doi.org/10.4330/wjc.v12.i10.501</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4330/wjc.v12.i10.501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4330%2Fwjc.v12.i10.501%26sid%3Dliteratum%253Aachs%26jtitle%3DWorld%2520Journal%2520of%2520Cardiology%26atitle%3DSafety%252Band%252Befficacy%252Bof%252Bsoluble%252Bguanylate%252Bcyclase%252Bstimulators%252Bin%252Bpatients%252Bwith%252Bheart%252Bfailure%25253A%252BA%252Bsystematic%252Breview%252Band%252Bmeta-analysis%26aulast%3DUllah%26aufirst%3DWaqas%26date%3D2020%26volume%3D12%26issue%3D10%26spage%3D501%26epage%3D511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Figueroa-Valverde  Lauro</span>, <span class="hlFld-ContribAuthor ">Diaz-Cedillo  Francisco</span>, <span class="hlFld-ContribAuthor ">Rosas-Nexticapa  Marcela</span>, <span class="hlFld-ContribAuthor ">Mateu-Armand  Virginia</span>, <span class="hlFld-ContribAuthor ">Garcimarero-Espino E.  Alejandra</span>, <span class="hlFld-ContribAuthor ">Lopez-Ramos  Maria</span>, <span class="hlFld-ContribAuthor ">Hau-Heredia  Lenin</span>, <span class="hlFld-ContribAuthor ">Borges-Ballote  Yaritza</span>, <span class="hlFld-ContribAuthor ">Cabrera-Tuz  Jhair</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Biological Activity of a Bis-steroid-methanocyclobutanaphthalene- dione Derivative against Ischemia/Reperfusion Injury via Calcium Channel Activation. </span><span class="cited-content_cbyCitation_journal-name">Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry</span><span> <strong>2020,</strong> <em>19 </em>
                                    (4)
                                     , 393-412. <a href="https://doi.org/10.2174/1871523018666191003152854" title="DOI URL">https://doi.org/10.2174/1871523018666191003152854</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1871523018666191003152854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1871523018666191003152854%26sid%3Dliteratum%253Aachs%26jtitle%3DAnti-Inflammatory%2520%2526%2520Anti-Allergy%2520Agents%2520in%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252BBiological%252BActivity%252Bof%252Ba%252BBis-steroid-methanocyclobutanaphthalene-%252Bdione%252BDerivative%252Bagainst%252BIschemia%25252FReperfusion%252BInjury%252Bvia%252BCalcium%252BChannel%252BActivation%26aulast%3DLauro%26aufirst%3DFigueroa-Valverde%26date%3D2020%26volume%3D19%26issue%3D4%26spage%3D393%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Steven G.  Chrysant</span>, <span class="hlFld-ContribAuthor ">George S.  Chrysant</span>. </span><span class="cited-content_cbyCitation_article-title">New and emerging cardiovascular and antihypertensive drugs. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Safety</span><span> <strong>2020,</strong> <em>19 </em>
                                    (10)
                                     , 1315-1327. <a href="https://doi.org/10.1080/14740338.2020.1810232" title="DOI URL">https://doi.org/10.1080/14740338.2020.1810232</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14740338.2020.1810232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14740338.2020.1810232%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Safety%26atitle%3DNew%252Band%252Bemerging%252Bcardiovascular%252Band%252Bantihypertensive%252Bdrugs%26aulast%3DChrysant%26aufirst%3DSteven%2BG.%26date%3D2020%26date%3D2020%26volume%3D19%26issue%3D10%26spage%3D1315%26epage%3D1327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ninian N  Lang</span>, <span class="hlFld-ContribAuthor ">Stephen J H  Dobbin</span>, <span class="hlFld-ContribAuthor ">Mark C  Petrie</span>. </span><span class="cited-content_cbyCitation_article-title">Vericiguat in worsening heart failure: agonising over, or celebrating, agonism in the VICTORIA trial. </span><span class="cited-content_cbyCitation_journal-name">Cardiovascular Research</span><span> <strong>2020,</strong> <em>116 </em>
                                    (12)
                                     , e152-e155. <a href="https://doi.org/10.1093/cvr/cvaa247" title="DOI URL">https://doi.org/10.1093/cvr/cvaa247</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/cvr/cvaa247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fcvr%2Fcvaa247%26sid%3Dliteratum%253Aachs%26jtitle%3DCardiovascular%2520Research%26atitle%3DVericiguat%252Bin%252Bworsening%252Bheart%252Bfailure%25253A%252Bagonising%252Bover%25252C%252Bor%252Bcelebrating%25252C%252Bagonism%252Bin%252Bthe%252BVICTORIA%252Btrial%26aulast%3DLang%26aufirst%3DNinian%2BN%26date%3D2020%26date%3D2020%26volume%3D116%26issue%3D12%26spage%3De152%26epage%3De155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ana I.  Casas</span>, <span class="hlFld-ContribAuthor ">Cristian  Nogales</span>, <span class="hlFld-ContribAuthor ">Hermann A. M.  Mucke</span>, <span class="hlFld-ContribAuthor ">Alexandra  Petraina</span>, <span class="hlFld-ContribAuthor ">Antonio  Cuadrado</span>, <span class="hlFld-ContribAuthor ">Ana I.  Rojo</span>, <span class="hlFld-ContribAuthor ">Pietro  Ghezzi</span>, <span class="hlFld-ContribAuthor ">Vincent  Jaquet</span>, <span class="hlFld-ContribAuthor ">Fiona  Augsburger</span>, <span class="hlFld-ContribAuthor ">Francois  Dufrasne</span>, <span class="hlFld-ContribAuthor ">Jalal  Soubhye</span>, <span class="hlFld-ContribAuthor ">Soni  Deshwal</span>, <span class="hlFld-ContribAuthor ">Moises  Di Sante</span>, <span class="hlFld-ContribAuthor ">Nina  Kaludercic</span>, <span class="hlFld-ContribAuthor ">Fabio  Di Lisa</span>, <span class="hlFld-ContribAuthor ">Harald H. H. W.  Schmidt</span>, . </span><span class="cited-content_cbyCitation_article-title">On the Clinical Pharmacology of Reactive Oxygen Species. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Reviews</span><span> <strong>2020,</strong> <em>72 </em>
                                    (4)
                                     , 801-828. <a href="https://doi.org/10.1124/pr.120.019422" title="DOI URL">https://doi.org/10.1124/pr.120.019422</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/pr.120.019422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fpr.120.019422%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Reviews%26atitle%3DOn%252Bthe%252BClinical%252BPharmacology%252Bof%252BReactive%252BOxygen%252BSpecies%26aulast%3DCasas%26aufirst%3DAna%2BI.%26date%3D2020%26date%3D2020%26volume%3D72%26issue%3D4%26spage%3D801%26epage%3D828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ehsan  Ataei Ataabadi</span>, <span class="hlFld-ContribAuthor ">Keivan  Golshiri</span>, <span class="hlFld-ContribAuthor ">Annika  Jüttner</span>, <span class="hlFld-ContribAuthor ">Guido  Krenning</span>, <span class="hlFld-ContribAuthor ">A.H. Jan  Danser</span>, <span class="hlFld-ContribAuthor ">Anton J.M.  Roks</span>. </span><span class="cited-content_cbyCitation_article-title">Nitric Oxide-cGMP Signaling in Hypertension. </span><span class="cited-content_cbyCitation_journal-name">Hypertension</span><span> <strong>2020,</strong> <em>76 </em>
                                    (4)
                                     , 1055-1068. <a href="https://doi.org/10.1161/HYPERTENSIONAHA.120.15856" title="DOI URL">https://doi.org/10.1161/HYPERTENSIONAHA.120.15856</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1161/HYPERTENSIONAHA.120.15856&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1161%2FHYPERTENSIONAHA.120.15856%26sid%3Dliteratum%253Aachs%26jtitle%3DHypertension%26atitle%3DNitric%252BOxide-cGMP%252BSignaling%252Bin%252BHypertension%26aulast%3DAtaei%2BAtaabadi%26aufirst%3DEhsan%26date%3D2020%26volume%3D76%26issue%3D4%26spage%3D1055%26epage%3D1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tan An  Dang</span>, <span class="hlFld-ContribAuthor ">Heribert  Schunkert</span>, <span class="hlFld-ContribAuthor ">Thorsten  Kessler</span>. </span><span class="cited-content_cbyCitation_article-title">cGMP Signaling in Cardiovascular Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cardiovascular Pharmacology</span><span> <strong>2020,</strong> <em>75 </em>
                                    (6)
                                     , 516-525. <a href="https://doi.org/10.1097/FJC.0000000000000744" title="DOI URL">https://doi.org/10.1097/FJC.0000000000000744</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/FJC.0000000000000744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FFJC.0000000000000744%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cardiovascular%2520Pharmacology%26atitle%3DcGMP%252BSignaling%252Bin%252BCardiovascular%252BDiseases%26aulast%3DDang%26aufirst%3DTan%2BAn%26date%3D2020%26volume%3D75%26issue%3D6%26spage%3D516%26epage%3D525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John C.  Burnett</span>. </span><span class="cited-content_cbyCitation_article-title">Vericiguat — Another Victory for Targeting Cyclic GMP in Heart Failure. </span><span class="cited-content_cbyCitation_journal-name">New England Journal of Medicine</span><span> <strong>2020,</strong> <em>382 </em>
                                    (20)
                                     , 1952-1953. <a href="https://doi.org/10.1056/NEJMe2006855" title="DOI URL">https://doi.org/10.1056/NEJMe2006855</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1056/NEJMe2006855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1056%2FNEJMe2006855%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520England%2520Journal%2520of%2520Medicine%26atitle%3DVericiguat%252B%2525E2%252580%252594%252BAnother%252BVictory%252Bfor%252BTargeting%252BCyclic%252BGMP%252Bin%252BHeart%252BFailure%26aulast%3DBurnett%26aufirst%3DJohn%2BC.%26date%3D2020%26volume%3D382%26issue%3D20%26spage%3D1952%26epage%3D1953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paul W.  Armstrong</span>, <span class="hlFld-ContribAuthor ">Burkert  Pieske</span>, <span class="hlFld-ContribAuthor ">Kevin J.  Anstrom</span>, <span class="hlFld-ContribAuthor ">Justin  Ezekowitz</span>, <span class="hlFld-ContribAuthor ">Adrian F.  Hernandez</span>, <span class="hlFld-ContribAuthor ">Javed  Butler</span>, <span class="hlFld-ContribAuthor ">Carolyn S.P.  Lam</span>, <span class="hlFld-ContribAuthor ">Piotr  Ponikowski</span>, <span class="hlFld-ContribAuthor ">Adriaan A.  Voors</span>, <span class="hlFld-ContribAuthor ">Gang  Jia</span>, <span class="hlFld-ContribAuthor ">Steven E.  McNulty</span>, <span class="hlFld-ContribAuthor ">Mahesh J.  Patel</span>, <span class="hlFld-ContribAuthor ">Lothar  Roessig</span>, <span class="hlFld-ContribAuthor ">Joerg  Koglin</span>, <span class="hlFld-ContribAuthor ">Christopher M.  O’Connor</span>. </span><span class="cited-content_cbyCitation_article-title">Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. </span><span class="cited-content_cbyCitation_journal-name">New England Journal of Medicine</span><span> <strong>2020,</strong> <em>382 </em>
                                    (20)
                                     , 1883-1893. <a href="https://doi.org/10.1056/NEJMoa1915928" title="DOI URL">https://doi.org/10.1056/NEJMoa1915928</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1056/NEJMoa1915928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1056%2FNEJMoa1915928%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520England%2520Journal%2520of%2520Medicine%26atitle%3DVericiguat%252Bin%252BPatients%252Bwith%252BHeart%252BFailure%252Band%252BReduced%252BEjection%252BFraction%26aulast%3DArmstrong%26aufirst%3DPaul%2BW.%26date%3D2020%26volume%3D382%26issue%3D20%26spage%3D1883%26epage%3D1893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Krassimira  Ivanova</span>, <span class="hlFld-ContribAuthor ">Ruth  Hemmersbach</span>. </span><span class="cited-content_cbyCitation_article-title">Guanylyl Cyclase-cGMP Signaling Pathway in Melanocytes: Differential Effects of Altered Gravity in Non-Metastatic and Metastatic Cells. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (3)
                                     , 1139. <a href="https://doi.org/10.3390/ijms21031139" title="DOI URL">https://doi.org/10.3390/ijms21031139</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21031139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21031139%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DGuanylyl%252BCyclase-cGMP%252BSignaling%252BPathway%252Bin%252BMelanocytes%25253A%252BDifferential%252BEffects%252Bof%252BAltered%252BGravity%252Bin%252BNon-Metastatic%252Band%252BMetastatic%252BCells%26aulast%3DIvanova%26aufirst%3DKrassimira%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D3%26spage%3D1139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sijia  Xiao</span>, <span class="hlFld-ContribAuthor ">Qianbin  Li</span>, <span class="hlFld-ContribAuthor ">Liqing  Hu</span>, <span class="hlFld-ContribAuthor ">Zutao  Yu</span>, <span class="hlFld-ContribAuthor ">Jie  Yang</span>, <span class="hlFld-ContribAuthor ">Qi  Chang</span>, <span class="hlFld-ContribAuthor ">Zhuo  Chen</span>, <span class="hlFld-ContribAuthor ">Gaoyun  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Soluble Guanylate Cyclase Stimulators and Activators: Where are We and Where to Go?. </span><span class="cited-content_cbyCitation_journal-name">Mini-Reviews in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (18)
                                     , 1544-1557. <a href="https://doi.org/10.2174/1389557519666190730110600" title="DOI URL">https://doi.org/10.2174/1389557519666190730110600</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1389557519666190730110600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1389557519666190730110600%26sid%3Dliteratum%253Aachs%26jtitle%3DMini-Reviews%2520in%2520Medicinal%2520Chemistry%26atitle%3DSoluble%252BGuanylate%252BCyclase%252BStimulators%252Band%252BActivators%25253A%252BWhere%252Bare%252BWe%252Band%252BWhere%252Bto%252BGo%25253F%26aulast%3DXiao%26aufirst%3DSijia%26date%3D2019%26volume%3D19%26issue%3D18%26spage%3D1544%26epage%3D1557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michel  Azizi</span>, <span class="hlFld-ContribAuthor ">Patrick  Rossignol</span>, <span class="hlFld-ContribAuthor ">Jean-Sébastien  Hulot</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging Drug Classes and Their Potential Use in Hypertension. </span><span class="cited-content_cbyCitation_journal-name">Hypertension</span><span> <strong>2019,</strong> <em>74 </em>
                                    (5)
                                     , 1075-1083. <a href="https://doi.org/10.1161/HYPERTENSIONAHA.119.12676" title="DOI URL">https://doi.org/10.1161/HYPERTENSIONAHA.119.12676</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1161/HYPERTENSIONAHA.119.12676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1161%2FHYPERTENSIONAHA.119.12676%26sid%3Dliteratum%253Aachs%26jtitle%3DHypertension%26atitle%3DEmerging%252BDrug%252BClasses%252Band%252BTheir%252BPotential%252BUse%252Bin%252BHypertension%26aulast%3DAzizi%26aufirst%3DMichel%26date%3D2019%26volume%3D74%26issue%3D5%26spage%3D1075%26epage%3D1083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Garyfallia I.  Makrynitsa</span>, <span class="hlFld-ContribAuthor ">Aikaterini A.  Zompra</span>, <span class="hlFld-ContribAuthor ">Aikaterini I.  Argyriou</span>, <span class="hlFld-ContribAuthor ">Georgios A.  Spyroulias</span>, <span class="hlFld-ContribAuthor ">Stavros  Topouzis</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic Targeting of the Soluble Guanylate Cyclase. </span><span class="cited-content_cbyCitation_journal-name">Current Medicinal Chemistry</span><span> <strong>2019,</strong> <em>26 </em>
                                    (15)
                                     , 2730-2747. <a href="https://doi.org/10.2174/0929867326666190108095851" title="DOI URL">https://doi.org/10.2174/0929867326666190108095851</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/0929867326666190108095851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F0929867326666190108095851%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medicinal%2520Chemistry%26atitle%3DTherapeutic%252BTargeting%252Bof%252Bthe%252BSoluble%252BGuanylate%252BCyclase%26aulast%3DMakrynitsa%26aufirst%3DGaryfallia%2BI.%26date%3D2019%26volume%3D26%26issue%3D15%26spage%3D2730%26epage%3D2747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Liang  Li</span>, <span class="hlFld-ContribAuthor ">Wenpeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Feng  Lin</span>, <span class="hlFld-ContribAuthor ">Xinqiang  Lu</span>, <span class="hlFld-ContribAuthor ">Wei  Chen</span>, <span class="hlFld-ContribAuthor ">Xingzhou  Li</span>, <span class="hlFld-ContribAuthor ">Xinbo  Zhou</span>, <span class="hlFld-ContribAuthor ">Ruibin  Su</span>, <span class="hlFld-ContribAuthor ">Lili  Wang</span>, <span class="hlFld-ContribAuthor ">Zhibing  Zheng</span>, <span class="hlFld-ContribAuthor ">Song  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of pyrazolo[3,4-b]pyridine-3-yl pyrimidine derivatives as sGC stimulators for the treatment of pulmonary hypertension. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>173 </em>, 107-116. <a href="https://doi.org/10.1016/j.ejmech.2019.04.014" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.04.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.04.014%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bpyrazolo%25255B3%25252C4-b%25255Dpyridine-3-yl%252Bpyrimidine%252Bderivatives%252Bas%252BsGC%252Bstimulators%252Bfor%252Bthe%252Btreatment%252Bof%252Bpulmonary%252Bhypertension%26aulast%3DLi%26aufirst%3DLiang%26date%3D2019%26volume%3D173%26spage%3D107%26epage%3D116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christin  Elgert</span>, <span class="hlFld-ContribAuthor ">Anne  Rühle</span>, <span class="hlFld-ContribAuthor ">Peter  Sandner</span>, <span class="hlFld-ContribAuthor ">Sönke  Behrends</span>. </span><span class="cited-content_cbyCitation_article-title">A novel soluble guanylyl cyclase activator, BR 11257, acts as a non-stabilising partial agonist of sGC. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2019,</strong> <em>163 </em>, 142-153. <a href="https://doi.org/10.1016/j.bcp.2019.02.007" title="DOI URL">https://doi.org/10.1016/j.bcp.2019.02.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2019.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2019.02.007%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DA%252Bnovel%252Bsoluble%252Bguanylyl%252Bcyclase%252Bactivator%25252C%252BBR%252B11257%25252C%252Bacts%252Bas%252Ba%252Bnon-stabilising%252Bpartial%252Bagonist%252Bof%252BsGC%26aulast%3DElgert%26aufirst%3DChristin%26date%3D2019%26volume%3D163%26spage%3D142%26epage%3D153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jesús  Tejero</span>, <span class="hlFld-ContribAuthor ">Sruti  Shiva</span>, <span class="hlFld-ContribAuthor ">Mark T.  Gladwin</span>. </span><span class="cited-content_cbyCitation_article-title">Sources of Vascular Nitric Oxide and Reactive Oxygen Species and Their Regulation. </span><span class="cited-content_cbyCitation_journal-name">Physiological Reviews</span><span> <strong>2019,</strong> <em>99 </em>
                                    (1)
                                     , 311-379. <a href="https://doi.org/10.1152/physrev.00036.2017" title="DOI URL">https://doi.org/10.1152/physrev.00036.2017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1152/physrev.00036.2017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1152%2Fphysrev.00036.2017%26sid%3Dliteratum%253Aachs%26jtitle%3DPhysiological%2520Reviews%26atitle%3DSources%252Bof%252BVascular%252BNitric%252BOxide%252Band%252BReactive%252BOxygen%252BSpecies%252Band%252BTheir%252BRegulation%26aulast%3DTejero%26aufirst%3DJes%25C3%25BAs%26date%3D2019%26volume%3D99%26issue%3D1%26spage%3D311%26epage%3D379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ligia Akemi  Kiyuna</span>, <span class="hlFld-ContribAuthor ">Rudá Prestes e  Albuquerque</span>, <span class="hlFld-ContribAuthor ">Che-Hong  Chen</span>, <span class="hlFld-ContribAuthor ">Daria  Mochly-Rosen</span>, <span class="hlFld-ContribAuthor ">Julio Cesar Batista  Ferreira</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting mitochondrial dysfunction and oxidative stress in heart failure: Challenges and opportunities. </span><span class="cited-content_cbyCitation_journal-name">Free Radical Biology and Medicine</span><span> <strong>2018,</strong> <em>129 </em>, 155-168. <a href="https://doi.org/10.1016/j.freeradbiomed.2018.09.019" title="DOI URL">https://doi.org/10.1016/j.freeradbiomed.2018.09.019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.freeradbiomed.2018.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.freeradbiomed.2018.09.019%26sid%3Dliteratum%253Aachs%26jtitle%3DFree%2520Radical%2520Biology%2520and%2520Medicine%26atitle%3DTargeting%252Bmitochondrial%252Bdysfunction%252Band%252Boxidative%252Bstress%252Bin%252Bheart%252Bfailure%25253A%252BChallenges%252Band%252Bopportunities%26aulast%3DKiyuna%26aufirst%3DLigia%2BAkemi%26date%3D2018%26volume%3D129%26spage%3D155%26epage%3D168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Figueroa-Valverde  Lauro</span>, <span class="hlFld-ContribAuthor ">Rosas-Nexticapa  Marcela</span>, <span class="hlFld-ContribAuthor ">Mateu-Armand  Virginia</span>, <span class="hlFld-ContribAuthor ">Herrera-Meza  Socorro</span>, <span class="hlFld-ContribAuthor ">Díaz-Cedillo  Francisco</span>, <span class="hlFld-ContribAuthor ">Montano-Tapia  Elizabeth</span>, <span class="hlFld-ContribAuthor ">García-Cervera  Elodia</span>, <span class="hlFld-ContribAuthor ">Pool-Gómez  Eduardo</span>, <span class="hlFld-ContribAuthor ">Hau-Heredia  Lenin</span>, <span class="hlFld-ContribAuthor ">García-Martínez  Rolando</span>, <span class="hlFld-ContribAuthor ">Lopez-Ramos  Maria</span>, <span class="hlFld-ContribAuthor ">Cauich-Carrillo  Regina</span>, <span class="hlFld-ContribAuthor ">Parra-Galindo  Perla</span>. </span><span class="cited-content_cbyCitation_article-title">New Amino-steroid-anthracenone with Biological Activity Against Ischemia-reperfusion Injury in a Wistar Rat Model. </span><span class="cited-content_cbyCitation_journal-name">The Open Pharmacology Journal</span><span> <strong>2018,</strong> <em>8 </em>
                                    (1)
                                     , 10-20. <a href="https://doi.org/10.2174/1874143601808010010" title="DOI URL">https://doi.org/10.2174/1874143601808010010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1874143601808010010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1874143601808010010%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Open%2520Pharmacology%2520Journal%26atitle%3DNew%252BAmino-steroid-anthracenone%252Bwith%252BBiological%252BActivity%252BAgainst%252BIschemia-reperfusion%252BInjury%252Bin%252Ba%252BWistar%252BRat%252BModel%26aulast%3DLauro%26aufirst%3DFigueroa-Valverde%26date%3D2018%26volume%3D8%26issue%3D1%26spage%3D10%26epage%3D20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anne  Sömmer</span>, <span class="hlFld-ContribAuthor ">Sönke  Behrends</span>. </span><span class="cited-content_cbyCitation_article-title">Methods to investigate structure and activation dynamics of GC-1/GC-2. </span><span class="cited-content_cbyCitation_journal-name">Nitric Oxide</span><span> <strong>2018,</strong> <em>78 </em>, 127-139. <a href="https://doi.org/10.1016/j.niox.2018.04.009" title="DOI URL">https://doi.org/10.1016/j.niox.2018.04.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.niox.2018.04.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.niox.2018.04.009%26sid%3Dliteratum%253Aachs%26jtitle%3DNitric%2520Oxide%26atitle%3DMethods%252Bto%252Binvestigate%252Bstructure%252Band%252Bactivation%252Bdynamics%252Bof%252BGC-1%25252FGC-2%26aulast%3DS%25C3%25B6mmer%26aufirst%3DAnne%26date%3D2018%26volume%3D78%26spage%3D127%26epage%3D139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">E.S.  Buys</span>, <span class="hlFld-ContribAuthor ">D.P.  Zimmer</span>, <span class="hlFld-ContribAuthor ">J.  Chickering</span>, <span class="hlFld-ContribAuthor ">R.  Graul</span>, <span class="hlFld-ContribAuthor ">Y.T.  Chien</span>, <span class="hlFld-ContribAuthor ">A.  Profy</span>, <span class="hlFld-ContribAuthor ">J.R.  Hadcock</span>, <span class="hlFld-ContribAuthor ">J.L.  Masferrer</span>, <span class="hlFld-ContribAuthor ">G.T.  Milne</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential. </span><span class="cited-content_cbyCitation_journal-name">Nitric Oxide</span><span> <strong>2018,</strong> <em>78 </em>, 72-80. <a href="https://doi.org/10.1016/j.niox.2018.05.009" title="DOI URL">https://doi.org/10.1016/j.niox.2018.05.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.niox.2018.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.niox.2018.05.009%26sid%3Dliteratum%253Aachs%26jtitle%3DNitric%2520Oxide%26atitle%3DDiscovery%252Band%252Bdevelopment%252Bof%252Bnext%252Bgeneration%252BsGC%252Bstimulators%252Bwith%252Bdiverse%252Bmultidimensional%252Bpharmacology%252Band%252Bbroad%252Btherapeutic%252Bpotential%26aulast%3DBuys%26aufirst%3DE.S.%26date%3D2018%26volume%3D78%26spage%3D72%26epage%3D80" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Min  Park</span>, <span class="hlFld-ContribAuthor ">Peter  Sandner</span>, <span class="hlFld-ContribAuthor ">Thomas  Krieg</span>. </span><span class="cited-content_cbyCitation_article-title">cGMP at the centre of attention: emerging strategies for activating the cardioprotective PKG pathway. </span><span class="cited-content_cbyCitation_journal-name">Basic Research in Cardiology</span><span> <strong>2018,</strong> <em>113 </em>
                                    (4)
                                     <a href="https://doi.org/10.1007/s00395-018-0679-9" title="DOI URL">https://doi.org/10.1007/s00395-018-0679-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00395-018-0679-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00395-018-0679-9%26sid%3Dliteratum%253Aachs%26jtitle%3DBasic%2520Research%2520in%2520Cardiology%26atitle%3DcGMP%252Bat%252Bthe%252Bcentre%252Bof%252Battention%25253A%252Bemerging%252Bstrategies%252Bfor%252Bactivating%252Bthe%252Bcardioprotective%252BPKG%252Bpathway%26aulast%3DPark%26aufirst%3DMin%26date%3D2018%26date%3D2018%26volume%3D113%26issue%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter  Sandner</span>, <span class="hlFld-ContribAuthor ">Eva-Maria  Becker-Pelster</span>, <span class="hlFld-ContribAuthor ">Johannes Peter  Stasch</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and development of sGC stimulators for the treatment of pulmonary hypertension and rare diseases. </span><span class="cited-content_cbyCitation_journal-name">Nitric Oxide</span><span> <strong>2018,</strong> <em>77 </em>, 88-95. <a href="https://doi.org/10.1016/j.niox.2018.05.001" title="DOI URL">https://doi.org/10.1016/j.niox.2018.05.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.niox.2018.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.niox.2018.05.001%26sid%3Dliteratum%253Aachs%26jtitle%3DNitric%2520Oxide%26atitle%3DDiscovery%252Band%252Bdevelopment%252Bof%252BsGC%252Bstimulators%252Bfor%252Bthe%252Btreatment%252Bof%252Bpulmonary%252Bhypertension%252Band%252Brare%252Bdiseases%26aulast%3DSandner%26aufirst%3DPeter%26date%3D2018%26volume%3D77%26spage%3D88%26epage%3D95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter  Sandner</span>. </span><span class="cited-content_cbyCitation_article-title">From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators. </span><span class="cited-content_cbyCitation_journal-name">Biological Chemistry</span><span> <strong>2018,</strong> <em>399 </em>
                                    (7)
                                     , 679-690. <a href="https://doi.org/10.1515/hsz-2018-0155" title="DOI URL">https://doi.org/10.1515/hsz-2018-0155</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1515/hsz-2018-0155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1515%2Fhsz-2018-0155%26sid%3Dliteratum%253Aachs%26jtitle%3DBiological%2520Chemistry%26atitle%3DFrom%252Bmolecules%252Bto%252Bpatients%25253A%252Bexploring%252Bthe%252Btherapeutic%252Brole%252Bof%252Bsoluble%252Bguanylate%252Bcyclase%252Bstimulators%26aulast%3DSandner%26aufirst%3DPeter%26date%3D2018%26date%3D2018%26volume%3D399%26issue%3D7%26spage%3D679%26epage%3D690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shalini  Krishnan</span>, <span class="hlFld-ContribAuthor ">Jan  Kraehling</span>, <span class="hlFld-ContribAuthor ">Frank  Eitner</span>, <span class="hlFld-ContribAuthor ">Agnès  Bénardeau</span>, <span class="hlFld-ContribAuthor ">Peter  Sandner</span>. </span><span class="cited-content_cbyCitation_article-title">The Impact of the Nitric Oxide (NO)/Soluble Guanylyl Cyclase (sGC) Signaling Cascade on Kidney Health and Disease: A Preclinical Perspective. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2018,</strong> <em>19 </em>
                                    (6)
                                     , 1712. <a href="https://doi.org/10.3390/ijms19061712" title="DOI URL">https://doi.org/10.3390/ijms19061712</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms19061712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms19061712%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DThe%252BImpact%252Bof%252Bthe%252BNitric%252BOxide%252B%252528NO%252529%25252FSoluble%252BGuanylyl%252BCyclase%252B%252528sGC%252529%252BSignaling%252BCascade%252Bon%252BKidney%252BHealth%252Band%252BDisease%25253A%252BA%252BPreclinical%252BPerspective%26aulast%3DKrishnan%26aufirst%3DShalini%26date%3D2018%26date%3D2018%26volume%3D19%26issue%3D6%26spage%3D1712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rohan C.  Shah</span>, <span class="hlFld-ContribAuthor ">Subramaniam  Sanker</span>, <span class="hlFld-ContribAuthor ">Katherine C.  Wood</span>, <span class="hlFld-ContribAuthor ">Brittany G.  Durgin</span>, <span class="hlFld-ContribAuthor ">Adam C.  Straub</span>. </span><span class="cited-content_cbyCitation_article-title">Redox regulation of soluble guanylyl cyclase. </span><span class="cited-content_cbyCitation_journal-name">Nitric Oxide</span><span> <strong>2018,</strong> <em>76 </em>, 97-104. <a href="https://doi.org/10.1016/j.niox.2018.03.013" title="DOI URL">https://doi.org/10.1016/j.niox.2018.03.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.niox.2018.03.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.niox.2018.03.013%26sid%3Dliteratum%253Aachs%26jtitle%3DNitric%2520Oxide%26atitle%3DRedox%252Bregulation%252Bof%252Bsoluble%252Bguanylyl%252Bcyclase%26aulast%3DShah%26aufirst%3DRohan%2BC.%26date%3D2018%26volume%3D76%26spage%3D97%26epage%3D104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Justin T.  Malinowski</span>, <span class="hlFld-ContribAuthor ">David J.  St. Jean</span>. </span><span class="cited-content_cbyCitation_article-title">Next-generation small molecule therapies for heart failure: 2015 and beyond. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (9)
                                     , 1429-1435. <a href="https://doi.org/10.1016/j.bmcl.2018.03.064" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.03.064</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.03.064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.03.064%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DNext-generation%252Bsmall%252Bmolecule%252Btherapies%252Bfor%252Bheart%252Bfailure%25253A%252B2015%252Band%252Bbeyond%26aulast%3DMalinowski%26aufirst%3DJustin%2BT.%26date%3D2018%26volume%3D28%26issue%3D9%26spage%3D1429%26epage%3D1435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paul W.  Armstrong</span>, <span class="hlFld-ContribAuthor ">Lothar  Roessig</span>, <span class="hlFld-ContribAuthor ">Mahesh J.  Patel</span>, <span class="hlFld-ContribAuthor ">Kevin J.  Anstrom</span>, <span class="hlFld-ContribAuthor ">Javed  Butler</span>, <span class="hlFld-ContribAuthor ">Adriaan A.  Voors</span>, <span class="hlFld-ContribAuthor ">Carolyn S.P.  Lam</span>, <span class="hlFld-ContribAuthor ">Piotr  Ponikowski</span>, <span class="hlFld-ContribAuthor ">Tracy  Temple</span>, <span class="hlFld-ContribAuthor ">Burkert  Pieske</span>, <span class="hlFld-ContribAuthor ">Justin  Ezekowitz</span>, <span class="hlFld-ContribAuthor ">Adrian F.  Hernandez</span>, <span class="hlFld-ContribAuthor ">Joerg  Koglin</span>, <span class="hlFld-ContribAuthor ">Christopher M.  O'Connor</span>. </span><span class="cited-content_cbyCitation_article-title">A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator. </span><span class="cited-content_cbyCitation_journal-name">JACC: Heart Failure</span><span> <strong>2018,</strong> <em>6 </em>
                                    (2)
                                     , 96-104. <a href="https://doi.org/10.1016/j.jchf.2017.08.013" title="DOI URL">https://doi.org/10.1016/j.jchf.2017.08.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jchf.2017.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jchf.2017.08.013%26sid%3Dliteratum%253Aachs%26jtitle%3DJACC%253A%2520Heart%2520Failure%26atitle%3DA%252BMulticenter%25252C%252BRandomized%25252C%252BDouble-Blind%25252C%252BPlacebo-Controlled%252BTrial%252Bof%252Bthe%252BEfficacy%2525C2%2525A0and%252BSafety%252Bof%252Bthe%252BOral%252BSoluble%252BGuanylate%252BCyclase%252BStimulator%26aulast%3DArmstrong%26aufirst%3DPaul%2BW.%26date%3D2018%26volume%3D6%26issue%3D2%26spage%3D96%26epage%3D104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter  Sandner</span>, <span class="hlFld-ContribAuthor ">Daniel P.  Zimmer</span>, <span class="hlFld-ContribAuthor ">G. Todd  Milne</span>, <span class="hlFld-ContribAuthor ">Markus  Follmann</span>, <span class="hlFld-ContribAuthor ">Adrian  Hobbs</span>, <span class="hlFld-ContribAuthor ">Johannes-Peter  Stasch</span>. </span><span class="cited-content_cbyCitation_article-title">Soluble Guanylate Cyclase Stimulators and Activators. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 355-394. <a href="https://doi.org/10.1007/164_2018_197" title="DOI URL">https://doi.org/10.1007/164_2018_197</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/164_2018_197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F164_2018_197%26sid%3Dliteratum%253Aachs%26atitle%3DSoluble%252BGuanylate%252BCyclase%252BStimulators%252Band%252BActivators%26aulast%3DSandner%26aufirst%3DPeter%26date%3D2018%26date%3D2019%26spage%3D355%26epage%3D394%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DReactive%252BOxygen%252BSpecies%26aulast%3DSchmidt%26aufirst%3DHarald%2BH.%2BH.%2BW.%26date%3D2021%26volume%3D264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anne  Sömmer</span>, <span class="hlFld-ContribAuthor ">Peter  Sandner</span>, <span class="hlFld-ContribAuthor ">Sönke  Behrends</span>. </span><span class="cited-content_cbyCitation_article-title">BAY 60–2770 activates two isoforms of nitric oxide sensitive guanylyl cyclase: Evidence for stable insertion of activator drugs. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2018,</strong> <em>147 </em>, 10-20. <a href="https://doi.org/10.1016/j.bcp.2017.11.010" title="DOI URL">https://doi.org/10.1016/j.bcp.2017.11.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2017.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2017.11.010%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DBAY%252B60%2525E2%252580%2525932770%252Bactivates%252Btwo%252Bisoforms%252Bof%252Bnitric%252Boxide%252Bsensitive%252Bguanylyl%252Bcyclase%25253A%252BEvidence%252Bfor%252Bstable%252Binsertion%252Bof%252Bactivator%252Bdrugs%26aulast%3DS%25C3%25B6mmer%26aufirst%3DAnne%26date%3D2018%26volume%3D147%26spage%3D10%26epage%3D20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andreas  Friebe</span>, <span class="hlFld-ContribAuthor ">Peter  Sandner</span>, <span class="hlFld-ContribAuthor ">Achim  Schmidtko</span>. </span><span class="cited-content_cbyCitation_article-title">Meeting report of the 8th International Conference on cGMP “cGMP: generators, effectors, and therapeutic implications” at Bamberg, Germany, from June 23 to 25, 2017. </span><span class="cited-content_cbyCitation_journal-name">Naunyn-Schmiedeberg's Archives of Pharmacology</span><span> <strong>2017,</strong> <em>390 </em>
                                    (12)
                                     , 1177-1188. <a href="https://doi.org/10.1007/s00210-017-1429-5" title="DOI URL">https://doi.org/10.1007/s00210-017-1429-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00210-017-1429-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00210-017-1429-5%26sid%3Dliteratum%253Aachs%26jtitle%3DNaunyn-Schmiedeberg%2527s%2520Archives%2520of%2520Pharmacology%26atitle%3DMeeting%252Breport%252Bof%252Bthe%252B8th%252BInternational%252BConference%252Bon%252BcGMP%252B%2525E2%252580%25259CcGMP%25253A%252Bgenerators%25252C%252Beffectors%25252C%252Band%252Btherapeutic%252Bimplications%2525E2%252580%25259D%252Bat%252BBamberg%25252C%252BGermany%25252C%252Bfrom%252BJune%252B23%252Bto%252B25%25252C%252B2017%26aulast%3DFriebe%26aufirst%3DAndreas%26date%3D2017%26date%3D2017%26volume%3D390%26issue%3D12%26spage%3D1177%26epage%3D1188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0022.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00449&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0008.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>1</b>–<b>18</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00449&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaOMe, DMF, 110 °C; (b) H<sub>2</sub> (65 bar), Raney nickel, DMF; (c) R<sup>2</sup>OCOCl, pyridine, or (i) triphosgene, pyridine, (ii) R<sup>2</sup>OH, pyridine; (d) R<sup>1</sup>X (X = halide or trichloromethanesulfonate), LiHMDS; (e) glycolaldehyde, NaBH<sub>3</sub>CN, AcOH, MeOH, 0 °C to rt; (f) methyl chloroformate, pyridine, rt; (g) NaHMDS, THF, 0 °C to rt.</p></p></figure><figure data-id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0009.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>19</b> and <b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00449&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) methyl 2-(2-fluorophenyl)acetate, LiHMDS; (b) aq NaCl solution, DMSO, microwave, 150 °C; (c) hydrazine hydrate, pyridine, reflux; (d) H<sub>2</sub>, 10% Pd/C, Et<sub>3</sub>N, EtOH, THF; (e) NaH, DMF, 80 °C; (f) H<sub>2</sub>, 10% Pd/C, pyridine; (g) methyl chloroformate, pyridine.</p></p></figure><figure data-id="sch3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0010.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compound <b>21</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00449&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) hydrazine hydrate; (b) POBr<sub>3</sub>, sulfolane, 150 °C; (c) 2-fluorobenzyl bromide, Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt; (d) CuCN, DMSO, 150 °C; (e) NaOMe, NH<sub>4</sub>Cl, AcOH, MeOH; (f) <b>1b</b>, DMF, Et<sub>3</sub>N, 100 °C; (g) H<sub>2</sub> (1 bar), 10% Pd/C, DMF; (h) methyl chloroformate, pyridine, DCM.</p></p></figure><figure data-id="sch4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0011.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compound <b>22</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00449&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) MeI, K<sub>2</sub>CO<sub>3</sub>, acetone; (b) TBAI, KO<i>t</i>-Bu, DCM, then aq HCl, Et<sub>2</sub>O; (c) dioxane, 60 °C; (d) 1,1,3,3-tetramethoxypropane, aq HCl, MeOH, EtOH, reflux; (e) NaOH; (f) HATU, NH<sub>4</sub>Cl, Hünig’s base, DMF; (g) POCl<sub>3</sub>, 120 °C; (h) NaOMe, NH<sub>4</sub>Cl, MeOH; (i) <b>1b</b>, DMF, Et<sub>3</sub>N, 100 °C; (j) H<sub>2</sub> (1 bar), 10% Pd/C, DMF, 0 °C; (k) methyl chloroformate, pyridine.</p></p></figure><figure data-id="sch5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0012.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compound <b>23</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00449&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) hydrazine hydrate, Et<sub>3</sub>N, reflux; (b) Et<sub>3</sub>N, MeCN; (c) Br<sub>2</sub>, AcOH, 50 °C; (d) POCl<sub>3</sub>, DCE, reflux; (e) H<sub>2</sub>, 5% Pd/C, Et<sub>3</sub>N, EtOAc; (f) NBS, DCM; (g) CuCN; (h) NaOMe, NH<sub>4</sub>Cl, AcOH; (i) <b>1b</b>, DMF, Et<sub>3</sub>N, 100 °C; (j) H<sub>2</sub> (1 bar), 10% Pd/C, DMF, MeOH; (k) methyl chloroformate, pyridine.</p></p></figure><figure data-id="sch6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0013.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of <b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00449&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Tf<sub>2</sub>O, 70 °C, then morpholine, 5 °C, then 40 °C; (b) MeSO<sub>3</sub>Me, 135 °C, then 100 °C; (c) 45% aq NaOH, 50 °C; (d) morpholine, Et<sub>3</sub>N, reflux; (e) MsOH, LiCl, EtOH, reflux; (f) formamide, NaOMe, MeOH, EtOH, 95–125 °C; (g) POCl<sub>3</sub>, sulfolane, 107 °C; (h) NaOMe, NH<sub>4</sub>Cl, MeOH, EtOH, 65 °C; (i) <b>1b</b>, DMF, Et<sub>3</sub>N, 100 °C; (j) H<sub>2</sub> (60 bar), 5% Pd/C, DMF, 60 °C; (k) methyl chloroformate, <i>i</i>-PrOH, MeOH, then Et<sub>3</sub>N, 50 °C.</p></p></figure><figure data-id="fig1" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0001.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Biotransformation products of <b>24</b> in human hepatocytes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00449&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0002.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Effects of <b>24</b> and NO on the stimulation of highly purified sGC and blocking effects of the sGC inhibitor ODQ.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00449&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0003.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effects of <b>24</b> on rat heart Langendorff preparations.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00449&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0004.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Increase in systolic blood pressure in mmHg during the course of the study with L-NAME-treated renin transgenic rats.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00449&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0005.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Right and left ventricle weight normalized on body weight (left/middle) and plasma atrial natriuretic peptide levels [in pg/mL] at the study end, after 3 weeks of treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00449&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0006.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effects on proteinuria at the study end after 3 weeks of treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00449&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/medium/jm-2017-00449k_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0007.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Kaplan–Meier survival curves.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00449/20170629/images/large/jm-2017-00449k_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00449&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i70">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10620" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10620" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 56 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Evgenov, O. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacher, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasko, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, H. H. H. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stasch, J.-P.</span><span> </span><span class="NLM_article-title">NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">755</span><span class="NLM_x">–</span> <span class="NLM_lpage">768</span><span class="refDoi"> DOI: 10.1038/nrd2038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1038%2Fnrd2038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=16955067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=755-768&author=O.+V.+Evgenovauthor=P.+Pacherauthor=P.+M.+Schmidtauthor=G.+Haskoauthor=H.+H.+H.+W.+Schmidtauthor=J.-P.+Stasch&title=NO-independent+stimulators+and+activators+of+soluble+guanylate+cyclase%3A+discovery+and+therapeutic+potential&doi=10.1038%2Fnrd2038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential</span></div><div class="casAuthors">Evgenov, Oleg V.; Pacher, Pal; Schmidt, Peter M.; Hasko, Gyoergy; Schmidt, Harald H. H. W.; Stasch, Johannes-Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">755-768</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Sol. guanylate cyclase (sGC) is a key signal-transduction enzyme activated by nitric oxide (NO).  Impaired bioavailability and/or responsiveness to endogenous NO has been implicated in the pathogenesis of cardiovascular and other diseases.  Current therapies that involve the use of org. nitrates and other NO donors have limitations, including non-specific interactions of NO with various biomols., lack of response and the development of tolerance following prolonged administration.  Compds. that activate sGC in an NO-independent manner might therefore provide considerable therapeutic advantages.  Here we review the discovery, biochem., pharmacol. and clin. potential of heme-dependent sGC stimulators (including YC-1, BAY 41-2272, BAY 41-8543, CFM-1571 and A-350619) and heme-independent sGC activators (including BAY 58-2667 and HMR-1766).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoq-7FoAzI40LVg90H21EOLACvtfcHk0lgGUnXvCak1Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltrw%253D&md5=6c2a2ad7db529a7fe366bcfa0d61a6af</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrd2038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2038%26sid%3Dliteratum%253Aachs%26aulast%3DEvgenov%26aufirst%3DO.%2BV.%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DSchmidt%26aufirst%3DP.%2BM.%26aulast%3DHasko%26aufirst%3DG.%26aulast%3DSchmidt%26aufirst%3DH.%2BH.%2BH.%2BW.%26aulast%3DStasch%26aufirst%3DJ.-P.%26atitle%3DNO-independent%2520stimulators%2520and%2520activators%2520of%2520soluble%2520guanylate%2520cyclase%253A%2520discovery%2520and%2520therapeutic%2520potential%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D755%26epage%3D768%26doi%3D10.1038%2Fnrd2038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Follmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griebenow, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartung, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mais, F.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mittendorf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schirok, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stasch, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoll, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Straub, A.</span><span> </span><span class="NLM_article-title">The chemistry and biology of soluble guanylate cyclase stimulators and activators</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">9442</span><span class="NLM_x">–</span> <span class="NLM_lpage">9462</span><span class="refDoi"> DOI: 10.1002/anie.201302588</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1002%2Fanie.201302588" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSiu77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=9442-9462&author=M.+Follmannauthor=N.+Griebenowauthor=M.+G.+Hahnauthor=I.+Hartungauthor=F.-J.+Maisauthor=J.+Mittendorfauthor=M.+Schaeferauthor=H.+Schirokauthor=J.-P.+Staschauthor=F.+Stollauthor=A.+Straub&title=The+chemistry+and+biology+of+soluble+guanylate+cyclase+stimulators+and+activators&doi=10.1002%2Fanie.201302588"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The Chemistry and Biology of Soluble Guanylate Cyclase Stimulators and Activators</span></div><div class="casAuthors">Follmann, Markus; Griebenow, Nils; Hahn, Michael G.; Hartung, Ingo; Mais, Franz-Josef; Mittendorf, Joachim; Schaefer, Martina; Schirok, Hartmut; Stasch, Johannes-Peter; Stoll, Friederike; Straub, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">9442-9462</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The vasodilatory properties of nitric oxide (NO) have been utilized in pharmacotherapy for more than 130 years.  Still today, NO-donor drugs are important in the management of cardiovascular diseases.  However, inhaled NO or drugs releasing NO and org. nitrates are assocd. with noteworthy therapeutic shortcomings, including resistance to NO in some disease states, the development of tolerance during long-term treatment, and nonspecific effects, such as post-translational modification of proteins.  The beneficial actions of NO are mediated by stimulation of sol. guanylate cyclase (sGC), a heme-contg. enzyme which produces the intracellular signaling mol. cGMP.  Recently, two classes of compds. have been discovered that amplify the function of sGC in a NO-independent manner, the so-called sGC stimulators and sGC activators.  The most advanced drug, the sGC stimulator riociguat, has successfully undergone Phase III clin. trials for different forms of pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1k3LI-HnJc7Vg90H21EOLACvtfcHk0lgGUnXvCak1Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSiu77K&md5=d84536785fcea442b23179a6d7bf7246</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Fanie.201302588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201302588%26sid%3Dliteratum%253Aachs%26aulast%3DFollmann%26aufirst%3DM.%26aulast%3DGriebenow%26aufirst%3DN.%26aulast%3DHahn%26aufirst%3DM.%2BG.%26aulast%3DHartung%26aufirst%3DI.%26aulast%3DMais%26aufirst%3DF.-J.%26aulast%3DMittendorf%26aufirst%3DJ.%26aulast%3DSchaefer%26aufirst%3DM.%26aulast%3DSchirok%26aufirst%3DH.%26aulast%3DStasch%26aufirst%3DJ.-P.%26aulast%3DStoll%26aufirst%3DF.%26aulast%3DStraub%26aufirst%3DA.%26atitle%3DThe%2520chemistry%2520and%2520biology%2520of%2520soluble%2520guanylate%2520cyclase%2520stimulators%2520and%2520activators%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D9442%26epage%3D9462%26doi%3D10.1002%2Fanie.201302588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Cerra, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellegrino, D.</span><span> </span><span class="NLM_article-title">Cardiovascular cGMP-generating systems in physiological and pathological conditions</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">585</span><span class="NLM_x">–</span> <span class="NLM_lpage">599</span><span class="refDoi"> DOI: 10.2174/092986707780059715</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.2174%2F092986707780059715" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=17346149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhs1yhur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=585-599&author=M.+C.+Cerraauthor=D.+Pellegrino&title=Cardiovascular+cGMP-generating+systems+in+physiological+and+pathological+conditions&doi=10.2174%2F092986707780059715"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiovascular cGMP-generating systems in physiological and pathological conditions</span></div><div class="casAuthors">Cerra, M. C.; Pellegrino, D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">585-599</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The intracellular messenger cyclic GMP (cGMP) represents the key signal in several transduction pathways throughout the animal world.  In the heart cGMP signaling contributes to functional interaction of different cell types.  Nitric oxide (NO) and natriuretic peptides (NPs), major autocrine-paracrine cardiovascular regulators, increment intracellular cGMP through guanylate cyclases (GCs).  NO and NPs interact with two GC types: cytosolic (sol.: sGC) and membrane bound [particulate: pGC (NP receptor types A and B)], resp.  Depending on sub-cellular localization and regulation of the enzymes, cGMP produced by either pGC or sGC exerts different complementary effects.  The two pathways are reciprocally regulated.  NPs-depending pGC is modulated by NO-cGMP signaling, and the activity of NO is influenced by cellular concns. of both NO itself and NPs.  This heterologous feedback regulates GCs, linking cardiovascular autocrine-paracrine activities of NPs and NO.  Importance of these cGMP converging routes goes far beyond their role under normal conditions.  They are of relevance esp. in disease states when tissue and circulating levels of NPs, and local NO prodn. are altered.  An example is the endothelial dysfunction assocd. with deficient NO prodn. and uncoupled endothelium-myocardium communications.  In this case, NPs-pGC-cGMP could supplement the reduced activity of NO-scGC-cGMP pathway.  In addn., these systems regulate cell growth and apoptosis, playing a role in myocardial pathol. morpho-functional remodeling.  Here we will review recent concepts on NO/NPs dependent control of heart function in vertebrates, also focusing on cGMP-activated downstream signaling and its role in health and disease conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4IxnrYfpG4LVg90H21EOLACvtfcHk0lgGUnXvCak1Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhs1yhur8%253D&md5=e908a3f3ba079740f192df00daf01396</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2174%2F092986707780059715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986707780059715%26sid%3Dliteratum%253Aachs%26aulast%3DCerra%26aufirst%3DM.%2BC.%26aulast%3DPellegrino%26aufirst%3DD.%26atitle%3DCardiovascular%2520cGMP-generating%2520systems%2520in%2520physiological%2520and%2520pathological%2520conditions%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2007%26volume%3D14%26spage%3D585%26epage%3D599%26doi%3D10.2174%2F092986707780059715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Gladwin, M. T.</span><span> </span><span class="NLM_article-title">Deconstructing endothelial dysfunction: soluble guanylyl cyclase oxidation and the NO resistance syndrome</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">2330</span><span class="NLM_x">–</span> <span class="NLM_lpage">2332</span><span class="refDoi"> DOI: 10.1172/JCI29807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1172%2FJCI29807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=16955136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD28Xps1Sgs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2006&pages=2330-2332&author=M.+T.+Gladwin&title=Deconstructing+endothelial+dysfunction%3A+soluble+guanylyl+cyclase+oxidation+and+the+NO+resistance+syndrome&doi=10.1172%2FJCI29807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Deconstructing endothelial dysfunction: soluble guanylyl cyclase oxidation and the NO resistance syndrome</span></div><div class="casAuthors">Gladwin, Mark T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2330-2332</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  In this issue of the JCI, Stasch and colleagues suggest that a novel drug, BAY 58-2667, potently activates a pool of oxidized and heme-free sol. guanylyl cyclase (sGC; see the related article beginning on page 2552).  The increased vasodilatory potency of BAY 58-2667 the authors found in a no. of animal models of endothelial dysfunction and in human blood vessels from patients with diabetes suggests that there exists a subphenotype of endothelial dysfunction characterized by receptor-level NO resistance.  Diseases assocd. with NO resistance would appear to be ideally suited for therapies directed at restoring redox homeostasis, sGC activity, and NO sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopNGJgNefaOLVg90H21EOLACvtfcHk0ljHKKSa4Ktjlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xps1Sgs7Y%253D&md5=9e5f9bf0c5d662275529e43902d83368</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1172%2FJCI29807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI29807%26sid%3Dliteratum%253Aachs%26aulast%3DGladwin%26aufirst%3DM.%2BT.%26atitle%3DDeconstructing%2520endothelial%2520dysfunction%253A%2520soluble%2520guanylyl%2520cyclase%2520oxidation%2520and%2520the%2520NO%2520resistance%2520syndrome%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2006%26volume%3D116%26spage%3D2330%26epage%3D2332%26doi%3D10.1172%2FJCI29807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Hoenicka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, C.</span><span> </span><span class="NLM_article-title">Cardiovascular effects of modulators of soluble guanylyl cyclase activity</span> <span class="citation_source-journal">Cardiovasc. Hematol. Agents Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">287</span><span class="NLM_x">–</span> <span class="NLM_lpage">301</span><span class="refDoi"> DOI: 10.2174/187152508785909555</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.2174%2F187152508785909555" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=18855642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlCntbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=287-301&author=M.+Hoenickaauthor=C.+Schmid&title=Cardiovascular+effects+of+modulators+of+soluble+guanylyl+cyclase+activity&doi=10.2174%2F187152508785909555"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiovascular effects of modulators of soluble guanylyl cyclase activity</span></div><div class="casAuthors">Hoenicka, Markus; Schmid, Christof</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular & Hematological Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">287-301</span>CODEN:
                <span class="NLM_cas:coden">CHAAA5</span>;
        ISSN:<span class="NLM_cas:issn">1871-5257</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Sol. guanylyl cyclase (sGC) is one of the key enzymes of the nitric-oxide (NO)/cyclic 3',5'-guanosine monophosphate (cGMP) pathway.  Located in virtually all mammalian cells, it controls the vessel tone, smooth muscle cell growth, platelet aggregation, and leukocyte adhesion.  In vivo sGC activity is mainly regulated by NO which in turn is released from L-arginine by nitric oxide synthases.  One of the main diseases of the cardiovascular system, endothelial dysfunction, leads to a diminished NO synthesis and thus increases vessel tone as well as the risk of thrombosis.  The predominant therapeutic approach to this condition is a NO replacement therapy, as exemplified by org. nitrates, molsidomin, and other NO releasing substances.  Recent advances in drug discovery provided a variety of other approaches to activate sGC, which may help to circumvent both the tolerance problem and some non-specific actions assocd. with NO donor drugs.  Substances like BAY 41-2272 stimulate sGC in a heme-dependent fashion and synergize with NO, allowing to enhance the effects both of endogenous NO and of exogenous NO donors.  On the other hand, heme-independent activators like BAY 58-2667 allow to activate sGC even if it is rendered unresponsive to NO due to oxidative stress or heme loss.  Furthermore, a few substances have been described as specific inhibitors of sGC that allow to alleviate the effects of excess NO prodn. as seen in shock.  This review discusses the cardiovascular effects of heme-dependent and heme-independent activators as well as of inhibitors of sGC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzFCLOV7NKCbVg90H21EOLACvtfcHk0ljHKKSa4Ktjlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlCntbjF&md5=329ce40010581e109f96a6331b8d754f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.2174%2F187152508785909555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152508785909555%26sid%3Dliteratum%253Aachs%26aulast%3DHoenicka%26aufirst%3DM.%26aulast%3DSchmid%26aufirst%3DC.%26atitle%3DCardiovascular%2520effects%2520of%2520modulators%2520of%2520soluble%2520guanylyl%2520cyclase%2520activity%26jtitle%3DCardiovasc.%2520Hematol.%2520Agents%2520Med.%2520Chem.%26date%3D2008%26volume%3D6%26spage%3D287%26epage%3D301%26doi%3D10.2174%2F187152508785909555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Priviero, F. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, R. C.</span><span> </span><span class="NLM_article-title">Heme-dependent and independent soluble guanylate cyclase activators and vasodilation</span> <span class="citation_source-journal">J. Cardiovasc. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">229</span><span class="NLM_x">–</span> <span class="NLM_lpage">233</span><span class="refDoi"> DOI: 10.1097/FJC.0b013e3181eb4e75</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1097%2FFJC.0b013e3181eb4e75" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=20571429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFKmur%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2010&pages=229-233&author=F.+B.+Privieroauthor=R.+C.+Webb&title=Heme-dependent+and+independent+soluble+guanylate+cyclase+activators+and+vasodilation&doi=10.1097%2FFJC.0b013e3181eb4e75"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Heme-Dependent and Independent Soluble Guanylate Cyclase Activators and Vasodilation</span></div><div class="casAuthors">Priviero, Fernanda B. M.; Webb, R. Clinton</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cardiovascular Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">229-233</span>CODEN:
                <span class="NLM_cas:coden">JCPCDT</span>;
        ISSN:<span class="NLM_cas:issn">0160-2446</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Since the discovery of nitric oxide (NO), which is released from endothelial cells as the main mediator of vasodilation, its target, the sol. guanylyl cyclase (sGC), has become a focus of interest for the treatment of diseases assocd. with endothelial dysfunction.  NO donors were developed to suppress NO deficiency; however, tolerance to org. nitrates was reported.  Non-NO-based drugs targeting sGC were developed to overcome the problem of tolerance.  In this review, we briefly describe the process of sGC activation by its main physiol. activator NO and the advances in the development of drugs capable of activating sGC in a NO-independent manner. sGC stimulators, as some of these drugs are called, require the integrity of the reduced heme moiety of the prosthetic group within the sGC and therefore are called heme-dependent stimulators.  Other drugs are able to activate sGC independent of heme moiety and are hence called heme-independent activators.  Because pathol. conditions modulate sGC and oxidize the heme moiety, the heme-independent sGC activators could potentially become drugs of choice because of their higher affinity to the oxidized enzyme.  However, these drugs are still undergoing clin. trials and are not available for clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO69av00aE9bVg90H21EOLACvtfcHk0lgAKXV1RE99aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFKmur%252FF&md5=6a2d08cf3f0894a5584cb988ed6ca344</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1097%2FFJC.0b013e3181eb4e75&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFJC.0b013e3181eb4e75%26sid%3Dliteratum%253Aachs%26aulast%3DPriviero%26aufirst%3DF.%2BB.%26aulast%3DWebb%26aufirst%3DR.%2BC.%26atitle%3DHeme-dependent%2520and%2520independent%2520soluble%2520guanylate%2520cyclase%2520activators%2520and%2520vasodilation%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D2010%26volume%3D56%26spage%3D229%26epage%3D233%26doi%3D10.1097%2FFJC.0b013e3181eb4e75" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Packer, C. S.</span><span> </span><span class="NLM_article-title">Soluble guanylate cyclase (sGC) down-regulation by abnormal extracellular matrix proteins as a novel mechanism in vascular dysfunction: implications in metabolic syndrome</span> <span class="citation_source-journal">Cardiovasc. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">302</span><span class="NLM_x">–</span> <span class="NLM_lpage">303</span><span class="refDoi"> DOI: 10.1016/j.cardiores.2005.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1016%2Fj.cardiores.2005.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=16412404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD28Xls1Wrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2006&pages=302-303&author=C.+S.+Packer&title=Soluble+guanylate+cyclase+%28sGC%29+down-regulation+by+abnormal+extracellular+matrix+proteins+as+a+novel+mechanism+in+vascular+dysfunction%3A+implications+in+metabolic+syndrome&doi=10.1016%2Fj.cardiores.2005.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble guanylate cyclase (sGC) down-regulation by abnormal extracellular matrix proteins as a novel mechanism in vascular dysfunction: Implications in metabolic syndrome</span></div><div class="casAuthors">Packer, C. Subah</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">302-303</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The role of endothelial NO prodn., accumulation of extracellular matrix proteins and altered activity of sol. guanylate cyclase in endothelial dysfunction and metabolic syndrome is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6CXr4qyhAqbVg90H21EOLACvtfcHk0lgAKXV1RE99aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xls1Wrtg%253D%253D&md5=c08169802b8f12d26d67479e3121a02b</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.cardiores.2005.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cardiores.2005.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DPacker%26aufirst%3DC.%2BS.%26atitle%3DSoluble%2520guanylate%2520cyclase%2520%2528sGC%2529%2520down-regulation%2520by%2520abnormal%2520extracellular%2520matrix%2520proteins%2520as%2520a%2520novel%2520mechanism%2520in%2520vascular%2520dysfunction%253A%2520implications%2520in%2520metabolic%2520syndrome%26jtitle%3DCardiovasc.%2520Res.%26date%3D2006%26volume%3D69%26spage%3D302%26epage%3D303%26doi%3D10.1016%2Fj.cardiores.2005.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Mayer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koesling, D.</span><span> </span><span class="NLM_article-title">cGMP signalling beyond nitric oxide</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">546</span><span class="NLM_x">–</span> <span class="NLM_lpage">548</span><span class="refDoi"> DOI: 10.1016/S0165-6147(00)01889-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1016%2FS0165-6147%2800%2901889-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=11698077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD3MXotFSms7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2001&pages=546-548&author=B.+Mayerauthor=D.+Koesling&title=cGMP+signalling+beyond+nitric+oxide&doi=10.1016%2FS0165-6147%2800%2901889-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">cGMP signalling beyond nitric oxide</span></div><div class="casAuthors">Mayer, Bernd; Koesling, Doris</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">546-548</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Many of the physiol. effects of nitric oxide are mediated by activation of sol. guanylyl cyclase, resulting in cellular cGMP accumulation.  In the 1990s, the benzylindazole deriv. YC-1 was identified as a novel modulator of cGMP signaling that exerted complex actions in a NO-independent manner.  A recent study describes a high-affinity YC-1 analog that decreases blood pressure in hypertensive rats and increases bleeding time, which suggests that this drug might have therapeutic potential as a vasodilator with antiplatelet activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxPGoC44V_-LVg90H21EOLACvtfcHk0lhBWLGAvV1sng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXotFSms7o%253D&md5=1904c0c74e65ba81ab8036825ff63826</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0165-6147%2800%2901889-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0165-6147%252800%252901889-7%26sid%3Dliteratum%253Aachs%26aulast%3DMayer%26aufirst%3DB.%26aulast%3DKoesling%26aufirst%3DD.%26atitle%3DcGMP%2520signalling%2520beyond%2520nitric%2520oxide%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2001%26volume%3D22%26spage%3D546%26epage%3D548%26doi%3D10.1016%2FS0165-6147%2800%2901889-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Nioche, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berka, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vipond, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raman, C. S.</span><span> </span><span class="NLM_article-title">Femtomolar sensitivity of a NO sensor from Clostridium botulinum</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">306</span><span class="NLM_x">, </span> <span class="NLM_fpage">1550</span><span class="NLM_x">–</span> <span class="NLM_lpage">1553</span><span class="refDoi"> DOI: 10.1126/science.1103596</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1126%2Fscience.1103596" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=15472039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVeqtr3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=2004&pages=1550-1553&author=P.+Niocheauthor=V.+Berkaauthor=J.+Vipondauthor=N.+Mintonauthor=A.+L.+Tsaiauthor=C.+S.+Raman&title=Femtomolar+sensitivity+of+a+NO+sensor+from+Clostridium+botulinum&doi=10.1126%2Fscience.1103596"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Femtomolar sensitivity of a NO sensor from Clostridium botulinum</span></div><div class="casAuthors">Nioche, Pierre; Berka, Vladimir; Vipond, Julia; Minton, Nigel; Tsai, Ah-Lim; Raman, C. S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">306</span>
        (<span class="NLM_cas:issue">5701</span>),
    <span class="NLM_cas:pages">1550-1553</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Nitric oxide (NO) is extremely toxic to Clostridium botulinum, but its mol. targets are unknown.  Here, the authors identify a heme protein sensor (SONO) that displays femtomolar affinity for NO.  The crystal structure of the SONO heme domain reveals a previously undescribed fold and a strategically placed tyrosine residue that modulates heme-nitrosyl coordination.  Furthermore, the domain architecture of a SONO ortholog cloned from Chlamydomonas reinhardtii indicates that NO signaling through cGMP arose before the origin of multicellular eukaryotes.  The authors' findings have broad implications for understanding bacterial responses to NO, as well as for the activation of mammalian NO-sensitive guanylyl cyclase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHl3CXdPf1ULVg90H21EOLACvtfcHk0lhBWLGAvV1sng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVeqtr3J&md5=b4832ef9edfbcd375eeff366ec35c6a2</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1126%2Fscience.1103596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1103596%26sid%3Dliteratum%253Aachs%26aulast%3DNioche%26aufirst%3DP.%26aulast%3DBerka%26aufirst%3DV.%26aulast%3DVipond%26aufirst%3DJ.%26aulast%3DMinton%26aufirst%3DN.%26aulast%3DTsai%26aufirst%3DA.%2BL.%26aulast%3DRaman%26aufirst%3DC.%2BS.%26atitle%3DFemtomolar%2520sensitivity%2520of%2520a%2520NO%2520sensor%2520from%2520Clostridium%2520botulinum%26jtitle%3DScience%26date%3D2004%26volume%3D306%26spage%3D1550%26epage%3D1553%26doi%3D10.1126%2Fscience.1103596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karow, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boon, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marletta, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Crystal structure of an oxygen-binding heme domain related to soluble guanylate cyclases</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">12854</span><span class="NLM_x">–</span> <span class="NLM_lpage">12859</span><span class="refDoi"> DOI: 10.1073/pnas.0405188101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1073%2Fpnas.0405188101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=15326296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnslCltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=12854-12859&author=P.+Pellicenaauthor=D.+S.+Karowauthor=E.+M.+Boonauthor=M.+A.+Marlettaauthor=J.+Kuriyan&title=Crystal+structure+of+an+oxygen-binding+heme+domain+related+to+soluble+guanylate+cyclases&doi=10.1073%2Fpnas.0405188101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of an oxygen-binding heme domain related to soluble guanylate cyclases</span></div><div class="casAuthors">Pellicena, Patricia; Karow, David S.; Boon, Elizabeth M.; Marletta, Michael A.; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">12854-12859</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Sol. guanylate cyclases are nitric oxide-responsive signaling proteins in which the nitric oxide sensor is a heme-binding domain of unknown structure that we have termed the heme-NO and oxygen binding (H-NOX) domain.  H-NOX domains are also found in bacteria, either as isolated domains, or are fused through a membrane-spanning region to methyl-accepting chemotaxis proteins.  We have detd. the crystal structure of an oxygen-binding H-NOX domain of one such signaling protein from the obligate anaerobe Thermoanaerobacter tengcongensis at 1.77-Å resoln., revealing a protein fold unrelated to known structures.  Particularly striking is the structure of the protoporphyrin IX group, which is distorted from planarity to an extent not seen before in protein-bound heme groups.  Comparison of the structure of the H-NOX domain in two different crystal forms suggests a mechanism whereby alteration in the degree of distortion of the heme group is coupled to changes on the mol. surface of the H-NOX domain and potentially to changes in intermol. interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZbFyxgC3LDbVg90H21EOLACvtfcHk0lhBWLGAvV1sng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnslCltbc%253D&md5=7b3bc4fa35cf69d5b806377466a826df</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0405188101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0405188101%26sid%3Dliteratum%253Aachs%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DKarow%26aufirst%3DD.%2BS.%26aulast%3DBoon%26aufirst%3DE.%2BM.%26aulast%3DMarletta%26aufirst%3DM.%2BA.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520structure%2520of%2520an%2520oxygen-binding%2520heme%2520domain%2520related%2520to%2520soluble%2520guanylate%2520cyclases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2004%26volume%3D101%26spage%3D12854%26epage%3D12859%26doi%3D10.1073%2Fpnas.0405188101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Wedel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humbert, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harteneck, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foerster, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malkewitz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohme, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koesling, D.</span><span> </span><span class="NLM_article-title">Mutation of His-105 in the β<sub>1</sub> subunit yields a nitric oxide-insensitive form of soluble guanylyl cyclase</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">2592</span><span class="NLM_x">–</span> <span class="NLM_lpage">2596</span><span class="refDoi"> DOI: 10.1073/pnas.91.7.2592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1073%2Fpnas.91.7.2592" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=2592-2596&author=B.+Wedelauthor=P.+Humbertauthor=C.+Harteneckauthor=J.+Foersterauthor=J.+Malkewitzauthor=E.+Bohmeauthor=G.+Schultzauthor=D.+Koesling&title=Mutation+of+His-105+in+the+%CE%B21+subunit+yields+a+nitric+oxide-insensitive+form+of+soluble+guanylyl+cyclase&doi=10.1073%2Fpnas.91.7.2592"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.91.7.2592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.91.7.2592%26sid%3Dliteratum%253Aachs%26aulast%3DWedel%26aufirst%3DB.%26aulast%3DHumbert%26aufirst%3DP.%26aulast%3DHarteneck%26aufirst%3DC.%26aulast%3DFoerster%26aufirst%3DJ.%26aulast%3DMalkewitz%26aufirst%3DJ.%26aulast%3DBohme%26aufirst%3DE.%26aulast%3DSchultz%26aufirst%3DG.%26aulast%3DKoesling%26aufirst%3DD.%26atitle%3DMutation%2520of%2520His-105%2520in%2520the%2520%25CE%25B21%2520subunit%2520yields%2520a%2520nitric%2520oxide-insensitive%2520form%2520of%2520soluble%2520guanylyl%2520cyclase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1994%26volume%3D91%26spage%3D2592%26epage%3D2596%26doi%3D10.1073%2Fpnas.91.7.2592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Zabel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hausler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weeger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, H. H.</span><span> </span><span class="NLM_article-title">Homodimerization of soluble guanylyl cyclase subunits. Dimerization analysis using a glutathione <i>S</i>-transferase affinity tag</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">274</span><span class="NLM_x">, </span> <span class="NLM_fpage">18149</span><span class="NLM_x">–</span> <span class="NLM_lpage">18152</span><span class="refDoi"> DOI: 10.1074/jbc.274.26.18149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1074%2Fjbc.274.26.18149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10373411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADyaK1MXktF2rtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=18149-18152&author=U.+Zabelauthor=C.+Hauslerauthor=M.+Weegerauthor=H.+H.+Schmidt&title=Homodimerization+of+soluble+guanylyl+cyclase+subunits.+Dimerization+analysis+using+a+glutathione+S-transferase+affinity+tag&doi=10.1074%2Fjbc.274.26.18149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Homodimerization of soluble guanylyl cyclase subunits. Dimerization analysis using a glutathione S-transferase affinity tag</span></div><div class="casAuthors">Zabel, Ulrike; Hausler, Christoph; Weeger, Monika; Schmidt, Harald H. H. W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">274</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">18149-18152</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Sol. guanylyl cyclase (sGC) is an α/β-heterodimeric hemoprotein that, upon interaction with the intercellular messenger mol. NO, generates cGMP.  Although the related family of particulate guanylyl cyclases (pGCs) forms active homodimeric complexes, it is not known whether homodimerization of sGC subunits occurs.  We report here the expression in Sf9 cells of glutathione S-transferase-tagged recombinant human sGCα1 and β1 subunits, applying a novel and rapid purifn. method based on GSH-Sepharose affinity chromatog.  Surprisingly, in intact Sf9 cells, both homodimeric GSTα/α and GSTβ/β complexes were formed that were catalytically inactive.  Upon coexpression of the resp. complementary subunits, GSTα/β or GSTβ/α heterodimers were preferentially formed, whereas homodimers were still detectable.  When subunits were mixed after expression, e.g. GSTβ and β or GSTα and β, no dimerization was obsd.  In conclusion, our data suggest the previously unrecognized possibility of a physiol. equil. between homo- and heterodimeric sGC complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1XE1FMz92BrVg90H21EOLACvtfcHk0ljQ05XvAkYCgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXktF2rtL8%253D&md5=12ec14790843c43f8cf099f61c1af118</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1074%2Fjbc.274.26.18149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.274.26.18149%26sid%3Dliteratum%253Aachs%26aulast%3DZabel%26aufirst%3DU.%26aulast%3DHausler%26aufirst%3DC.%26aulast%3DWeeger%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DH.%2BH.%26atitle%3DHomodimerization%2520of%2520soluble%2520guanylyl%2520cyclase%2520subunits.%2520Dimerization%2520analysis%2520using%2520a%2520glutathione%2520S-transferase%2520affinity%2520tag%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D18149%26epage%3D18152%26doi%3D10.1074%2Fjbc.274.26.18149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Zabel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weeger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, H. H. W.</span><span> </span><span class="NLM_article-title">Human soluble guanylate cyclase: functional expression and revised isoenzyme family</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">335</span><span class="NLM_x">, </span> <span class="NLM_fpage">51</span><span class="NLM_x">–</span> <span class="NLM_lpage">57</span><span class="refDoi"> DOI: 10.1042/bj3350051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1042%2Fbj3350051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=9742212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADyaK1cXms1Ohurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=335&publication_year=1998&pages=51-57&author=U.+Zabelauthor=M.+Weegerauthor=M.+Laauthor=H.+H.+W.+Schmidt&title=Human+soluble+guanylate+cyclase%3A+functional+expression+and+revised+isoenzyme+family&doi=10.1042%2Fbj3350051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Human soluble guanylate cyclase: functional expression and revised isoenzyme family</span></div><div class="casAuthors">Zabel, Ulrike; Weeger, Monika; La, Mylinh; Schmidt, Harald H. H. W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">335</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-57</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Sol. guanylate cyclase (sGC), a heterodimeric (α/β) heme protein that converts GTP to the second messenger cGMP, functions as the receptor for nitric oxide (NO) and nitrovasodilator drugs.  Three distinct cDNA species of each subunit (α1-α3, β1-β3) have been reported from various species.  From human sources, none of these have been expressed as functionally active enzyme.  Here the authors described the expression of human α/β heterodimeric sGC in Sf9 cells yielding active recombinant enzyme that was stimulated by the nitrovasodilator sodium nitroprusside or the NO-independent activator 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole (YC-1).  At the protein level, both α and β subunits were detected in human tissues, suggesting co-expression also in vivo.  Moreover, resequencing of the human cDNA clones [originally termed α3 and β3] revealed several sequencing errors in human α3; correction of these eliminated major regions of divergence from rat and bovine α1.  As human β3 also displays more than 98% similarity to rat and bovine β1 at the amino acid level, α3 and β3 represent the human homologs of rat and bovine α1 and β1, and the isoenzyme family is decreased to two isoforms for each subunit (α1, α2; β1, β2).  Having access to the human key enzyme of NO signaling will now permit the study of novel sGC-modulating compds. with therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVl92c04nUBLVg90H21EOLACvtfcHk0ljQ05XvAkYCgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXms1Ohurg%253D&md5=0eb51bff28b1e54b4f447d60329d3f27</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1042%2Fbj3350051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj3350051%26sid%3Dliteratum%253Aachs%26aulast%3DZabel%26aufirst%3DU.%26aulast%3DWeeger%26aufirst%3DM.%26aulast%3DLa%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DH.%2BH.%2BW.%26atitle%3DHuman%2520soluble%2520guanylate%2520cyclase%253A%2520functional%2520expression%2520and%2520revised%2520isoenzyme%2520family%26jtitle%3DBiochem.%2520J.%26date%3D1998%26volume%3D335%26spage%3D51%26epage%3D57%26doi%3D10.1042%2Fbj3350051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Murad, F.</span><span> </span><span class="NLM_article-title">Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">355</span><span class="NLM_x">, </span> <span class="NLM_fpage">2003</span><span class="NLM_x">–</span> <span class="NLM_lpage">2011</span><span class="refDoi"> DOI: 10.1056/NEJMsa063904</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1056%2FNEJMsa063904" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=17093251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFymur3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2006&pages=2003-2011&author=F.+Murad&title=Shattuck+Lecture.+Nitric+oxide+and+cyclic+GMP+in+cell+signaling+and+drug+development&doi=10.1056%2FNEJMsa063904"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Nitric oxide and cyclic GMP in cell signaling and drug development</span></div><div class="casAuthors">Murad, Ferid</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2003-2011</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  The topics discussed include: guanylyl cyclase activity; endothelial activity; nitric oxide synthase; activation of sol. guanylyl cyclase; steady-state levels of cGMP; and cGMP signaling in drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohrhWHak3qNrVg90H21EOLACvtfcHk0ljQ05XvAkYCgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFymur3J&md5=39e95c4acecc494cb06967644671887b</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMsa063904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMsa063904%26sid%3Dliteratum%253Aachs%26aulast%3DMurad%26aufirst%3DF.%26atitle%3DShattuck%2520Lecture.%2520Nitric%2520oxide%2520and%2520cyclic%2520GMP%2520in%2520cell%2520signaling%2520and%2520drug%2520development%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D355%26spage%3D2003%26epage%3D2011%26doi%3D10.1056%2FNEJMsa063904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Stasch, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hobbs, A. J.</span><span> </span><span class="NLM_article-title">NO-independent, haem-dependent soluble guanylate cyclase stimulators</span> <span class="citation_source-journal">Handb. Exp. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">191</span><span class="NLM_x">, </span> <span class="NLM_fpage">277</span><span class="NLM_x">–</span> <span class="NLM_lpage">308</span><span class="refDoi"> DOI: 10.1007/978-3-540-68964-5_13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1007%2F978-3-540-68964-5_13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=19089334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitlaisLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2009&pages=277-308&author=J.+P.+Staschauthor=A.+J.+Hobbs&title=NO-independent%2C+haem-dependent+soluble+guanylate+cyclase+stimulators&doi=10.1007%2F978-3-540-68964-5_13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">NO-independent, haem-dependent soluble guanylate cyclase stimulators</span></div><div class="casAuthors">Stasch, Johannes-Peter; Hobbs, Adrian J.</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of Experimental Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">cGMP: Generators, Effectors and Therapeutic Implications</span>),
    <span class="NLM_cas:pages">277-308</span>CODEN:
                <span class="NLM_cas:coden">HEPHD2</span>;
        ISSN:<span class="NLM_cas:issn">0171-2004</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  The nitric oxide (NO) signalling pathway is altered in cardiovascular diseases, including systemic and pulmonary hypertension, stroke, and atherosclerosis.  The vasodilatory properties of NO have been exploited for over a century in cardiovascular disease, but NO donor drugs and inhaled NO are assocd. with significant shortcomings, including resistance to NO in some disease states, the development of tolerance during long-term treatment, and non-specific effects such as post-translational modification of proteins.  The development of pharmacol. agents capable of directly stimulating the NO receptor, sol. guanylate cyclase (sGC), is therefore highly desirable.  The benzylindazole compd. YC-1 was the first sGC stimulator to be identified; this compd. formed a lead structure for the development of optimized sGC stimulators with improved potency and specificity for sGC, including CFM-1571, BAY 41-2272, BAY 41-8543, and BAY 63-2521.  In contrast to the NO- and haem-independent sGC activators such as BAY 58-2667, these compds. stimulate sGC activity independent of NO and also act in synergy with NO to produce anti-aggregatory, anti-proliferative, and vasodilatory effects.  Recently, aryl-acrylamide compds. were identified independent of YC-1 as sGC stimulators; although structurally dissimilar to YC-1, they have a similar mode of action and promote smooth muscle relaxation.  Pharmacol. stimulators of sGC may be beneficial in the treatment of a range of diseases, including systemic and pulmonary hypertension, heart failure, atherosclerosis, erectile dysfunction, and renal fibrosis.  An sGC stimulator, BAY 63-2521, is currently in clin. development as an oral therapy for patients with pulmonary hypertension.  It has demonstrated efficacy in a proof-of-concept study, reducing pulmonary vascular resistance and increasing cardiac output from baseline.  A full, phase 2 trial of BAY 63-2521 in pulmonary hypertension is underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrxCcRDKhcS7Vg90H21EOLACvtfcHk0ljQ05XvAkYCgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitlaisLY%253D&md5=d417b58908ffa19b40838209ac6b90f0</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2F978-3-540-68964-5_13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-540-68964-5_13%26sid%3Dliteratum%253Aachs%26aulast%3DStasch%26aufirst%3DJ.%2BP.%26aulast%3DHobbs%26aufirst%3DA.%2BJ.%26atitle%3DNO-independent%252C%2520haem-dependent%2520soluble%2520guanylate%2520cyclase%2520stimulators%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2009%26volume%3D191%26spage%3D277%26epage%3D308%26doi%3D10.1007%2F978-3-540-68964-5_13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Schmidt, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stasch, J. P.</span><span> </span><span class="NLM_article-title">NO- and haem-independent soluble guanylate cyclase activators</span> <span class="citation_source-journal">Handb. Exp. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">191</span><span class="NLM_x">, </span> <span class="NLM_fpage">309</span><span class="NLM_x">–</span> <span class="NLM_lpage">339</span><span class="refDoi"> DOI: 10.1007/978-3-540-68964-5_14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1007%2F978-3-540-68964-5_14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=19089335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitlaisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2009&pages=309-339&author=H.+H.+Schmidtauthor=P.+M.+Schmidtauthor=J.+P.+Stasch&title=NO-+and+haem-independent+soluble+guanylate+cyclase+activators&doi=10.1007%2F978-3-540-68964-5_14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">NO- and haem-independent soluble guanylate cyclase activators</span></div><div class="casAuthors">Schmidt, Harald H. H. W.; Schmidt, Peter M.; Stasch, Johannes-Peter</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of Experimental Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">cGMP: Generators, Effectors and Therapeutic Implications</span>),
    <span class="NLM_cas:pages">309-339</span>CODEN:
                <span class="NLM_cas:coden">HEPHD2</span>;
        ISSN:<span class="NLM_cas:issn">0171-2004</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  Oxidative stress, a risk factor for several cardiovascular disorders, interferes with the NO/sGC/cGMP signalling pathway through scavenging of NO and formation of the strong intermediate oxidant, peroxynitrite.  Under these conditions, endothelial and vascular dysfunction develops, culminating in different cardio-renal and pulmonary-vascular diseases.  Substituting NO with org. nitrates that release NO (NO donors) has been an important principle in cardiovascular therapy for more than a century.  However, the development of nitrate tolerance limits their continuous clin. application and, under oxidative stress and increased formation of peroxynitrite foils the desired therapeutic effect.  To overcome these obstacles of nitrate therapy, direct NO- and haem-independent sGC activators have been developed, such as BAY 58-2667 (cinaciguat) and HMR1766 (ataciguat), showing unique biochem. and pharmacol. properties.  Both compds. are capable of selectively activating the oxidized/haem-free enzyme via binding to the enzyme's haem pocket, causing pronounced vasodilatation.  The potential importance of these new drugs resides in the fact that they selectively target a modified state of sGC that is prevalent under disease conditions as shown in several animal models and human disease.  Activators of sGC may be beneficial in the treatment of a range of diseases including systemic and pulmonary hypertension (PH), heart failure, atherosclerosis, peripheral arterial occlusive disease (PAOD), thrombosis and renal fibrosis.  The sGC activator HMR1766 is currently in clin. development as an oral therapy for patients with PAOD.  The sGC activator BAY 58-2667 has demonstrated efficacy in a proof-of-concept study in patients with acute decompensated heart failure (ADHF), reducing pre- and afterload and increasing cardiac output from baseline.  A phase IIb clin. study for the indication of ADHF is currently underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYfXnvGGXe2rVg90H21EOLACvtfcHk0lg_LXKUXRPiOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitlaisb4%253D&md5=a38ffd43e7f3769198b1654c74ffa16c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2F978-3-540-68964-5_14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-540-68964-5_14%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DH.%2BH.%26aulast%3DSchmidt%26aufirst%3DP.%2BM.%26aulast%3DStasch%26aufirst%3DJ.%2BP.%26atitle%3DNO-%2520and%2520haem-independent%2520soluble%2520guanylate%2520cyclase%2520activators%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2009%26volume%3D191%26spage%3D309%26epage%3D339%26doi%3D10.1007%2F978-3-540-68964-5_14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Stasch, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evgenov, O. V.</span><span> </span><span class="NLM_article-title">Soluble guanylate cyclase stimulators in pulmonary hypertension</span> <span class="citation_source-journal">Handb. Exp. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">218</span><span class="NLM_x">, </span> <span class="NLM_fpage">279</span><span class="NLM_x">–</span> <span class="NLM_lpage">313</span><span class="refDoi"> DOI: 10.1007/978-3-662-45805-1_12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1007%2F978-3-662-45805-1_12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=24092345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsVOjtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=218&publication_year=2013&pages=279-313&author=J.-P.+Staschauthor=O.+V.+Evgenov&title=Soluble+guanylate+cyclase+stimulators+in+pulmonary+hypertension&doi=10.1007%2F978-3-662-45805-1_12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble Guanylate Cyclase Stimulators in Pulmonary Hypertension</span></div><div class="casAuthors">Stasch, Johannes-Peter; Evgenov, Oleg V.</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of Experimental Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">218</span>
        (<span class="NLM_cas:issue">Pharmacotherapy of Pulmonary Hypertension</span>),
    <span class="NLM_cas:pages">279-313</span>CODEN:
                <span class="NLM_cas:coden">HEPHD2</span>;
        ISSN:<span class="NLM_cas:issn">0171-2004</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  Sol. guanylate cyclase (sGC) is a key enzyme in the nitric oxide (NO) signalling pathway.  On binding of NO to its prosthetic heme group, sGC catalyzes the synthesis of the second messenger cyclic guanosine monophosphate (cGMP), which promotes vasodilation and inhibits smooth muscle proliferation, leukocyte recruitment, platelet aggregation and vascular remodelling through a no. of downstream mechanisms.  The central role of the NO-sGC-cGMP pathway in regulating pulmonary vascular tone is demonstrated by the dysregulation of NO prodn., sGC activity and cGMP degrdn. in pulmonary hypertension (PH).  The sGC stimulators are novel pharmacol. agents that directly stimulate sGC, both independently of NO and in synergy with NO.  Optimization of the first sGC stimulator, YC-1, led to the development of the more potent and more specific sGC stimulators, BAY 41-2272, BAY 41-8543 and riociguat (BAY 63-2521).  Other sGC stimulators include CFM-1571, BAY 60-4552, vericiguat (BAY 1021189), the acrylamide analog A-350619 and the aminopyrimidine analogs.  BAY 41-2272, BAY 41-8543 and riociguat induced marked dose-dependent redns. in mean pulmonary arterial pressure and vascular resistance with a concomitant increase in cardiac output, and they also reversed vascular remodelling and right heart hypertrophy in several exptl. models of PH.  Riociguat is the first sGC stimulator that has entered clin. development.  Clin. trials have shown that it significantly improves pulmonary vascular haemodynamics and increases exercise ability in patients with pulmonary arterial hypertension (PAH), chronic thromboembolic PH and PH assocd. with interstitial lung disease.  Furthermore, riociguat reduces mean pulmonary arterial pressure in patients with PH assocd. with chronic obstructive pulmonary disease and improves cardiac index and pulmonary vascular resistance in patients with PH assocd. with left ventricular systolic dysfunction.  These promising results suggest that sGC stimulators may constitute a valuable new therapy for PH.  Other trials of riociguat are in progress, including a study of the haemodynamic effects and safety of riociguat in patients with PH assocd. with left ventricular diastolic dysfunction, and long-term extensions of the phase 3 trials investigating the efficacy and safety of riociguat in patients with PAH and chronic thromboembolic PH.  Finally, sGC stimulators may also have potential therapeutic applications in other diseases, including heart failure, lung fibrosis, scleroderma and sickle cell disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt7DHbIDkxIrVg90H21EOLACvtfcHk0lg_LXKUXRPiOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsVOjtb0%253D&md5=e03a5623d72204f41ca7f0324482238b</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2F978-3-662-45805-1_12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-662-45805-1_12%26sid%3Dliteratum%253Aachs%26aulast%3DStasch%26aufirst%3DJ.-P.%26aulast%3DEvgenov%26aufirst%3DO.%2BV.%26atitle%3DSoluble%2520guanylate%2520cyclase%2520stimulators%2520in%2520pulmonary%2520hypertension%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2013%26volume%3D218%26spage%3D279%26epage%3D313%26doi%3D10.1007%2F978-3-662-45805-1_12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Ghofrani, H.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galie, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimminger, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruenig, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humbert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jing, Z.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keogh, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langleben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilama, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritsch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuser, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, L. J.</span><span> </span><span class="NLM_article-title">Riociguat for the treatment of pulmonary arterial hypertension</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">369</span><span class="NLM_x">, </span> <span class="NLM_fpage">330</span><span class="NLM_x">–</span> <span class="NLM_lpage">340</span><span class="refDoi"> DOI: 10.1056/NEJMoa1209655</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1056%2FNEJMoa1209655" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=23883378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2nur7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=330-340&author=H.-A.+Ghofraniauthor=N.+Galieauthor=F.+Grimmingerauthor=E.+Gruenigauthor=M.+Humbertauthor=Z.-C.+Jingauthor=A.+M.+Keoghauthor=D.+Langlebenauthor=M.+O.+Kilamaauthor=A.+Fritschauthor=D.+Neuserauthor=L.+J.+Rubin&title=Riociguat+for+the+treatment+of+pulmonary+arterial+hypertension&doi=10.1056%2FNEJMoa1209655"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Riociguat for the treatment of pulmonary arterial hypertension</span></div><div class="casAuthors">Ghofrani, Hossein-Ardeschir; Galie, Nazzareno; Grimminger, Friedrich; Gruenig, Ekkehard; Humbert, Marc; Jing, Zhi-Cheng; Keogh, Anne M.; Langleben, David; Kilama, Michael Ochan; Fritsch, Arno; Neuser, Dieter; Rubin, Lewis J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">330-340</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Riociguat, a sol. guanylate cyclase stimulator, has been shown in a phase 2 trial to be beneficial in the treatment of pulmonary arterial hypertension.  METHODS: In this phase 3, double-blind study, we randomly assigned 443 patients with symptomatic pulmonary arterial hypertension to receive placebo, riociguat in individually adjusted doses of up to 2.5 mg three times daily (2.5 mg-max. group), or riociguat in individually adjusted doses that were capped at 1.5 mg three times daily (1.5 mg-max. group).  The 1.5 mg-max. group was included for exploratory purposes, and the data from that group were analyzed descriptively.  Patients who were receiving no other treatment for pulmonary arterial hypertension and patients who were receiving endothelin-receptor antagonists or (nonintravenous) prostanoids were eligible.  The primary end point was the change from baseline to the end of week 12 in the distance walked in 6 min.  Secondary end points included the change in pulmonary vascular resistance, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, World Health Organization (WHO) functional class, time to clin. worsening, score on the Borg dyspnea scale, quality-of-life variables, and safety.  RESULTS: By week 12, the 6-min walk distance had increased by a mean of 30 m in the 2.5 mg-max. group and had decreased by a mean of 6 m in the placebo group (least-squares mean difference, 36 m; 95% confidence interval, 20 to 52; P<0.001).  Prespecified subgroup analyses showed that riociguat improved the 6-min walk distance both in patients who were receiving no other treatment for the disease and in those who were receiving endothelin-receptor antagonists or prostanoids.  There were significant improvements in pulmonary vascular resistance (P<0.001), NT-proBNP levels (P<0.001), WHO functional class (P = 0.003), time to clin. worsening (P = 0.005), and Borg dyspnea score (P = 0.002).  The most common serious adverse event in the placebo group and the 2.5 mg-max. group was syncope (4% and 1%, resp.).  CONCLUSIONS: Riociguat significantly improved exercise capacity and secondary efficacy end points in patients with pulmonary arterial hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCUP-sJMAaXrVg90H21EOLACvtfcHk0lg_LXKUXRPiOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2nur7K&md5=dc8f91183c5bfc8c1ec0d0f56b2ac0e2</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1209655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1209655%26sid%3Dliteratum%253Aachs%26aulast%3DGhofrani%26aufirst%3DH.-A.%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DGrimminger%26aufirst%3DF.%26aulast%3DGruenig%26aufirst%3DE.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DJing%26aufirst%3DZ.-C.%26aulast%3DKeogh%26aufirst%3DA.%2BM.%26aulast%3DLangleben%26aufirst%3DD.%26aulast%3DKilama%26aufirst%3DM.%2BO.%26aulast%3DFritsch%26aufirst%3DA.%26aulast%3DNeuser%26aufirst%3DD.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26atitle%3DRiociguat%2520for%2520the%2520treatment%2520of%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D330%26epage%3D340%26doi%3D10.1056%2FNEJMoa1209655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Ghofrani, H.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Armini, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimminger, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeper, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonneau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkins, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritsch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuser, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weimann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span> </span><span class="NLM_article-title">Riociguat for the treatment of chronic thromboembolic pulmonary hypertension</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">369</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">329</span><span class="refDoi"> DOI: 10.1056/NEJMoa1209657</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1056%2FNEJMoa1209657" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=23883377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2nur7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=319-329&author=H.-A.+Ghofraniauthor=A.+M.+D%E2%80%99Arminiauthor=F.+Grimmingerauthor=M.+M.+Hoeperauthor=P.+Jansaauthor=N.+H.+Kimauthor=E.+Mayerauthor=G.+Simonneauauthor=M.+R.+Wilkinsauthor=A.+Fritschauthor=D.+Neuserauthor=G.+Weimannauthor=C.+Wang&title=Riociguat+for+the+treatment+of+chronic+thromboembolic+pulmonary+hypertension&doi=10.1056%2FNEJMoa1209657"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Riociguat for the treatment of chronic thromboembolic pulmonary hypertension</span></div><div class="casAuthors">Ghofrani, Hossein-Ardeschir; D'Armini, Andrea M.; Grimminger, Friedrich; Hoeper, Marius M.; Jansa, Pavel; Kim, Nick H.; Mayer, Eckhard; Simonneau, Gerald; Wilkins, Martin R.; Fritsch, Arno; Neuser, Dieter; Weimann, Gerrit; Wang, Chen</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">319-329</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Riociguat, a member of a new class of compds. (sol. guanylate cyclase stimulators), has been shown in previous clin. studies to be beneficial in the treatment of chronic thromboembolic pulmonary hypertension.  METHODS In this phase 3, multicenter, randomized, double-blind, placebo-controlled study, we randomly assigned 261 patients with inoperable chronic thromboembolic pulmonary hypertension or persistent or recurrent pulmonary hypertension after pulmonary endarterectomy to receive placebo or riociguat.  The primary end point was the change from baseline to the end of week 16 in the distance walked in 6 min.  Secondary end points included changes from baseline in pulmonary vascular resistance, N-terminal pro-brain natriuretic peptide (NT-proBNP) level, World Health Organization (WHO) functional class, time to clin. worsening, Borg dyspnea score, quality-of-life variables, and safety.  RESULTS By week 16, the 6-min walk distance had increased by a mean of 39 m in the riociguat group, as compared with a mean decrease of 6 m in the placebo group (least-squares mean difference, 46 m; 95% confidence interval [CI], 25 to 67; P<0.001).  Pulmonary vascular resistance decreased by 226 dyn·sec·cm-5 in the riociguat group and increased by 23 dyn·sec·cm-5 in the placebo group (least-squares mean difference, -246 dyn·sec·cm-5; 95% CI, -303 to -190; P<0.001).  Riociguat was also assocd. with significant improvements in the NT-proBNP level (P<0.001) and WHO functional class (P = 0.003).  The most common serious adverse events were right ventricular failure (in 3% of patients in each group) and syncope (in 2% of the riociguat group and in 3% of the placebo group).  CONCLUSIONS Riociguat significantly improved exercise capacity and pulmonary vascular resistance in patients with chronic thromboembolic pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2KTSYf5k0YLVg90H21EOLACvtfcHk0ljKREcJYOtfww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2nur7J&md5=4b274ffd0efef3d69383bd7d4d1c9275</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1209657&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1209657%26sid%3Dliteratum%253Aachs%26aulast%3DGhofrani%26aufirst%3DH.-A.%26aulast%3DD%25E2%2580%2599Armini%26aufirst%3DA.%2BM.%26aulast%3DGrimminger%26aufirst%3DF.%26aulast%3DHoeper%26aufirst%3DM.%2BM.%26aulast%3DJansa%26aufirst%3DP.%26aulast%3DKim%26aufirst%3DN.%2BH.%26aulast%3DMayer%26aufirst%3DE.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DWilkins%26aufirst%3DM.%2BR.%26aulast%3DFritsch%26aufirst%3DA.%26aulast%3DNeuser%26aufirst%3DD.%26aulast%3DWeimann%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DC.%26atitle%3DRiociguat%2520for%2520the%2520treatment%2520of%2520chronic%2520thromboembolic%2520pulmonary%2520hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D319%26epage%3D329%26doi%3D10.1056%2FNEJMoa1209657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Hambly, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granton, J.</span><span> </span><span class="NLM_article-title">Riociguat for the treatment of pulmonary hypertension</span> <span class="citation_source-journal">Expert Rev. Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">679</span><span class="NLM_x">–</span> <span class="NLM_lpage">695</span><span class="refDoi"> DOI: 10.1586/17476348.2015.1106316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1586%2F17476348.2015.1106316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=26599488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFals73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=679-695&author=N.+Hamblyauthor=J.+Granton&title=Riociguat+for+the+treatment+of+pulmonary+hypertension&doi=10.1586%2F17476348.2015.1106316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Riociguat for the treatment of pulmonary hypertension</span></div><div class="casAuthors">Hambly, Nathan; Granton, John</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Respiratory Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">679-695</span>CODEN:
                <span class="NLM_cas:coden">ERRMBF</span>;
        ISSN:<span class="NLM_cas:issn">1747-6348</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Nitric oxide (NO) is a crit. signaling mol. in the pulmonary vasculature.  NO activates sol. guanylate cyclase (sGC) resulting in the synthesis of cGMP - a key mediator of pulmonary artery vasodilatation that may also inhibit smooth muscle proliferation and platelet aggregation.  Pulmonary hypertension, a serious, progressive and often fatal disease is characterized by NO-sGC-sGMP pathway dysregulation.  Riociguat is a member of a novel therapeutic class known as sol. guanylate stimulators.  Riociguat has a dual mode of action, acting in synergy with endogenous NO and also directly stimulating sGC independently of NO availability.  Phase 3 randomized control trials have demonstrated that riociguat improves clin., physiol. and hemodynamic parameters in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.  In this review we will discuss the pharmacol. properties of riociguat and its appropriate implementation into clin. practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxwFllA7zb87Vg90H21EOLACvtfcHk0ljKREcJYOtfww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFals73O&md5=cf270fc6d7dc20a805b0a10919644d14</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1586%2F17476348.2015.1106316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F17476348.2015.1106316%26sid%3Dliteratum%253Aachs%26aulast%3DHambly%26aufirst%3DN.%26aulast%3DGranton%26aufirst%3DJ.%26atitle%3DRiociguat%2520for%2520the%2520treatment%2520of%2520pulmonary%2520hypertension%26jtitle%3DExpert%2520Rev.%2520Respir.%2520Med.%26date%3D2015%26volume%3D9%26spage%3D679%26epage%3D695%26doi%3D10.1586%2F17476348.2015.1106316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Frey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueck, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artmeier-Brandt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weimann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wensing, G.</span><span> </span><span class="NLM_article-title">Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63–2521: an ascending-dose study in healthy male volunteers</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">926</span><span class="NLM_x">–</span> <span class="NLM_lpage">934</span><span class="refDoi"> DOI: 10.1177/0091270008319793</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1177%2F0091270008319793" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=18519919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpslWqur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=926-934&author=R.+Freyauthor=W.+Mueckauthor=S.+Ungerauthor=U.+Artmeier-Brandtauthor=G.+Weimannauthor=G.+Wensing&title=Single-dose+pharmacokinetics%2C+pharmacodynamics%2C+tolerability%2C+and+safety+of+the+soluble+guanylate+cyclase+stimulator+BAY+63%E2%80%932521%3A+an+ascending-dose+study+in+healthy+male+volunteers&doi=10.1177%2F0091270008319793"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers</span></div><div class="casAuthors">Frey, Reiner; Mueck, Wolfgang; Unger, Sigrun; Artmeier-Brandt, Ulrike; Weimann, Gerrit; Wensing, Georg</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">926-934</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The aim of the study was to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of BAY 63-2521, a new drug in development for pulmonary hypertension.  Fifty-eight healthy male volunteers received a single oral dose of BAY 63-2521 (0.25-5 mg) or placebo.  No serious adverse events were reported; there were no life-threatening events.  Heart rate over 1 min, an indicator of the effect of a vasodilating agent on the cardiovascular system in healthy subjects, was increased dose dependently vs. placebo at BAY 63-2521 doses of 1 to 5 mg (P < .01).  Mean arterial and diastolic pressures were decreased vs. placebo at doses of 1 mg (P < .05) and 5 mg (P < .01).  Systolic pressure was not significantly affected.  BAY 63-2521 was readily absorbed and exhibited dose-proportional pharmacokinetics.  The pharmacodynamic and pharmacokinetic properties of BAY 63-2521 suggest that it can offer a unique mode of action in the treatment of pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom6tfQEA1oN7Vg90H21EOLACvtfcHk0ljKREcJYOtfww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpslWqur0%253D&md5=770d25ef69e46729dbf3a1bc2080d40f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1177%2F0091270008319793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270008319793%26sid%3Dliteratum%253Aachs%26aulast%3DFrey%26aufirst%3DR.%26aulast%3DMueck%26aufirst%3DW.%26aulast%3DUnger%26aufirst%3DS.%26aulast%3DArtmeier-Brandt%26aufirst%3DU.%26aulast%3DWeimann%26aufirst%3DG.%26aulast%3DWensing%26aufirst%3DG.%26atitle%3DSingle-dose%2520pharmacokinetics%252C%2520pharmacodynamics%252C%2520tolerability%252C%2520and%2520safety%2520of%2520the%2520soluble%2520guanylate%2520cyclase%2520stimulator%2520BAY%252063%25E2%2580%25932521%253A%2520an%2520ascending-dose%2520study%2520in%2520healthy%2520male%2520volunteers%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2008%26volume%3D48%26spage%3D926%26epage%3D934%26doi%3D10.1177%2F0091270008319793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Gheorghiade, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greene, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippatos, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maggioni, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ponikowski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraigher-Krainer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samano, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roessig, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pieske, B.</span><span> </span><span class="NLM_article-title">Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial</span> <span class="citation_source-journal">JAMA, J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">314</span><span class="NLM_x">, </span> <span class="NLM_fpage">2251</span><span class="NLM_x">–</span> <span class="NLM_lpage">2262</span><span class="refDoi"> DOI: 10.1001/jama.2015.15734</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1001%2Fjama.2015.15734" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=314&publication_year=2015&pages=2251-2262&author=M.+Gheorghiadeauthor=S.+J.+Greeneauthor=J.+Butlerauthor=G.+Filippatosauthor=C.+S.+Lamauthor=A.+P.+Maggioniauthor=P.+Ponikowskiauthor=S.+J.+Shahauthor=S.+D.+Solomonauthor=E.+Kraigher-Krainerauthor=E.+T.+Samanoauthor=K.+M%C3%BCllerauthor=L.+Roessigauthor=B.+Pieske&title=Effect+of+vericiguat%2C+a+soluble+guanylate+cyclase+stimulator%2C+on+natriuretic+peptide+levels+in+patients+with+worsening+chronic+heart+failure+and+reduced+ejection+fraction%3A+the+SOCRATES-REDUCED+randomized+trial&doi=10.1001%2Fjama.2015.15734"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1001%2Fjama.2015.15734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2015.15734%26sid%3Dliteratum%253Aachs%26aulast%3DGheorghiade%26aufirst%3DM.%26aulast%3DGreene%26aufirst%3DS.%2BJ.%26aulast%3DButler%26aufirst%3DJ.%26aulast%3DFilippatos%26aufirst%3DG.%26aulast%3DLam%26aufirst%3DC.%2BS.%26aulast%3DMaggioni%26aufirst%3DA.%2BP.%26aulast%3DPonikowski%26aufirst%3DP.%26aulast%3DShah%26aufirst%3DS.%2BJ.%26aulast%3DSolomon%26aufirst%3DS.%2BD.%26aulast%3DKraigher-Krainer%26aufirst%3DE.%26aulast%3DSamano%26aufirst%3DE.%2BT.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26aulast%3DRoessig%26aufirst%3DL.%26aulast%3DPieske%26aufirst%3DB.%26atitle%3DEffect%2520of%2520vericiguat%252C%2520a%2520soluble%2520guanylate%2520cyclase%2520stimulator%252C%2520on%2520natriuretic%2520peptide%2520levels%2520in%2520patients%2520with%2520worsening%2520chronic%2520heart%2520failure%2520and%2520reduced%2520ejection%2520fraction%253A%2520the%2520SOCRATES-REDUCED%2520randomized%2520trial%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D2015%26volume%3D314%26spage%3D2251%26epage%3D2262%26doi%3D10.1001%2Fjama.2015.15734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Pieske, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filippatos, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maggioni, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ponikowski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraigher-Krainer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samano, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scalise, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roessig, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gheorghiade, M.</span><span> </span><span class="NLM_article-title">Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES)</span> <span class="citation_source-journal">Eur. J. Heart Failure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1026</span><span class="NLM_x">–</span> <span class="NLM_lpage">38</span><span class="refDoi"> DOI: 10.1002/ejhf.135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1002%2Fejhf.135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=25056511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFSqtbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&pages=1026-38&author=B.+Pieskeauthor=J.+Butlerauthor=G.+Filippatosauthor=C.+Lamauthor=A.+P.+Maggioniauthor=P.+Ponikowskiauthor=S.+Shahauthor=S.+Solomonauthor=E.+Kraigher-Krainerauthor=E.+T.+Samanoauthor=A.+V.+Scaliseauthor=K.+Muellerauthor=L.+Roessigauthor=M.+Gheorghiade&title=Rationale+and+design+of+the+SOluble+guanylate+Cyclase+stimulatoR+in+heArT+failurE+Studies+%28SOCRATES%29&doi=10.1002%2Fejhf.135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES)</span></div><div class="casAuthors">Pieske, Burkert; Butler, Javed; Filippatos, Gerasimos; Lam, Carolyn; Maggioni, Aldo Pietro; Ponikowski, Piotr; Shah, Sanjiv; Solomon, Scott; Kraigher-Krainer, Elisabeth; Samano, Eliana Tibana; Scalise, Andrea Viviana; Mueller, Katharina; Roessig, Lothar; Gheorghiade, Mihai; N/A</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Heart Failure</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1026-1038</span>CODEN:
                <span class="NLM_cas:coden">EJHFFS</span>;
        ISSN:<span class="NLM_cas:issn">1388-9842</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Aims : The clin. outcomes for patients with worsening chronic heart failure (WCHF) remain exceedingly poor despite contemporary evidence-based therapies, and effective therapies are urgently needed.  Accumulating evidence supports augmentation of cyclic guanosine monophosphate (cGMP) signalling as a potential therapeutic strategy for HF with reduced or preserved ejection fraction (HFrEF and HFpEF, resp.).  Direct sol. guanylate cyclase (sGC) stimulators target reduced cGMP generation due to insufficient sGC stimulation and represent a promising method for cGMP enhancement.  Methods : The phase II Sol. guanylate Cyclase stimulatoR in heArT failurE Study (SOCRATES) program consists of two randomized, parallel-group, placebo-controlled, double-blind, multicentre studies, SOCRATES-REDUCED (in patients with LVEF <45%) and SOCRATES-PRESERVED (in those with LVEF ≥45%), that will explore the pharmacodynamic effects, safety and tolerability, and pharmacokinetics of four dose regimens of the once-daily oral sGC stimulator vericiguat (BAY 1021189) over 12 wk compared with placebo.  These studies will enrol patients stabilized during hospitalization for HF at the time of discharge or within 4 wk thereafter.  The primary endpoint in SOCRATES-REDUCED is change in NT-proBNP at 12 wk.  The primary endpoints in SOCRATES-PRESERVED are change in NT-proBNP and left atrial vol. at 12 wk.  Perspectives : SOCRATES will be the first program to enrol specifically both inpatients and outpatients with WCHF and patients with reduced or preserved ejection fraction.  Results will inform the benefits of pursuing subsequent event-driven clin. outcome trials with sGC stimulators in this patient population.  Trial registration : NCT01951625 (SOCRATES-REDUCED) and NCT01951638 (SOCRATES-PRESERVED).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHF8JLa8U8grVg90H21EOLACvtfcHk0lgGtHSspBDUEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFSqtbfO&md5=cbf713b3a50b74cf4334a54a13240614</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fejhf.135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejhf.135%26sid%3Dliteratum%253Aachs%26aulast%3DPieske%26aufirst%3DB.%26aulast%3DButler%26aufirst%3DJ.%26aulast%3DFilippatos%26aufirst%3DG.%26aulast%3DLam%26aufirst%3DC.%26aulast%3DMaggioni%26aufirst%3DA.%2BP.%26aulast%3DPonikowski%26aufirst%3DP.%26aulast%3DShah%26aufirst%3DS.%26aulast%3DSolomon%26aufirst%3DS.%26aulast%3DKraigher-Krainer%26aufirst%3DE.%26aulast%3DSamano%26aufirst%3DE.%2BT.%26aulast%3DScalise%26aufirst%3DA.%2BV.%26aulast%3DMueller%26aufirst%3DK.%26aulast%3DRoessig%26aufirst%3DL.%26aulast%3DGheorghiade%26aufirst%3DM.%26atitle%3DRationale%2520and%2520design%2520of%2520the%2520SOluble%2520guanylate%2520Cyclase%2520stimulatoR%2520in%2520heArT%2520failurE%2520Studies%2520%2528SOCRATES%2529%26jtitle%3DEur.%2520J.%2520Heart%2520Failure%26date%3D2014%26volume%3D16%26spage%3D1026%26epage%3D38%26doi%3D10.1002%2Fejhf.135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><div class="note"><p class="first last">Clinicaltrials.gov. Identifier: NCT02861534 (accessed August 5, 2016).</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinicaltrials.gov.+Identifier%3A+NCT02861534+%28accessed+August+5%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dgov%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Mittendorf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weigand, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alonso-Alija, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bischoff, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feurer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerisch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kern, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knorr, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muenter, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radtke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schirok, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlemmer, K.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahl, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Straub, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wunder, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stasch, J.-P.</span><span> </span><span class="NLM_article-title">Discovery of riociguat (BAY 63–2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">853</span><span class="NLM_x">–</span> <span class="NLM_lpage">865</span><span class="refDoi"> DOI: 10.1002/cmdc.200900014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1002%2Fcmdc.200900014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=19263460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD1MXls1Kgt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=853-865&author=J.+Mittendorfauthor=S.+Weigandauthor=C.+Alonso-Alijaauthor=E.+Bischoffauthor=A.+Feurerauthor=M.+Gerischauthor=A.+Kernauthor=A.+Knorrauthor=D.+Langauthor=K.+Muenterauthor=M.+Radtkeauthor=H.+Schirokauthor=K.-H.+Schlemmerauthor=E.+Stahlauthor=A.+Straubauthor=F.+Wunderauthor=J.-P.+Stasch&title=Discovery+of+riociguat+%28BAY+63%E2%80%932521%29%3A+a+potent%2C+oral+stimulator+of+soluble+guanylate+cyclase+for+the+treatment+of+pulmonary+hypertension&doi=10.1002%2Fcmdc.200900014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Riociguat (BAY 63-2521): A Potent, Oral Stimulator of Soluble Guanylate Cyclase for the Treatment of Pulmonary Hypertension</span></div><div class="casAuthors">Mittendorf, Joachim; Weigand, Stefan; Alonso-Alija, Cristina; Bischoff, Erwin; Feurer, Achim; Gerisch, Michael; Kern, Armin; Knorr, Andreas; Lang, Dieter; Muenter, Klaus; Radtke, Martin; Schirok, Hartmut; Schlemmer, Karl-Heinz; Stahl, Elke; Straub, Alexander; Wunder, Frank; Stasch, Johannes-Peter</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">853-865</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Direct stimulation of sol. guanylate cyclase (sGC),a key signal-transduction enzyme activated by nitric oxide (NO), represents a promising therapeutic strategy for the treatment of a range of diseases, including the severely disabling pulmonary hypertension (PH).  Impairments of the NO-sGC signaling pathway have been implicated in the pathogenesis of cardiovascular and other diseases.  Optimization of the unfavorable drug metab. and pharmacokinetic (DMPK) profile of previous sGC stimulators provided riociguat I, which is currently being investigated in phase III clin. trials for the oral treatment of PH.  The compd. I exhibited an improved DMPK profile and exerted strong effects on pulmonary hemodynamics and exercise capacity in patients with PH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5xPY0dXoV5rVg90H21EOLACvtfcHk0lgGtHSspBDUEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXls1Kgt70%253D&md5=c31bd046ee1a1de3014867d10a4e161c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200900014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200900014%26sid%3Dliteratum%253Aachs%26aulast%3DMittendorf%26aufirst%3DJ.%26aulast%3DWeigand%26aufirst%3DS.%26aulast%3DAlonso-Alija%26aufirst%3DC.%26aulast%3DBischoff%26aufirst%3DE.%26aulast%3DFeurer%26aufirst%3DA.%26aulast%3DGerisch%26aufirst%3DM.%26aulast%3DKern%26aufirst%3DA.%26aulast%3DKnorr%26aufirst%3DA.%26aulast%3DLang%26aufirst%3DD.%26aulast%3DMuenter%26aufirst%3DK.%26aulast%3DRadtke%26aufirst%3DM.%26aulast%3DSchirok%26aufirst%3DH.%26aulast%3DSchlemmer%26aufirst%3DK.-H.%26aulast%3DStahl%26aufirst%3DE.%26aulast%3DStraub%26aufirst%3DA.%26aulast%3DWunder%26aufirst%3DF.%26aulast%3DStasch%26aufirst%3DJ.-P.%26atitle%3DDiscovery%2520of%2520riociguat%2520%2528BAY%252063%25E2%2580%25932521%2529%253A%2520a%2520potent%252C%2520oral%2520stimulator%2520of%2520soluble%2520guanylate%2520cyclase%2520for%2520the%2520treatment%2520of%2520pulmonary%2520hypertension%26jtitle%3DChemMedChem%26date%3D2009%26volume%3D4%26spage%3D853%26epage%3D865%26doi%3D10.1002%2Fcmdc.200900014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Gnoth, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopfe, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czembor, W.</span><span> </span><span class="NLM_article-title">Determination of riociguat and its major human metabolite M-1 in human plasma by stable-isotope dilution LCMS/MS</span> <span class="citation_source-journal">Bioanalysis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">193</span><span class="NLM_x">–</span> <span class="NLM_lpage">205</span><span class="refDoi"> DOI: 10.4155/bio.14.257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.4155%2Fbio.14.257" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=193-205&author=M.+J.+Gnothauthor=P.+M.+Hopfeauthor=W.+Czembor&title=Determination+of+riociguat+and+its+major+human+metabolite+M-1+in+human+plasma+by+stable-isotope+dilution+LCMS%2FMS&doi=10.4155%2Fbio.14.257"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.4155%2Fbio.14.257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Fbio.14.257%26sid%3Dliteratum%253Aachs%26aulast%3DGnoth%26aufirst%3DM.%2BJ.%26aulast%3DHopfe%26aufirst%3DP.%2BM.%26aulast%3DCzembor%26aufirst%3DW.%26atitle%3DDetermination%2520of%2520riociguat%2520and%2520its%2520major%2520human%2520metabolite%2520M-1%2520in%2520human%2520plasma%2520by%2520stable-isotope%2520dilution%2520LCMS%252FMS%26jtitle%3DBioanalysis%26date%3D2015%26volume%3D7%26spage%3D193%26epage%3D205%26doi%3D10.4155%2Fbio.14.257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Becker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reber, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weimann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arens, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mück, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dietrich, H.</span><span> </span><span class="NLM_article-title">Pharmacokinetic interaction of riociguat with ketoconazole, clarithromycin, and midazolam</span> <span class="citation_source-journal">Pulm. Circ.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">S49</span><span class="NLM_x">–</span> <span class="NLM_lpage">57</span><span class="refDoi"> DOI: 10.1086/685016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1086%2F685016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=27162627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFSrsLfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=S49-57&author=C.+Beckerauthor=R.+Freyauthor=D.+Thomasauthor=M.+Reberauthor=G.+Weimannauthor=E.+R.+Arensauthor=W.+M%C3%BCckauthor=S.+Ungerauthor=H.+Dietrich&title=Pharmacokinetic+interaction+of+riociguat+with+ketoconazole%2C+clarithromycin%2C+and+midazolam&doi=10.1086%2F685016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic interaction of riociguat with ketoconazole, clarithromycin, and midazolam</span></div><div class="casAuthors">Becker, Corina; Frey, Reiner; Unger, Sigrun; Thomas, Dirk; Reber, Michael; Weimann, Gerrit; Dietrich, Hartmut; Arens, Erich R.; Mueck, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Circulation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">Suppl.1</span>),
    <span class="NLM_cas:pages">S49-S57</span>CODEN:
                <span class="NLM_cas:coden">PCUIAX</span>;
        ISSN:<span class="NLM_cas:issn">2045-8940</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Riociguat is a sol. guanylate cyclase stimulator for the treatment of pulmonary hypertension that is principally metabolized via the cytochrome P 450 (CYP) pathway.  Three studies in healthy males investigated potential pharmacokinetic interactions between riociguat and CYP inhibitors (ketoconazole, clarithromycin, and midazolam).  In two studies, subjects were pretreated with either oncedaily ketoconazole 400 mg or twice-daily clarithromycin 500 mg for 4 days before cotreatment with either riociguat 0.5 mg ± ketoconazole 400 mg or riociguat 1.0 mg ± clarithromycin 500 mg.  In the third study, subjects received riociguat 2.5 mg 3 times daily (tid) for 3 days, followed by cotreatment with riociguat 2.5 mg tid ± midazolam 7.5 mg.  Pharmacokinetic parameters, the effect of smoking on riociguat pharmacokinetics, safety, and tolerability were assessed.  Pre- and cotreatment with ketoconazole and clarithromycin led to increased riociguat exposure.  Pre- and cotreatment with riociguat had no significant effect on midazolam plasma concns.  In all studies, the bioavailability of riociguat was reduced in smokers because its clearance to the metabolite M1 increased.  Riociguat ± ketoconazole, clarithromycin, or midazolam was generally well tolerated.  The most common treatment-emergent adverse events (TEAEs) across all studies were headache and dyspepsia.  One serious TEAE was reported in the midazolam study.  Owing to the potential for hypotension, concomitant use of riociguat with multipathway inhibitors, such as ketoconazole, should be approached with caution.  Coadministration of riociguat with strong CYP3A4 inhibitors, for example, clarithromycin, does not require addnl. dose adjustment.  No significant drugdrug interaction was revealed between riociguat and midazolam.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHFwlD1XDMPrVg90H21EOLACvtfcHk0lim10WuPnLJ8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFSrsLfL&md5=1f1f0a6e9638cc98bf7e7e9d19eb6cdc</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1086%2F685016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F685016%26sid%3Dliteratum%253Aachs%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DFrey%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DD.%26aulast%3DReber%26aufirst%3DM.%26aulast%3DWeimann%26aufirst%3DG.%26aulast%3DArens%26aufirst%3DE.%2BR.%26aulast%3DM%25C3%25BCck%26aufirst%3DW.%26aulast%3DUnger%26aufirst%3DS.%26aulast%3DDietrich%26aufirst%3DH.%26atitle%3DPharmacokinetic%2520interaction%2520of%2520riociguat%2520with%2520ketoconazole%252C%2520clarithromycin%252C%2520and%2520midazolam%26jtitle%3DPulm.%2520Circ.%26date%3D2016%26volume%3D6%26spage%3DS49%26epage%3D57%26doi%3D10.1086%2F685016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Frey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wensing, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mück, W.</span><span> </span><span class="NLM_article-title">Assessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63–2521)</span> <span class="citation_source-journal">Pulm. Circ.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">S15</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span><span class="refDoi"> DOI: 10.1086/685017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1086%2F685017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=27162624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFSrsb%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=S15-26&author=R.+Freyauthor=C.+Beckerauthor=S.+Ungerauthor=A.+Schmidtauthor=G.+Wensingauthor=W.+M%C3%BCck&title=Assessment+of+the+effects+of+renal+impairment+and+smoking+on+the+pharmacokinetics+of+a+single+oral+dose+of+the+soluble+guanylate+cyclase+stimulator+riociguat+%28BAY+63%E2%80%932521%29&doi=10.1086%2F685017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)</span></div><div class="casAuthors">Frey, Reiner; Becker, Corina; Unger, Sigrun; Schmidt, Anja; Wensing, Georg; Mueck, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Circulation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">Suppl.1</span>),
    <span class="NLM_cas:pages">S15-S26</span>CODEN:
                <span class="NLM_cas:coden">PCUIAX</span>;
        ISSN:<span class="NLM_cas:issn">2045-8940</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Renal impairment is a common comborbidity in patients with pulmonary hypertension.  The breakdown of riociguat, an oral sol. guanylate cyclase stimulator used to treat pulmonary hypertension, may be affected by smoking because polycyclic arom. hydrocarbons in tobacco smoke induce expression of one of the metabolizing enzymes, CYP1A1.  Two nonrandomized, nonblinded studies were therefore performed to investigate the pharmacokinetics and safety of a single oral dose of riociguat 1.0 mg in individuals with mild, moderate, or severe renal impairment compared with age-, wt.-, and sex-matched healthy controls, including either smokers and nonsmokers (study I) or nonsmokers alone (study II).  Pharmacokinetic analyses focused on the integrated per-protocol data set of both studies (N = 63).  In patients with renal impairment, the renal clearance of riociguat was reduced and its terminal half-life prolonged compared with those in healthy controls.  There was a monotonic relationship between creatinine clearance on treatment day and riociguat renal clearance (R2 = 0.62).  However, increased riociguat exposure with decreasing renal function was not strictly proportional.  Riociguat exposure appeared to be greater in nonsmokers than in the combined population of smokers and nonsmokers, irresp. of renal function.  Adverse events were mild to moderate and in line with the mode of action of riociguat.  No serious adverse events occurred.  In conclusion, renal impairment was assocd. with reduced riociguat clearance compared with that in controls; however, riociguat exposure in patients with renal impairment was highly variable, and ranges overlapped with those obsd. in healthy controls.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRNCc4ajIfn7Vg90H21EOLACvtfcHk0lim10WuPnLJ8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFSrsb%252FP&md5=c6ba0209863fa85dd89bda789526d5cf</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1086%2F685017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F685017%26sid%3Dliteratum%253Aachs%26aulast%3DFrey%26aufirst%3DR.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DUnger%26aufirst%3DS.%26aulast%3DSchmidt%26aufirst%3DA.%26aulast%3DWensing%26aufirst%3DG.%26aulast%3DM%25C3%25BCck%26aufirst%3DW.%26atitle%3DAssessment%2520of%2520the%2520effects%2520of%2520renal%2520impairment%2520and%2520smoking%2520on%2520the%2520pharmacokinetics%2520of%2520a%2520single%2520oral%2520dose%2520of%2520the%2520soluble%2520guanylate%2520cyclase%2520stimulator%2520riociguat%2520%2528BAY%252063%25E2%2580%25932521%2529%26jtitle%3DPulm.%2520Circ.%26date%3D2016%26volume%3D6%26spage%3DS15%26epage%3D26%26doi%3D10.1086%2F685017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Saleh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wensing, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mück, W.</span><span> </span><span class="NLM_article-title">Bioavailability, pharmacokinetics, and safety of riociguat given as an oral suspension or crushed tablet with and without food</span> <span class="citation_source-journal">Pulm. Circ.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">S66</span><span class="NLM_x">–</span> <span class="NLM_lpage">74</span><span class="refDoi"> DOI: 10.1086/685020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1086%2F685020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=27162630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFSrsb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=S66-74&author=S.+Salehauthor=R.+Freyauthor=C.+Beckerauthor=S.+Ungerauthor=G.+Wensingauthor=W.+M%C3%BCck&title=Bioavailability%2C+pharmacokinetics%2C+and+safety+of+riociguat+given+as+an+oral+suspension+or+crushed+tablet+with+and+without+food&doi=10.1086%2F685020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Bioavailability, pharmacokinetics, and safety of riociguat given as an oral suspension or crushed tablet with and without food</span></div><div class="casAuthors">Saleh, Soundos; Frey, Reiner; Becker, Corina; Unger, Sigrun; Wensing, Georg; Mueck, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Circulation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">Suppl.1</span>),
    <span class="NLM_cas:pages">S66-S74</span>CODEN:
                <span class="NLM_cas:coden">PCUIAX</span>;
        ISSN:<span class="NLM_cas:issn">2045-8940</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Riociguat is approved for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.  Some patients have difficulty swallowing tablets; therefore, 2 randomized, nonblinded, crossover studies compared the relative bioavailability of riociguat oral suspensions and immediate-release (IR) tablet and of crushed-tablet prepns. vs. whole IR tablet.  In study 1, 30 healthy subjects received 5 single riociguat doses: 0.3 and 2.4 mg (0.15 mg/mL suspensions), 0.15 mg (0.03 mg/mL), and 1.0 mg (whole IR tablet) under fasted conditions and 2.4 mg (0.15 mg/mL) after a high-fat, high-calorie American-style breakfast.  In study 2, 25 healthy men received 4 single 2.5-mg doses: whole IR tablet and crushed IR tablet suspended in applesauce and water, resp., under fasted conditions, and whole IR tablet after a continental breakfast.  In study 1, dose-normalized pharmacokinetics of riociguat oral suspensions and 1.0-mg whole IR tablet were similar in fasted conditions; 90% confidence intervals for riociguat area under the curve (AUC) to dose and mean max. concn. (Cmax) to dose were within bioequivalence criteria.  After food, dosenormalized AUC and Cmax decreased by 15% and 38%, resp.  In study 2, riociguat exposure was similar for all prepns.; AUC ratios for crushed-IR-tablet prepns. to whole IR tablet were within bioequivalence criteria.  The Cmax increased by 17% for crushed IR tablet in water vs. whole IR tablet.  Food intake decreased Cmax of the whole tablet by 16%, with unaltered AUC vs. fasted conditions.  Riociguat bioavailability was similar between the oral suspensions and the whole IR tablet; exposure was similar between whole IR tablet and crushed-IR-tablet prepns.  Minor food effects were obsd.  Results suggest that riociguat formulations are interchangeable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCzk2V8OkU_7Vg90H21EOLACvtfcHk0lim10WuPnLJ8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFSrsb7E&md5=cf030ca125a218be4d27507767c73bf1</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1086%2F685020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F685020%26sid%3Dliteratum%253Aachs%26aulast%3DSaleh%26aufirst%3DS.%26aulast%3DFrey%26aufirst%3DR.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DUnger%26aufirst%3DS.%26aulast%3DWensing%26aufirst%3DG.%26aulast%3DM%25C3%25BCck%26aufirst%3DW.%26atitle%3DBioavailability%252C%2520pharmacokinetics%252C%2520and%2520safety%2520of%2520riociguat%2520given%2520as%2520an%2520oral%2520suspension%2520or%2520crushed%2520tablet%2520with%2520and%2520without%2520food%26jtitle%3DPulm.%2520Circ.%26date%3D2016%26volume%3D6%26spage%3DS66%26epage%3D74%26doi%3D10.1086%2F685020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blode, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshikawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, Y.</span><span> </span><span class="NLM_article-title">Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in healthy young Chinese male non-smokers and smokers: results of a randomized, double-blind, placebo-controlled study</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">615</span><span class="NLM_x">–</span> <span class="NLM_lpage">624</span><span class="refDoi"> DOI: 10.1007/s40262-015-0337-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1007%2Fs40262-015-0337-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=26507720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsleku7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=615-624&author=X.+Zhaoauthor=Z.+Wangauthor=Y.+Wangauthor=H.+Zhangauthor=H.+Blodeauthor=K.+Yoshikawaauthor=C.+Beckerauthor=S.+Ungerauthor=R.+Freyauthor=Y.+Cui&title=Pharmacokinetics+of+the+soluble+guanylate+cyclase+stimulator+riociguat+in+healthy+young+Chinese+male+non-smokers+and+smokers%3A+results+of+a+randomized%2C+double-blind%2C+placebo-controlled+study&doi=10.1007%2Fs40262-015-0337-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat in Healthy Young Chinese Male Non-Smokers and Smokers: Results of a Randomized, Double-Blind, Placebo-Controlled Study</span></div><div class="casAuthors">Zhao, Xia; Wang, Zining; Wang, Yukun; Zhang, Hong; Blode, Hartmut; Yoshikawa, Kenichi; Becker, Corina; Unger, Sigrun; Frey, Reiner; Cui, Yimin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">615-624</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Background and Objectives: The aim of this study was to investigate the pharmacokinetics, safety, and tolerability of riociguat after single and multiple oral doses of 1 or 2 mg three times daily (tid), and to det. the effect of smoking on riociguat pharmacokinetics in Chinese men.  Methods: In a randomized, double-blind, placebo-controlled, single-center study stratified for smokers and non-smokers, healthy Chinese men aged 18-45 years received two riociguat doses: Dose Step 1 (1 mg) then Dose Step 2 (2 mg) conducted after the safety and tolerability at Dose Step 1 was confirmed.  For each step, 12 subjects received riociguat and six received placebo.  A single dose was given on Day 1, followed by a 48-h pharmacokinetic profile.  Multiple-dose treatment tid was then given for 6 days (Days 3-8), with a last single dose on Day 9, followed by a 72-h pharmacokinetic profile.  Primary outcomes were pharmacokinetic parameters for riociguat after single and multiple dosing.  Results: Thirty-six subjects (18 smokers; 18 non-smokers) were randomized and provided valid pharmacokinetic data.  Riociguat and its pharmacol. active metabolite M1 (BAY 60-4552) showed nearly dose-proportional pharmacokinetics.  Accumulation was minimal in smokers and approx. two-fold in non-smokers.  Exposure for riociguat was decreased by ≥60 % in smokers.  No serious or significant adverse events occurred during the study.  Conclusions: Riociguat pharmacokinetics showed dose proportionality in healthy Chinese men, as previously demonstrated in healthy white male individuals.  Exposure to riociguat was substantially decreased in smokers compared with non-smokers.  Riociguat was well tolerated in Chinese men.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8zNDtaEJ7y7Vg90H21EOLACvtfcHk0licoKX1AQtf3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsleku7nI&md5=7883041ec30d2df946fffc9b6166f843</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1007%2Fs40262-015-0337-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-015-0337-4%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DBlode%26aufirst%3DH.%26aulast%3DYoshikawa%26aufirst%3DK.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DUnger%26aufirst%3DS.%26aulast%3DFrey%26aufirst%3DR.%26aulast%3DCui%26aufirst%3DY.%26atitle%3DPharmacokinetics%2520of%2520the%2520soluble%2520guanylate%2520cyclase%2520stimulator%2520riociguat%2520in%2520healthy%2520young%2520Chinese%2520male%2520non-smokers%2520and%2520smokers%253A%2520results%2520of%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520study%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2016%26volume%3D55%26spage%3D615%26epage%3D624%26doi%3D10.1007%2Fs40262-015-0337-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span>Highlights of Prescribing Information: Riociguat (Adempas); <span class="NLM_contrib-group">U.S. Food and Drug Administration</span><span class="NLM_x">: </span><span class="NLM_publisher-loc">Silver Spring, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">; </span><a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204819s002lbl.pdf" class="extLink">http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204819s002lbl.pdf</a> (accessed April 4, 2014).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=U.S.+Food+and+Drug+Administration&title=Highlights+of+Prescribing+Information%3A+Riociguat+%28Adempas%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DHighlights%2520of%2520Prescribing%2520Information%253A%2520Riociguat%2520%2528Adempas%2529%26aulast%3D%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Bitterli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlenmeyer, H.</span><span> </span><span class="NLM_article-title">Some derivatives of triazolopyrimidine</span> <span class="citation_source-journal">Helv. Chim. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1951</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">835</span><span class="NLM_x">–</span> <span class="NLM_lpage">840</span><span class="refDoi"> DOI: 10.1002/hlca.19510340311</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1002%2Fhlca.19510340311" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1951&pages=835-840&author=P.+Bitterliauthor=H.+Erlenmeyer&title=Some+derivatives+of+triazolopyrimidine&doi=10.1002%2Fhlca.19510340311"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fhlca.19510340311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhlca.19510340311%26sid%3Dliteratum%253Aachs%26aulast%3DBitterli%26aufirst%3DP.%26aulast%3DErlenmeyer%26aufirst%3DH.%26atitle%3DSome%2520derivatives%2520of%2520triazolopyrimidine%26jtitle%3DHelv.%2520Chim.%2520Acta%26date%3D1951%26volume%3D34%26spage%3D835%26epage%3D840%26doi%3D10.1002%2Fhlca.19510340311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Reinecke, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodrow, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, E. S.</span><span> </span><span class="NLM_article-title">Pyrazolo[3,4-<i>c</i>]pyridazines from hydrazine and aminothiophenecarboxylates</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1018</span><span class="NLM_x">–</span> <span class="NLM_lpage">1021</span><span class="refDoi"> DOI: 10.1021/jo00029a046</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00029a046" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1992&pages=1018-1021&author=M.+G.+Reineckeauthor=T.+A.+Woodrowauthor=E.+S.+Brown&title=Pyrazolo%5B3%2C4-c%5Dpyridazines+from+hydrazine+and+aminothiophenecarboxylates&doi=10.1021%2Fjo00029a046"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjo00029a046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00029a046%26sid%3Dliteratum%253Aachs%26aulast%3DReinecke%26aufirst%3DM.%2BG.%26aulast%3DWoodrow%26aufirst%3DT.%2BA.%26aulast%3DBrown%26aufirst%3DE.%2BS.%26atitle%3DPyrazolo%255B3%252C4-c%255Dpyridazines%2520from%2520hydrazine%2520and%2520aminothiophenecarboxylates%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1992%26volume%3D57%26spage%3D1018%26epage%3D1021%26doi%3D10.1021%2Fjo00029a046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Wunder, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stasch, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hütter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alonso-Alija, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hüser, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohrmann, E.</span><span> </span><span class="NLM_article-title">A cell-based cGMP assay useful for ultra-high-throughput screening and identification of modulators of the nitric oxide/cGMP pathway</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">339</span><span class="NLM_x">, </span> <span class="NLM_fpage">104</span><span class="NLM_x">–</span> <span class="NLM_lpage">112</span><span class="refDoi"> DOI: 10.1016/j.ab.2004.12.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1016%2Fj.ab.2004.12.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=15766716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD2MXit1eqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=2005&pages=104-112&author=F.+Wunderauthor=J.-P.+Staschauthor=J.+H%C3%BCtterauthor=C.+Alonso-Alijaauthor=J.+H%C3%BCserauthor=E.+Lohrmann&title=A+cell-based+cGMP+assay+useful+for+ultra-high-throughput+screening+and+identification+of+modulators+of+the+nitric+oxide%2FcGMP+pathway&doi=10.1016%2Fj.ab.2004.12.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A cell-based cGMP assay useful for ultra-high-throughput screening and identification of modulators of the nitric oxide/cGMP pathway</span></div><div class="casAuthors">Wunder, Frank; Stasch, Johannes-Peter; Huetter, Joachim; Alonso-Alija, Cristina; Hueser, Joerg; Lohrmann, Emanuel</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">104-112</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">We have established a rapid, homogeneous, cell-based, and highly sensitive assay for guanosine 3'-5'-cyclic monophosphate (cGMP) that is suitable for fully automated ultra-high-throughput screening.  In this assay system, cGMP prodn. is monitored in living cells via Ca2+ influx through the olfactory cyclic nucleotide-gated cation channel CNGA2, acting as the intracellular cGMP sensor.  A stably transfected Chinese hamster ovary (CHO) cell line was generated recombinantly expressing sol. guanylate cyclase, CNGA2, and aequorin as a luminescence indicator for the intracellular calcium concn.  This cell line was used to screen more than 900,000 compds. in an automated ultra-high-throughput screening assay using 1536-well microtiter plates.  In this way, we have been able to identify BAY 58-2667, a member of a new class of amino dicarboxylic acids that directly activate sol. guanylate cyclase.  The assay system allows the real-time cGMP detection within living cells and makes it possible to screen for activators and inhibitors of enzymes involved in the nitric oxide/cGMP pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlaXais-WpGbVg90H21EOLACvtfcHk0licoKX1AQtf3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXit1eqsLs%253D&md5=786bd47ac381d859ce8eee7af9ac498b</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2004.12.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2004.12.025%26sid%3Dliteratum%253Aachs%26aulast%3DWunder%26aufirst%3DF.%26aulast%3DStasch%26aufirst%3DJ.-P.%26aulast%3DH%25C3%25BCtter%26aufirst%3DJ.%26aulast%3DAlonso-Alija%26aufirst%3DC.%26aulast%3DH%25C3%25BCser%26aufirst%3DJ.%26aulast%3DLohrmann%26aufirst%3DE.%26atitle%3DA%2520cell-based%2520cGMP%2520assay%2520useful%2520for%2520ultra-high-throughput%2520screening%2520and%2520identification%2520of%2520modulators%2520of%2520the%2520nitric%2520oxide%252FcGMP%2520pathway%26jtitle%3DAnal.%2520Biochem.%26date%3D2005%26volume%3D339%26spage%3D104%26epage%3D112%26doi%3D10.1016%2Fj.ab.2004.12.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Hillisch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wild, H.</span><span> </span><span class="NLM_article-title">Computational chemistry in the pharmaceutical industry: from childhood to adolescence</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1958</span><span class="NLM_x">–</span> <span class="NLM_lpage">1962</span><span class="refDoi"> DOI: 10.1002/cmdc.201500346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1002%2Fcmdc.201500346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=26358802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVyju73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1958-1962&author=A.+Hillischauthor=N.+Heinrichauthor=H.+Wild&title=Computational+chemistry+in+the+pharmaceutical+industry%3A+from+childhood+to+adolescence&doi=10.1002%2Fcmdc.201500346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Computational Chemistry in the Pharmaceutical Industry: From Childhood to Adolescence</span></div><div class="casAuthors">Hillisch, Alexander; Heinrich, Nikolaus; Wild, Hanno</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1958-1962</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Computational chem. within the pharmaceutical industry has grown into a field that proactively contributes to many aspects of drug design, including target selection and lead identification and optimization.  While methodol. advancements have been key to this development, organizational developments have been crucial to our success as well.  In particular, the interaction between computational and medicinal chem. and the integration of computational chem. into the entire drug discovery process have been invaluable.  Over the past ten years we have shaped and developed a highly efficient computational chem. group for small-mol. drug discovery at Bayer HealthCare that has significantly impacted the clin. development pipeline.  In this article we describe the setup and tasks of the computational group and discuss external collaborations.  We explain what we have found to be the most valuable and productive methods and discuss future directions for computational chem. method development.  We share this information with the hope of igniting interesting discussions around this topic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAFXZ0bBJeBrVg90H21EOLACvtfcHk0ljyz8LrIcG91g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVyju73L&md5=1d5d7d908463585ac45b048a395b0dac</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500346%26sid%3Dliteratum%253Aachs%26aulast%3DHillisch%26aufirst%3DA.%26aulast%3DHeinrich%26aufirst%3DN.%26aulast%3DWild%26aufirst%3DH.%26atitle%3DComputational%2520chemistry%2520in%2520the%2520pharmaceutical%2520industry%253A%2520from%2520childhood%2520to%2520adolescence%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D1958%26epage%3D1962%26doi%3D10.1002%2Fcmdc.201500346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Burkhard, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wuitschik, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers-Evans, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carreira, E. M.</span><span> </span><span class="NLM_article-title">Oxetanes as versatile elements in drug discovery and synthesis</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">9052</span><span class="NLM_x">–</span> <span class="NLM_lpage">9067</span><span class="refDoi"> DOI: 10.1002/anie.200907155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1002%2Fanie.200907155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVCjsb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=9052-9067&author=J.+A.+Burkhardauthor=G.+Wuitschikauthor=M.+Rogers-Evansauthor=K.+M%C3%BCllerauthor=E.+M.+Carreira&title=Oxetanes+as+versatile+elements+in+drug+discovery+and+synthesis&doi=10.1002%2Fanie.200907155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Oxetanes as Versatile Elements in Drug Discovery and Synthesis</span></div><div class="casAuthors">Burkhard, Johannes A.; Wuitschik, Georg; Rogers-Evans, Mark; Mueller, Klaus; Carreira, Erick M.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">9052-9067</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Sizable resources, both financial and human, are invested each year in the development of new pharmaceutical agents.  However, despite improved techniques, the new compds. often encounter difficulties in satisfying and overcoming the numerous physicochem. and many pharmacol. constraints and hurdles.  Oxetanes have been shown to improve key properties when grafted onto mol. scaffolds.  Of particular interest are oxetanes that are substituted only in the 3-position, since such units remain achiral and their introduction into a mol. scaffold does not create a new stereocenter.  This Minireview gives an overview of the recent advances made in the prepn. and use of 3-substituted oxetanes.  It also includes a discussion of the site-dependent modifications of various physicochem. and biochem. properties that result from the incorporation of the oxetane unit in mol. architectures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrV5kqCeZ5EGbVg90H21EOLACvtfcHk0ljyz8LrIcG91g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVCjsb7M&md5=52d9b21c280702ff7f95d27d07ea5eed</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Fanie.200907155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200907155%26sid%3Dliteratum%253Aachs%26aulast%3DBurkhard%26aufirst%3DJ.%2BA.%26aulast%3DWuitschik%26aufirst%3DG.%26aulast%3DRogers-Evans%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26aulast%3DCarreira%26aufirst%3DE.%2BM.%26atitle%3DOxetanes%2520as%2520versatile%2520elements%2520in%2520drug%2520discovery%2520and%2520synthesis%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2010%26volume%3D49%26spage%3D9052%26epage%3D9067%26doi%3D10.1002%2Fanie.200907155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Wuitschik, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carreira, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parrilla, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuler, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers-Evans, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, K.</span><span> </span><span class="NLM_article-title">Oxetanes in drug discovery: structural and synthetic insights</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3227</span><span class="NLM_x">–</span> <span class="NLM_lpage">3246</span><span class="refDoi"> DOI: 10.1021/jm9018788</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9018788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFKjt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3227-3246&author=G.+Wuitschikauthor=E.+M.+Carreiraauthor=B.+Wagnerauthor=H.+Fischerauthor=I.+Parrillaauthor=F.+Schulerauthor=M.+Rogers-Evansauthor=K.+M%C3%BCller&title=Oxetanes+in+drug+discovery%3A+structural+and+synthetic+insights&doi=10.1021%2Fjm9018788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Oxetanes in Drug Discovery: Structural and Synthetic Insights</span></div><div class="casAuthors">Wuitschik, Georg; Carreira, Erick M.; Wagner, Bjorn; Fischer, Holger; Parrilla, Isabelle; Schuler, Franz; Rogers-Evans, Mark; Muller, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3227-3246</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The use of oxetanes as replacements for gem-di-Me or carbonyl groups and their effects on the aq. soly., lipophilicity, metabolic stability, and conformation for various compds. are studied; methods for the prepn. of a variety of substituted oxetanes are given.  The magnitude of changes in properties and in metabolic stability with oxetane substitution depends on the structural context; for example, substitution of a gem-di-Me group with an oxetane, aq. soly. may increase by a factor of 4 to more than 4000 while reducing the rate of metabolic degrdn. in most cases.  Incorporation of an oxetane into an aliph. chain increases in some cases the preference for synclinal conformations rather than antiplanar conformations of the chain.  Spirocyclic oxetanes such as an oxazaspiroheptane resemble commonly used fragments in drug discovery, such as morpholines, and in some cases increase aq. soly. more effectively than morpholines.  An improved chemoselective oxidn. of 3-oxetanol to 3-oxetanone is disclosed; olefination of 3-oxetanone by a variety of methods yields alkylideneoxetanes I [R = (EtO)2P(:O), OHC, O2N, EtO2C, NC, PhO2S, MeCO, 1-(4-chlorophenyl)-1-cyclobutanecarbonyl].  I (R = EtO2C, OHC, O2N) undergo addn. reactions with nucleophiles such as amines, carbonyl compds., and arylboronic acids to give oxetanes such as II.  The crystal structures of a variety of oxetanes are detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYbJqJGrlPJrVg90H21EOLACvtfcHk0ljyz8LrIcG91g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFKjt7s%253D&md5=e95742d38e933c2fb0d76d638ccc773c</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm9018788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9018788%26sid%3Dliteratum%253Aachs%26aulast%3DWuitschik%26aufirst%3DG.%26aulast%3DCarreira%26aufirst%3DE.%2BM.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DParrilla%26aufirst%3DI.%26aulast%3DSchuler%26aufirst%3DF.%26aulast%3DRogers-Evans%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26atitle%3DOxetanes%2520in%2520drug%2520discovery%253A%2520structural%2520and%2520synthetic%2520insights%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3227%26epage%3D3246%26doi%3D10.1021%2Fjm9018788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. J.</span><span> </span><span class="NLM_article-title">Molecular property design: does everyone get it?</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">722</span><span class="NLM_x">–</span> <span class="NLM_lpage">725</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00157</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00157" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptVGksr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=722-725&author=P.+D.+Leesonauthor=R.+J.+Young&title=Molecular+property+design%3A+does+everyone+get+it%3F&doi=10.1021%2Facsmedchemlett.5b00157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Property Design: Does Everyone Get It?</span></div><div class="casAuthors">Leeson, Paul D.; Young, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">722-725</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The principles of mol. property optimization in drug design have been understood for decades, yet much drug discovery activity today is conducted at the periphery of historical druglike property space.  Lead optimization trajectories aimed at reducing physicochem. risk, assisted by ligand efficiency metrics, could help to reduce clin. attrition rates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_t8gIn79arVg90H21EOLACvtfcHk0lhbLG-U6KDyTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptVGksr4%253D&md5=5a807a8d049ce8cf4adc186891a9234d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00157%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26atitle%3DMolecular%2520property%2520design%253A%2520does%2520everyone%2520get%2520it%253F%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D722%26epage%3D725%26doi%3D10.1021%2Facsmedchemlett.5b00157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Sharkovska, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalk, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrenz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wellkisch, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geschka, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Relle, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hocher, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stasch, J.-P.</span><span> </span><span class="NLM_article-title">Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models</span> <span class="citation_source-journal">J. Hypertens.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1666</span><span class="NLM_x">–</span> <span class="NLM_lpage">1675</span><span class="refDoi"> DOI: 10.1097/HJH.0b013e32833b558c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1097%2FHJH.0b013e32833b558c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=20613628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptVCnu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=1666-1675&author=Y.+Sharkovskaauthor=P.+Kalkauthor=B.+Lawrenzauthor=M.+Godesauthor=L.+S.+Hoffmannauthor=K.+Wellkischauthor=S.+Geschkaauthor=K.+Relleauthor=B.+Hocherauthor=J.-P.+Stasch&title=Nitric+oxide-independent+stimulation+of+soluble+guanylate+cyclase+reduces+organ+damage+in+experimental+low-renin+and+high-renin+models&doi=10.1097%2FHJH.0b013e32833b558c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models</span></div><div class="casAuthors">Sharkovska, Yuliya; Kalk, Philipp; Lawrenz, Bettina; Godes, Michael; Hoffmann, Linda Sarah; Wellkisch, Kathrin; Geschka, Sandra; Relle, Katharina; Hocher, Berthold; Stasch, Johannes-Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hypertension</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1666-1675</span>CODEN:
                <span class="NLM_cas:coden">JOHYD3</span>;
        ISSN:<span class="NLM_cas:issn">0263-6352</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The nitric oxide-sol. guanylate cyclase (sGC)-cGMP signal transduction pathway is impaired in different cardiovascular diseases, including pulmonary hypertension, heart failure and arterial hypertension.  Riociguat is a novel stimulator of sol. guanylate cyclase (sGC).  However, little is known about the effects of sGC stimulators in exptl. models of hypertension.  We thus investigated the cardio-renal protective effects of riociguat in low-renin and high-renin rat models of hypertension.  The vasorelaxant effect of riociguat was tested in vitro on isolated saphenous artery rings of normal and nitrate tolerant rabbits.  The cardiovascular in-vivo effects of sGC stimulation were evaluated in hypertensive renin-transgenic rats treated with the nitric oxide-synthase inhibitor N-nitro-L-arginine Me ester (L-NAME) (high-renin model) and in rats with 5/6 nephrectomy (low-renin model).  In both animal models, riociguat treatment improved survival and normalized blood pressure.  Moreover, in the L-NAME study part, riociguat reduced cardiac target organ damage as indicated by lower plasma ANP, lower relative left ventricular wt. and lower cardiac interstitial fibrosis, and reduced renal target organ damage as indicated by lower plasma creatinine and urea, less glomerulosclerosis and less renal interstitial fibrosis.  In the 5/6 nephrectomy study part, riociguat reduced cardiac target organ damage as indicated by lower plasma ANP, lower relative left ventricular wt., lower myocyte diam. and lower arterial media/lm ratio, and reduced renal target organ damage as indicated by improved creatinine clearance and less renal interstitial fibrosis.  We demonstrate for the first time that the novel sGC stimulator riociguat shows in 2 independent models of hypertension a potent protection against cardiac and renal target organ damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0juIRGvsi4bVg90H21EOLACvtfcHk0lhbLG-U6KDyTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptVCnu7c%253D&md5=ab79d2d2ca05457bc9e23f9cbfca9960</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1097%2FHJH.0b013e32833b558c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FHJH.0b013e32833b558c%26sid%3Dliteratum%253Aachs%26aulast%3DSharkovska%26aufirst%3DY.%26aulast%3DKalk%26aufirst%3DP.%26aulast%3DLawrenz%26aufirst%3DB.%26aulast%3DGodes%26aufirst%3DM.%26aulast%3DHoffmann%26aufirst%3DL.%2BS.%26aulast%3DWellkisch%26aufirst%3DK.%26aulast%3DGeschka%26aufirst%3DS.%26aulast%3DRelle%26aufirst%3DK.%26aulast%3DHocher%26aufirst%3DB.%26aulast%3DStasch%26aufirst%3DJ.-P.%26atitle%3DNitric%2520oxide-independent%2520stimulation%2520of%2520soluble%2520guanylate%2520cyclase%2520reduces%2520organ%2520damage%2520in%2520experimental%2520low-renin%2520and%2520high-renin%2520models%26jtitle%3DJ.%2520Hypertens.%26date%3D2010%26volume%3D28%26spage%3D1666%26epage%3D1675%26doi%3D10.1097%2FHJH.0b013e32833b558c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Dubin, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, S. J.</span><span> </span><span class="NLM_article-title">Soluble guanylate cyclase stimulators: a novel treatment option for heart failure associated with cardiorenal syndromes?</span> <span class="citation_source-journal">Curr. Heart Failure Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">132</span><span class="NLM_x">–</span> <span class="NLM_lpage">139</span><span class="refDoi"> DOI: 10.1007/s11897-016-0290-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1007%2Fs11897-016-0290-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=27118234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC28XntVOgur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=132-139&author=R.+F.+Dubinauthor=S.+J.+Shah&title=Soluble+guanylate+cyclase+stimulators%3A+a+novel+treatment+option+for+heart+failure+associated+with+cardiorenal+syndromes%3F&doi=10.1007%2Fs11897-016-0290-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble Guanylate Cyclase Stimulators: a Novel Treatment Option for Heart Failure Associated with Cardiorenal Syndromes?</span></div><div class="casAuthors">Dubin, Ruth F.; Shah, Sanjiv J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Heart Failure Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">132-139</span>CODEN:
                <span class="NLM_cas:coden">CHFRCF</span>;
        ISSN:<span class="NLM_cas:issn">1546-9549</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Heart failure in the setting of chronic kidney disease (CKD) is an increasingly common scenario and carries a poor prognosis.  Clinicians lack tools for primary or secondary heart failure prevention in patients with cardiorenal syndromes.  In patients without CKD, angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARB) and statins mitigate cardiovascular risk in large part due to salutary effects on the endothelium.  In the setting of CKD, use of these therapies is limited by adverse effects of hyperkalemia in pre-dialysis CKD (ACE-I/ARB), or potential increased risk of stroke in end-stage renal disease (statins).  The sol. guanylate cyclase (sGC) stimulators are a novel class of medications that promote endothelial and myocardial function with no known risk of hyperkalemia or stroke.  In this review, we discuss the evidence emerging from recent clin. trials of sGC stimulators in pulmonary hypertension and heart failure, the diseased pathways involved in cardiorenal syndromes likely to be restored by sGC stimulators, and several strategies for designing future clin. trials of cardiorenal syndromes that might shorten the timeline for discovery and approval of effective cardiovascular therapies in these high-risk patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxrjVgp8bdTbVg90H21EOLACvtfcHk0lhbLG-U6KDyTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntVOgur4%253D&md5=dd2f59e79d0515c7a2064cd41024ce57</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1007%2Fs11897-016-0290-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11897-016-0290-z%26sid%3Dliteratum%253Aachs%26aulast%3DDubin%26aufirst%3DR.%2BF.%26aulast%3DShah%26aufirst%3DS.%2BJ.%26atitle%3DSoluble%2520guanylate%2520cyclase%2520stimulators%253A%2520a%2520novel%2520treatment%2520option%2520for%2520heart%2520failure%2520associated%2520with%2520cardiorenal%2520syndromes%253F%26jtitle%3DCurr.%2520Heart%2520Failure%2520Rep.%26date%3D2016%26volume%3D13%26spage%3D132%26epage%3D139%26doi%3D10.1007%2Fs11897-016-0290-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Follmann, M.; Stasch, J.-P.; Redlich, G.; Griebenow, N.; Lang, D.; Wunder, F.; Huebsch, W.; Lindner, N.; Vakalopoulos, A.; Tersteegen, A.</span><span> </span><span class="NLM_article-title">Preparation of annelated pyrimidine derivatives useful in the treatment and prophylaxis of cardiovascular diseases</span>. WO2013030288,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=M.+Follmann&author=J.-P.+Stasch&author=G.+Redlich&author=N.+Griebenow&author=D.+Lang&author=F.+Wunder&author=W.+Huebsch&author=N.+Lindner&author=A.+Vakalopoulos&author=A.+Tersteegen&title=Preparation+of+annelated+pyrimidine+derivatives+useful+in+the+treatment+and+prophylaxis+of+cardiovascular+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFollmann%26aufirst%3DM.%26atitle%3DPreparation%2520of%2520annelated%2520pyrimidine%2520derivatives%2520useful%2520in%2520the%2520treatment%2520and%2520prophylaxis%2520of%2520cardiovascular%2520diseases%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Follmann, M.; Stasch, J.-P.; Redlich, G.; Ackerstaff, J.; Griebenow, N.; Knorr, A.; Wunder, F.; Li, V. M.-J.; Baerfacker, L.; Weigand, S.</span><span> </span><span class="NLM_article-title">Bicyclic aza-heterocycles as guanylate cyclase inhibitors and their preparation and use in the treatment of cardiovascular diseases</span>. WO 2012028647,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+Follmann&author=J.-P.+Stasch&author=G.+Redlich&author=J.+Ackerstaff&author=N.+Griebenow&author=A.+Knorr&author=F.+Wunder&author=V.+M.-J.+Li&author=L.+Baerfacker&author=S.+Weigand&title=Bicyclic+aza-heterocycles+as+guanylate+cyclase+inhibitors+and+their+preparation+and+use+in+the+treatment+of+cardiovascular+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFollmann%26aufirst%3DM.%26atitle%3DBicyclic%2520aza-heterocycles%2520as%2520guanylate%2520cyclase%2520inhibitors%2520and%2520their%2520preparation%2520and%2520use%2520in%2520the%2520treatment%2520of%2520cardiovascular%2520diseases%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Follmann, M.; Stasch, J.-P.; Redlich, G.; Ackerstaff, J.; Griebenow, N.; Knorr, A.; Wunder, F.; Li, V. M.-J.; Schirok, H.; Jautelat, R.</span><span> </span><span class="NLM_article-title">Substituted methyl pyrimidin-5-yl carbamates as guanylate cyclase inhibitors and their preparation and use in the treatment of cardiovascular diseases</span>. WO 2012010578,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+Follmann&author=J.-P.+Stasch&author=G.+Redlich&author=J.+Ackerstaff&author=N.+Griebenow&author=A.+Knorr&author=F.+Wunder&author=V.+M.-J.+Li&author=H.+Schirok&author=R.+Jautelat&title=Substituted+methyl+pyrimidin-5-yl+carbamates+as+guanylate+cyclase+inhibitors+and+their+preparation+and+use+in+the+treatment+of+cardiovascular+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFollmann%26aufirst%3DM.%26atitle%3DSubstituted%2520methyl%2520pyrimidin-5-yl%2520carbamates%2520as%2520guanylate%2520cyclase%2520inhibitors%2520and%2520their%2520preparation%2520and%2520use%2520in%2520the%2520treatment%2520of%2520cardiovascular%2520diseases%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Alonso-Alija, C.; Bischoff, E.; Muenter, K.; Stasch, J.-P.; Stahl, E.; Weigand, S.; Feurer, A.</span><span> </span><span class="NLM_article-title">Preparation of [(pyrazolopyridinyl)pyrimidinyl]carbamates stimulating soluble guanylate cyclase for treating cardiovascular diseases and/or sexual dysfunction</span>. WO 2003095451,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=C.+Alonso-Alija&author=E.+Bischoff&author=K.+Muenter&author=J.-P.+Stasch&author=E.+Stahl&author=S.+Weigand&author=A.+Feurer&title=Preparation+of+%5B%28pyrazolopyridinyl%29pyrimidinyl%5Dcarbamates+stimulating+soluble+guanylate+cyclase+for+treating+cardiovascular+diseases+and%2For+sexual+dysfunction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAlonso-Alija%26aufirst%3DC.%26atitle%3DPreparation%2520of%2520%255B%2528pyrazolopyridinyl%2529pyrimidinyl%255Dcarbamates%2520stimulating%2520soluble%2520guanylate%2520cyclase%2520for%2520treating%2520cardiovascular%2520diseases%2520and%252For%2520sexual%2520dysfunction%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Follmann, M.; Stasch, J.-P.; Redlich, G.; Ackerstaff, J.; Griebenow, N.; Wunder, F.; Li, V. M.-J.; Mittendorf, J.; Jautelat, R.</span><span> </span><span class="NLM_article-title">Carbamate-substituted diaminopyrimidines as guanylate cyclase inhibitors and their preparation and use in the treatment of cardiovascular diseases</span>. WO 2012010576,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+Follmann&author=J.-P.+Stasch&author=G.+Redlich&author=J.+Ackerstaff&author=N.+Griebenow&author=F.+Wunder&author=V.+M.-J.+Li&author=J.+Mittendorf&author=R.+Jautelat&title=Carbamate-substituted+diaminopyrimidines+as+guanylate+cyclase+inhibitors+and+their+preparation+and+use+in+the+treatment+of+cardiovascular+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFollmann%26aufirst%3DM.%26atitle%3DCarbamate-substituted%2520diaminopyrimidines%2520as%2520guanylate%2520cyclase%2520inhibitors%2520and%2520their%2520preparation%2520and%2520use%2520in%2520the%2520treatment%2520of%2520cardiovascular%2520diseases%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Schirok, H.; Mittendorf, J.; Stasch, J.-P.; Wunder, F.; Stoll, F.; Schlemmer, K.-H.</span><span> </span><span class="NLM_article-title">Azabicyclic derivatives as stimulators of guanylate cyclase, their preparation, pharmaceutical compositions, and use for the treatment of cardiovascular disorders</span>. WO 2008031513,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=H.+Schirok&author=J.+Mittendorf&author=J.-P.+Stasch&author=F.+Wunder&author=F.+Stoll&author=K.-H.+Schlemmer&title=Azabicyclic+derivatives+as+stimulators+of+guanylate+cyclase%2C+their+preparation%2C+pharmaceutical+compositions%2C+and+use+for+the+treatment+of+cardiovascular+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSchirok%26aufirst%3DH.%26atitle%3DAzabicyclic%2520derivatives%2520as%2520stimulators%2520of%2520guanylate%2520cyclase%252C%2520their%2520preparation%252C%2520pharmaceutical%2520compositions%252C%2520and%2520use%2520for%2520the%2520treatment%2520of%2520cardiovascular%2520disorders%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Follmann, M.; Stasch, J.-P.; Redlich, G.; Ackerstaff, J.; Griebenow, N.; Knorr, A.; Wunder, F.; Li, V. M.-J.; Mittendorf, J.; Schlemmer, K.-H.; Jautelat, R.</span><span> </span><span class="NLM_article-title">Substituted 6-fluoro-1<i>H</i>-pyrazolo[4,3-<i>b</i>]pyridines as guanylate cyclase inhibitors and their preparation and use in the treatment of cardiovascular diseases</span>. WO 2012059549,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+Follmann&author=J.-P.+Stasch&author=G.+Redlich&author=J.+Ackerstaff&author=N.+Griebenow&author=A.+Knorr&author=F.+Wunder&author=V.+M.-J.+Li&author=J.+Mittendorf&author=K.-H.+Schlemmer&author=R.+Jautelat&title=Substituted+6-fluoro-1H-pyrazolo%5B4%2C3-b%5Dpyridines+as+guanylate+cyclase+inhibitors+and+their+preparation+and+use+in+the+treatment+of+cardiovascular+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFollmann%26aufirst%3DM.%26atitle%3DSubstituted%25206-fluoro-1H-pyrazolo%255B4%252C3-b%255Dpyridines%2520as%2520guanylate%2520cyclase%2520inhibitors%2520and%2520their%2520preparation%2520and%2520use%2520in%2520the%2520treatment%2520of%2520cardiovascular%2520diseases%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Follmann, M.; Stasch, J.-P.; Redlich, G.; Straub, A.; Ackerstaff, J.; Griebenow, N.; Knorr, A.; Wunder, F.; Li, V. M.-J.</span><span> </span><span class="NLM_article-title">Substituted imidazopyridazines as guanylate cyclase inhibitors and their preparation and use in the treatment of cardiovascular diseases</span>. WO 2012152630,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+Follmann&author=J.-P.+Stasch&author=G.+Redlich&author=A.+Straub&author=J.+Ackerstaff&author=N.+Griebenow&author=A.+Knorr&author=F.+Wunder&author=V.+M.-J.+Li&title=Substituted+imidazopyridazines+as+guanylate+cyclase+inhibitors+and+their+preparation+and+use+in+the+treatment+of+cardiovascular+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFollmann%26aufirst%3DM.%26atitle%3DSubstituted%2520imidazopyridazines%2520as%2520guanylate%2520cyclase%2520inhibitors%2520and%2520their%2520preparation%2520and%2520use%2520in%2520the%2520treatment%2520of%2520cardiovascular%2520diseases%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Straub, A.; Feurer, A.; Alonso-Alija, C.; Stasch, J.-P.; Perzborn, E.; Huetter, J.; Dembowsky, K.; Stahl, E.</span><span> </span><span class="NLM_article-title">Substituted pyrazole derivatives condensed with six-membered heterocyclic rings as cardiovascular agents and their preparation</span>. WO 2000006569,<span class="NLM_x"> </span><span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=A.+Straub&author=A.+Feurer&author=C.+Alonso-Alija&author=J.-P.+Stasch&author=E.+Perzborn&author=J.+Huetter&author=K.+Dembowsky&author=E.+Stahl&title=Substituted+pyrazole+derivatives+condensed+with+six-membered+heterocyclic+rings+as+cardiovascular+agents+and+their+preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DStraub%26aufirst%3DA.%26atitle%3DSubstituted%2520pyrazole%2520derivatives%2520condensed%2520with%2520six-membered%2520heterocyclic%2520rings%2520as%2520cardiovascular%2520agents%2520and%2520their%2520preparation%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Walsky, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span> </span><span class="NLM_article-title">Validated assays for human cytochrome P450 activities</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">647</span><span class="NLM_x">–</span> <span class="NLM_lpage">660</span><span class="refDoi"> DOI: 10.1124/dmd.32.6.647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1124%2Fdmd.32.6.647" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=15155557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktlOgt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2004&pages=647-660&author=R.+L.+Walskyauthor=R.+S.+Obach&title=Validated+assays+for+human+cytochrome+P450+activities&doi=10.1124%2Fdmd.32.6.647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Validated assays for human cytochrome P450 activities</span></div><div class="casAuthors">Walsky, Robert L.; Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">647-660</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The measurement of the effect of new chem. entities on human cytochrome P 450 marker activities using in vitro experimentation represents an important exptl. approach in drug development.  In vitro drug interaction data can be used in guiding the design of clin. drug interaction studies, or, when no effect is obsd. in vitro, the data can be used in place of an in vivo study to claim that no interaction will occur in vivo.  To make such a claim, it must be assured that the in vitro expts. are performed with abs. confidence in the methods used and data obtained.  To meet this need, 12 semiautomated assays for human P 450 marker substrate activities have been developed and validated using approaches described in the GLP (good lab. practices) as per the code of U.S. Federal Regulations.  The assays that were validated are: phenacetin O-deethylase (CYP1A2), coumarin 7-hydroxylase (CYP2A6), bupropion hydroxylase (CYP2B6), amodiaquine N-deethylase (CYP2C8), diclofenac 4'-hydroxylase and tolbutamide methylhydroxylase (CYP2C9), (S)-mephenytoin 4'-hydroxylase (CYP2C19), dextromethorphan O-demethylase (CYP2D6), chlorzoxazone 6-hydroxylase (CYP2E1), felodipine dehydrogenase, testosterone 6β-hydroxylase, and midazolam 1'-hydroxylase (CYP3A4 and CYP3A5).  High-pressure liq. chromatog.-tandem mass spectrometry, using stable isotope-labeled internal stds., has been applied as the anal. method.  This anal. approach, through its high sensitivity and selectivity, has permitted the use of very low incubation concns. of microsomal protein (0.01-0.2 mg/mL).  Anal. assay accuracy and precision values were excellent.  Enzyme kinetic and inhibition parameters obtained using these methods demonstrated high precision and were within the range of values previously reported in the scientific literature.  These methods should prove useful in the routine assessments of the potential for new drug candidates to elicit pharmacokinetic drug interactions via inhibition of cytochrome P 450 activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwF04TGeyYbbVg90H21EOLACvtfcHk0lh28Ez7XH4o0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktlOgt74%253D&md5=35532b907c15f1053aa8233dab2ec581</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1124%2Fdmd.32.6.647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.32.6.647%26sid%3Dliteratum%253Aachs%26aulast%3DWalsky%26aufirst%3DR.%2BL.%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DValidated%2520assays%2520for%2520human%2520cytochrome%2520P450%2520activities%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2004%26volume%3D32%26spage%3D647%26epage%3D660%26doi%3D10.1124%2Fdmd.32.6.647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsky, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkatakrishnan, K.</span><span> </span><span class="NLM_article-title">Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">246</span><span class="NLM_x">–</span> <span class="NLM_lpage">255</span><span class="refDoi"> DOI: 10.1124/dmd.106.012633</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1124%2Fdmd.106.012633" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=17093004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVKrs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=246-255&author=R.+S.+Obachauthor=R.+L.+Walskyauthor=K.+Venkatakrishnan&title=Mechanism-based+inactivation+of+human+cytochrome+p450+enzymes+and+the+prediction+of+drug-drug+interactions&doi=10.1124%2Fdmd.106.012633"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions</span></div><div class="casAuthors">Obach, R. Scott; Walsky, Robert L.; Venkatakrishnan, Karthik</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">246-255</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The ability to use vitro inactivation kinetic parameters in scaling to in vivo drug-drug interactions (DDIs) for mechanism-based inactivators of human cytochrome P 450 (P 450) enzymes was examd. using eight human P 450-selective marker activities in pooled human liver microsomes.  These data were combined with other parameters (systemic Cmax, estd. hepatic inlet Cmax, fraction unbound, in vivo P 450 enzyme degrdn. rate consts. estd. from clin. pharmacokinetic data, and fraction of the affected drug cleared by the inhibited enzyme) to predict increases in exposure to drugs, and the predictions were compared with in vivo DDIs gathered from clin. studies reported in the scientific literature.  In general, the use of unbound systemic Cmax as the inactivator concn. in vivo yielded the most accurate predictions of DDI with a mean -fold error of 1.64.  Abbreviated in vitro approaches to identifying mechanism-based inactivators were developed.  Testing potential inactivators at a single concn. (IC25) in a 30-min preincubation with human liver microsomes in the absence and presence of NADPH followed by assessment of P 450 marker activities readily identified those compds. known to be mechanism-based inactivators and represents an approach that can be used with greater throughput.  Measurement of decreases in IC50 occurring with a 30-min preincubation with liver microsomes and NADPH was also useful in identifying mechanism-based inactivators, and the IC50 measured after such a preincubation was highly correlated with the kinact/K1 ratio measured after a full characterization of inactivation.  Overall, these findings support the conclusion that P 450 in vitro inactivation data are valuable in predicting clin. DDIs that can occur via this mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpPRf5ZGrW6LVg90H21EOLACvtfcHk0lj1-j0WsJUsxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVKrs7k%253D&md5=71733cfafba3b2c9cc6b47a46e7b3f40</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1124%2Fdmd.106.012633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.106.012633%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DWalsky%26aufirst%3DR.%2BL.%26aulast%3DVenkatakrishnan%26aufirst%3DK.%26atitle%3DMechanism-based%2520inactivation%2520of%2520human%2520cytochrome%2520p450%2520enzymes%2520and%2520the%2520prediction%2520of%2520drug-drug%2520interactions%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2007%26volume%3D35%26spage%3D246%26epage%3D255%26doi%3D10.1124%2Fdmd.106.012633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Obach, R. S.</span><span> </span><span class="NLM_article-title">Predicting clearance in humans from in vitro data</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">334</span><span class="NLM_x">–</span> <span class="NLM_lpage">339</span><span class="refDoi"> DOI: 10.2174/156802611794480873</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.2174%2F156802611794480873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=21320062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslSntbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=334-339&author=R.+S.+Obach&title=Predicting+clearance+in+humans+from+in+vitro+data&doi=10.2174%2F156802611794480873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting clearance in humans from in vitro data</span></div><div class="casAuthors">Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">334-339</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The use of in vitro metab. in scaling to predict human clearance of new chem. entities has become a commonplace activity in the research and development of new drugs.  The measurement of in vitro lability in human liver microsomes, a rich source of drug metabolizing cytochrome P 450 enzymes, has become a high throughput screen in many research organizations which is a testament to its usefulness in drug design.  In this chapter, the methods used to scale in vitro intrinsic clearance data to predict in vivo clearance are described.  Importantly, the numerous assumptions that are required in order to use in vitro data in this manner are laid out.  These include assumptions regarding the scaling process as well as tech. aspects of the generation of the in vitro data.  Finally, some other drug clearance processes that have been emerging as important are described with regard to ongoing research efforts to develop clearance prediction methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHL7BnSTNtWbVg90H21EOLACvtfcHk0lj1-j0WsJUsxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslSntbk%253D&md5=38df8707bb77fdc8b6bb6ef2144a79da</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.2174%2F156802611794480873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611794480873%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DPredicting%2520clearance%2520in%2520humans%2520from%2520in%2520vitro%2520data%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D334%26epage%3D339%26doi%3D10.2174%2F156802611794480873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Artursson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlsson, J.</span><span> </span><span class="NLM_article-title">Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">175</span><span class="NLM_x">, </span> <span class="NLM_fpage">880</span><span class="NLM_x">–</span> <span class="NLM_lpage">885</span><span class="refDoi"> DOI: 10.1016/0006-291X(91)91647-U</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1016%2F0006-291X%2891%2991647-U" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1673839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADyaK3MXhslOrt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=1991&pages=880-885&author=P.+Arturssonauthor=J.+Karlsson&title=Correlation+between+oral+drug+absorption+in+humans+and+apparent+drug+permeability+coefficients+in+human+intestinal+epithelial+%28Caco-2%29+cells&doi=10.1016%2F0006-291X%2891%2991647-U"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells</span></div><div class="casAuthors">Artursson, P.; Karlsson, J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">880-5</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    </div><div class="casAbstract">Monolayers of a well differentiated human intestinal epithelial cell line, Caco-2, were used as a model to study passive drug absorption across the intestinal epithelium.  Absorption rate consts. (expressed as apparent permeability coeffs.) were detd. for 20 drugs and peptides with different structural properties.  The permeability coeffs. ranged from approx. 5 × 10-8 to 5 × 10-5 cm/s.  A good correlation was obtained between data on oral absorption in humans and the results in the Caco-2 model.  Drugs that are completely absorbed in humans had permeability coeffs. >1 × 10-6 cm/s.  Drugs that are absorbed to >1% but <100% had permeability coeffs. of 0.1-1.0 × 10-6 cm/s while drugs and peptides that are absorbed to <1% had permeability coeffs. of ≤1 × 10-7 cm/s.  The results indicate that Caco-2 monolayers can be used as a model for studies on intestinal drug absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdvsEluSXCILVg90H21EOLACvtfcHk0lj1-j0WsJUsxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhslOrt7c%253D&md5=3b1e14cae3beb0345014284e3aa6a7c0</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2F0006-291X%2891%2991647-U&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-291X%252891%252991647-U%26sid%3Dliteratum%253Aachs%26aulast%3DArtursson%26aufirst%3DP.%26aulast%3DKarlsson%26aufirst%3DJ.%26atitle%3DCorrelation%2520between%2520oral%2520drug%2520absorption%2520in%2520humans%2520and%2520apparent%2520drug%2520permeability%2520coefficients%2520in%2520human%2520intestinal%2520epithelial%2520%2528Caco-2%2529%2520cells%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1991%26volume%3D175%26spage%3D880%26epage%3D885%26doi%3D10.1016%2F0006-291X%2891%2991647-U" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Hoenicka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, E.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apeler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirichoke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schröder, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerzer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stasch, J.-P.</span><span> </span><span class="NLM_article-title">Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: stimulation by YC-1, nitric oxide, and carbon monoxide</span> <span class="citation_source-journal">J. Mol. Med. (Heidelberg, Ger.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">14</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span><span class="refDoi"> DOI: 10.1007/s001090050292</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1007%2Fs001090050292" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=9930922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADyaK1MXjtVKrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=1999&pages=14-23&author=M.+Hoenickaauthor=E.-M.+Beckerauthor=H.+Apelerauthor=T.+Sirichokeauthor=H.+Schr%C3%B6derauthor=R.+Gerzerauthor=J.-P.+Stasch&title=Purified+soluble+guanylyl+cyclase+expressed+in+a+baculovirus%2FSf9+system%3A+stimulation+by+YC-1%2C+nitric+oxide%2C+and+carbon+monoxide&doi=10.1007%2Fs001090050292"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: Stimulation by YC-1, nitric oxide, and carbon monoxide</span></div><div class="casAuthors">Hoenicka, Markus; Becker, Eva-Maria; Apeler, Heiner; Sirichoke, Tim; Schroder, Henning; Gerzer, Rupert; Stasch, Johannes-Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Medicine (Berlin)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14-23</span>CODEN:
                <span class="NLM_cas:coden">JMLME8</span>;
        ISSN:<span class="NLM_cas:issn">0946-2716</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">Sol. guanylyl cyclase (sGC) is the main receptor for nitric oxide, a messenger mol. with multiple clin. implications.  Understanding the activation of sGC is an important step for establishing new therapeutic principles.  We have now overexpressed sGC in a baculovirus/Sf9 system optimized for high protein yields to facilitate spectral and kinetic studies of the activation mechanisms of this enzyme.  It was expressed in a batch fermenter using a defined mixt. of viruses encoding the α1 and β1 subunits of the rat lung enzyme.  The expressed enzyme was purified from the cytosolic fraction by anion exchange chromatog., hydroxyapatite chromatog., and size exclusion chromatog.  By use of this new method 2.5 L culture yielded about 1 mg of apparently homogeneous sGC with a content of about one heme per heterodimer without the need of a heme reconstitution step.  The enzyme did not contain stoichiometric amts. of copper.  The basal activities of the purified enzyme were 153 and 1259 nmol min-1 mg-1 in the presence of Mg2+ and Mn2+, resp.  The nitric oxide releasing agent 2-(N,N-diethylamino)-diazenolate-2-oxide (DEA/NO) stimulated the enzyme 160-fold with Mg2+, whereas the NO-independent activator 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole (YC-1) induced an increase in the activity of 101-fold at a concn. of 300 μM.  The combination of DEA/NO (10 μM) and YC-1 (100 μM) elicited a dose-dependent synergistic stimulation with a max. of a 792-fold increase over the basal activity in the presence of Mg2+, resulting in a specific activity of 121 μmol min-1 mg-1.  The synergistic stimulation of DEA/NO and YC-1 was attenuated by the sGC inhibitor 1H-(1,2,4)oxadiazole(4,3-a)quinoxalin-1-one (ODQ) (10 μM) by 94%.  In a different exptl. setup a satd. carbon monoxide soln. in the absence of ambient oxygen or NO stimulated the enzyme 15-fold in the absence and 1260-fold in the presence of YC-1 compared to an argon control.  The heme spectra of the enzyme showed a shift of the Soret peak from 432 to 399 and 424 nm in the presence of DEA/NO or carbon monoxide, resp.  The heme spectra were not affected by YC-1 in the absence or in the presence of DEA/NO or of carbon monoxide, which reflects the fact that YC-1 does not interact directly with the heme group of the enzyme.  In summary, this study shows that our expression/purifn. procedure is suitable for producing large amts. of highly pure sGC which contains one heme per heterodimer without a reconstitution step.  The activator expts. show that in a synergistic stimulation with YC-1 sGC can be activated maximally both by nitric oxide and by carbon monoxide and that YC-1 does not directly act via heme.  The described method should help to facilitate the investigation of the new therapeutic principle of NO-independent guanylyl cyclase activators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0MAMDq3YYc7Vg90H21EOLACvtfcHk0lgAa7BXV4KpNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjtVKrsA%253D%253D&md5=0c1873bb3bde09bb9096fef30343da1a</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1007%2Fs001090050292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs001090050292%26sid%3Dliteratum%253Aachs%26aulast%3DHoenicka%26aufirst%3DM.%26aulast%3DBecker%26aufirst%3DE.-M.%26aulast%3DApeler%26aufirst%3DH.%26aulast%3DSirichoke%26aufirst%3DT.%26aulast%3DSchr%25C3%25B6der%26aufirst%3DH.%26aulast%3DGerzer%26aufirst%3DR.%26aulast%3DStasch%26aufirst%3DJ.-P.%26atitle%3DPurified%2520soluble%2520guanylyl%2520cyclase%2520expressed%2520in%2520a%2520baculovirus%252FSf9%2520system%253A%2520stimulation%2520by%2520YC-1%252C%2520nitric%2520oxide%252C%2520and%2520carbon%2520monoxide%26jtitle%3DJ.%2520Mol.%2520Med.%2520%2528Heidelberg%252C%2520Ger.%2529%26date%3D1999%26volume%3D77%26spage%3D14%26epage%3D23%26doi%3D10.1007%2Fs001090050292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Schermuly, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stasch, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pullamsetti, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middendorff, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlüter, K.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dingendorf, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hackemack, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolosionek, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaulen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumitrascu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissmann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mittendorf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klepetko, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeger, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghofrani, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimminger, F.</span><span> </span><span class="NLM_article-title">Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">–</span> <span class="NLM_lpage">891</span><span class="refDoi"> DOI: 10.1183/09031936.00114407</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1183%2F09031936.00114407" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=18550612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1KqsbjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2008&pages=881-891&author=R.+T.+Schermulyauthor=J.-P.+Staschauthor=S.+S.+Pullamsettiauthor=R.+Middendorffauthor=D.+M%C3%BCllerauthor=K.-D.+Schl%C3%BCterauthor=A.+Dingendorfauthor=S.+Hackemackauthor=E.+Kolosionekauthor=C.+Kaulenauthor=R.+Dumitrascuauthor=N.+Weissmannauthor=J.+Mittendorfauthor=W.+Klepetkoauthor=W.+Seegerauthor=H.+A.+Ghofraniauthor=F.+Grimminger&title=Expression+and+function+of+soluble+guanylate+cyclase+in+pulmonary+arterial+hypertension&doi=10.1183%2F09031936.00114407"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension</span></div><div class="casAuthors">Schermuly, R. T.; Stasch, J.-P.; Pullamsetti, S. S.; Middendorff, R.; Mueller, D.; Schlueter, K.-D.; Dingendorf, A.; Hackemack, S.; Kolosionek, E.; Kaulen, C.; Dumitrascu, R.; Weissmann, N.; Mittendorf, J.; Klepetko, W.; Seeger, W.; Ghofrani, H. A.; Grimminger, F.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">881-891</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Alterations of the nitric oxide receptor, sol. guanylate cyclase (sGC) may contribute to the pathophysiol. of pulmonary arterial hypertension (PAH).  In the present study, the expression of sGC in explanted lung tissue of PAH patients was studied and the effects of the sGC stimulator BAY 63-2521 on enzyme activity, and hemodynamics and vascular remodelling were investigated in two independent animal models of PAH.  Strong upregulation of sGC in pulmonary arterial vessels in the idiopathic PAH lungs compared with healthy donor lungs was demonstrated by immunohistochem.  Upregulation of sGC was detected, similarly to humans, in the structurally remodelled smooth muscle layer in chronic hypoxic mouse lungs and lungs from monocrotaline (MCT)-injected rats.  BAY 63-2521 is a novel, orally available compd. that directly stimulates sGC and sensitizes it to its physiol. stimulator, nitric oxide.  Chronic treatment of hypoxic mice and MCT-injected rats, with fully established PAH, with BAY 63-2521 (10 mg·kg-1·day-1) partially reversed the PAH, the right heart hypertrophy and the structural remodelling of the lung vasculature.  Upregulation of sol. guanylate cyclase in pulmonary arterial smooth muscle cells was noted in human idiopathic pulmonary arterial hypertension lungs and lungs from animal models of pulmonary arterial hypertension.  Stimulation of sol. guanylate cyclase reversed right heart hypertrophy and structural lung vascular remodelling.  Sol. guanylate cyclase may thus offer a new target for therapeutic intervention in pulmonary arterial hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1n8mqzLY9hLVg90H21EOLACvtfcHk0lgAa7BXV4KpNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1KqsbjM&md5=f45a8e5f806616cd5b20363b6c8dec8a</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1183%2F09031936.00114407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00114407%26sid%3Dliteratum%253Aachs%26aulast%3DSchermuly%26aufirst%3DR.%2BT.%26aulast%3DStasch%26aufirst%3DJ.-P.%26aulast%3DPullamsetti%26aufirst%3DS.%2BS.%26aulast%3DMiddendorff%26aufirst%3DR.%26aulast%3DM%25C3%25BCller%26aufirst%3DD.%26aulast%3DSchl%25C3%25BCter%26aufirst%3DK.-D.%26aulast%3DDingendorf%26aufirst%3DA.%26aulast%3DHackemack%26aufirst%3DS.%26aulast%3DKolosionek%26aufirst%3DE.%26aulast%3DKaulen%26aufirst%3DC.%26aulast%3DDumitrascu%26aufirst%3DR.%26aulast%3DWeissmann%26aufirst%3DN.%26aulast%3DMittendorf%26aufirst%3DJ.%26aulast%3DKlepetko%26aufirst%3DW.%26aulast%3DSeeger%26aufirst%3DW.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DGrimminger%26aufirst%3DF.%26atitle%3DExpression%2520and%2520function%2520of%2520soluble%2520guanylate%2520cyclase%2520in%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2008%26volume%3D32%26spage%3D881%26epage%3D891%26doi%3D10.1183%2F09031936.00114407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Geschka, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kretschmer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharkovska, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evgenov, O. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrenz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hucke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hocher, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stasch, J.-P.</span><span> </span><span class="NLM_article-title">Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">e21853</span><span class="refDoi"> DOI: 10.1371/journal.pone.0021853</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;key=10.1371%2Fjournal.pone.0021853" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e21853&author=S.+Geschkaauthor=A.+Kretschmerauthor=Y.+Sharkovskaauthor=O.+V.+Evgenovauthor=B.+Lawrenzauthor=A.+Huckeauthor=B.+Hocherauthor=J.-P.+Stasch&title=Soluble+guanylate+cyclase+stimulation+prevents+fibrotic+tissue+remodeling+and+improves+survival+in+salt-sensitive+Dahl+rats&doi=10.1371%2Fjournal.pone.0021853"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0021853&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0021853%26sid%3Dliteratum%253Aachs%26aulast%3DGeschka%26aufirst%3DS.%26aulast%3DKretschmer%26aufirst%3DA.%26aulast%3DSharkovska%26aufirst%3DY.%26aulast%3DEvgenov%26aufirst%3DO.%2BV.%26aulast%3DLawrenz%26aufirst%3DB.%26aulast%3DHucke%26aufirst%3DA.%26aulast%3DHocher%26aufirst%3DB.%26aulast%3DStasch%26aufirst%3DJ.-P.%26atitle%3DSoluble%2520guanylate%2520cyclase%2520stimulation%2520prevents%2520fibrotic%2520tissue%2520remodeling%2520and%2520improves%2520survival%2520in%2520salt-sensitive%2520Dahl%2520rats%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26spage%3De21853%26doi%3D10.1371%2Fjournal.pone.0021853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i65"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00449">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_42087"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b00449">10.1021/acs.jmedchem.7b00449</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline"><sup>1</sup>H NMR spectra of selected compounds <b>3</b>, <b>21</b>, <b>22</b>, and <b>24</b>; CYP-inhibition results of <b>24</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00449/suppl_file/jm7b00449_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00449/suppl_file/jm7b00449_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00449/suppl_file/jm7b00449_si_001.pdf">jm7b00449_si_001.pdf (679.41 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00449/suppl_file/jm7b00449_si_002.csv">jm7b00449_si_002.csv (1.38 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-12%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00449%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00449" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66798a19dda4a2a6","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
